邢唷>? UX?HIJKLMNOPQRST欹€ 餜單bjbj肴肴8墷墷+P P 8 污?.#)9)9)9)m*aF%Id       $^X/Y塉m*m*塉塉/9)9)4堐塉nS9)9)A蓉塉 uX9)鄤ui鳚.6往(-炢0污貔X%XPX龙l塉塉塉塉塉塉塉//塉塉塉污塉塉塉塉X塉塉塉塉塉塉塉塉塉P  _: 梑|T8TS惻u襨o僫r4N奮o僨[c_^Nwo僨[O2020t^3g27錯裇^ |T8TS惻u襨N/fN蛓US靣剉舥襨 /fT蛓舥襨剉;`饄 S靊;熍u襨0燪秗舥襨0爛S惻u襨0z伵u襨0|T8TST迉舥襨I{ 鶺嶯顅MR癳媁燪秗舥襨SARS-CoV-2 a觛 O璬剉艔?`  O觛'`0魜舥'`孴魜{k'` vQ騗蟸b:NhQtsQ鑜剉&q筽0惽彏[寶剉hQ鶺郪膥廭R纇Km蔛舥烻8hx懤hKm SARS-CoV-2舥烻SOHT皊燪秗舥襨b_` N孴KNMR裇皊剉 6 蛓燪秗舥襨%N蛻%`'`|T8TS慄~T乢SARS0-NN|T8T鼅T乢MERSI{ N T ADDIN NE.Ref.{7AB79A83-3B84-4717-9975-49ADCE0D6A25}[1]0鶺嶯|T8TS惻u襨錘蔛SARS0MERS0SARS-CoV-2 gP杽v4N奮籰梪蟸寶孴g癳剉 0癳媁燪秗舥襨a觛剉簚巔蕥梪筫Hh 諎L?{NHr  0 ADDIN NE.Ref.{0DF54945-39F8-458D-BF98-6C671ADCAD3B}[2-3]0 0fkIlOS孴;SbYn 2019 癳媁燪秗舥襨a觛V{eu蔛魦f 0Qe籰筫Hh-N╟P冋?u剉梑舥襨o僫r 俌m9S鏃/)RXb鏃0`!媁r^pb }0)R鬩鏃梘0?栐kY\0/l筓I{ ADDIN NE.Ref.{482E4441-FA8F-4237-9058-789076F9D9BB}[4-5] 錘蔛g癳剉鴙sQ剉o僫rx裇俌^t穇夋0誰蒪鏃\I{\RP[o僫r珗SOY瀃寶翄瀃颯齹 gHe0(W^Nwo僨[O€t^o僨[NN訷XTO剉膥莮 N,R梩^訷XTO剉N禰錱桒vsQcWS 耂€'Y蠎噀.s 垟鵞g癳剉o僫r蹚U\ 漁nc猒翄;Sf[剉漁nc 6R歔哊梑|T8TS惻u襨o僫r剉o僨[c_  ^g鵞顅MR梑|T8TS惻u襨o僫r(W4N奮剉TtO(u0€剉o僨[裿賬鶴哊wQSO剉t筫Hh :N4N奮剺2枌T籰梪|T8TS惻u襨@b魜緐舥衏汷耂€ ADDIN NE.Ref.{32068C8D-F5EC-4E81-B930-D88B9B305F5A}[5-10]0 ^y蟸(lx憊憫b6RBR^y蟸(lx憊憫b6RBR;N亯惽N^y蟸(lx憊憚v)Y6q昢ir>U瞞x戅z塏  愰b'`慴6RS渷 N^y蟸(lx憊憚v;m'` 蹚 €;柇e舥襨棙抾蜰珗a觛縖;N苸迉1? ;朾k舥襨(W縖;N苸迉魰ibce 螿\舥襨Y6R vQ(W舥襨u}ThTg-NwQ g蛻亯\O(u 8^翂剉o僫r geY鳶諲鏃 HYPERLINK "javascript:;" Oseltamivir 0Nbs|鏃( HYPERLINK "javascript:;" Zanamivir)孴^蒪s|鏃(Peramivir) ADDIN NE.Ref.{D26BC0C4-7724-4180-BC2F-FE36B8941C13}[11-13]01.1 o冦N≧汻f[耂peh?-1 ^y蟸(lx憫b6RBR;N亯o冦N≧汻f[耂peo僫rT饄@團m藛}v觺T噑鉔"鉙guir)R(uJSpg抍膌eY鳶諲鏃烻媁o僫r觺T噑:N42%蟸潃乷憊憀廁NeY鳶諲鏃x懶v ^梒yp450剉昢ir孴慴6RBR75%剉賬o兿懴~x懶vb__蹚eQSO猒痵烻媁JSpg1^3 hx懶v剉JSpg6^10 h99%蟸線ndNbs|鏃觺T噑10%*g裿Km0R鉔"導NirS8TeQ鰁8TeQ蠎4%^17%珗hQ珟8T6e@n2.5^5.1 hhQ钀錘烻媁蟸線nd^蒪s|鏃SOY觺T噑30(WSO匭 gf>f鉔"Y ?uo坢d朖Spg:N20 h^蒪s|鏃90%蟸線亽c膌1.2 梑舥襨悢^翄h?-2 ^y蟸(lx憫b6RBR;N亯梑舥襨悢^翄o僫rT饄籰梪筫Hh剺2柟eHheY鳶諲鏃eY鳶諲鏃yb芉(u嶯b篘孴e"1乗?Q鍅剉2u媁孴YN媁Ama蔛統AmaeY鳶諲鏃b篘孴e"13乗R梩^剉2u媁孴YN媁Ama剉剺2柺S統AmaNbs|鏃yb芉(u嶯b篘孴e"7乗?Q鍅剉2u媁孴YN媁Ama籰梪(u嶯b篘孴5乗?Q鍅剉2u媁孴YN媁Ama剺2^蒪s|鏃^蒪s|鏃(W鶴皊Ama莡秗剉48 h匭 ;N亯(u嶯Ama舥襨_w崉vnf怉mL?`a扱02u媁AmL?`a扱 _N颯錘(u嶯eY鳶諲鏃N齹6R剉蛻媁Ama-1.3 亂(u孴Na(u篘h?-3 ^y蟸(lx憫b6RBR亂(u孴Na(u篘o僫rT饄亂(u孴Na(u篘eY鳶諲鏃鵞o兞T菑Oe€亂(uNbs|鏃1.鵞Nbs|鏃bsN謡菑Oe€亂(u2. g|T8TS惥u舥b\o(W|T8TS惥u舥俌頣楿0ba'`;朸X'`簚緐舥 €Na(u3.^y蟸緗^y舥騍€Na(u^蒪s|鏃鵞,gobvQ諲^y蟸(lx憊憫b6RBR g菑Oe騍€亂(u1.4 8^翂剉o僫r(u誰(u蠎h?-4 ^y蟸(lx憊憫b6RBR(uo児eHh ADDIN NE.Ref.{C4D2B188-DEAC-4B34-8770-EF0A0AFE9B75}[12,14-15]o僫rT饄籰梪筫Hh剺2柟eHheY鳶諲鏃75 mg 鉙g bid 迯(u5 d1乗?Q鍅╟P傿R蠎0^8g劅 蟢!k3.0 mg"kg-1 bid9^11g劅 蟢!k3.5 mg"kg-1 bid 梪 z5 de"1乗?Q鍅╟P傿R蠎SO(嵪15 kg 蟢!k30 mg bidSO(嵪?5^23 kg 蟢!k45 mg bidSO蛻 23^40 kg 蟢!k60 mg bidSO(嵪40 kg 蟢!k 75 mg bid 梪 z5 d75 mg qd 梪 z10 d N厤菑6hTNbs|鏃10 mg 鉙g bid 梪 z5 d10 mg qd 梪 z10 d10 mg 8TeQ bid 梪 z5 d禰璣 O璬10 mg 8TeQ bid 梪 z10 d>y:S O璬10 mg 8TeQ bid 梪 z10 d 颯錘Tv^^蒪s|鏃{徢u300 mg Y 侓n鑜 qd 鬾鑜鰁魰N\嶯30 min蛻莡600 mg Y 侓n鑜 qd 1^5 d 鬾鑜鰁魰N\嶯40 min?Q鍅US!kBR蠎10 mg"kg-1 vQ諲 Tb篘-1.5 o僨[裿匭筟h?-5 ^y蟸(lx憊憫b6RBRo僨[裿匭筟o僫rT饄No偼S擽yr妅篘(uoeY鳶諲鏃g8^翂No偼S擽S靊v`胈0UTT孴4Y踰 'YYpe€齹陙L銐%N蛻No偼S擽S靊胈媉1Y8^0kv雞裇\O0_8^L圍N 緗^y晀N0坢SS慂Q@0鶴@?`觺爛巔0潃巔I{潃/線烺齹NhQ(u嶯{?N潃烺齹NhQ€ N梺宼eBR蠎(u嶯%N蛻潃烺齹NhQ€剉塠hQ'`孴o冦N≧汻f[\*gxvz線烺齹NhQ€O(u翂h?-6?Q鍅 g╟P?^11*NgtZ?QO(ueY鳶諲鏃 ADDIN NE.Ref.{A9C9B754-8563-48A6-A93E-E1C4C93B03C6}[16]奩 Zg/鶷sNg1.FDA奩 ZgC 顅MR*g gfnx翄nch圍yeY鳶諲鏃鵞U[嘫Ou螛i2.鶷sNgLR eY鳶諲鏃蔛vQ鉔"導Nir颯嶯sNAl-N纇鶴 FOSm儚NO NO_w峴N?Q襨'`蚐擽€t^篘€t^篘Nt^{徍N鴙詋€(uo儔[hQ'`孴 gHe'`鄀;`SO頬_Nbs|鏃8^翂No偼S擽S靊胈媉NP Uf |T8T鹼邁莡秗 寑墍細踰 sQ倐踰 薽鬩苸迉螿\ 4Y踰 4YUf 脌爛S惽u秗 -N胈抾苸迉螿\ h兓灩u 3€a觛 瞮&P 裇韕 b楄?l縺I{潃線烺齹NhQ鄀宼eBR蠎?Q鍅7乗?Q鍅O(u,go兓l梪Ama剉塠hQ'`孴 gHe'`\Nfnx奩 Zg/鶷sNg奩 ZgC Na(u ADDIN NE.Ref.{8154265C-4022-4CBB-B613-DFAECCD4A3A3}[17]顅MR:ON鶷sNg嘫sYO(uNbs|鏃剉鴙sQxvz Na(u€t^篘e"65乗€t^€O(uNbs|鏃剉蟸寶 gP 擽Na(uv^芠R裿Km^蒪s|鏃N,No偼S擽S靊胈5u_8^ @堉|GS貧 藛}v?\ 脌爛S惽u秗 畍菑Oe 邩ir!j蕓%N蛻No偼S擽S靊OKQ }v苸迉螿\ -N'`抾苸迉螿\ 磃裇'`潃巔 臑竨 Stevens-Johnson鼅T乢 %`'`線p堩z 緗^y^y蟸莡秗I{潃線烺齹NhQ線烺齹湒峹€Na(u wQSO翂h?-7?Q鍅NOSO蛻?Q 癳u?Q(uo儎v塠hQ'`\Nfnx奩 Zg/鶷sNg奩 Zg(uoR:NC 奩 Zg嘫sYNa(u\*gfnx,go儚柡N{|sNAl抍膌 鶷sNg嘫sYNa(u€t^篘€t^篘潃 線b胈烺齹螿 擽Na(u,goh?-6 eY鳶諲鏃鰛蔞 齎匭b篘線烺齹NhQ€(uo宼e寑Pnd枃s/mL"min-1籰梪筫Hh剺2柟eHh6075 mg bid 5 d75 mg qd30^6030 mg bid 5 d30 mg qd10^3030 mg qd 5 d30 mg,qod@埐m悙g悙gMR颯圢w嵥YBR蠎 悙gT賬圢30 mg悙gMR颯圢w嵥YBR蠎 悙gT賬圢30 mgy仠悙g悙gMR30 mgw嵥YBR蠎 蟢5 d賬圢30 mg悙gMR30 mgw嵥YBR蠎 蟢7 d賬N30 mg葉+gg線伵u*g╟P*g╟P鑜1.鵞嶯@埐m悙g€ 俌済(W悙gg魰Ama莡秗(W48 h匭燫蛻 颯錘(W悙gMR賬圢30 mgw嵥YBR蠎2.eY鳶諲鏃棙抾(W寑Pnd枃s30剉?Q鄀宼eBR蠎 寑Pnd枃s(W10^30KN魰剉?Q 蟢!k75 mg qd 5 d寑Pnd枃s10 悙g?QN╟PO(u0h?-7 ^蒪s|鏃bt^€線烺齹NhQ宼eBR蠎寑Pnd枃s/mL"min-1╟P兿k)YBR蠎/mge"5060030^4920010^2910010,{N)Y100 mg 蜰,{孨)Y_薡蟢)Y15 mgh?-8 ^蒪s|鏃?Q鍅線烺齹譙_c╟P傿R蠎/mg"kg-1,qdt^劅寑Pnd枃s/mL"min-1e"5031^4910^3010@埐m悙g鶴u^30 d61.51.01.0鐍錘0.151.0 悙gT2 h賬o31^90 d82.01.3鐍錘0.21.3鐍錘0.251.3 悙gT2 h賬o91^180 d102.51.61.6鐍錘0.251.6 悙gT2 h賬o181 d^5乗123.01.91.9鐍錘0.301.9 悙gT2 h賬o6^17乗102.51.61.6鐍錘0.251.6 悙gT2 h賬o1.6 o僨[鷁畫 h?-9 ^y蟸(lx憊憫b6RBRo僨[鷁畫o僫rT饄o僨[鷁畫eY鳶諲鏃1.g(ueY鳶諲鏃颯齹Ou_8^L圍N0緗^y晀Nb{^蓧No偼S擽 梺壽廘?N奮芠R裿Km2.eY鳶諲鏃颯N邩ir TgbR_g(u N邩ir Tg颯衏貧o僫r€譙'` 鍌€鶴皊8^翂脌爛SNo偼S擽 颯9e:NTg(u3.鍌裇皊ogo僫r FO輱粂 N!kgo凍e魰\嶯2 h (W N!kg(u鰁魰 cMRck8^BR蠎O(u N梺墳X蠎Nbs|鏃1.cknxYe瞼€O(u8TeQ緥Y08TeQo兞T闟齹(Wyr妅8TeQ緥Y-NO(u RRO(uvQ諲緥YO(u8TeQo僫r2.裿Km€/el蓇c孴|T8T慴6R剉莡秗 俌済鶴皊擽鍕蔛鰁\Po3.頣楿b€COPD €O(u梑Amao僫r鰁 郪8TeQNbs|鏃颯齹O黐魜%N蛻剉lS惿uc 郪dk鷁畫 愰beY鳶諲鏃HQL埢l梪^蒪s|鏃1.€Tv^ g緗^y緐舥 (WO(u鍕o僫r籰梪g魰 ZP}Y4N奮裿Km 臺亯鰁-Nbk籰梪2.€Tv^ g胈@垺{緐舥 dko僫roR\O(uOO烻 g緐舥v`S Ee籰梪MR擽HQ膵0O胈仧R齹 籰梪g魰鑜a裿Km胈5uch 臺亯鰁-Nbk籰梪3.@?^膲纇錱uS纇錱線0潃烺齹0@堉|05u銐(yr+RS靊@垯0@堶xN@圓旤P 4.奩 Z纇Km: 蟢g裿Km1!k 魐0R\PoT 6 *Ng2 M2粂P[怱悜b6RBR\O(u嶯2u媁Ama舥襨M2藛}v 鵞YN媁Ama舥襨鄀He M2藛}v/fAma舥襨S渷 NwQ g粂P[怱忹m'`剉渷藛}v (W舥襨Y6R剉閑g6柕k肙蹚舥襨剉1侒X M2粂P[怱悜b6RBR;朾k舥襨N縖;N苸迉渷崌T 蜰 €;朾k舥襨Y6R08^翂剉o僫r/f褢R鱬鷢孴褢RYN鷢 ADDIN NE.Ref.{5E76A7C8-D0B1-494D-8DD2-9EE27076F828}[18-19]0 2.1 梑舥襨悢^翄褢R鱬鷢0褢RYN鷢蟸g(u嶯2u媁Ama剉剺2枌T籰梪0褟t^eg彇@wM2亃豐SOV27A0S31N0A30T孴L26FI{鶴皊 顅MR郠NN@b gAmL垊v2u媁Ama舥襨(俌H3N20H1N1I{)龕鵞褢R鱬{|o僫ru哊€o?` 郪dkN峇╟PO(u鍕{|o僫r(u嶯Ama舥襨剉籰梪 顅MR(W4N奮 N;N亯(u嶯籰梪^褢頷舥€剉棨樆烓u 颯\O:N鎉薳Y鬩剉厪㏑o僫r02.2 o僨[裿h?-1 M2粂P[怱悜b6RBR剉o僨[裿o僫rT饄No偼S擽yr妅篘(uo褢R鱬鷢褢RYN鷢^y蟸鹼邁No偼S擽aw w湒峹0)wUf01Y w0qQNm1Y孖{ 0脌爛SNo偼S擽v`胈0UTT0孲邩0縊貀I{ 0@埐m鹼邁No偼S擽}v苸迉螿\0-N'`抾苸迉螿\ I{潃線烺齹NhQ{彟^線烺齹NhQ鄀宼eBR蠎 -N0蛻線烺齹NhQ梺壪Q\BR蠎 葉+gg線p垇y(u褢R鱬鷢 褢RYN鷢%N蛻潃烺齹NhQ0線p堩zCrCld"10 mL"min-1 螿蠎O(u蟢)Y100 mg ?Q鍅癳u?Q孴 1 乗錘 NtZ?Q亂(u, 癳u?Q孴 1 乗錘 NtZ?Q亂(u kv雞?Q亂(u 粸箄AmLg剉\?Q亂(u0褢R鱬鷢1^9 乗\?Q cSO(嵪?!k 1.5^3 mg"kg-1 q8h, 蟢錯BR蠎N厤菑150mgb1!k 2.2^4.4 mg"kg-1 q12h9^12 乗\?Q q12h鉙g100 mge"12 乗 (u蠎 Tb篘褢RYN鷢Gr10 乗?Q鍅 qd 蟢!k5 mg"kg-1 FO;`蠎N厤菑0.15 ge"10 乗?Q鍅 (u蠎 Tb篘奩 Zg/鶷sNg褢R鱬鷢颯惽徫€豽 鄀誰抍d桖[蝷?Q剉螛i U[嘫Na(u颯1usNAl抍膌 鶷sNg嘫sY亂(u€t^篘€t^篘潃 線b胈烺齹螿 擽Na(u,go 寑鱾US鱴x??lv憫b6RBR 鍕{|o僫r^\嶯8h鱾{|^1寳b舥襨o僫r 惽彂b6R鱴x?k臑鱾1?lv慃m'` 螿\DNAbRNA舥襨剉Y6R0鍕o僫r蹚eQ珗舥襨a觛剉苸迉匭鱴xS vQir\O:N舥襨Tbv憚v込塏慴6RBR r^pb舥襨閑gl廢_婲鯪 \O(u嶯|T8TS悧b舥襨o僫r g)R鬩鏃梘 鬴fm鏃I{ ADDIN NE.Ref.{B8C604D7-6603-4FF5-BFCF-4F24AC3A092A}[20-21]0 o冦N≧汻f[耂pe ADDIN NE.Ref.{0D746542-8AC1-4494-9FE4-8439893E3B44}[20-21] h?-1 )R鬩鏃梘蔛鬴fm鏃剉;N亯o冦N≧汻f[耂peo僫rT饄藛}v觺T噑鉔"鉙guir)R(uJSpg抍膌)R鬩鏃梘郠NNN觺T^桟YP45045%0.5^2 h30%^55%?\瞞 15%獆縊 鬴fm鏃1%^2%^桟YP4505%^9%(譙邩irq_蚑)Y 佡~o傽團mJSpg:N3.50.9\鰁 鉙g賬oTJSpg:N4.80.9\鰁863獆縊   51?\瞞 3.2 梑舥襨悢^翄 ADDIN NE.Ref.{2943A80D-16B4-4697-8D6B-479668C528B3}[22] h?-2 )R鬩鏃梘蔛鬴fm鏃;N亯梑舥襨悢^翄o僫rT饄;N亯悢^翄)R鬩鏃梘1.(u嶯|T8TST迉舥襨舥襨'`|T8TSa觛 俌簚巔 /el巔 ;煄p 絋醆巔 絋觺渷韕 鉙絋钀舥襨a觛2. 畍眜箄舥襨a觛3.AmL?`a扱4.US瘇眜箄舥襨'`覊渷巔鬴fm鏃1.鬴fm鏃;N亯(u嶯籰梪鑍苸迉舥襨a觛2.US瘇眜箄舥襨'`覊渷巔3.3 亂(u孴Na(u篘h?-3 )R鬩鏃梘蔛鬴fm鏃亂(u孴Na(u篘o僫rT饄亂(u孴Na(u篘)R鬩鏃梘1.鵞,g罷菑Oe€亂(u2.陙珟MQ玼'`潃巔€亂(u3. g0W-Nwm+岪0pR苸迉'`+岪垼`€亂(u4.饊z亷p莡秗bfnx g饊z亷p€亂(u5. g胈伵u騍bf>f胈伵u莡秗€亂(u6. g;m≧'`觺T€亂(u鬴fm鏃1.鵞,gob€?fm鏃菑Oe€亂(u2.%N蛻}v苸迉螿\莡0-N'`抾苸迉螿\莡0+岪0@\g螿\莡€Na(u3.%N蛻MQ玼烺齹:w€Na(u3.4 8^翂(u誰(u蠎 ADDIN NE.Ref.{E47D4E5D-318D-497B-9A38-BAC62DDFAE4E}[23]h?-4 )R鬩鏃梘蔛鬴fm鏃梑舥襨籰梪筫Hho僫rT饄籰梪筫Hh)R鬩鏃梘舥襨'`|T8TSa觛1.鉙g賬o 蟢!k150 mg tid 梪 z:N7 d?Q鍅蟢錯10 mg"kg-1 R4!k賬o2.Y 侓n鑜 蟢!k250^500 mg bid 蟢!k鬾鑜20 min錘 N 梪 z:N3^7 d?Q鍅蟢錯10^15 mg"kg-1 R2!k賬o3.寑墍鑜\ 1!k5^7.5 mg"kg-1 qd ba鑜\ 梪 z:N5^7 d4.8TeQ賬o ,golBR s^GW錯BR蠎20^30 mg ?Q鍅s^GW錯BR蠎15^20 mg籰梪癳媁燪秗舥襨簚巔500 mg/!k 蟢錯2^3!kY 亾忚l銐 鷁畫梪 z10 d鬴fm鏃hV榌鹹i剉€剺2朇MVa觛駤黐籰梪BR蠎5 mg"kg-1 Y 亾忚l1 h錘 N q12h 梪 z7^14 d魚c籰梪BR蠎5 mg"kg-1 Y 亾忚l1 h錘 N qd 蟢hT7 !kb6 mg"kg-1 qd 蟢hT 5 !k擽漁nc€*NSO臽礠nx歔魚c籰梪剉c韣鰁魰鑜)R鬩鏃梘墊垟BR孴\筟飝鑜\瞞錘0.9%/lS爺鑜\瞞b5%a勚|鑜\瞞z蕬:N葉Sm1 mg"mL-1b5 mg"mL-1鬴fm鏃墊垟BR孴\秐BR鑜\瞞鬾鑜葉SmN齹厤菑10 mg"mL-10 3.5 o僨[裿h?-5 )R鬩鏃梘蔛鬴fm鏃o僨[裿o僫rT饄No偼S擽yr妅篘(uo)R鬩鏃梘1.g;N亯剉襨'`/f秐@?`+岪2.N,俬Q珟No偼S擽 gNO@垕S |T8T餠緰 寑踰 sQ倐巔 畍箄 v襲 坢SNo 孲邩臽陗S f纎鵣 慴翋 @埰€ }GS貧 脌爛S惽u秗 1佈S 畍箄 ,T汻_8^ ON汻 瞮ON 裇韕 Ama莡秗I{潃線烺齹NhQ潃烺齹_8^€Na(u %N蛻潃烺齹_8^€梺塡Po線烺齹NhQBR蠎宼e 翂h?-6?Q鍅6乗錘 N?Q鍅鉙gBR蠎*g歔奩 Z/鶷sNg1.FDA奩 ZgX ,go g儚:_剉魜xu\O(u 奩 Z嘫sY亂(u,go2.鶷sNgL4 ,go\蠎颯彇sNAl抍膌 EeN╟P凓TsNg嘫sYO(u 俌?uo償^俧\P鶷sN sNAl擽"N_€t^篘65乗錘 N€篘(uo\鄀EQR剉xvzpenc N╟P€篘O(u,go鬴fm鏃g%N蛻孴g8^翂剉o僫rNo偼S擽/f@埐mf[蚐擽 S靊-N'`抾苸迉螿\莡0+岪垖T@\g螿\莡潃線烺齹NhQ潃烺齹_8^鄀宼eBR蠎 線烺齹NhQBR蠎宼e 翂h?-7?Q鍅\Nfnx?Q鍅(uo儎v塠hQ'`孴 gHe'`駤黐籰梪5 mg"kg-1 (Y楐n1 h) q12h qQ2^3hT魚c籰梪5 mg"kg-1 qd 迯韣5^7 d ;`梪 z3^4hT ADDIN NE.Ref.{71D74AE9-97C6-48FF-BF4A-36DA7CF4BE5C}[24]奩 Z/鶷sNg1.FDA奩 ZgC ,go?W╟P傿R蠎 N颯齹_w峹ub_孴趢蝷襨'` \鄀硩Y o倉Y剉奩 Zg嘫sY(uo凒[gqxvzpenc2.鶷sNgL3R \Nfnx,go?f&T彇sNAl抍膌 鶷sNg嘫sYNa(u 俌(uo償^\Pbk鶷sN€t^篘€t^篘線\t鋘菑噑M朜O (uo僊R孴(uog魰yr+R鑜a膵0O線烺齹h?-6 線烺齹NhQ鰁)R鬩鏃梘賬o傿R蠎宼eh寑Pnd枃s/mL"min-1宼eT賬o傿R蠎50鄀宼eBR蠎30^50200^400 mg qd fO(u30200 mg qdh?-7 線烺齹NhQ鰁Y 侓n鑜鬴fm鏃賬o傿R蠎宼eh寑Pnd枃s/mL"min-1R薡BR蠎/mg"kg-1魚cBR蠎/mg"kg-1e"705.0 q12h5.0 q24h50^692.5 q12h2.5 q24h25^492.5 q24h1.25 q24h10^241.25 q24h0.625 q24h101.25 NhT3!k@埐m悙gT 0.625 NhT3!k@埐m悙gT 3.6 o僨[鷁畫h?-8 )R鬩鏃梘蔛鬴fm鏃o僨[鷁畫o僫rT饄o僨[鷁畫)R鬩鏃梘1.U[嘫N擽鍕DdeQ颯8TeQ媁o僫rb`椦廲k(W蹚L?TeQ籰梪剉€2.JT鍂€f嬚`|T8T鹼邁v`S 饊z亷p 秐@?`+岪b胈乿`S剉SO乢蔛莡秗3.f婮T€(W鸑UO臽礠N亯Sb_0墊巟bSb4xo僫r鰛蔞4.)R鬩鏃梘gb'YBR蠎g(u鵞潃烺齹0@坅 gNo偼S擽 鷁畫歔g蹚L園?^膲@垻~藛}v4ls^0}v苸迉pe0@\gpe 0@埐muS潃烺齹0TSH 纇錱 $\vQ@垻~藛}v纇錱S靊(W_薡MR0籰梪,{2hT0,{4hT 5.;N亯蟸線抍膌 o僫rO(W苸迉匭膭飝pehT6.€Tv^ g胈@垺{緐舥 dko僫roR\O(uOO烻 g緐舥v`S Ee籰梪MR擽HQ膵0O胈仧R齹 籰梪g魰\O}Y4N奮裿Km 臺亯鰁-Nbk籰梪7.鵞蝷?Q剉No俼_蚑颯齹1u嶯7u'`bsY'`鎵)R鬩鏃梘_w 籰梪g魰蔛籰梪T6*Ng7u'`bsY'`擽O(u颯`怳[筫誰8.'YBR蠎擽(u颯魜胈乢c砙 鵞 g|T8TS惥u€ba'`;朸X'`簚舥b頣楿€ 颯魜|T8T餠緰0鴢踰I{ 'YBR蠎擽(u鰁芠R裿Km胈伵`礠9.)R鬩鏃梘鑜\瞞蹚eQ@埐mSm菑貧颯鶴皊秐@埌sa Ee(W'YBR蠎擽(u鰁 鬾恇a 鷁畫秐瞞Sm1 mg"mL-1 鬾鑜鰁魰亯Bl20 min錘 N鬴fm鏃1.;N亯襨'`:N抾苸迉螿\莡-N'`抾苸迉螿\莡  +岪垖T@\g螿\莡 v^f_w嶛Q@垖Ta觛 臺亯鰁椲廘圔R蠎宼e -N'`抾苸迉pe(W 500"L-1 錘 Nb@\gpe(W 25 000"L-1 錘 N鰁擽S_俧\P(uo2.(W≧ir_w嵕|P[ub螿\v^颯齹鵞篘{| bu杒汻_c砙 7u'`(W(uog魰孴(uoT髞\90 d匭擽怳[3.奩 Z剉sY'`O(u鬴fm鏃颯齹 b蝷?Q_c砙 N鷁畫奩 ZO(u0鷁畫颯齹奩 Z剉sY'`(WO(u,g罷籰梪鰁椙懼S gHe剉怳[猚絜4.鬴fm鏃嶯≧ir颯錘wQ g魜Lv'` 珗:N/fN蛓\o(W剉魜Lvir5.鬴fm鏃N齹籰a鑍苸迉舥襨a觛 FO g㏑嶯;朾k緐舥v`S 郪dk(u嶯~偹n舥€Tv^鑍苸迉舥襨a觛鰁€_€_g魚c(uo 2朾kY裇6.1u嶯鍕o g:R纎'` 怣Q舥篘剉畍b蠟渷魐鎵墊+g秗b秐瞞秗剉o僫r4 MQ玼寕俓O(u剉梑舥襨o僫r ?栐kY\(Abidol)0]xU<\yr(Nitazoxanide)0/l筓(Chloroquine)GW:N^1寗v梑舥襨o僫r |Q g裇%cMQ玼寕侜g6R0?栐kY\\O:N@堓Q }v憫b6RBR 惽彂b6RAma舥襨仠N縖;N苸迉剉崌T €;柇e舥襨剉Y6R ]xU<\yr剉\O(u:g6R顅MR\NnZi /l筓颯惽彂b6R燪秗舥襨N篘SO苸迉ACE2譙SO剉觺T 慴6R舥襨剉礝eQ ADDIN NE.Ref.{30DED8CE-6C5E-4FB3-BA46-9DAC42F63CC7}[25-28]0齎匭Y垟鵞/l筓0/l筓(u嶯COVID-19剉Yy?N奮諎寶ck(W_U\04.1 ?栐kY\0]xU<\yr0/l筓o冦N≧汻f[耂pe ADDIN NE.Ref.{0C84585A-B865-4709-8B44-00A06D03105F}[27-31] h?-1 ?栐kY\0]xU<\yr0/l筓;N亯o冦N≧汻f[耂peo僫rT饄@團m藛}v觺T噑鉔"悇_鉙guir)R(uJSpg抍膌?栐kY\89.2%^91.6%CYP3A4sQ.曘N"寁UGT1A9 潃爛猒痵輣鵞uir)R(u35.6%11.9-20.3h鉙gBR蠎N TJSpgN T 40%錘烻媁抍鶴SOY vQ-N38.9%彇獆縊抍鶴 N硩0.12%彇?\抍鶴]xU<\yr98%^99%;N亯(W潃伀堛N"孃N;m'`ir(?fU<\yr70%1^1.6 h苺Al抍膌:N;N 線亽c膌NO嶯10%/l筓55%89%蟸潃丆YP2D6, CYP3A4鉔"89%譙邩irq_蚑 2.5-10d70%蟸線抍膌35%:N烻b_  8%彇獆縊抍膌/l筓40%;N亯蟸潃丆YP2D6v戙N"73%40 d4 h4.2 梑舥襨悢^翄h?-2 ?栐kY\0]xU<\yr0/l筓;N亯梑舥襨悢^翄o僫rT饄;N亯梑舥襨悢^翄?栐kY\1.d枂N鵞2u0YN媁Ama舥襨 gHeY 貜鵞Y蛓|T8TS惻u襨GW g慴6R\O(u S靊N媁Ama舥襨0;熍u襨0z伵u襨0|T8TST迉舥襨0飃(凣Y舥襨0IlfW舥襨孴YN0N媁舥襨'`潃巔舥襨0燪秗舥襨I{ gS渷孴鄀S渷舥襨0RNA孴DNA舥襨0PH漁V崒TN漁V嵟u襨 ADDIN NE.Ref.{2CF86265-4606-4760-AF38-70C32FDCBFFE}[25]2. 0癳媁燪秗舥襨簚巔蕥梪筫Hh諎L?{mQHr ,{NHr  0\?栐kY\硚eQ癳燪簚巔b篘€N,偦l梪(uo ADDIN NE.Ref.{D570E038-576C-4D73-B855-CC54DF2DD592}[2-3]]xU<\yr梑烻k唎僫r xvzhfvQ_N/fN蛓\o(W剉梑舥襨o僫r (WAma0n彾r舥襨0YN潃孴N潃舥襨0HIV舥襨剉籰梪筫b椫S梍N歔He済 顅MR(W_U\sQ嶯癳燪舥襨筫b梽vxvz ADDIN NE.Ref.{61DE9375-A02B-46F7-A995-064DE9B9802B}[31]/l筓1.梑烻k唎僫r (WSARS0MERS02019-nCoVI{燪秗舥襨剉SOYxvz-N諷梍N歔He済 ADDIN NE.Ref.{F59DD77C-9727-4FF2-A70E-1DCAE7D97164}[32]2. 0癳媁燪秗舥襨簚巔蕥梪筫Hh諎L?{mQHr ,{NHr  0\/l筓硚eQ癳燪簚巔b篘€N,偦l梪(uo ADDIN NE.Ref.{8674CBDE-6B1F-446F-B04C-3139FD58176B}[2-3]/l筓梑烻k唎僫r 鵞Y蛓舥襨GW g慴6R\O(u 俌{vi楉p舥襨0鑋aS舥襨0~偹n舥襨 SOY g梑SARS\O(u ADDIN NE.Ref.{DBC936E8-54B9-4490-ABBD-4261A68C6BDF}[33-34] 4N奮xvz鵞nf悑W2019-nCoV{徢u\O(uv^N>fW ADDIN NE.Ref.{3D2031EB-4BB5-4D6C-91F3-E84370DF1E9E}[35-36]4.3 亂(u孴Na(u篘h?-3 ?栐kY\0]xU<\yr0/l筓亂(u孴Na(u篘o僫rT饄亂(u孴Na(u篘?栐kY\1.鵞?栐kY\蔛vQ6RBR-N厪檈菑Oe€亂(u2. g?b觺舥豐b烺齹NhQ剉€Na(u v^鑜a裿Km胈5u]xU<\yr1. g,go兦廜e騍€亂(u2.胈@垺{緐舥€Na(u3.脌爛S惥u舥€Na(u/l筓1.鵞X[(W4O裇茐Q渷b茐螒9e豐剉%`'`焨緐錘Y剉悢^翄€亂(u2.胈伵u0'`胈媉1Y8^騍0*g蟸爚ck剉NO緮@埱u孴/bNOA旲埱u b胈≧菑50 bpm €擽Na(uGrBR 亂(u鑜\BR3.蛻媁Y媁'`慹€ 鰯Q\舥 緗^y舥€Na(u4.a勚|6-鱴x??lv慂ON莡€亂(u/l筓1.鵞4-(l鶺筓IU{|STir菑Oe蔛a勚|6-鱴x??lv慂ON莡€亂(u2. gf瀀:_/l筓1.鑜\瞞臢汷Y 侓n鑜 蟢!k鬾鑜鰁魰(W1 h錘 N 亂bk\OY 仺c鑜2.颯齹O黐魜y侞l0邩2kN/c0v`胈UTTI{坢SSNo偼S擽 鷁畫欥ebmTg(u3.颯齹O黐魜茐汻!j蕓 (uo僈NMR 梺T;SuJT鍂/f&T g茐Q渷舥豐臽礠 €(uog魰俌 g茐Q渷舥豐b寑鄀汻剉SO乢孴莡秗 検S鰁孴;Su焞4.鑜a%N蛻NO@堉|螛i 俌済鶴皊NO@堉|莡秗鰁 梺壥S鰁裿Km@堉|孴籰梪5. (uog魰棓?Y裿Km@?^膲 俌鶴皊QT鯺b胈噑螿ba ,T汻 NM 螿蠎b\Po6.o僫r鴙扤\O(uN(l膫墬gT(u楐晹? hg(u 怣QN m0W臑{|T(u N梑x憃僫r魰敄4 hg(u N梣N玼讉魰敄10 d N痵b[ }T(u鰁 芠R裿Km痵b[ }剉o僫rSm 臺亯鰁\Po/l筓1.蟢錯g'YBR蠎N梍厤菑6.5 mg"kg-12.蟢!kgo償^ T鰁蹚bn?u[rvY 瀀燫€€譙'`3.颯齹O黐魜茐汻9e豐 (uo僈NMR 梺T;SuJT鍂/f&T g茐Q渷舥豐臽礠 go僊R蹚L圏w钀纇錱0(uog魰俌 g茐Q渷舥豐b寑鄀汻剉SO乢孴莡秗 擽蔛鰁孴;Su焞4.鑜a%N蛻NO@堉|螛i 俌済鶴皊NO@堉|莡秗鰁 梺壥S鰁裿Km@堉|孴籰梪5.(uog魰棓?Y裿Km@?^膲 俌鶴皊QT鯺b胈噑螿ba ,T汻 NM 螿蠎b\Po6.o僫r菑蠎b菑Oe黐魜-N襨莡秗 颯O(u/lS鯏蟢)Y8 g,R!kg(u  蟢hT3^4 d 髞籰梪\PbkTpeg7.o僫r鴙扤\O(u颯瀀燫SO匭0W貧洀Sm N鯺昋T魰g剉o僫rbvQ諲魜胈媉1Y8^o僫rT(u 颯黐魜胈媉1Y8^N梑x憃O(u魰敄4 h(l鶺謡鱾{|梑u }颯瀀:_vQ魐;栟n^y蟸寑墍4Y剉\OhQN塻|fNTv^黐魜@坥僑m NGSNM栔|oT(u鰁 鑜a裿Kmv^宼eBR蠎5 r^pb }r^pb }IFN /f:gSOa觛舥襨鰁u剉N蛓謡藛}v IFNN珗舥襨a觛苸迉 N剉r^pb }譙SO觺T 纎;m珗a觛苸迉梑舥襨藛}v鶺郪 ub梑舥襨藛}vmRNA 駤uY蛓梑舥襨藛}v 蜰 €M栥壟u襨RNA v^慴6R舥襨RNA孴藛}v(Tb 蜰 €裇%c梑舥襨\O(u ADDIN NE.Ref.{8E24EFD7-97F6-4586-B2C0-A49D3087463A}[38]05.1 o冦N≧汻f[耂peh?-1 r^pb };N亯o冦N≧汻f[耂peo兞TT饄@團m藛}v觺T噑鉔"悇_JSpg抍膌IFN-2a鄀;N亯線3.7^8.5\鰁(s^GW5.1\鰁SO匭M栥IFN-1b鄀;N亯線4.53hSO匭M栥 \蠎?\蔛獆縊抍膌IFN-2b鄀;N亯線2hSO匭M栥 乬甠蠎錘烻b_o兺懓e蹚eQ@埅_痵5.2 梑舥襨悢^翄r^pb }颯 gHe慴6R|T8TST迉舥襨0Ama舥襨0YN潃孴N潃舥襨0眜箄舥襨0篘{|sN4Y$v舥襨0-NN|T8T鼅T乢燪秗舥襨I{鵞{vi楉p舥襨0堻\W舥襨0肳ZS蒪舥襨0HIV-10臑韕舥襨04l醠'`鉙巔舥襨_N g慴6R\O(u ADDIN NE.Ref.{D17FDD27-D071-475A-8D52-42B6AE893F7C}[39]05.3 亂(u孴Na(u篘h?-2 r^pb }亂(u孴Na(u篘O(u{|+Ryr妅篘亂(u1.鵞IFN菑Oe€2.陙珟MQ玼'`ba'`潃巔€3.%N蛻胈@垺{舥騍€4.%N蛻潃線烺齹蔛託烺齹_8^€5.kv雞蔛-N^y蟸鹼邁烺齹_c$O€6.%N蛻緗^y舥;N亯:N慴翋 b g%N蛻緗^y舥騍€7.*g gHe6R剉NO@堉| 貧@堉|b謡?\舥€8.*g gHe6R剉2u秗z仧R齹螿 2u秗z仧R齹蹚€Na(u陙珟MQ玼'`緐舥鰯Q\舥 0茐Q渷舥0貧@垕S0;`苺 }51 mol"L-1yr+R/f魰苺 }GS貧:N;N剉€ 5.4 8^翂(u誰(u蠎h?-3 IFN(u嶯SASR02019-nCov0MERS籰梪筫Hh ADDIN NE.Ref.{9139D63B-0240-43DD-B011-50885A3CA269}[31,40-41]緐舥T饄籰梪筫HhMERSIFN-2a蟢hT180 g ih IFN-2b蟢hT100^180 g ihIFN1a0.25 mg/mL/d ihSASRIFN100NU/d imbih 2019-nCovIFNS8TeQ╟P儂zl婼)b'lq毠e誰 b篘蟢!k500NUb鴙S_BR蠎50 g 燫eQmp虄鑜\(u4l2 mL bid?Q鍅BR蠎IFN 20N^40NU/kgb2^4 g"kg-1 燫2 mL鑜\(u4l bid 梪 z5^7 dIFN2b稶2br^pb }稶BR?u嶯憉SOh坆楋ye"0.9 m2 300mg/75mg Bid2乗錘 N?Q鍅 0.9 m2>SOh坆楋ye"0.6 m2 200mg/50mg Bid鉙g秐瞞14錯-6g?Q鍅16/4mg/kg/!k Bid6*Ng錘 N-18乗?Q鍅SO蛻d"15kg12/3mg/kg/!kBidSO蛻 15k ,68:>@DFHJ€  R f D F L N T 礓赝耐耐劁镐瑫寱瑫瑫瑫儠tltZt"hQB*H*KHOJ^JaJphhQOJQJjh? hhOJQJUh豦OJQJo(h~BOJQJo(h? hhOJQJo(h? hWOJQJh? hWOJQJo(hU(h{H!OJQJo(h霮OJQJo(hU(hU(OJQJhU(hU(OJQJo(hU(OJQJo(#hL4hhCJ OJPJQJaJo( HJJL`  $$Ifa$gd?dgd? dゐgdw劒dWD`劒gd~\劏dWD`劏gd~\ & Fdゐgdw劋dWD`劋gd~\劋WD`劋$a$gdL4T b t v @ B L N P R \ ^ ` d j p 箸筠缫箸没茅苗濈戠没茅脜殷溢濈髚pgp^hi8UOJQJo(h5UOJQJo(h? h{H!OJQJo(hw"OJQJo(h? h蝵aOJQJo(h)_h)_OJQJo(h? h(OJQJo("hQB*H*KHOJ^JaJphhQOJQJjh? hhOJQJUh? h?FOJQJo(h~BOJQJo(h? hhOJQJo(h? h$dGOJQJo($ 04RV|~68DFHJLN^` (BDxz鲫揸拚奚奚藿奚蕻Ξ敭迚乼fY迚迚蕻壆h^mh~\OJPJQJh^mhhOJPJQJo(h^mh蠬OJPJQJh? hho(h? hhOJQJ"hQB*H*KHOJ^JaJphhQOJQJjh? hhOJQJUh? h(OJQJo(h? hOJQJo(hU(OJQJo(h? hhOJQJo(h? h$dGOJQJo(h O8OJQJo("z| xz箬勹筚栀箬袤梵傺倏俪珴悅wi[h蠬hoXOJPJQJo(h蠬hhOJPJQJo(hoXOJPJQJo(hoXhoXOJPJQJo(hoXhoXOJPJQJh? hoX5丱JQJo(hhOJQJh~\h~\OJQJo("hQB*H*KHOJ^JaJphhQOJQJjh? hhOJQJUh? hhOJQJh? hhOJQJo(  $&(DFLNhj~€涫浜『『『唟mc唟哻唌唌啍{唟哻唌唌h?OJQJaJh?h?OJQJaJo(h?OJQJaJo(h?hhOJQJaJo(h?h?OJQJaJh?hh5丱JQJaJh顰5丱JQJaJh?hh5丱JQJaJo(3h?h蠬5丱JQJ\乛JaJfHq 6h?hh5丱JQJ\乛JaJfHo(q &&>z[OOOOOO $$Ifa$gd?kd$$IfT攂謭?n x ?€o€€€€U€6644 layt?奣:Rh[OOOOOO $$Ifa$gd?kd$$IfT?謭?n x ?oU6644 layt?奣hjt[OOOOOO $$Ifa$gd?kd$$IfT謭?n x ?oU6644 layt?奣絷芟芟芰宫墶cI3h?h蠬5丱JQJ\乛JaJfHq 6h?hh5丱JQJ\乛JaJfHo(q h? hoX5乷(h蠬hhOJPJQJo(h蠬OJPJQJh蠬OJPJQJo(h蠬h蠬OJPJQJh? hh5h?h?OJQJaJo(h?hhOJQJaJh?hhOJQJaJo(h?OJQJaJh?OJQJaJo($[VL@ d$Ifgd蠬 dゐgdwdkdq$$IfT敿謭?n x ?oU6644 layt?奣"&8:BFfhjl  "&<PRTVt淙阀阀檵檵€s檵檚媭s檚媠fs檵檵檚€檚媐s檧h?h?OJQJaJh?hhOJQJaJh?OJQJaJo(h?h?OJQJaJo(h?hhOJQJaJo(h?hh5丱JQJ\乤J!h?hh5丱JQJ\乤Jo(6h?hh5丱JQJ\乛JaJfHo(q 6h?h蠬5丱JQJ\乛JaJfHo(q ($&0:DF8hkd$$IfT諪??€ D6    44 laytyI奣$d$Ifa$gd碈s $d$Ifa$BkdD$$IfT??644 layt?奣FP(xhkd8$$IfT諪?? D6    44 laytyI奣$d$Ifa$gd?$d$Ifa$gd謕(*4vg$d$Ifa$gd?$d$Ifa$gd?$d$Ifa$gd謕jkd$$IfT斱諪?? D6    44 laytyI奣{8Bkd$$IfT??644 laytu2奣$d$Ifa$gd:8 dゐgdwhkdH$$IfT諪?? D6    44 laytyI奣",<麝苷枪畳x抙WG9.h:8OJQJaJo(h:8hhOJQJaJo(h:8hh5丱JQJ\乤J!h:8hh5丱JQJ\乤Jo(h:8hhOJQJ\乤Jo(3h:8h:85丱JQJ\乛JaJfHq 6h:8hh5丱JQJ\乛JaJfHo(q hoXOJPJQJo(h:8hhOJPJQJo(h:8h:8OJPJQJo( h:85乷(h蝦h:8OJPJQJo(h蝦h:8OJPJQJh? hh5 ",>v d$If$d$Ifa$gd謕Ukd6$$IfT??G?644 laytu2奣$d$Ifa$gd碈s $d$Ifa$>@Jj<Wkd*$$IfT斱??G?€644 laytu2奣$If$d$Ifa$gd謕Ukd$$IfT??G?€644 laytu2奣<@JLNhlnp  "$*.箦涨记箦俭弩逭澹泿€ykaQCh:8hh5丱JQJaJh:8hh5丱JQJaJo(h? hoX5乷(h:8hhOJPJQJo( h:85乷(h蝦h:8OJPJQJo(h蝦h:8OJPJQJh? hh5?h:8hhOJQJ^JaJfHo(q h:8OJQJaJo(h:8hhOJQJ\乤Jh:8hhOJQJ\乤Jo(h:8hhOJQJaJo(h:8hhOJQJaJ$v$d$Ifa$gd鉱 dゐgdwdUkd$$IfT??G?€644 laytu2奣$If$d$Ifa$gd謕.2JL  襻卫潍螞妟妟l沴a汿D?h&u<OJQJ\乤Jh:8hyIOJQJ\乤Jo(h&u<OJQJ\乤Jo(h:8OJQJ\乤Jh:8hhOJQJ\乤Jh:8hh5丱JQJ\乤J!h:8hh5丱JQJ\乤Jo(h:8hhOJQJ\乤Jo((h:8hQB*H*KHOJ^JaJphh:8hQ5丱JQJaJ$jh:8hh5丱JQJUaJh:8hh5丱JQJaJo(h:8h:85丱JQJaJ@dkdw$$If諪?? 6    44 layt碈s$d$Ifa$gd碈s $d$Ifa$>kd$$If??644 layt |\M$d$Ifa$gd:8fkd $$If?諪?? 6    44 layt1tL$d$Ifa$gd&u<$d$Ifa$gdyI$d$Ifa$gd$d$Ifa$gd( "$&PRVZ\b|~ "$24:@DH翡粼淝浼浏洧漪浼挴洧掫卿呍鋤鋤洧鋮鋤鋤洧鋤鋤洧鋮h鉱 OJQJ\乤JhyIOJQJ\乤Jo(h:8h&u<OJQJ\乤Jo(h&u<OJQJ\乤Jo(h&u<H*OJQJ\乤Jh&u<OJQJ\乤Jh鉱 OJQJ\乤Jo(h鉱 h鉱 OJQJ\乤Jo(h:8hhOJQJ\乤Jo(hOJQJ\乤J0HJNP`bhpz|~€ .24@FNPRTV`dfrx疣锗锗揉亨函啶嗾鄺亨赫嗳嗾嗪锗む锗赫嗳嗾嗪锗揉赫鄬嗪锗h1tLOJQJ\乤Jh鉱 OJQJ\乤Jo(h&u<OJQJ\乤JhOJQJ\乤Jh:8hhOJQJ\乤Jh&u<OJQJ\乤Jo(h鉱 OJQJ\乤Jh:8hhOJQJ\乤Jo(h鉱 h鉱 OJQJ\乤Jo(7$V|m^^$d$Ifa$gd1tL$d$Ifa$gd:8$d$Ifa$gd(hkd $$If4攇諪??` 6    44 layt1tL d$Ifgd&u<x€  ":<@BFJV^`hj疴尊署怵尊筐尊尊筐署尊尊尊囀饄lahyI5丱JPJQJh蝦hyIOJPJQJh? hh5丆JaJo(h&u<H*OJQJ\乤Jh:8h&u<OJQJ\乤Jo(h&u<OJQJ\乤Jh:8h鉱 OJQJ\乤Jo(h&u<OJQJ\乤Jh鉱 OJQJ\乤Jo(h鉱 OJQJ\乤Jh:8hhOJQJ\乤Jh:8hhOJQJ\乤Jo($X\yj$d$Ifa$gd1tL$d$Ifa$gd&u<$d$Ifa$gd(hkd> $$If4斳諪??  6    44 layt1tL\^`zz7Bkd| $$IfT??644 laytu2奣$d$Ifa$gdyI dゐgdwdfkd $$If數諪?? 6    44 layt碈sjlxz€.胥张珐放檱vfvfTF?hyIhhOJQJ\乤JhyIhhOJQJaJo("h? hh5丆JOJQJ\乤JhyIhh5丱JQJ\乤J!hyIhh5丱JQJ\乤Jo("h? hhCJOJQJ\乤Jo(hyIhhOJQJ\乤Jo(hyIhyI5丱JQJaJhyIhh5丱JQJaJhyIhh5丱JQJaJo(hyIhoXOJPJQJo(hyIhhOJPJQJo(hyIhyI5丱JPJQJn~{l]Q]] $$Ifa$gd['L$d$Ifa$gd['L$d$Ifa$gd(hkd $$IfT諪?Y?d` 6    44 layt碈s奣$d$Ifa$gd碈s $d$Ifa$ .ln(*PRTVX`箝坌勐槽③Ⅲ⒙亸l徛槽③衉坌虏邰坌虏hyIhhOJQJaJ(hyIhQB*H*KHOJ^JaJphhyIhQOJQJ\乤J$jhyIhhOJQJU\乤JhyIhhOJQJ\乤Jo(h? hhCJOJQJ\乤JhyIhhOJQJ\乤Jh['LOJQJaJo(hyIhhOJQJaJo(hyIhh\乤Jh['LOJQJ\乤Jo(%€qbVb $$Ifa$gd['L$d$Ifa$gd['L$d$Ifa$gd(kd $$IfT4旝謀?Y?`d``f]644 laytu2奣R€qbVCC$d$Ifa$gd['L $$Ifa$gd['L$d$Ifa$gd['L$d$Ifa$gd(kdr$$IfT4擠謀?Y? d `f]644 laytu2奣RTVX`€qbVC$d$Ifa$gd['L $$Ifa$gd['L$d$Ifa$gd['L$d$Ifa$gd(kdP$$IfT4攨謀?Y? d `f]644 laytu2奣BP^€qbbV $$Ifa$gd['L$d$Ifa$gd['L$d$Ifa$gd(kd.$$IfT4攁謀?Y? d `f]644 laytu2奣@P\^`bjln.08:<fjlnprxz|襻葬舍否岌嵩岱襻襻駯墫t杅裨岱襻襻Xh['Lh['LOJQJaJo(h['LhhOJQJaJo((hyIhQB*H*KHOJ^JaJphhyIhQOJQJaJ!jhyIhhOJQJUaJh['Lh['LOJQJ\乤Jo("h? hhCJOJQJ\乤Jo(h['LOJQJaJo(h['LOJQJ\乤Jo(hyIhhOJQJ\乤Jo(hyIhhOJQJaJo("^`bdj€qbbb$d$Ifa$gd['L$d$Ifa$gd(kd$$IfT4 謀?Y?`d``f]644 laytu2奣<l€qbbVV $$Ifa$gd['L$d$Ifa$gd['L$d$Ifa$gd(kd$$IfT4敹謀?Y? d `f]644 laytu2奣lnprz€qbbV $$Ifa$gd['L$d$Ifa$gd['L$d$Ifa$gd(kd$$IfT4敩謀?Y? d `f]644 laytu2奣|€t !!"!^!`!b!l!n!??????矜帜裰分瀳炛鸟謭帜裰瀳帜裰堉膥m]h1yhh5丱JQJ\乤J!h1yhh5丱JQJ\乤Jo(h? hh5乷(*h['LOJQJ^JaJfHo(q 0hyIhhOJQJ^JaJfHo(q h['LOJQJ\乤Jo("h? hhCJOJQJ\乤Jo(hyIhhOJQJ\乤Jo(h['LOJQJaJo(hyIhhOJQJaJo(  €qeVe$d$Ifa$gd['L $$Ifa$gd['L$d$Ifa$gd(kd$$IfT4斄謀?Y? d `f]644 laytu2奣 €q_qN$$7$8$H$Ifa$gd['L$劋$IfWD`劋a$gd['L$d$Ifa$gd['Lkd$$IfT4攛謀?Y?`d``f]644 laytu2奣 !!`!€q_qS $$Ifa$gd['L$劋$IfWD`劋a$gd['L$d$Ifa$gd['Lkd$$IfT4謀?Y? d `f]644 laytu2奣`!b!d!f!n!?€q_qS $$Ifa$gd['L$劋$IfWD`劋a$gd['L$d$Ifa$gd['Lkdx$$IfT4?謀?Y? d `f]644 laytu2奣??????"€{lYYY$d$Ifa$gd1y$ da$gd1ydkdV$$IfT4攎謀?Y? d `f]644 laytu2奣???????????????" " """"""$"("*","2"4"筲意衣番啌聯聯xk]kS]S]I]kShawOJQJaJh1yOJQJaJh1yhhOJQJaJo(h1yhhOJQJaJh1yh1yOJQJaJo(h1y5丠*OJQJaJh1yhh5丱JQJaJh1y5丱JQJaJh(5丱JQJaJh1y5丱JQJaJh1yhh5丱JQJaJo(h1yhh5丱JQJ\乤J!h1yhh5丱JQJ\乤Jo(h1y5丱JQJ\乤J" ""."@"$d$Ifa$gd1yhkdB$$IfT諪??€E€€|6    44 layt[z奣4":">"B"D"F"H"N"P"R"T"Z"`"d"f"h"j"l"n"p"v"z"~"€"???????????????????????????#####"#$#,#.#0#B#D#F#L#N#P#T#V#^#`#b#t#v#x#~#€#??????耒隈谙隈阽耒耒褛褛珩缵褛馅褛珩珩珩隈阽褛乡隈隈阽褛褛珩隈隈阽裣珩阽褛褛珩乡褛珩隈隈h1yOJQJaJo(h1yhhOJQJaJh1yOJQJaJh1yhhOJQJaJo(R@"B"N"j"|"$d$Ifa$gd1yhkd$$IfT諪??E|6    44 layt[z奣|"~"???$d$Ifa$gd1yhkdb$$IfT諪??E|6    44 layt[z奣????#$d$Ifa$gd1yhkd$$IfT諪??E|6    44 layt[z奣##$#V#?$d$Ifa$gd1yhkd`$$IfT諪??E|6    44 layt[z奣?????tt$d$Ifa$gd1y$d$Ifa$gd1yhkd$$IfT諪??E|6    44 layt[z奣?????%%ym $$Ifa$gdaw $$Ifa$gd?$a$gdawdhkd^$$IfT諪??E|6    44 layt[z奣???????$$,$.$V$X$p$r$x$z$|$€$??????????筱阅点缘隳隳愕隳点点你ㄣ檥c}3hawhaw5丱JQJ\乛JaJfHq 6hawhh5丱JQJ\乛JaJfHo(q h? hhCJOJQJaJhLhCJOJQJaJo(hLhhLhCJOJQJaJhLhhLhCJOJQJaJo(hLhhhCJOJQJaJhLhhhCJOJQJaJo(h1yhhOJQJaJ????????% %%%%%%&%(%,%逅讲そ攞薲藍K4K4K-hawhawOJQJ^JaJfHq 0hawhawOJQJ^JaJfHo(q -haw5丱JQJ^JaJfHo(q 0hawhaw5丱JQJ^JaJfHq hawhaw5丠*OJQJaJhawhaw5丱JQJaJh(5丱JQJaJhawhaw5丱JQJaJ3hawhaw5丱JQJ^JaJfHo(q 3hawhh5丱JQJ\乛JaJfHq %%%&%(%4%<%CQkdd$$If??)?€ 644 laytaw $$Ifa$gdaw $$Ifa$gd?Qkd$$If??)?€ 644 laytaw,%.%2%4%<%>%B%D%H%J%R%T%Z%h%j%n%?????????暄貉貉暄貉貉害押ρ簭sYs@0hce5丱JQJ\乛JaJfHo(q 3hu2haw5丱JQJ\乛JaJfHq 6hu2hh5丱JQJ\乛JaJfHo(q -hh5丱JQJ\乛JaJfHq 'hawOJQJ^JaJfHq -hawhawOJQJ^JaJfHq 0hawhawOJQJ^JaJfHo(q *hawOJQJ^JaJfHo(q <%>%J%R%T%\%?CQkdH$$If??)?€ 644 laytaw $$Ifa$gdaw $$Ifa$gd?Qkd$$If??)?€ 644 laytaw???????6Wkd,$$IfT4??? 644 laytce奣 $$Ifa$gdu2 $$Ifa$gdaw$a$gdawQkd$$If??)?€ 644 laytaw???????????????疣暇稷抶j_QjA1hawhh5丱JQJaJo(hawhu25丠*OJQJaJhawhu25丱JQJaJh(5丱JQJaJhawhu25丱JQJaJ3hawhh5丱JQJ^JaJfHo(q hu2hh5丱JQJaJo(6hcehh5丱JQJ\乛JaJfHo(q !hcehce5丠*OJQJ\乤J!hcehce5丱JQJ\乤Jo(hcehce5丱JQJ\乤Jhcehce5丱JQJaJo(??&&&"&,&.&Dkd$$IfT4謭?  .?  Y#644 laytce奣 $$Ifa$gdu2 $$Ifa$gdaw??&&&& &&&&&&,&.&2&4&8&:&<&>&@&B&H&J&L&P&R&T&X&h&l&n&v&x&z&~&€&褙笋礼笋礼柴ゑ旕缞笋笋u笋u駅`u袼h^mOJQJaJo(h^mOJQJaJhceOJQJaJhceOJQJaJo(hu2OJQJaJhawhhOJQJ\乤Jo(hawh^mOJQJaJo(hu2hu2OJQJaJo(hu2OJQJaJo(hawhhOJQJaJ0hawhhOJQJ^JaJfHo(q hawhhOJQJaJo($.&>&B&J&R&f&€&?Ekd$$IfT謭?  .? Y#644 laytce奣 $$Ifa$gdce $$Ifa$gdaw€&????????????????????????????????'''''"'$'*','.'0'4'6'8'箦斟死宄濠冲涘冲涘愬叐鍂逭謇隋冲冲冲涘愬泤鍂hawh^mOJQJaJo(hceOJQJaJo(h^mOJQJaJo(hawhceOJQJaJo(hceOJQJaJhawhhOJQJaJhu2OJQJaJo(hu2OJQJaJhawhhOJQJ\乤Jo(hawhhOJQJaJo(hawh^mOJQJaJ.????????EkdW$$IfT謭?  .? Y#644 laytce奣 $$Ifa$gdce $$Ifa$gdu2???'''6'8'Ekd $$IfT謭?  .? Y#644 laytce奣 $$Ifa$gdce $$Ifa$gdu28'>'@'B'D'N'P'V'X'^'`'f'j'p'r't'z'|'?????????????????????????矜芴窨窨窨癖瘰狂滖睉嚤駓裉窨窨癖駵癖憞瘪yqh? hh5hawh^mOJQJaJo(hceOJQJaJhceOJQJaJo(h^mOJQJaJo(h顰OJQJaJhawhceOJQJaJo(hawhhOJQJaJhawhhOJQJ\乤Jo(hu2OJQJaJhu2OJQJaJo(hawhhOJQJaJo(*8'J'P'X'`'t'??Ekd $$IfT謭?  .? Y#644 laytce奣 $$Ifa$gdce $$Ifa$gdaw??????? $$Ifa$gd^m $$Ifa$gdce $$Ifa$gdaw???? (]XQB$d$Ifa$gd顰ゐgdwdkd?$$IfT謭?  .? Y#644 laytce奣??????(((("(4(8(B(F(T(????)))皲萃贸硦yi[P[E[;[E[;h?OJQJaJh顰OJQJaJo(h?OJQJaJo(h顰hhOJQJaJo(h顰hh5丱JQJ\乤J!h顰hh5丱JQJ\乤Jo(h顰hhOJQJ\乤Jo(h顰5丱JQJaJh顰hh5丱JQJaJh顰hh5丱JQJaJo(h? hh5乷(h蝦hhOJPJQJ\乷( h蝦5乗h蝦h蝦OJPJQJh蝦h蝦OJPJQJo( ("(,(6(8(B(?)P@@=d$Ifgd?Qkd?$$If???644 layt$d$Ifa$gd碈s$d$Ifa$gd>kdi"$$If??644 layt顰).)0)2)^)b)l)p)????** ***<*z*~*???????+N+P+T+t+v+??????????矜苕务民骜面畅駵矜绸民咇叐矜湬矜瘵民骜娉}oh顰h顰OJPJQJo(h? hho(-h顰hhOJQJ^JaJfHq h顰hhOJQJaJh?OJQJaJh顰hhOJQJ\乤Jo(h?OJQJaJo(h顰hhOJQJ\乤Jh顰OJQJaJh顰OJQJaJo(h顰hhOJQJaJo(*)`)b)l)?*|* $Ifgd?$d$Ifa$gdQkd9#$$If???644 layt=d$Ifgd?|*~*??P+???AQkd$$$If???644 layt $Ifgd?$d$Ifa$gdSkd?$$If斱???644 layt???X-r-????//sgX$d$Ifa$gd碈s $d$Ifa$Bkd?$$IfT??644 laytM奣$d$Ifa$gdMゐgdw$劋dpWD[$\$`劋a$dgd[z劋dWD`劋gd顰 dゐgdKbr ????x,?????B-D-R-T-X-Z-b-d-j-n-p-r-箦筘守守汞節故貚€n^O?h? hh5丱JQJ\乤Jh顰OJPJQJ\乤Jo(h顰hhOJPJQJ\乤J"h顰hhOJPJQJ\乤Jo(h顰5丱JQJ\乤Jh顰h顰OJPJQJ\乤J"hQB*H*KHOJ^JaJphhQOJQJaJ!jh? hhOJQJUaJh? hhOJQJaJo(h? hhOJQJaJh顰hhOJPJQJo(h顰h顰OJPJQJr-?????????????? ////箦笤虏厳uguWF6F6hhh5丱JQJ\乤J!hhh5丱JQJ\乤Jo(hhhOJQJ\乤Jo(hhM5丱JQJaJhhh5丱JQJaJo("h顰hhOJPJQJ\乤Jo(h? hh5丱JQJaJo(h顰5丱JQJaJh顰h顰OJPJQJ\乤J"h顰hhOJPJQJ\乤Jo( h? hhCJKHOJQJaJh? hhCJKHaJo(h? hhCJKHaJ///(/2/??,0?xxlff] $Ifgd;$If $$Ifa$gdht4$d$Ifa$gdht4hkd?$$IfT諪?. ?(*56    44 layt?奣$d$Ifa$gd碈s/&/(/0/2/??????0P0R0T0V0Z0\0`0b0h0l0x0|0???????????箧筘筘特筘筘仑簇姗溫庁冐尕筘s伢鎕Yh? hbCJOJQJaJhbOJQJaJo(hhhOJQJ\乤Jo(h;OJQJaJo(hhtH*OJQJaJhhtOJQJaJh(OJQJaJo(hhtOJQJaJo(h;OJQJaJhhh\乤Jo(hhhOJQJaJo(hhtOJQJaJhhhOJQJaJ"???????J2€tkeee\ $Ifgdt$If d$If $d$Ifa$kd?$$IfT4旝謀?. !?`(`*8 644 laytht4奣?????11214181<1>1@1B1D1F1H1b1f1h1€1???????????????????22 222,20262H2箦箦咨准桩咨住杮笞勺忌勺∽勺∽勺勺勺勺杉僧咨咨4hbB*CJOJQJ^JaJfHph333q hbOJQJaJo(hhtOJQJaJhhtH*OJQJaJhhtOJQJaJhhtOJQJaJo(hhhOJQJaJo(hbhbOJQJaJo(hbhbOJQJaJ0J2L2N2P2`2?€tkeLd$-DIfM [$\$$If d$If $d$Ifa$kdp&$$IfT4擠謀?. !? (*8 644 layt奣H2L2N2P2`2r2???????????333??X4蹒诅塘初缱鐪愼倁gu\PA9hQOJQJjh? hhOJQJUh? hhOJQJo(h顰5丱JQJo(h顰hhOJPJQJo(h顰h顰OJPJQJh? hh5丱JQJo(hhhCJ\乤J,hhtCJ^JaJfHo(q hhhCJ\乤Jo(hhtCJaJhhhCJaJhhhOJQJ\乤Jo(hhhOJQJaJo(hhh\乤J??????€tkeLd$-DIfM [$\$$If d$If $d$Ifa$kdF'$$IfT4攨謀?. !? (*8 644 layt奣???3n4p4545€xncaWK $$Ifa$gdw & FゐgdKbr 刦WD`刦gd顰 & FゐgdKbr凕WD`凕kd($$IfT4?謀?. !? (*8 644 layt奣X4Z4h4j4l4n4p4r4€4??????55 5555疝鹨墙菠搯搈揻_OAO4Ohw5丱JQJaJo(hwh cc5丱JQJaJhwhh5丱JQJaJo( h? hw h? hh0hKbrhQB*H*KHOJPJQJ^JaJphhKbrhQOJPJQJ!jhKbrhhOJPJQJUhKbrhhOJPJQJo(hsOJPJQJo(h? hh5乷(h? hhOJQJh? hhOJQJo("hQB*H*KHOJ^JaJphjh? hhOJQJU5 52565p5z5|5????????????????????666 6666&6D6F6j6l6笞晒涩涩涩伞蓷蓷∩棥棥蓪oohpNhbCJOJQJaJo(hbCJOJQJaJo(hbOJQJaJo(hwOJQJaJhwOJQJaJo(hwhhOJQJaJhwhh5丱JQJaJo(hwhhOJQJaJo(6hwhh5丱JQJ\乛JaJfHo(q hw5丱JQJaJo(&4565@5L5R5b5j5p5 $$Ifa$gdDkd)$$IfT攁??644 laytw奣p5r5|5??????[OOOOOOO $$Ifa$gdkde)$$IfT斖謭?X %Q?d644 laytw奣????66l6?[OOOOOO $$Ifa$gdkd8*$$IfT敔謭?X %Q?d644 laytw奣l6????????77"7$7(70747<7>7F7胥芟始疂敐倽tdVdIdhof+5丱JQJaJo(hof+hof+5丱JQJaJhof+hh5丱JQJaJo(h? hh5丱JQJo("hQB*H*KHOJ^JaJphhQ5丱JQJ jh? hh5丱JQJUhof+h?OJPJQJo(hof+hhOJPJQJo( h?5hsh?OJPJQJ h? hhhwhhOJQJaJo(hbhbOJQJaJo(???(7X7[YRF $$Ifa$gdof+ゐgdwB'kd +$$IfT擽謭?X %Q?d644 laytw奣F7T7V7X7Z7d7n7p7r7z7|7???????8 8 8"8$8,8.8R8T8n8p8r8t8渌哗粶哗巵巗巋巋巋巋哗巵巋幓㈱h? hh5丱JQJo(hwB'OJQJaJo(hbhbOJQJaJo(hof+hhOJQJaJhof+hhOJQJaJo(hof+5丱JQJaJo("h? hh5丆JOJQJaJo(hof+hh5丱JQJaJo(0hof+5丱JQJ\乛JaJfHo(q 6hof+hh5丱JQJ\乛JaJfHo(q X7Z7d7p7r7|7??YMAA $$Ifa$gdwB' $$Ifa$gdwB'Qkd;,$$If??4?644 laytwB' $$Ifa$gd碈s $$Ifa$>kd?$$If??644 laytwB'?8"8$8.8V8p8r8CQkd!-$$If??4?644 laytwB' $$Ifa$gdwB'Qkd?$$If??4?644 laytwB' $$Ifa$gdwB'r8t8?????$剎$IfWD,`剎a$gd*C $$Ifa$gd*C>kd?$$If??644 laytGm $$Ifa$gdGmゐgda t8z8~8????????????99>9@9D9d9f9j9?????????:: :6:::<:箢嘈滦敌櫺媬s媠媠~is媔s媠袐~s~is媔s媉h? hh5乷(hGmOJQJaJhGmOJQJaJo(hGmhhOJQJaJhGmhhOJQJaJo(6hGmhh5丱JQJ\乛JaJfHo(q hGm5丱JQJaJo(hGmh苐65丱JQJaJhGmhh5丱JQJaJo(hof+hhOJPJQJo( h?5hsh?OJPJQJ%????9@9f9??$剢?$IfWD^剢`?a$gd*C $$Ifa$gd*CQkd?$$If??A?644 laytGm????:8:ww$勀$IfWDQ`勀a$gd*C$勣勀$IfVD?WDQ^勣`勀a$gd*C $$Ifa$gd*CQkdd.$$If??A?644 laytGm8:::<:生鼹?;;RCC$d$Ifa$gd*CBkdJ/$$IfT??644 laytoU奣$d$Ifa$gdEnゐgddEQkd?$$If??A?644 laytGm<:B:D:F:R:T:机晋批曲生漾怔蔸啁琥斛 ;;箢嵊鹿搂聸媫媘婹@0ha hh5丱JQJ\乤J!ha hh5丱JQJ\乤Jo(6ha hh5丱JQJ\乛JaJfHo(q ha ha 5丱JQJaJo(ha ha 5丱JQJaJha hh5丱JQJaJo(h? hh5丱JQJ"hQB*H*KHOJ^JaJphhQ5丱JQJ jh? hh5丱JQJUhof+hhOJPJQJo(hof+h?OJPJQJ h?5hsh?OJPJQJ;;;.;嶜<j<奎 $$Ifa$gd $$Ifa$gd*C$d$Ifa$gd*CUkd?$$IfT???644 layt*C奣;;,;.;2;:;<;F;H;N;T;^;`;p;r;v;x;|;€;侞咞孄嶜扄欫淃????蝶畸甥他啕猁沱妍觖鼷??<<< <<<&<*<.<0<6<8<<<><B<F<H<L<`<b<d<f<j<n<v<x<扅擖楛欬秉疱族族淄族淄淄酌赘遄遄妥遄遄妥遄妥遄妥遄妥米缸遄遄遄妥米缸遄遄妥妥遄遄妥hH*OJQJaJhOJQJaJhOJQJaJha hOJQJaJo(hOJQJaJo(ha hOJQJ\乤Jo(H秉滁伏裹近奎咙命冱狳妩琰顸簏觞====="=$=<=@=B=P=X=Z=^=翩荇卫棒腊腊@皹棒缞z妎奷奪Lha h轜OJQJaJo(h轜OJQJaJh轜OJQJaJo(h?OJQJaJo(ha hhOJQJ\乤Jo(ha hhOJQJaJo(hOJQJ\乤JhOJQJ\乤Jo(ha hOJQJ\乤Jo(ha hOJQJ\乤JhhOJQJaJo(hOJQJaJha hOJQJaJo(hOJQJaJo(奎咙命==$=2Ykd?$$IfT4旪??? 644 layt奣 $$Ifa$gd$d$Ifa$gd*CYkd"0$$IfT4???`644 layt|iR奣$=B=擙0>2>簋齄 ?4? $$Ifa$gddEゐgddEUkdD1$$IfT???644 layt*C奣 $$Ifa$gd*C^=b=n=p=r=x=z=~=€=咠圐孆嶟???除魁笼谬升妄?冽泯妪辇睚稞觚>>>.>2>6>圑夻嶠怇翩垩孥嫜嫫嫫婕孥焰坻坻籍翩坻郏坻搧t乯hdEOJQJaJhdECJOJQJ\乤J"h? hhCJOJQJ\乤Jo(h?hhCJOJQJaJo(hdEOJQJaJo(ha h轜OJQJaJo(h轜OJQJaJhbOJQJaJo(h轜OJQJaJh轜OJQJaJo(ha hhOJQJaJo(h轜H*OJQJaJ'怇據楟淊濥〓 ̄???唼狺妣琬膻稔颃簋齄?? ??? ?"?*?鲭偬俾鲭迟藤脉胭憚vfXfHfhdEhdE5丱JQJaJo(hdEhdE5丱JQJaJhdEhh5丱JQJaJo(hof+hhOJPJQJo(hof+h?OJPJQJhsh?OJPJQJ h? hhh? hh5丱JQJo(hdECJOJQJ\乤Jo(hdEOJQJaJhdECJOJQJ\乤J"h? hhCJOJQJ\乤Jo(hdEH*OJQJaJh(OJQJaJ*?2?R?V?Z?b?d?€????6@扏擛燖禓窣篅藹蠤闌A AA,AjAlAnA碅禔続繟訟BZB\B咮圔擝欱淏湓窃宫」椆」壒」壒椆」椆」壒壒」壒筿ghOJQJaJha hOJQJaJo(h DOJQJaJhdEhhOJQJaJo(hOJQJaJhOJQJaJo(hhhOJQJaJhhhOJQJaJo(h?5丱JQJaJo(hdEhh5丱JQJaJo(6hdEhh5丱JQJ\乛JaJfHo(q (4?6?@?J?X?Z?d?;hkd*2$$IfT諪?l?nH 6    44 layt 1奣 $$Ifa$gd? $$Ifa$gd 1Bkd?$$IfT??644 layt奣d??8@F@扏擛朄楡濦窣maX $Ifgd $$Ifa$gd 1kd?$$IfT4謀?l?`n`HU}644 layt 1奣$If$If^gd 窣篅粿継藹 AlA€tn_VV $Ifgd?$IfWD`?gdG4$If $$Ifa$gd 1kd?$$IfT4斮謀?l? n HU}644 layt 1奣lAnApArAzA碅€tnnn$If $$Ifa$gd 1kd?$$IfT4攝謀?l? n HU}644 layt 1奣碅禔繟B"BZB€tkee$If $Ifgd $$Ifa$gd 1kdQ5$$IfT4攗謀?l? n HU}644 layt 1奣ZB\B^B`BfB圔蜝奀€znzeee $Ifgd 劋$IfWD`劋$Ifkd/6$$IfT4攎謀?l?`n`HU}644 layt 1奣淏燘珺瓸藼蜝贐郆釨鍮闎霣頑CC|C~C咰圕奀孋濩菴DD DDXDZD\DhD矜厥厥朗穸矜世圣槬儱蕌世蔶世蔶蕌蔶蕌hOJQJaJo(hdEhhOJQJaJo((hhQB*H*KHOJ^JaJphhhQOJQJaJ!jhhhOJQJUaJhOJQJaJhOJQJaJhhhOJQJaJo(hhOJQJaJo(hH*OJQJaJha hOJQJaJo($奀孋嶤怌濩DZD€zn_zz?$IfWD`?gdG4 劋$IfWD`劋$Ifkd7$$IfT4攳謀?l? n HU}644 layt 1奣ZD\D^D`DhD€znzz 劋$IfWD`劋$Ifkd?$$IfT4謀?l? n HU}644 layt 1奣―谼贒€~r3>kd?$$If??644 layt? $$Ifa$gd?kd?$$IfT4斪謀?l? n HU}644 layt 1奣―癉碊銬鍰闐霥駾鯠鳧 E E&E(E4E6EEVEXEdEfEtEvE~E蜮租式菠枀鈝i^i^iTiwiTi駾h辠fhh5丱JQJaJo(h?OJQJaJh?OJQJaJo(h?hhOJQJaJo(h?h?OJQJaJo(!h?hh5丠*OJQJaJo(h?5丠*OJQJaJo(h?hh5丱JQJaJh?5丱JQJaJh(5丱JQJaJo(h?5丱JQJaJo(h?5丱JQJaJh?hh5丱JQJaJo(h? hh5丱JQJo(贒鳧E EE E"E.ETEOQkd[:$$If???} 644 layt?Qkd?$$If???} 644 layt? $$Ifa$gdHTEVE^ErEtEvE瓻OMD $Ifgd?Qkd3;$$If???} 644 layt? $$Ifa$gdHQkd旺$$If???} 644 layt?~E侲篍糆繣翬菶蘀諩谽蹺轊釫鍱鐴餎駿鯡鳨麰FFF襻郧籍犪搩u僥T釗僽僥酕hLguhLguOJQJaJo(!h筕"hh5丠*OJQJaJo(h筕"h筕"5丠*OJQJaJh筕"h筕"5丱JQJaJh筕"h筕"5丱JQJaJo(h筕"5丱JQJaJo(hLgu5丠*OJQJaJo(h?hLgu5丱JQJaJhLgu5丱JQJaJh(5丱JQJaJo(hLgu5丱JQJaJo(h辠fhh5丱JQJaJo(h辠fh辠f5丱JQJaJ瓻癊蜤鐴FF FF0FOdkd<$$If諪??y6    44 laytLgu $$Ifa$gdH>kd?$$If??644 laytLguFFFF$F&F(F.F6F8FFFHFNFPFVFXFZF`FhFjFxFzF侳奆孎嶧擣淔濬瓼癋禙腇艶蘁蠪褾 G"G*G,G4G6G>G矜矜矜伛婉尕矜矜伛婉骜骜尕裢矜伛尕窨竦嵉}ho4hh5丱JQJaJo(hof+hhOJPJQJo(hof+h?OJPJQJhsh?OJPJQJh? hh5乷(hLguhLguOJQJaJo(hLguOJQJaJo(h辠fh筕"OJQJaJo(h筕"OJQJaJo(h辠fhhOJQJaJo(+0F2F>FPFbF $$Ifa$gdHdkd孅$$If諪??y6    44 laytLgubFdFpF侳朏 $$Ifa$gdHdkd=$$If諪??y6    44 laytLgu朏楩窮蜦 $$Ifa$gdHdkd忼$$If諪??y6    44 laytLgu蜦蠪谾鶩G $$Ifa$gdHdkd >$$If諪??y6    44 laytLguG G"G6G^G`GjGF: $$Ifa$gd羑?>kd?$$If??644 layto4 $$Ifa$gdo4ゐgd?dkd咡$$If諪??y6    44 laytLgu>GBGJGLGTG\GvG~G€G凣篏糋繥腉谿贕HHH6H8HOJQJaJh羑?hhOJQJaJh羑?h眏OJQJaJhqn>OJQJaJo(ho4hhOJQJaJho4hhOJQJaJo(6ho4hh5丱JQJ\乛JaJfHo(q ho4h?5丱JQJaJo(ho4hh5丱JQJaJo(ho4h?5丱JQJaJ jGtGvG€G糋H8HI,IJ奐K-$If^gdqn> $$Ifa$gd羑?Qkdl?$$If???644 laytJO $IfgdS dI↖領JJJlJ圝奐嶫銳鍶闖霬餔鬔KKKKKKKK K$K&K0K2K6K窴篕糑綤翶躃轐銴鍷箧苕箧苕箧苕湘下存象妞栨栨栨枆苕r鎔鎟h羑?H*OJQJaJh羑?hEbOJQJaJh羑?OJQJaJho4hhOJQJaJho4hhOJQJaJo(ho4hh5丱JQJaJo(h羑?h騧{H*OJQJaJh羑?h(OJQJaJh羑?h騧{OJQJaJhqn>OJQJaJh羑?hhOJQJaJh羑?h眏OJQJaJ(KKKKKK KCUkdq@$$If4敚???  644 laytJO$If $$Ifa$gd羑?Ukd?$$If4???``644 laytJO K"K$K&K(K2KLCUkdyA$$If4斏???  644 laytJO$If $$Ifa$gd羑?Ukd魼$$If4攝???  644 laytJO鍷闗頚餕LXL\LdLfLjL歀豅贚轑MTM扢擬楳淢贛躆轒郙釳鍹﨧NNNNBNDN孨箬筵笪垠捏垠嫩筵竽筵蠖巰巜kbkbkhxlOJQJo(h? hhOJQJo(hEb5丱JQJhEbhhOJPJQJo(hEbhEbOJPJQJhEbhEbOJPJQJo(hEbhhOJPJQJho4hhOJQJaJo(hqn>OJQJaJh羑?hEbOJQJaJh羑?h眏OJQJaJh羑?H*OJQJaJh羑?hhOJQJaJ!LfL贚M擬躆轒郙NPP禤頟|zsk$a$gdxlゐgdxl 動WDd`動gdEbゐgdEb$ゐ7$8$H$a$gdEbSkd鼳$$If攎???644 laytJO$If $Ifgdqn> 孨嶯朜狽郚鍺鐽OBODO琌甇糘綩贠闛PPPPPP"P$P6P8P燩皴劐裢褙疾紶捡伛貣坺ozoz^Q^hxlhQOJPJQJ!jhxlhhOJPJQJUhxlOJPJQJo(hxlhhOJPJQJo(hr8hr8OJPJQJo(h? hh5乷("hQB*H*KHOJ^JaJphhQOJQJaJ!jh? hhOJQJUaJh? h礚-OJaJh? hhOJQJaJh? hhOJQJo(h? hhOJQJaJo(癙睵碢禤綪翽蔖蘌訮諴頟鯬鳳黀QQQQ Q"Q(Q*Q.Q0Q2Q缰壤阿皰皰皞tdVtVtVtV俈tHhxlhx5丱JQJaJhxlhh5丱JQJaJhxlhh5丱JQJaJo(hxlhh5丱JQJaJhxlhh5丱JQJaJo(hxlhxl5丱JQJaJo(hxlhxl5丱JQJaJhxlhh5丱JQJaJo(h? hho(hxlhxlOJPJQJo(!jhxlhhOJPJQJU0hxlhQB*H*KHOJPJQJ^JaJph頟鳳QQ"Q*Q0Q2QW@WBWDW鲭萏刻獦妟j軼IWIW?"h? hhCJOJQJ\乤Jo(h飈hQH*OJQJaJ$jh飈hhH*OJQJUaJh飈hhOJQJ\乤Jo(h? hhCJOJQJ\乤Jh飈hhOJQJ\乤J"h飈B*H*KHOJ^JaJph(h飈hQB*H*KHOJ^JaJphh飈hQOJQJaJ!jh飈hhOJQJUaJh飈hhOJQJaJo(h飈OJQJaJo(h飈OJQJaJ*V,V6VBW€tc$$7$8$H$Ifa$gd飈 $d$Ifa$~kd薌$$IfT擶??[??644 layt飈奣BWDWJWX騒€tcc$$7$8$H$Ifa$gd飈 $d$Ifa$~kdyH$$IfT敳??[??644 layt飈奣DWJWNWZWXXXXXX XxXzX釾鋁鎄闤頧餢騒鬤黊JY疱资宫箺箥鍗坠梴椆譳[Mh飈hOJQJaJo(h飈hOJQJ\乤Jo(h? hhCJOJQJaJo("h飈B*H*KHOJ^JaJphh飈OJQJaJ(h飈hQB*H*KHOJ^JaJphh飈hQOJQJaJ!jh飈hhOJQJUaJh飈hhOJQJaJh飈hhOJQJaJo(h飈OJQJaJo(h飈hhOJQJ\乤Jo(騒鬤黊刏€q`$$7$8$H$Ifa$gdPb$d$Ifa$gd媡~kdI$$IfT攬??[??644 layt飈奣JYRYVYXY繷耏衁襓鋂鯵ZZpZrZ€Z俍刏哯圸怹抁燴猌甖禯竄繸耑箦郧圆藻箦郧圆藻妰u榚WeJeJhE5丱JQJaJo(hEh飈5丱JQJaJhEhh5丱JQJaJo(h?hhOJPJQJo( hr85乷(h駗yhr8OJPJQJo(h? hh5乷(h? hCJOJQJaJo((h飈hQB*H*KHOJ^JaJphh飈hQOJQJaJ!jh飈hfOJQJUaJh飈hOJQJaJo(h飈hOJQJaJ刏哯圸諾€ugX$d$Ifa$gdE$ゐ7$8$H$a$gd V $?7$8$H$a$~kd笽$$IfT攬??[??644 layt飈奣諾豘鈀騔~ d$IfgdS$d$Ifa$gdPbekdYJ$$If???644 laytE耑豘鈀餤鬦[[$[&[([*[\[`[j[癧篬糩綶靃頪鶾黐B\D\H\J\\\p\r\燶萛衆疬鹣勘Ρ鸨Ρ樋笨宝宝宝媬媡嫳t宝眃hEhOJQJ\乤Jo(hEm OJQJaJhEhhOJQJaJhEhhOJQJaJhEhhOJQJ\乤JhEm OJQJaJo(hEhhOJQJaJo(hEhhOJQJ\乤Jo(hEhh5丱JQJ\乤J!hEhh5丱JQJ\乤Jo(hEhh5丱JQJaJo(!騔鬦&[^[wnb d$IfgdEm d$If$d$Ifa$gdPbxkd镴$$If????644 laytEm ^[`[j[俒歔瞇wll^d$G$IfgdEm d$G$If$d$Ifa$gdPbxkd廗$$If????644 laytEm 瞇碵篬鳾n\瀄芢ulll` d$IfgdEm d$If$d$Ifa$gdPbzkd5L$$If斱????644 laytEm 芢萛衆]2]R]俔wkkk_ d$IfgdEm d$Ifgd媡$d$Ifa$gdPbxkd袻$$If????644 laytEm 衆襖診豛赲]]4]6]P]R]T]V]刔哴怾燷╙琞碷禲綸繻襗註<^>^F^H^耒褛耒耒褛耒裥玫lzWz(h?hQB*H*KHOJ^JaJphh?hQ5丱JQJaJ$jh?hh5丱JQJUaJh?5丱JQJaJo(h?5丱JQJaJh?hh5丱JQJaJo(h?hhOJPJQJo(h駗yhr8OJPJQJh? hh5乷(hEhOJQJaJhEm OJQJaJhEhOJQJaJo(俔刔哴燷J^{th d$Ifgd?ゐgdRe $?7$8$H$a$xkdiM$$If????644 laytEm J^L^V^`^j^yy$d$Ifa$gd?$d$Ifa$gd鞞gkdN$$If攙???644 layt?H^L^^^`^h^l^v^|^俕刕坁奮恀朸榐歗淾瀆甞耝腲蔨衈郶鈄鋇鎊館騘鴁鷁__ _____疬线橡堪ぐ織堪ぐ媩郡織郡縫縞挨翱椏翱挨h/cCJKH^JaJo(h?hhCJ\乤Jh鞞h鞞CJKH^JaJh鞞CJKH^JaJh?CJKH^JaJo(h?CJKH^JaJh?hhCJKH^JaJh?hhCJKH^JaJo(h?hh5丱JQJ\乤J!h?hh5丱JQJ\乤Jo(h?hhOJQJ\乤Jo(&j^l^v^瀆鎊qbFFd$-DIfM [$\$gd鞞$d$Ifa$gd鞞kd昇$$If攍諪?+?( ?6    44 layt?___$_&_,_._2_4_6_B_D_F_H_J_T_\_b_d_h_j_p_r_x_z_俖刜哶皴杖窦裾瘼枌|振捡m馺P`闸h孻'h孻'CJKH^JaJo(h孻'CJKH^JaJo(h?h孻'CJKH^JaJh?hhOJQJ\乤Jo(h?hh\乤Jh?hhCJ\乤Jh?CJKH^JaJo(h鞞CJKH^JaJo(h?CJKH^JaJh/cCJKH^JaJo(h?hhCJKH^JaJo(h/cCJKH^JaJh?hhCJKH^JaJ鎊_H_J_T_UF$d$Ifa$gd鞞kdUO$$If擲諪?+?( ?6    44 layt鞞d$-DIfM [$\$gd/cT_哶琠I:$d$Ifa$gd鞞kd#P$$If敭諪?+?( ?6    44 layt鞞 d$Ifgd?d$-DIfM [$\$gd孻'哶奯宊抇擾瀇燺琠綺繽腳芲襙訽鑏阓頮餩鬫鯻`` `` `"`.`0`4`:`B`J`\`^`b`矜宙宙秩含含棳棳|nanh?hOJQJaJh?hOJQJaJo(h?hOJQJ\乤Jo(h?OJQJaJo(h?OJQJaJo(h?OJQJaJh?hhOJQJaJo(h?h?OJQJaJo(h?hhOJQJaJo(h?hhOJQJ\乤Jo(h?OJQJ\乤Jh?hhOJQJ\乤J"琠<`@`B`J`╜Skd鉖$$If擯諪?+?( ?6    44 layt鞞$d$Ifa$gd鞞$d$Ifa$gd?b`d`h`l`n`x`z`|`~`俙奰抈擿朻渀瀈猔琡碻禶腵蔪蘞衊豟赻鈆鋊鴃鲭菪蓦蓥菪菪鲂鲂堇宫煈乿h乆乆hrhr5丱JQJaJo(hrhr5丱JQJaJhRe5丱JQJaJhrhh5丱JQJaJo(h?hhOJPJQJo(h?hr8OJPJQJh駗yhr8OJPJQJ h? hhh?hOJQJ\乤Jo(h?hOJQJaJh?hOJQJaJo(h?OJQJaJo(h?OJQJaJ╜猔琡腵鯼qkdU$d$Ifa$gdReゐgdrkd$$If擯諪?+?( ?6    44 layt鞞鯼鴃a aa{{$d$Ifa$gd?$d$Ifa$gdfekdcR$$If???644 laytr鴃a a aa&aPaRa`axaza|a~a€a禷竌篴糰綼繿蝍黙0bHbJbLbNbPbjbxb~b€b俠宐琤钷修婪珴挐劺x漬潉纗潚漝潉纗漌挐劺hrhhOJQJaJhnOJQJaJh茾OJQJaJhrhhCJaJo(hrhnOJQJaJo(hnOJQJaJo(hrhhOJQJaJo(hrhhCJ\乤JhnCJaJo(hrhhOJQJ\乤Jo(hrhhOJQJ\乤Jhrhh5丱JQJaJo(!hrhh5丱JQJ\乤Jo("aa&aRa`azasdKBB d$Ifd$-DIfM [$\$$d$Ifa$gdfkd驲$$If諪?nb?o€ ?6    44 layt抰^za|a~a€a哸]N5, d$Ifd$-DIfM [$\$$d$Ifa$gdfkd薙$$If4旍謀?nby?`o`€?644 layt抰^哸篴糰綼繿QB)d$-DIfM [$\$$d$Ifa$gdfkd豑$$If4敩謀?nby? o €?644 layt抰^ d$Ifgd茾繿蝍JbLbNbTE$d$Ifa$gdfkd譛$$If4攣謀?nby? o €?644 layt抰^ d$IfNbPbXb€b俠;kd諺$$If4敩謀?nby? o €?644 layt抰^ d$Ifd$-DIfM [$\$俠宐鋌騜@cBc:kd鉝$$If4謀?nby?`o`€?644 layt抰^ d$If d$G$If$d$Ifa$gdf琤纀耣芺襜詁豣鈈cc>c@cBcDcNcjclcncpc琧碿禼鈉鋍鎐鑓騝dd ddddd$d&d0d2dOJQJaJh+J>h+J>OJQJaJo(hrh狣OJQJ\乤Jo(hrhnOJQJaJo(hnOJQJaJhrh狣5丱JQJaJo(hnOJQJaJo(hrh狣OJQJaJhrh狣OJQJaJo(-猤\h抙i>i€i躨阨d$Ifgd媡m$ d$Ifgd媡 d$Ifgd狣$d$Ifa$gd狣m$d$Ifgd狣m$ jjj jj]NBB4d$Ifgd媡m$ d$Ifgd媡$d$Ifa$gd媡kd/`$$If4斲謀?nby?`o`€?644 laytS*pjrjvj抝攋榡歫渏爅琷甹磈秊蔶蝚謏豭躩鈐鋔鎗鑚k k&k(k\kbk刱唊坘妅攌爇╧鲭萦萆鲭菥萦菥萦莩荪曒堓埑莩荪曒齿lh+J>hh5丱JQJaJh? hh5丱JQJo(hrh狣OJQJaJhrh狣OJQJ\乤Jo(hrhnOJQJaJo(hnOJQJaJo(h+J>OJQJaJo(hS*OJQJaJh+J>OJQJaJhrh狣OJQJaJo(hS*H*OJQJaJhS*OJQJaJ%j鋔鎗鑚阩鴍O@44 d$Ifgd媡$d$Ifa$gd媡kdkd:c$$If4旪謀?nby? o €?644 layt抰^ d$Ifgd媡╧琸甼発瞜簁緆謐豮辦鄈鰇鴎鷎黭lllll疱咨鹕鹕酣槇ylalTlJ=hm_hhOJQJaJhm_OJQJaJh+J>hm_OJQJaJhm_OJQJaJo(h+J>hm_OJQJaJh+J>hhKHOJQJaJht1hh5並HOJQJaJht1hh5並HOJQJaJ"ht1hh5並HOJQJaJo(hm_5並HOJQJaJo(h+J>hh5丱JQJaJh+J>h+J>5丱JQJaJhRe5丱JQJaJh+J>hh5丱JQJaJo(鄈鴎鷎l>lpl渓rdYY $$1$Ifa$$$1$Ifa$gd?~kdGd$$IfT攪??K? ?644 laytm_奣$$1$Ifa$gdXll"l$l&l(l*l0l6l8l:llJlLlNlPlRlTlVlZl`ldlfljlllnlpl|l~l€l俵刲唋坙妉宭巐杔榣歭瀕爈鲨掼涯涯押熏鲅难难⊙貉擌熏含涯埬涯涯褅p{hm_OJQJaJo(h+J>hm_OJQJaJhXOJQJaJo(ht1hhOJQJaJo(ht1OJQJaJo(h+J>hhOJQJaJo(ht1OJQJaJh+J>hhOJQJaJh+J>hhOJQJaJht1OJQJaJh+J>hhOJQJaJo(h]OJQJaJ,渓瀕猯詌 m8m€rddV$$1$Ifa$gdX$$1$Ifa$gdm_$$1$Ifa$gd?~kd鮠$$IfT攪??K? ?644 laytp`€奣╨猯發瞝秎竘簂糽緇膌蔿蘬蝜衛襩詌鄉鎙鑜阬靗頻騦鴏黮mmmm mmmm m"m$m&m(m*m2m4m6m8m:mhm_OJQJaJo(h+J>hm_OJQJaJhm_OJQJaJh+J>hm_OJQJaJo(h+J>hm_OJQJaJhm_OJQJaJ58m:mLmtm╩謒€rddV$$1$Ifa$gdX$$1$Ifa$gdm_$$1$Ifa$gd?~kd眅$$IfT攪??K? ?644 laytp`€奣Zm\m^m`mfmlmnmpmtm€m俶唌坢妋宮巑抦榤渕瀖╩磎秏簃糾緈續耺膍苖萴衜襪詍謒豰趍鄊鴐鷐皲卒卒弯娩裢皲卒卒镐弯娩裢皲篆卒卒酌錆ohm_hm_CJOJQJaJo(hm_hm_CJOJQJaJhm_hm_CJOJQJaJhm_hm_CJOJQJaJo(hXOJQJaJo(hm_OJQJaJo(hm_OJQJaJhm_OJQJaJh+J>hm_OJQJaJh+J>hm_OJQJaJh+J>hm_OJQJaJo()謒豰黰$nBnVn€~~vjj $$Ifa$gd粀R$a$gdk,W~kd_f$$IfT攪??K? ?644 laytp`€奣鷐黰nn n"n$n.n0n4n6nh?OJQJaJhk,WOJQJaJhk,WhhOJQJaJhk,WhhOJQJaJo(hk,WhhKHOJQJaJhk,W5丱JQJaJhk,WhRe5丱JQJaJhk,Whh5丱JQJaJo(hk,Whh5丱JQJaJh? hh5丱JQJo(hk,WOJQJaJo(0hk,Whk,WOJQJ^JaJfHo(q hk,Whk,WOJQJaJo(hk,Whk,WOJQJaJ苙萵蕁鬾鰊x7@kd莏$$If攪??644 laytk,W $$Ifa$gdk,Wxkd/j$$If??G?a ' ?644 laytk,W鰊o oooo坥鰋.p|pp $$Ifa$gd粀Rfkd(k$$If擠諪??,[6    44 laytk,W$$Ifa$gd粀Rm$$$1$Ifa$gd粀R4o8o>kdBl$$If??644 layt$d$Ifa$gdゐgd$a$fkd祂$$If旜諪??,[6    44 laytk,WtLtNtVtXt`tbt則妕蝨 uuuRu~u蘵蝩鷘黸vvvPvTv\vvv皲皲皲亳漶像淠湎漶漶洗皲皲腺漶像漶漶漶像湎皲像黉裣裣褓腺搐hh狣OJQJaJo(hh狣OJQJ\乤Jo(hhhOJQJ\乤Jo(h苶POJQJaJo(hOJQJaJhOJQJaJo(hhhOJQJaJhhhOJQJaJo(;餾騭鴖:t唗uTuRv $Ifgd$Ifm$$If$d$Ifa$gd憒Skd搈$$If斱???r644 laytRvTv\v寁緑Vw渨陊RxHy $Ifgd%t $Ifgd媡$d$Ifa$gd憒Qkd n$$If???r644 layt vvzv|v€v倂唙妚恦紇緑聉衯詖wwDwFwTwZw歸鑧陊靪顆x x$x6x8x:xxPxRxTx倄剎秞竫蕏蘹蝬衳yy"yFyHyJyLy箝垩墓郛筵筵筵筵筵筵筵筵ん郛螽ぎ垠垠郛郅郛郛郛蹟h? hh5丱JQJo(hh狣OJQJ\乤Jo(h%tOJQJaJh%tOJQJaJo(hH*OJQJaJhk,WhOJQJaJhOJQJaJhh狣OJQJaJo(hOJQJaJhh狣OJQJaJ1HyJyLyZy纙聑躾{m$ゐ$1$9DIfa$gd癦[ $7$8$H$a$$劋d7$8$H$WD`劋a$gd癦[$ゐ7$8$H$a$gd 1Qkd}n$$If???r644 laytLyRyXyZybyhy寉抷攜鋣靬zz z&zFzHz皕瞶簔紌纙聑蘻趜躾鲨弁就境途途途廷槩啟蛓l^Qh?ghhOJPJQJh?ghhOJPJQJo(h~Z~`~妦悀秪紐陗額疴鹌鸸疄篂憙x僲b儀儀b儀b儀W僢僢僢h(OJQJaJo(hOJQJaJo(hKhh^JaJh頸OJQJaJo(h頸hhOJQJaJo(h頸hhOJQJaJh頸h頸5丱JQJaJo(hb*5丱JQJaJhb*5丱JQJaJo(6h頸hh5丱JQJ\乛JaJfHo(q h頸h頸5丱JQJaJh頸hh5丱JQJaJo("恾瞹磢緘葈蕔衹鎪JD$IfQkdt$$If??4?644 laytb* $$Ifa$gdb* $$Ifa$gd~>kd瞫$$If??644 layt頸 $$Ifa$gd頸鎪~~:~\~寏竳靱額魚d $Ifgd( $$Ifa$gd~Qkd倀$$If??4?644 laytb*$If 額魚(*.028:<@Bbfhpr€箦兹急颧葰妢錽f]O?h?*hh5丱JQJ\乤Jh?ghhOJPJQJo(h@D▍簠紖葏蕝螀 "翮芤喷喷喷喷喷喷喷喷欧弨t€eVh:$h(KHOJQJaJh:$h:$KHOJQJaJh:$KHOJQJaJh:$hhKHOJQJaJh:$KHOJQJaJo(h簉hhOJQJaJh簉hhOJQJaJo(h-@hh5丱JQJaJh-@h-@OJQJaJh-@OJQJaJh-@OJQJaJo(h-@hhOJQJaJh-@OJQJaJo(紖蕝>rtvx~Nkd襹$$If4敺謀? ?`(`?644 layt-@ $Ifgd:$$If"$*.<>Bfjprtv|~拞瑔軉鄦鰡4\j剣唶垏枃槆瑖竾鄧顕翦厣寮迳瀹爯倁h[hQh[h[hu悅uh[h[h:$OJQJaJh:$h:$OJQJaJh:$hhOJQJaJh簉hhOJQJaJh簉hhOJQJaJo(h簉hh5丱JQJaJo(h簉hh5丱JQJaJh:$hh5丱JQJaJh:$KHOJQJaJo(h:$h:$KHOJQJaJh9CH*KHOJQJaJh:$hhKHOJQJaJh9CKHOJQJaJ~畣軉6l剣唶垏妵TNN$Ifkd遾$$If4旍謀? ? ( ?644 layt-@ d$If妵槆簢饑驀魢鰢~Wkd迆$$If4攔謀? ? ( ?644 layt-@$If顕饑驀魢鼑r|~€倛剤妶巿槇皥矆胥优斧烋銛唙hZJ6'jh5*hh5丠*OJQJUaJh謓hh5丱JQJaJo(h5*hh5丱JQJaJh5*h謓5丱JQJaJh5*hh5丱JQJaJo(h5*hh5丱JQJaJh? hh5乷(h:$h:$OJQJaJh:$hhOJQJaJh簉hhOJQJaJh簉hhOJQJaJo(h簉hh5丱JQJaJo(h簉hh5丱JQJaJh:$hh5丱JQJaJ~€倛*][O $$Ifa$gd謓kd$$If4旚謀? ? ( ?644 layt-@矆$&(*02:<DFJN\^fhnvxz疖疖嘶乺乺eVGVh謓h5*KH^J_HaJh謓hhKH^J_HaJh謓hhPJ^JaJh謓hhOJQJ^JaJ'h謓hhKHOJQJ^J_HaJo(h謓hh5丱JQJ^JaJ*h謓hh5並HOJQJ^J_HaJo(h5*hh5丱JQJaJo(!h5*hh5丠*OJQJaJo('jh5*hh5丠*OJQJUaJh5*hQ5丠*OJQJaJ*,2<FLzj$$1$9DIfa$gd9W $1$9DIfgd謓$$1$9DIfa$gd5*gkd軃$$If擕?'&"?62 4ayt謓LN^h缐虊^NNN>$$1$9DIfa$gd9W$$1$9DIfa$gd5*kd垇$$If擕謀? ?'&&&n&&D?62 4ayt鑇?z|~€剦唹妷帀槈殙湁瀴爥獕畨笁緣缐聣膲茐葔蕢螇覊貕鎵鑹饓驂鰤鷫 钸舆糯哳哂吲触哂庍钸舆r哳吲触遝哳吲h5*KH^J_HaJo(h謓hhPJ^JaJh謓hhOJQJ^JaJh謓hh^JaJh5*KH^J_HaJh躖2H*KHOJQJ_HaJ h?*h躖2KHOJQJ_HaJh躖2KHOJQJ_HaJh謓KH^J_HaJh謓hhKH^J_HaJ!h謓KHOJQJ^J_HaJo('虊螇袎覊02]QQA5 $$Ifa$gd9W$$1$9DIfa$gd5* $$Ifa$gd5*kd爞$$If4謀? ?'&``&n`&D?62 4ayt鑇?(.06@BHNPRTXZ^bjlnptvz~垔寠帄枈湂瑠畩镟雅韩棲娧~裷裠镟裌裷裠镟雅韩娧~裠h5*KH^J_HaJo(h躖2KHOJQJ_HaJh躖2KH^J_HaJh5*KH^J_HaJh謓hhPJ^JaJ'h謓hhKHOJQJ^J_HaJo(h謓hhOJQJ^JaJh謓hh^JaJh謓KH^J_HaJh謓hhKH^J_HaJh躖2H*KHOJQJ_HaJ h?*h躖2KHOJQJ_HaJ"246B帄悐]QAA5 $$Ifa$gd9W$$1$9DIfa$gd5* $$Ifa$gd5*kd鷥$$If4斳謀? ?'&  &n &D?62 4ayt鑇?悐拪攰枈緤缞]QQA5 $$Ifa$gd9W$$1$9DIfa$gd謓 $$Ifa$gd5*kdT$$If4擠謀? ?'& `&n &D?62 4ayt鑇?畩矈秺笂紛緤聤見詩軍迠鋳陫鞀願饖驃魥鴬鷬 $*,24<镟雅韩棲棲娧~裮雅裚镟雅貉m雅押珚褈裮h躖2KHOJQJ_HaJ!h謓KHOJQJ^J_HaJo(h5*KH^J_HaJh謓hhPJ^JaJ'h謓hhKHOJQJ^J_HaJo(h謓hhOJQJ^JaJh謓hh^JaJh謓KH^J_HaJh謓hhKH^J_HaJh躖2H*KHOJQJ_HaJ h?*h躖2KHOJQJ_HaJ%缞聤詩迠 ]MM=-$$1$9DIfa$gd9W$$1$9DIfa$gd謓$$1$9DIfa$gd5*kd畣$$If4?謀? ?'&  &n &D?62 4ayt鑇?PR]QQA5 $$Ifa$gd9W$$1$9DIfa$gd謓 $$Ifa$gd5*kd$$If4擮謀? ?'&``&n`&D?62 4ayt鑇?<>BFHNPT`bjlrxz|~€倠唻垕寢蜥颐番潐潐潀胮胈梅肣@ h?*h躖2KHOJQJ_HaJh躖2KHOJQJ_HaJ!h謓KHOJQJ^J_HaJo(h5*KH^J_HaJh謓hhPJ^JaJ'h謓hhKHOJQJ^J_HaJo(h謓hhOJQJ^JaJh謓hh^JaJh謓KH^J_HaJh謓hhKH^J_HaJh5*H*KHOJQJ_HaJ h?*h5*KHOJQJ_HaJh5*KHOJQJ_HaJRTbl聥螊]MMM=$$1$9DIfa$gd9W$$1$9DIfa$gd5*kdb$$If4?謀? ?'&  &n &D?62 4ayt鑇?寢悑湅瀷爧▼瑡皨簨缷聥膵茓葖蕥虌袐詪趮鄫鈰鑻陭驄魦鴭鼖 疳嗅尼顶疳臋嵝崮釒r醘嵝岫ヰ醂嵝釞h苶PKH^J_HaJo(h5*KH^J_HaJh謓hhPJ^JaJh謓hhOJQJ^JaJh謓hh^JaJh謓hh^JaJo( h?*h躖2KHOJQJ_HaJh躖2KHOJQJ_HaJh謓KH^J_HaJ!h謓KHOJQJ^J_HaJo(h謓hhKH^J_HaJh躖2H*KHOJQJ_HaJ"螊袐覌詪 ]TH8$$1$9DIfa$gd苶P $$Ifa$gd5* $$Ifa$kd紛$$If4?謀? ?'&``&n`&D?62 4ayt鑇? QH8$$1$9DIfa$gd5* $$Ifa$kd$$If4?謀? ?'&  &n &D?62 4ayt鑇? $$Ifa$gd9W $*,.046:>FHJLPRVZdhjlnprtx|倢垖褫裥恋俩翛妠祅俩翛妠俩c罵俩羉裥?h謓KHOJQJ^J_HaJo(h謓hh^JaJh5*KH^J_HaJo(h躖2H*KHOJQJ_HaJ h?*h躖2KHOJQJ_HaJh躖2KHOJQJ_HaJh謓KH^J_HaJh5*KH^J_HaJh謓hhKH^J_HaJh謓hhPJ^JaJ'h謓hhKHOJQJ^J_HaJo(h謓hhOJQJ^JaJ jvxz|=44 $$Ifa$kdp$$If4?謀? ?'& `&n`&D?62 4ayt鑇?$$1$9DIfa$gd9W$$1$9DIfa$gd謓垖妼拰攲槍湆瀸▽獙磳緦葘蕦貙趯BD翦灼峰珷憞zl\Q\>0>h烔=hQ5丱JQJaJ$jh烔=hh5丱JQJUaJh烔=5丱JQJaJh烔=hh5丱JQJaJo(h?ghhOJPJQJo(hkd$$If??644 layt隠$d$Ifa$gd烔=v聧"^槑鄮 枏&T"矐z軖迴鄴dQkd貝$$If???€r644 layt廠.$If詯謵(46npt啈帒矐螒袘:<xz湌趻軖迴鄴鈷鎾箧厥厥劓箧厥亟丿厥亍梸gNg0hPhhOJPJQJaJfHo(q -hPhPOJPJQJaJfHq 0hPhPOJPJQJaJfHo(q h? hh5乷(h烔=hhOJQJ\乤Jh隠hh5丱JQJaJh隠OJQJ\乤Jo(h隠h隠OJQJ\乤Jh隠hhOJQJ\乤Jh隠hhOJQJaJh隠h隠OJQJaJ @JR~魮鰮^`nprv€帞悢鴶鷶暧懦抨興VE;Eh譠OJQJaJ!jh? hbOJQJUaJh7hhOJPJQJo(-h}sh億OJPJQJaJfHq hPOJQJaJo("hQB*H*KHOJ^JaJphhQOJQJaJ!jh? hhOJQJUaJ#h? hhKHOJQJ^JaJo(h? hhOJQJaJo(,h? hhOJQJaJfHo(q )h? hhOJQJaJfHq tv BDN^hx€l^^^^^$$1$Ifa$gdbgkdQ$$If???€$?644 laytho'$$1$Ifa$gdho'ゐgd7凔WD`凔劋dWD`劋gdP 鷶 @DLN\^fhvx~€剷垥悤挄枙槙殨爼稌笗簳紩緯罆聲臅茣葧跁钶疟煴煴煴煴煴煴煴煃|峮_峾峾峾峗峮峾hho'KHOJQJ^JaJo(hho'KHOJQJ^JaJ hho'hhKHOJQJ^JaJ#hho'hhKHOJQJ^JaJo(#hho'hh5並HOJQJ^JaJ&hho'hh5並HOJQJ^JaJo(/h? hh5丱JQJaJfHo(q !jh? hbOJQJUaJ"hbB*H*KHOJ^JaJph%€啎垥挄*kd駪$$If斅謭?o}?€o€9€€9€€?644 laytho'$$1$Ifa$gdb笗紩葧鋾鴷$$1$Ifa$gdb跁軙迺鈺鋾顣饡魰鰰鴷 &FVX^`drt倴帠悥枛槚瑬畺礀稏簴紪緰罇鏂陽驏魱鴸鷸鼥 LNP疝鹦攫摒芯蘧疝瓠柧柧鹁芯杽柧芯叙经緰#hho'OJQJaJfHq ,hho'hhOJQJaJfHo(q  hho'hhKHOJQJ^JaJ#hho'hhKHOJQJ^JaJo(hho'KHOJQJ^JaJ#hho'hho'KHOJQJ^JaJo(hho'KHOJQJ^JaJo(4&H8***$$1$Ifa$gdbkd鶔$$If攙謭?o}?o99?644 laytJ"<HTdt剸$$1$Ifa$gdb剸問悥槚畺8***$$1$Ifa$gdbkd $$If斅謭?o}?o99?644 laytJ"<畺稏罇詵钖$$1$Ifa$gdb钖陽魱N8***$$1$Ifa$gdbkd $$If斅謭?o}?o99?644 laytJ"<NR^n€$$1$Ifa$gdbPRTVXZ\^~倵剹寳帡槜灄牀 镙屋垒镙锎潝唜g^gLg>h? hh5丱JQJo("hQB*H*KHOJQJaJphhQ5丱JQJ jh? hh5丱JQJUh7h?OJPJQJo(h7hhOJPJQJo(h億5丱JQJ-h}sh億OJPJQJaJfHq h? hh5丱JQJhho'KHOJQJ^JaJhho'KHOJQJ^JaJo(#hho'hhKHOJQJ^JaJo( hho'hhKHOJQJ^JaJ€倵剹80)ゐgdJ"<$a$gdbkd$$If斅謭?o}?o99?644 laytJ"<&*FLZ`dlnvx倶皹稑跇軜FH燧焐供箿帨巜bwbwbwbwH2jh5IhhOJQJUaJfHq )h5IhhOJQJaJfHq ,h5IhhOJQJaJfHo(q h5IhhOJQJaJo(h5IhhOJQJaJh5Ih?5丱JQJaJo(h5Ihh5丱JQJaJo(&h5Ih?5並HOJQJ^JaJo(h5I5並HOJQJ^JaJ&h5Ihh5並HOJQJ^JaJo(NPZbu $$Ifa$gd2 $$Ifa$gdbekd$$If???644 layt5I $$Ifa$gd5Ibdx鷻zq $Ifgd $$Ifa$gdbxkd煑$$If???-?644 layt5[H皺矙紮緳罊袡詸謾錂鴻鼨詺隁鞖饸晷恍瓨刾^凬瑼6Nh5IOJQJaJo(h5IhhOJQJaJh5Ihh5丱JQJaJo(#h OJQJaJfHq &h OJQJaJfHo(q &h5IOJQJaJfHo(q )h5IhhOJQJaJfHq h5IhhOJQJaJo((h5IhQB*H*KHOJ^JaJph2jh5IhhOJQJUaJfHq )h5IhQOJQJaJfHq 鷻鼨顨zq $Ifgd $$Ifa$gdbxkdE$$If???-?644 layt5[顨饸驓 @{rf $$Ifa$gd dh 劍dhWD`劍xkd鶚$$If???-?644 layt5[饸驓鴼鼩 >BLPRZ^fhprv褛涯赌盯摙卽卽卽hZhZG%h hh0J5丱JQJ\乤Jo(h hhOJQJaJo(h hhOJQJaJh hh5丱JQJaJo(h hh5丱JQJaJh 5並HOJQJ^JaJ&h hh5並HOJQJ^JaJo(h7hhOJPJQJo(h7hhOJPJQJh億5丱JQJ-h}sh億OJPJQJaJfHq h? hh0JOJQJaJ@BL\ $$Ifa$gdh|Z $$Ifa$gd}sekd瓩$$If???644 layt?T\^r皼鏇*`ztttt$If $$Ifa$gd}sxkd=$$If???-?644 layt5[v倹姏寷悰疀礇錄隂(*.4PR^bvz劀啘姕钯沦奥溌溌妛顆頶YNY@Yh?Th?TOJQJaJo(h?TOJQJaJo(h hhOJQJaJo(h hh5丱JQJaJo(%h hh0J5丱JQJ\乤Jo("h hh0J5丱JQJaJo(&h?TOJQJaJfHo(q #h?TOJQJaJfHq ,h hhOJQJaJfHo(q )h hhOJQJaJfHq "h hh0J5丱JQJ\乤J`bv:zqq $$Ifa$ $$Ifa$gd}sxkd銡$$If???-?644 layt5[姕寽悳挏槣湝葴8<>DHLTV^鲨扌判盒邯榿xj]S?&h縠h5並HOJQJ^JaJo(hhOJPJQJh7hhOJPJQJh7hhOJPJQJo(h億5丱JQJ-h}sh億OJPJQJaJfHq "h? hh0J5丱JQJ\乤Jh hh5丱JQJaJo(h?TOJQJaJo(hH*OJQJaJh hhOJQJaJo(hOJQJaJh h(OJQJaJo(h?TOJQJaJ:<>V劃帩敐灊wkkkk $$Ifa$gd2 dhゐgdWdhxkd棝$$If???-?644 layt5[^b倽劃帩挐敐槤湞獫矟礉紳聺臐虧軡逎鏉铦鞚  &(46:碣嘶粨唜唜mxmx唌x哶xTmx唜唜h?\OJQJaJo(hMhMOJQJaJo(hMOJQJaJo(h縠hMOJQJaJo(h縠hMOJQJaJh縠h﹛5丱JQJaJo(hM5丱JQJaJhM5丱JQJaJo(h縠h5丱JQJaJo(h7hOJPJQJo(&h縠h5並HOJQJ^JaJo(#h縠h5並HOJQJ^JaJ 獫緷逎铦HbVJAJ $$Ifa$ $$Ifa$gdM $$Ifa$gd5[kd=$$If謀?C?+?44 layt?\:<BFJLNVXZ^`df|~€倿劄獮瑸疄盀矠緸臑茷葹蕿虨譃転逓酁鉃翩翩冁亵亵速临临臭侉翩冁舁洃泝uh]憶h孻'OJQJaJo(h孻'h孻'OJQJaJh孻'h孻'OJQJaJo(h?\h孻'H*OJQJaJh孻'OJQJaJh縠h孻'OJQJaJh?\OJQJaJo(h?\hMH*OJQJaJhMOJQJaJhMhMOJQJaJo(h縠hMOJQJaJh縠hMOJQJaJo(hMOJQJaJo($HJLNX獮^UI@4 $$Ifa$gd?\ $$Ifa$ $$Ifa$gd $$Ifa$kd6$$If4攂謀?C?``+?44 layt?\獮瑸疄盀矠^UI@4 $$Ifa$gdM $$Ifa$ $$Ifa$gd $$Ifa$kdN$$If4攁謀?C?  `+?44 layt?\鉃錇隇馂魹鸀  "$&068:<DJNRZ^`jz|殶湡灍牊疴这这始庹庹庹饧qcqc紞h?\hMOJQJaJo(h?\h?\OJQJaJo(h?\h?\H*OJQJaJh縠h?\OJQJaJh?\OJQJaJh?\OJQJaJo(h縠hMOJQJaJh縠hMOJQJaJo(hMOJQJaJo(h孻'h孻'OJQJaJh孻'h孻'OJQJaJo(h?\h孻'H*OJQJaJo(" \^UI@4 $$Ifa$gdM $$Ifa$ $$Ifa$gd $$Ifa$kd]$$If4謀?C?   +?44 layt?\\^`j|湡^UI== $$Ifa$gd $$Ifa$gdM $$Ifa$kdl$$If4謀?C?   +?44 layt?\湡灍牊簾^UI= $$Ifa$gdM $$Ifa$gd $$Ifa$kd{$$If4 謀?C? `+?44 layt?\牊簾紵緹罒臒螣袩鞜顭馃驘魺鵁8 88.808284868D8F8L8R8V8Z8h8j8l8~8€8??????胥裰然悱悱戎然惬悱悱戎然炪汇汇悈悈恵恜hOJQJaJo(hOJQJaJhMOJQJaJo(h縠hOJQJaJo(h?\hMOJQJaJUh?\hMOJQJaJo(h?\h?\OJQJaJh縠hMOJQJaJo(h縠hMOJQJaJh?\h?\OJQJaJo(h縠h?\OJQJaJo((簾紵緹罒袩顭qh\PD $$Ifa$gdM $$Ifa$gd?\ $$Ifa$gd $$Ifa$kd參$$If4諪??   ?    44 layt?\顭馃驘魺808^UII= $$Ifa$gdM $$Ifa$gd $$Ifa$kd]$$If4謀?C?  +?44 layt?\g-40kg10/2.5mg/kg/!kBidSO蛻e"40kg200mg/50mg /!k Bid緩鏃€詋鳶諲--800/150 mg1Gr  鉙g qd6.5 o僨[裿 ADDIN NE.Ref.{90F92D1F-8087-4E50-8B26-2CFAD2083DF4}[53-54]h?-5 藛}vv憫b6RBR{|梑舥襨o僫ro僨[裿o僫rT饄No偼S擽yr妅篘(uom9S鏃/)RXb鏃g8^翂剉No偼S擽:Ny侞l0v`胈0UTT0貧u筶 No懬u孴貧苺鶹噾@埱u潃/線烺齹1{忬?N潃烺齹NhQ鄀宼eBR蠎2.蛻潃烺齹NhQ€亂(u3.線烺齹NhQ鄀宼eBR蠎4.@埐m悙gby仠悙g€鄀宼eBR蠎?Q鍅14錯錘 NtZ?Q(uo儎v塠hQ'`0 gHe'`蔛o冦N≧汻f[\Nfnx ?Q鍅BR蠎宼e 翂h?-4奩 Zg/鶷sNg1.奩 ZgD崣e>f:y(W篘SO-NNO gxub_剉螛i N鄀宼eBR蠎 FO1u嶯鉙g瞞SO+T g貧Sm剉YN噾孴N孨噾 擽怣QO(u鉙g秐瞞 N╟P?錯1!k剉賬o児eHh2.鶷sNg≧ir瀃寶颯彇sNAl抍膌 /f&T彇篘{|sNAl抍膌\NnZi Na(u€t^篘65乗蔛錘 N€t^篘N儚t^{€(uo償^T{剉頬_\Nfnx 擽Na(u緩鏃/€詋鳶諲y侞l0v`胈0UTT04Y踰0畍箄0潃v慓S貧0寑踰0ON汻0@垖€P憺X燫0貧丂埱u0謡?\舥0_8^僗I{潃/線烺齹1. {?N潃_c$O€Na(u 蛻潃_c$OChild PughC €亂(u2.線烺齹_c$O€ 鄀宼e(uo傿R蠎 CRRT鰁鄀宼eBR蠎?Q鍅\*gnx歔,g罷(W3^17乗?Q鍅€-N剉塠hQ'`孴梪He N鷁畫3^17乗?Q鍅€O(u,g罷3乗錘 N?Q鍅N梍g(u,g罷奩 Zg/鶷sNg1.FDA奩 Zg:NC ,go冿S惽徫€豽 奩 ZgNa(u2.≧ir瀃寶>f:y,go冿S彇sNAl抍膌 \Nfnx,go?f&T彇篘{|sNAl抍膌 郪o僫rRP[蠎\ JSpg 颯齹彇篘{|sNAl抍膌 Na(u€t^篘65乗蔛錘 N€篘N儚t^{€鵞,go償^T{/f&TX[(W頬_\Nfnx 擽(孨a(uo僾^裿Km6.6 o僨[鷁畫h?-6 藛}vv憫b6RBR{|梑舥襨o僫ro僨[鷁畫o僫rT饄o僨[鷁畫m9S鏃/)RXb鏃1.鉙g瞞SO厪檈-N+TYN噾孴N孨噾Sm儚貧 郪dk :N怣Q?Q鍅(uo兦徬扅[魜魜{k'`剉R懢|bN孨噾-N襨 O(u鉙g秐瞞鰁{樉|nx0W梴BR蠎 臺亯鰁颯(u!h芉剉BR蠎鑜\hV賬o2.teGr絋 N N齹€T糣0癱_b婼巟0&TR m9S鏃孴)RXb鏃剉AUCR+RM朜O45%孴47% 0俌済r 鑜a宼eBR蠎 芠R裿KmNo偼S擽3.鷁畫歔g裿Kmu筶 No憣T苺鶹噾剉4ls^ $\vQ鵞嶯貧@b g饊z亷p舥騍剉€  g饊z亷p莡秗9hnc4N奮梺塡Po4.擽怣QN鯺昋Tc魰g剉o僫r俌/l飩Oe0NY<\N0 }0KQ蒪 }0筓鷭n憑|o僫r T€TO(u 錘蔛怣Q(WHQ)Y'`昋T鼅T乢bNO緮@埱u剉€-NO(u5.NaN鯺昉R魰g剉o僫r線 Nz佔SSO;柇eBR 0W貧洀 ?朜b鏃 T(u6.鷁畫歔g裿Km潃烺齹 $\vQ鵞嶯 g潃巔俌YN潃0N潃 b潃烺齹NhQ剉€椲廘堲f憳A~剉潃烺齹裿Km7.鷁畫歔g纇Km@堉|0sNx憣T5u銐(?ls^8.N鉙g怳[o僒€(u颯齹OM朜O鉙g怳[o儎v gP?` 鷁畫菓(uvQ諲b__剉怳[猚絜9.,go僫r:NCYP3A4剉慴6RBR 蟸菑CYP3A4鉔" EeNCYP3A4昢ir0CYP3A4慴6Rb駤黐o僫rT(u桸a蛻10.颯齹N術汵4Yb[虄 }02u]xU0f]xUT(u鰁_w嵦Skx袾7h蚐擽11.GrBR颯4Ob€N4O邩irg(u r櫍`€颯錘 ?u鉙g秐瞞 FON梍O(uZ€(lo慞g(崱{ 颯錘O(uPVC孴Ex鰛12.怣Q閑?Q*g緩42hT剉雡ck蝷劅 錘蔛鶴uT\嶯14 d剉硩g?QO(u鉙g瞞 &TR裇uN孨噾鴙sQNo倠N鯪剉螛i枮X燫13.sQ鑜MQ玼蛻鷁鼅T莡剉裇u 怣Q:gO'`a觛€鶴皊巔莡蚐擽婳俌鑍苸迉舥襨0aSl簚蔞k喓€巔0觺8hI{ 緩鏃/€詋鳶諲1.,g罷{槒 Tg 邩ir{|媁NOq_蚑,g罷剉磃2椣 g(u鰁擽teGrTg N颯癱巟b婼巟0俌og,g罷鰁魰N0R12 h 擽=\隷eg俌og,g罷鰁魰厤菑12 h 擽9hncR(W N!k賬o凍e魰g(u NN*NBR蠎o僫r{N Tg N颯蘏Pg(u2.1u嶯{彟^b-N潃烺齹_c$O€-N緩鏃剉8n粂@坥僑mGS貧 @b錘(WO(u,g罷鰁鷁畫裿Km潃烺齹3.俌済鶴皊蛻畍蚐擽剉SO乢孴莡秗 擽藌sS\P(u,g罷4.譙,g罷剉€俌癳裇潃烺齹湒峹b潃烺齹湒峹v`SS靊潃乿?N奮>fW?`GS貧孴/b鶴皊錘 N莡秗ON汻 邩2k螿 v`胈 臑竨 ?\r傫m 潃亱S踰 潃縺'Y  O(u菑 z-N%N芠裿Km鴙sQch %N蛻€擽€Q喫zsS-N璭b葉bk籰梪5.緩鏃/fN蛓CYP3A慴6RBR0CYP2D61_慴6RBR孴P謡藛}v慴6RBR €詋鳶諲/fN蛓CYP3A孴CYP2D6慴6RBR @b錘N;N亯蟸1uCYP3A孴/bCYP2D6鉔"寗vo兞TTv^(uo桸a蛻 @b錘擽亂bkN錘 No兞TT€(uaSl塻^0飩鬩詋0飩駛0)R弝s^0/嶖S迯I{7 慴6RRNATb{|梑舥襨o僫r誰9S蒪鏃Favipiravir  ^t穇f鏃Remdesivir 孨€GW:N貧 愰b'`RNAZ€Tv憫b6RBR 惽忋Sg8T6eTlS:NwQ guir;m'`8h鱾 N鱴x戙N"宨r 觺刧N VdT鴙f:y鶴OS T\O(ud枟bAma;m'`Y 貜S靊檒抾舥襨0}v蓡舥襨0IlfW舥襨0臑舥襨0爛舥襨02u媁舥襨0夎恖亷p舥襨0oR榺舥襨0|T8TST迉舥襨孴鷭俌舥襨I{^t穇f鏃SOY苸迉瀃寶蔛≧ir瀃寶觺済翄瀃 鵞篘a觛燪秗舥襨孴T蛓Y嘸噀g恘剉燪秗舥襨GWwQ g乬:_剉SOY梑舥襨;m'` 鍕o僫r騗蟸孾b籰梪肳ZS蒪舥襨a觛剉b!g4N奮諎寶NCT02818582 鬩m檒鏃o穬梍齎邩罷孴o僫rt@\FDA yb芉(u嶯梑Ama籰梪0xvzhf鬩m檒鏃h埌s鶴鵞c[倐'`AmaA媁孴B媁舥襨S靊€^y蟸(lx憊憫b6RBR虄*h 剉;m'`  T鰁鬩m檒鏃鵞2u媁Ama剉Y蛓歂媁 gHe S靊H1N10H1N20H5N10H5N20H5N60H7N9孴N9N27.3 亂(u孴Na(u篘h?-3 慴6RRNATb{|梑舥襨o僫r亂(u孴Na(u篘o僫rT饄亂(u孴Na(u篘誰9S蒪鏃1.鵞鍕o僫rbR菑Oe€亂(u2.踰螛蔛貧?\x慇埱u€Na(u^t穇f鏃(WeP穅bt^譙諎€-N/f塠hQ剉 俧*g裇皊(WU[嘫0?Q鍅蔛€t^篘-N剉o僫rNo偼S擽 潃線烺齹NhQ€俧鄀亂(u/Na(u剉S鬩m檒鏃o鵞鬩m檒鏃ob6RBR-N剉鸑UObR菑Oe婳俌菑Oe蚐擽 @垺{'`4l縺 h兓灩u Yb_'`慹 亂(u7.4 8^翂o僫r(u誰(u蠎h?-4 慴6RRNATb{|梑舥襨o僫r籰梪筫Hho僫rT饄籰梪筫Hh誰9S蒪鏃1.梑Ama籰梪鶴皊Ama莡秗T=\閑賬o ,{1)Y賬o?!k 蟢!k1 600 mg,{2^5)Y 蟢錯2!k 蟢!k600 mg2.梑癳燪舥襨籰梪誰9S蒪鏃鉙g 枡BR1 600 mg q12h ,{孨)Y薡 魚c蠎600 mg q12h鉙gT€T-r^pb }S8TeQ b篘蟢!k500NU 燫eQmp虄鑜\(u4l2 mL bid^t穇f鏃1.梑肳ZS蒪籰梪筫Hh,{1)Y枡!k峸傿R蠎200 mg iv (鬾鑜30 min) 6qT蟢)Y魚cBR蠎:N100 mg iv(鬾鑜30 min) 梪 z:N10 d2.梑SARS籰梪筫誰,{1)Y200 mgBR蠎 KNT100 mg qd 迯韣O(u9 d鬩m檒鏃o齎FDABR媁:N剠渷Sc圙r 臢(u嶯12乗蔛錘 N剉?Q鍅蔛b篘 US!kg1BRsS颯SO(嵪?0~80 kg(WAma莡秗裇uT48 h匭USBRg(u40 mgSO(嵪慹"80 kg(WAma莡秗裇uT48 h匭USBRg(u80 mg7.5 o僨[裿 ADDIN NE.Ref.{8099D126-DDCF-4F5E-B607-683BF2E9BFD5}[57,59,65-66]h?-5 慴6RRNATb{|梑舥襨o僫ro僨[裿o僫rT饄No偼S擽yr妅篘(uo誰9S蒪鏃N,No偼S擽@?\x憺X燫 y侞l -N'`抾苸迉pe螿\ ASTGOT 瀀燫 ALTGPT 瀀燫 L圍N_8^I{%N蛻No偼S擽OKQ 菑Oe蚐擽 簚巔 r裇'`潃巔 潃烺齹NhQ h埉vOW{k鼅T乢 %`'`線_c$O }v苸迉螿\ @\g螿\ ^y蟸鹼邁莡秗 鶴@?`觺爛巔I{潃線烺齹NhQ*g翂鴙sQS?Q鍅*g g鵞?Q鍅(uo凐vsQ剉蟸寶奩 Zg/鶷sNg1.奩 Zg g趢蝷魜{k孴魜xu剉≧ir瀃寶S 亂(u2.誰9S蒪鏃颯錘彇篘sNAl-N剉抍膌 (u嶯鶷sNg嘫sY鰁 亯葉bk鶷sN€t^篘€t^篘剉ut烺齹螿1_ 郪dk擽(W聣遊€秗礠剉 T鰁蹚L堎~o^t穇f鏃 gsQRDV剉塠hQ'`xvz儚\ ≧ir瀃寶>f:y塠hQ'`儚}Y潃線烺齹NhQ*g翂鴙sQS?Q鍅俧鄀鴙sQS奩 Zg/鶷sNg俧鄀鴙sQS€t^篘俧鄀鴙sQS鬩m檒鏃og;N亯No偼S擽:N/el巔 (W4N奮xvz-N裇u噑:N3%潃/線烺齹1.潃烺齹NhQ Child-PughRB \鄀BR蠎宼epencChild-PughRC 1u嶯 g賬o兿~寶 擽(孨aO(u2.線烺齹NhQCrCle"50 mL"min-1SO-N鬩m檒鏃剉o冦N≧汻f[ g4N奮aIN剉豐S?Q鍅齎颯(u嶯e"12乗R\t^錯,g魦ffN颯(u嶯10 kg錘 N?Q鍅 (W12乗錘 NbSO蛻NO嶯40 kg剉€-N剉塠hQ'`孴 gHe'`\*gnx歔奩 Zg/鶷sNg顅MR貜 gnx歔vQ(W奩 Zg魰(uo儎v塠hQ'`剉翄nc 1u嶯皊(W癳oxvzpenc\N硩 鶷sNg擽怣Q鶷sN€t^篘顅MRD崣e g衏汷sQ嶯貧劅篘梺壪Q蠎剉penc7.6 o僨[鷁畫錘蔛鴙sQxvz ADDIN NE.Ref.{CA0D3997-3B62-4A05-BFB1-8CA5763DF85B}[67]h?-6 RNAZ€Tv憫b6RBR{|梑舥襨o僫ro僨[裿o僫rT饄o僨[鷁畫騗孾b/ck(W蹚L垊v鴙sQxvz{v皨鱏誰9S蒪鏃1.潃烺齹湒峹剉€颯齹O鶴皊@坥僑m瀀燫 鷁畫O(u鰁裿Km潃烺齹秗礠2.誰9S蒪鏃颯R蘬髞緗瞞 颯O≧ir~w8N(嵪懴Q\ 鷁畫\PoT髞\1hT匭菓諷 gHe怳[猚絜3.誰9S蒪鏃鵞CYP2C8 g慴6R\O(u /f洃'lSv憚v:_He慴6RBR髞\梖嬚` N'Yo僫r鴙扤\O(u6儽x0鵞YNp?l鶺Z0^t伱€Z喴[€Na(u3.螛襕h埩嫞`€Na(u4.,g罷+T粸臑 胈伵u0貧@垕S€Na(u5.袕≧XTNa(u6.SO)ne"39.1! b@圵BC11.0109"L-1 b-N'`抾苸迉75% b蛻莡Ama€\鄀xvzpenc/ecO(u1.菑OeSO(嵤S鵞,g罷菑Oe€亂(u2.螛襕a扱€N淸(u3.>伱€Z喴[€Na(u4.SO)n厤菑39.1!鰁0}v苸迉;`pe>10109"L-10-N'`抾苸迉~vR詋>80%€\鄀xvzpenc1.鵞,g罷菑Oe€亂(u2.螛襕a扱€Na(u3.,g罷+T粸臑 胈伵u0貧@垕S€Na(u4.,g罷鎮襕f$O>伱€ €t^SO1_蔛>乑喛O弉€Na(u NN淸gO(uNo偼S擽1.颯翂v`胈0UTT0y侞l0脌钀N0鏿胈0硚頬I{脌爛SNo偼S擽2.vP翂(uoT潃烺齹_8^0胈竊b畍箄1.vP翂v`胈2. g噀.sS悾`€goT,{ N)Y鶴皊湗b?l縺 閉渷EQ@ hQ珟YYr倯e筽v^vPav襲1.脌爛S恄c砙 h埌s:Nv`胈0UTT0y伬€0y侞l0y佦u2.畍蔛vQD桍N_c砙 h埌s:NhQ珟\畍箄, r偄~, 俌垟\'Y\, c婼*塺? MR鴢0y佽愂ST虁儚蛻 \PoT梑菑Oe籰梪颯銐3.^y蟸鹼邁_c砙4YUf04Y踰0餠&PI{4.vQ諲俌}v苸迉 NM朓{潃線烺齹NhQ鈋€_ g潃伵u騍bgo僊R潃烺齹_8^€Na(u*g gD崣e>f:y潃線烺齹NhQ€g(u宼eBR蠎 t拵Ng輨9h0鬵醼 g魜潃_c$O剉\o(W襨'` 鷁畫Na(u*g gD崣e>f:y潃線烺齹NhQ€g(u宼eBR蠎 t拵Ng輨9h0'Y臑 g魜潃_c$O剉\o(W襨'` Na(u?Q鍅\Nfnx宼e(uo傿R蠎5乗錘 N1!k1抾 tid5^10乗1!k2抾 tid10乗錘 N€1!k4抾 tid?Q鍅擽L懪`螿蠎5乗錘 N1!k1抾1/4媹  tid5^10乗1!k2抾1/2媹  tid10乗錘 N€1!k4抾1媹  tid奩 Z孴鶷sNg(uo\Nfnx\NfnxU[嘫0鶷sNg嘫sYNa(u0€t^篘\Nfnx\Nfnx65乗蔛錘 N€t^篘go凍e颯L懪`螿蠎o僨[鷁畫1.g(u,g罷擽u惇_{n簚烻R US!kBR蠎菑'Y颯齹q_蚑梪Hev^瀀燫o僫r剉oR蚐擽2.螛襕h埩嫞`€N淸O(u襕(Wh€ h埌s:N`襕 b珟稱 bnm縺 b筟湗R楄` b踁襕3.g(u,g罷g魰N淸 T鰁g(u薾e?`-No 俌耂0?0臑獋0ZQ耂I{4.go?g罷g魰蘝遬0R懯S洀0u稱0筶{佭榠r1.螛襕h埩嫞`€N淸O(u0襕(Wh€ h埌s:N`襕 b珟稱 bnm縺 b筟湗R楄` b踁襕2.,g罷@b+T膥Rg輨9h0鬵醼 g魜潃_c颯齹 N淸g(uo3.g(u,g罷g魰N淸 T鰁g(u薾e?`-No 俌耂0?0臑獋0ZQ耂I{4.go?g罷g魰蘝遬0R懯S洀0u稱0筶{佭榠r1.,g罷襕蒕 f黐魜脌爛SN NY裇u(Wzzygo凍e 郪dk鷁畫mTgo 颯怱_螿\脌爛SNo偼S擽 $\vQ }eg>伱€Z喴[€2.螛襕h埩嫞`€N淸O(u0襕(Wh€ h埌s:N`襕 b珟稱 bnm縺 b筟湗R楄` b踁襕3.,g罷@b+T膥Rg輨9h0'Y臑 g魜潃_c颯齹 N淸g(uo4.g(u,g罷g魰N淸 T鰁g(u薾e?`-No 俌耂0?0臑獋0ZQ耂I{5.go?g罷g魰蘝遬0R懯S洀0u稱0筶{佭榠r ADDIN NE.Bib耂€噀.s[1]Ng沴, NgO? 媅廩l_. 廩鶺郪膥f[(W O觛舥2枾c-N剉擽(u蹚U\[J]. uir€b/g惀b 2018, 34(3): 43-52.[2]齎禰kSueP穅訷濺lQ匰. 癳媁燪秗舥襨簚巔蕥梪筫Hh諎L?{NHr [J]. 胈簚@垺{舥Bg譥,2020,39(2):103-107.[3]齎禰kSueP穅訷濺lQ匰. 癳媁燪秗舥襨簚巔蕥梪筫Hh(諎L?{mQHr)[J]. -N齎a觛6RBg譥 2020, 19(2): 192-195.[4]H^,RsZ,俶軃j?I{.癳媁燪秗舥襨a觛簚巔剉-N;S蕥梪筫Hh蔛剺2柟eHh[J].匭褃%`qS蛻莡Bg譥,2020,26(1):6-8.[5]NS-N褃€b'Yf[ TNm;Sf[b朌朸\ TNm;Sb杝Q嶯癳媁燪秗舥襨簚巔-N;S蕥梪筫Hh蔛剺2柟eHh[J/OL].;So凕[:1-5[2020-03-23].http://kns.cnki.net/kcms/detail/42.1293.r.20200211.1104.002.html.[6]RCS荝, 媠Sfo? 癳媁燪秗舥襨2019-nCoV 剉vTo僫rxvzV{eu[J]. o僨[f[,2020,55(2):181-188.[7]媅rg,b,O?崌e.癳媁燪秗舥襨(2019-nCoV)籰梪o僫rSO匭Yxvz蔛o僫rx裇蹚U\[J/OL].舥襨f[:1-6[2020-03-23].https://doi.org/10.13242/j.cnki.bingduxuebao.003646.[8]Ng*Yu,鵩畇,)R,I{.S琋OS孴;Sb杝Q嶯 癳媁燪秗舥襨a觛剉簚巔 蕥梪鷁畫筫HhV2.0 [J/OL].OS孴;Sf[Bg譥:1-5[2020-03-23].http://kns.cnki.net/kcms/detail/11.5882.r.20200130.1430.002.html.[9]Li G, De C E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV)[J]. NAT REV DRUG DISCOV,2020, 19(3): 149-150.[10]Nguyen T M, Zhang Y, Pandolfi P P. Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses[J]. CELL RES,2020, 30(3): 189-190.[11]FDA Label. TAMIFLUoseltamivir phosphate Capsules, for Oral Suspension [Z]. https://www.fda.gov/drugs/information-drug-class 2018.[12]Product Information: RELENZA(R) oral inhalation powder, zanamivir oral inhalation powder.GlaxoSmithKline, Research Triangle Park,NC[Z].2006.[13]媠j_, 醼%f. ^蒪s|鏃[J]. -N齎o僫rSf[Bg譥,2015, 25(4): 328.[14]齎禰kSueP穅訷XTO.AmL?`a扱蕥梪筫Hh(2018t^Hr頞Hr)[J]. O觛舥酧o`,2018, 31(6): 500-504.[15]FDA Label[Z].2018.https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206426s005lbl.pdf.[16]AmL?`a扱蕥璭N籰梪cWS(2011t^Hr)[J]. >y:S;Sf[Bg譥 2011, 9(5): 66-74.[17]-NNS;Sf[O鬡;Sf[RO. U[嘫Ama2柣lN禰qQ茓[J]. -NNS鬡;Sf[Bg譥 2019, 22(2): 73-78.[18]Hussain M, Galvin H D, Haw T Y, et al. Drug resistance in influenza A virus: the epidemiology and management[J]. INFECT DRUG RESIST,2017(10): 121-134.[19]Duwe S. Influenza viruses - antiviral therapy and resistance[J]. GMS Infect Dis,2017(5): c4.[20]FDA Label[Z]. 2020.https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020903s056,021546s012lbl.pdf.[21]FDA Label[Z].2017.https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209347lbl.pdf.[22]So L K, Lau A C, Yam L Y, et al. Development of a standard treatment protocol for severe acute respiratory syndrome[J]. LANCET,2003, 361(9369): 1615-1617.[23]Kotton C N, Kumar D, Caliendo A M, et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation[J]. TRANSPLANTATION,2018, 102(6): 900-931.[24]-NNS;Sf[O?Q褃f[ROa觛f[膥, hQ齎?Q褃4N奮舥襨a觛OS\O膥, 0-NNS?Q褃Bg譥 0憦訷XTO. ?Q鍅鑍苸迉舥襨'`緐舥蕥璭孴2柣l剉鷁畫[J]. -NNS?Q褃Bg譥 2012, 50(4): 290-292.[25]Boriskin Y S, Leneva I A, Pecheur E I, et al. Arbidol: a broad-spectrum antiviral compound that blocks viral fusion[J]. CURR MED CHEM,2008, 15(10): 997-1005.[26]Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro[J]. CELL RES,2020, 30(3): 269-271.[27]FDA Label[Z].2002.https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21498_Alinia_lbl.pdf.[28]FDA Label[Z]. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/006002s045lbl.pdf.[29]Blaising J, Polyak S J, Pecheur E I. Arbidol as a broad-spectrum antiviral: an update[J]. Antiviral Res,2014(107): 84-94.[30]Deng P, Zhong D, Yu K, et al. Pharmacokinetics, metabolism, and excretion of the antiviral drug arbidol in humans[J]. Antimicrob Agents Chemother,2013, 57(4): 1743-1755.[31]Musher D M, Logan N, Mehendiratta V,et al. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide[J]. J Antimicrob Chemother,2007, 59(4): 705-710.[32]de Wilde A H, Jochmans D, Posthuma C C, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture[J]. Antimicrob Agents Chemother,2014, 58(8): 4875-4884.[33]Devaux C A, Rolain J M, Colson P,et al. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?[J]. Int J Antimicrob Agents,2020: 105938.[34]Savarino A, Di T L, Donatelli I,et al. New insights into the antiviral effects of chloroquine[J]. LANCET INFECT DIS,2006, 6(2): 67-69.[35]H枦Q, R9N? R墐, I{. kxx憻/l筓籰梪nf悑W2019燪秗舥襨舥COVID-19 €Rekxvz[J/OL].Ym_l'Yf[f[(;Sf[Hr):1-8[2020-03-23].http://kns.cnki.net/kcms/detail/33.1248.R.20200309.1507.006.html.[36]]趮, HN陽wZ, 俶`*t, I{. kxx憻/l筓剉4N奮otf[xvz蹚U\[J]. -N齎4N奮otf[N籰梪f[ 2020, 25(2): 221-226.[37]齎禰kSueP穅訷濺lQ匰 齎禰-N;So儭{t@\濺lQ. sQ嶯pS裇癳媁燪秗舥襨簚巔蕥梪筫Hh諎L?{NHr 剉愬w[Z].齎kS濺;S齉020200184鱏. 2020-03-03.[38]騍R楖z, u峼f, 體癳ga, I{. `!媁r^pb }剉梑舥襨:g6Rxvz蹚U\[J]. 決婲;Sf[ 2015, 39(7): 557-560.[39]H柗\,鍅cu,箯烻,I{.畍 N鑜\-r^pb }籰梪2019t^癳媁燪秗舥襨剉猒翄隷惸?O[J/OL].;So凕[:1-19[2020-03-23].http://kns.cnki.net/kcms/detail/42.1293.R.20200210.1759.002.html.[40]Omrani A S, Saad M M, Baig K,et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study[J]. LANCET INFECT DIS,2014, 14(11): 1090-1095.[41]Cinatl J, Morgenstern B, Bauer G, et al. Treatment of SARS with human interferons[J]. LANCET,2003, 362(9380): 293-294.[42]-NNS;Sf[O|T8T舥f[RO|T8T籰梪f[膥. S8TeQ梪誰(W|T8T緐舥-N剉擽(uN禰qQ茓[J]. -NNS;Sf[Bg譥,2016, 34(96): 2696-2708.[43]3uf瞫, \慛Sf, _齎b. r^pb }(W?Q褃4N奮Tt擽(uN禰qQ茓[J]. -NNS瀃(u?Q褃4N奮Bg譥,2018, 33(17): 1301-1308.[44]Omrani A S, Saad M M, Baig K,et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study[J]. LANCET INFECT DIS,2014, 14(11): 1090-1095.[45]Cinatl J, Morgenstern B, Bauer G, et al. Treatment of SARS with human interferons[J]. LANCET,2003, 362(9380): 293-294.[46]FDA Label[Z].2000.https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21226lbl.pdf.[47]FDA Label[Z].2019.https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021976s056,202895s027lbl.pdf.[48]FDA Label[Z].2000.https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21251lbl.pdf.[49]FDA Label[Z].2019.https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021976s056,202895s027lbl.pdf.[50]Lim J, Jeon S, Shin H Y,et al. Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR[J]. J KOREAN MED SCI,2020, 35(6): e79.[51]Li L, He H, Lan Y, et al. Dual therapy with lopinavir/ritonavir plus lamivudine could be a viable alternative for antiretroviral-therapy-naive adults with HIV-1 infection regardless of HIV viral load or subgenotype in resource-limited settings: A randomised, open-label and non-inferiority study from China[J]. Indian J Med Microbiol,2018, 36(4): 513-516.[52]Lim J, Jeon S, Shin H Y, et al. The Author's Response: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR[J]. J KOREAN MED SCI,2020, 35(7): e89.[53]Yang J, Nikanjam M, Best B M, et al. Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood[J]. J CLIN PHARMACOL,2018, 58(12): 1604-1617.[54]Ebrahim I, Maartens G, Wiesner L,et al. Pharmacokinetic profile and safety of adjusted doses of darunavir/ritonavir with rifampicin in people living with HIV[J]. J Antimicrob Chemother,2020.[55]Furuta Y, Gowen B B, Takahashi K, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor[J]. Antiviral Res,2013, 100(2): 446-454.[56]Sheahan T P, Sims A C, Graham R L, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses[J]. SCI TRANSL MED,2017, 9(396):e3653.[57]Reina J, Reina N. Baloxavir marboxil: a potent cap-dependent endonuclease inhibitor of influenza viruses[J]. Rev Esp Quimioter,2019, 32(1): 1-5.[58]Golini F, Thach S S, Birge C H, et al. Competition between cellular and viral mRNAs in vitro is regulated by a messenger discriminatory initiation factor[J]. Proc Natl Acad Sci USA,1976, 73(9): 3040-3044.[59]Tchesnokov E P, Feng J Y, Porter D P,et al. Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir[J]. Viruses,2019, 11(4):326.[60]Warren T K, Jordan R, Lo M K, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys[J]. NATURE,2016, 531(7594): 381-385.[61]恄P[褢, 媠s^. 梑癳媁燪秗舥襨\o汻o僫r  ^t穇夋梉J]. -N齎皊鉔擽(uo僨[,2020, 37(3): 264-268.[62]Reina J, Reina N.Favipiravir, a new concept of antiviral drug against influenza viruses[J]. Rev Esp Quimioter,2017, 30(2): 79-83.[63]Sheahan T P, Sims A C, Leist S R, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV[J]. NAT COMMUN,2020, 11(1): 222.[64]Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro[J]. CELL RES,2020, 30(3): 269-271.[65]Gordon C J, Tchesnokov E P, Feng J Y, et al. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus[J]. J BIOL CHEM,2020.[66]FG H, N S, N H. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents[J]. N Engl J Med,2018, 379(10): 913-923.[67]Furuta Y, Takahashi K, Shiraki K,et al. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections[J]. Antiviral Res,2009, 82(3): 95-102.[68]Ngf[梘, ][t, 鵩蔕璡. 瀃(u4N奮-No僨[-Nbo冭R [M]. S琋篘lkSu鶴Hr>y, 2013.[69]Ay鷁s^, AySf沍, 媠SfZ. N TBR蠎褢眰na棙抾鵞AmL?`a扱剉梪He蔛鵞€@n苸迉郪P[剉q_蚑[J]. 皊鉔;Sf[,2016, 44(12): 1664-1669.[70]_[sO, *PZS6q, 9\o倝s,I{. a扱愴pnN褢眰na棙抾籰梪Ama7h舥婳愴p梪He詋儚[J]. -N;SBg譥,2015, 56(5): 402-404.[71]Ng齎銻, u峐? `\譥沵, I{. 褢眰na棙抾籰梪AmL?`a扱螛韕痳簚翄蘏騰彇:g鵞gqxvz[J]. -N齎-N堺S觺TBg譥,2013, 33(12): 1631-1635.[72]Ay鷁s^, AySf沍, 媠SfZ. N TBR蠎褢眰na棙抾鵞AmL?`a扱剉梪He蔛鵞€@n苸迉郪P[剉q_蚑[J]. 皊鉔;Sf[,2016, 44(12): 1664-1669.[73]體, 媠駛. 迯眰nv鰛蔞T€T)R鬩鏃梘S8TeQ籰梪\?Q|T8TST迉舥襨a觛剉梪He聣遊[J]. NLu-N;So?2018, 13(7): 1666-1668.[74]韾wm, hg蹚, 殶UZ乕, I{. 迯眰nv鰛蔞鵞\ 熍u襨a觛T簚cpe剉q_蚑[J]. 砽WS-N;S,2007(3): 35-36.[75]珒(, 飃 f噀, 褠睷s^, I{. 迯眰nv鰛蔞SOY梑2u媁Ama舥襨剉瀃寶xvz[J]. -No儼eoN4N奮ot 2007(1): 5-9.[76]珒(, hgP[餦, 褠睷s^, I{. 迯眰nv鰛蔞2柣lAma舥襨FM1a觛\ 焺v瀃寶xvz[J]. -No働g,2008(8): 1230-1233.[77]sQ噀緩, \g藋6O, _lwmf, I{. ?栐kY\N迯眰nv鰛蔞鵞-NN|T8T鼅T乢燪秗舥襨剉SO匭Y慴6R\O(u詋儚[J]. ^N;Sf[ 2018, 39(23): 3454-3458.[78]媠圼決. 迯眰nv鰛蔞梑Ama舥襨ot:g6Rxvz[J]. 4N奮Tt(uo傿g譥 2019, 12(5): 53-54.[79]H朂N慛, 媠鰯#Z, 臑Il. 迯眰nv鰛蔞梑Ama舥襨4N奮梪He聣遊[J]. u儉;So 2017, 36(8): 666-667.[80]TOO, 1g鍅Z, 睈"k, I{. 弖螛銐襨鰛蔞梑舥襨蔛梑虄剉SOYo僅ef[瀃寶xvz[J]. -No儼eoN4N奮ot 2013, 24(3): 234-238.[81]縲櫃dW, 輴h藌, l歰f:? I{. 弖螛銐襨鰛蔞T€T?栐kY\籰梪癳媁燪秗舥襨簚巔剉轛~?`xvz[J]. -NI僶 2020 515 : 1167-1170.[82]崪‐‐, 貧駛pg, 鰁嘯Y? I{. 弖螛銐襨鰛蔞^1寳b舥襨烺Hexvz[J]. 癳-N;S 2019, 51(12): 5-8.[83]睈"k, Ng/ctQ, 1g鍅Z, I{. 弖螛銐襨鰛蔞SO匭梑舥襨\O(u剉瀃寶xvz[J]. -No儼eoN4N奮ot 2014, 25(1): 14-17.[84]Ng`j€,疩ey,誯蕏,I{.癳媁燪秗舥襨簚巔蕥梪筫Hh-Nbo ?uR恎Notxvz蹚U\[J/OL].-No働g:1-10[2020-03-27].http://kns.cnki.net/kcms/detail/44.1286.r.20200302.1359.005.html.[85]鸑O皵,蟼le,R8l&t,I{.hQ齎Tw:S-N;So兓l梪癳媁燪秗舥襨簚巔COVID-19 剉蕥梪筫HhR恎[J].-NI僶?2020,51(5):1139-1146.[86]齎禰o儀Q訷XTO. -NNS篘lqQ孴齎4N奮(uo儃樺w[M]. S琋-N齎;So冄y€b鶴Hr>y 2017.[87]1g噀 ? 亪噣颭. -N;S蕥璭f[[M]. S琋篘lkSu鶴Hr>y 2013. ADDIN NE.Bibw岻N禰膥gb{篘R 鞐 -Nq\'Yf[縺$v2柣l-N胈 oR;N鸑o^螢\峐 -Nq\'Yf[D朸\,{mQ;Sb ;N鸑o^籙蕇蕇 WS筫;S褃'Yf[鄐_l;Sb oR;N鸑o^H pg -Nq\'Yf[D朸\,{N;Sb oR;N鸑o^媠螢R -Nq\'Yf[D朸\,{N;Sb oR;N鸑o^睈颭 -Nq\'Yf[Y[8愘N獈鮛;Sb ;N鸑o^ _ pg ^Nw-N;Sb ;No^~橆Ng eP WS钀b:S;`;Sb ;N鸑;S^臑uQ -Nq\'Yf[縺$v2柣l-N胈 ;N鸑o^媠 荝 WS筫;S褃'Yf[鄐_l;Sb ;N鸑o^hT,gpg -Nq\'Yf[D朸\,{N;Sb ;N鸑o^梘 NS ^Nw-N;Sb ;N鸑-No^"?f駛 -Nq\'Yf[D朸\,{mQ;Sb ;N鸑o^YOwm3t -Nq\kp琾_裇:S;Sb oR;N鸑o^0u 3t -Nq\'Yf[D朸\,{擭;Sb oR;N鸑o^Ng塻蛃 -Nq\'Yf[D朸\,{kQ;Sb ;N鸑o^珒齎 h -Nq\^,{孨篘l;Sb ;N鸑o^臑E枃 -Nq\'Yf[D朸\,{ N;Sb oR;N鸑o^褠譥NS ^Nwo僨[O ;N鸑o^ oRt婲晐Q貀fNbXT c覻l{R:N廭 媠 荝 ^Nwo僨[O ;No^ f[/g钀;N鸑媠枠f_ ^Nw-N;Sb ;N鸑o^搻 薘 WS筫;S褃'Yf[鄐_l;Sb ;No^鎉鏬慛 -Nq\'Yf[D朸\,{N;Sb ;No^RSf&t ^Nw篘l;Sb杘R;N鸑 oR;N鸑o^UOOg闚 ^轢-N;So?Yf[z樂_;Sb ;N鸑o^?b"嵦[ -Nq\'Yf[縺$v2柣l-N胈 ;No^祂 紁 ^轢;S褃'Yf[D朸\,{孨;Sb oR;N鸑o^祂Sf ^Nw-N;Sb ;No^貧 鹐 -Nq\'Yf[D朸\,{mQ;Sb oR;N鸑o^臑 )R -Nq\'Yf[D朸\,{N;Sb ;No^臑裮$ WS筫;S褃'Yf[鄐_l;Sb ;No^m_wm箖 WS钀b:S;`;Sb oR;N鸑o^"孻棁e -Nq\'Yf[D朸\,{mQ;Sb ;No^V岹oGo ^Nw-N;Sb ;No^貀fN媠悩wZ -Nq\'Yf[D朸\,{mQ;Sb o^貧`軓 -Nq\'Yf[Y[8愘N獈鮛;Sb o^Sf慛 -Nq\'Yf[D朸\,{N;Sb o^ PAGE \* MERGEFORMAT 108284868F8j8^UII= $$Ifa$gdM $$Ifa$gd $$Ifa$kdg$$If4謀?C?  +?44 layt?\j8l8~8???^RFFF $$Ifa$gd縠 $$Ifa$gd5[kdq$$If4謀?C?  +?44 layt?\????????0929@9B9D9L9P9p9??疣一播攱攜斠eSeC3hw"*hd5丱JQJaJo(hw"*hh5丱JQJaJo(#hw"*hw"*5並HOJQJ^JaJ&hw"*hh5並HOJQJ^JaJo("hQB*H*KHOJQJaJphhQ5丱JQJ jh? hh5丱JQJUh7hhOJPJQJh億5丱JQJ-h}sh億OJPJQJaJfHq h? hh5丱JQJo(h縠h﹛5丱JQJaJo(h縠h5丱JQJaJo(???D9r9`[QE $$Ifa$gdw"* dhゐgdw"*dhkd{$$If斢謀?C?+?44 layt?\r9t9~9?? $Ifgd2 $$Ifa$gd&Gekd啩$$If???644 laytw"*?????:6:T:sg^R@@@$$IfWD`a$gdw"* $$Ifa$gdw"* $Ifgdw"* $$Ifa$gd&Gkd$$If諪?n ?q?6    44 layt&G?????????: :.:0:4:6:8:::D:F:T:X:z:|:~:侜愈羸埴蔸狷聱斛?; ;,;p;箦箦筅叔赖箦坤枂x喞道錵箦]髃箦靛箦箦hOhOOJQJaJo(hw"*hdOJQJaJhw"*hhOJQJ\乤Jhw"*hhOJQJ\乤Jo(hw"*hw"*OJQJ\乤J!hw"*hh5丱JQJ\乤Jo(hw"*OJQJaJo(hw"*OJQJaJhw"*hh5丱JQJaJo(hw"*OJQJ\乤Jhw"*hhOJQJaJo(hw"*hhOJQJaJ$T:|:~:€:侜K?6 $Ifgdw"* $$Ifa$gd&Gkd$$If4攚謀?n ?``?644 laytd$$IfWD`a$gdw"*侜圍埴蔸啁A5 $$Ifa$gd&Gkd%$$If4?謀?n ?  ?644 laytd$$Ifa$gdw"* $$Ifa$gdw"*啁狷聱凔躯甥6kdN$$If4?謀?n ?  ?644 laytd$$IfWD`a$gdw"* $$Ifa$gdw"* $Ifgdw"*p;r;t;v;凔圎忹披躯甥望<<<F<凕咟腰蔹=== =$=:=<=d=f=|=~=€=朂楜欭濤?饼笼啐猃妪>V>X>Z>^>r>翩翩厥艚敖娼版魻骠骠悁犳翩翩翩魫€犳v骠鎣骠悁犳hdOJQJaJhw"*hdOJQJ\乤Jo(hw"*hhOJQJ\乤Jo(hw"*hh5丱JQJaJo(hw"*hdOJQJaJhw"*hhOJQJaJhw"*hhOJQJ\乤Jhw"*hw"*OJQJ\乤Jhw"*hhOJQJaJo(hw"*OJQJaJo(.甥他望整<$$Ifa$gdd $$Ifa$gdw"* $Ifgdw"* $$Ifa$gd&G<<(<咟扅唿]Q?33 $$Ifa$gdw"*$$IfWD`a$gdd $$Ifa$gd&Gkdw$$If4攧謀?n ?  ?644 laytd唿= ="=$=*=楜KBB66 $$Ifa$gdw"* $Ifgdw"*kd牠$$If4斺謀?n ?``?644 laytd$?$IfWD`?a$gdw"*楜欭淉濤?猃]TTH2$?$IfWD^?`a$gdd $$Ifa$gdw"* $Ifgdw"*kd僧$$If4斸謀?n ?  ?644 laytd猃X>Z>\>^>f>G>>2 $$Ifa$gdw"* $Ifgdw"*kd虔$$If4旀謀?n ?  ?644 laytd$?$IfWD^?`a$gddr>?炳楚叠浸傀渠绳瑶政觜???"?$?(?翡云暺乺乥UGUG8hB0J5丱JQJaJo(hBhhOJQJaJo(hBhhOJQJaJhBhh5丱JQJaJo(hB5並HOJQJ^JaJ&hBhh5並HOJQJ^JaJo(h7hhOJPJQJh7h億OJPJQJ-h}sh億OJPJQJaJfHq h? hh5丱JQJo(hw"*hdOJQJ\乤Jo(hw"*hhOJQJ\乤Jo(hw"*OJQJaJo(f>炳楚叠绳KF< dhゐgdBgdw"*kd$$If4斖謀?n ?  ?644 laytd$$IfWD`a$gdw"*绳齄???u_$?勣$IfWD?^?`勣a$gd\| $$Ifa$gdBekdD$$If???644 laytB$?刬$IfVDWD2^?`刬a$gdB??$??N@窣LA扐鬉BjB郆zfffffffff$勧$IfVD?WD?`勧a$gdB $$Ifa$gdBxkd圆$$If??$ ??644 laytB (?.?0?D?H?L?R?T?Z????@@@ @$@:@L@N@R@~@凘楡禓窣粿镙镙镙屋镙姬摟摟|лoaQaoQEhBKHOJQJaJhBhhOJQJ\乤Jo(hBhhOJQJ\乤JhBOJQJ\乤Jo(,hBhhOJQJ\乤JfHq &h1OJQJaJfHo(q )hBhhOJQJaJfHq #hBOJQJaJfHq hB0J5丱JQJaJo("hBhh0J5丱JQJaJo(hBhh0J5丱JQJaJ粿蜙褸谸銨頏鯜兀A AAA AJALAPA\A怉扐朅ˋ瓵睞窤篈糀繟翧華蔄贏蹵駻鬉鳤BBB BhBjBnB艬轇郆C C襻襻襻襻襻襻襻蔗柔锐狁狁狁狁狁狁嵴狁峋睙緫唙緫hBhh5丱JQJaJo(hBOJQJaJo(hBhhOJQJaJo("hBhh0J5丱JQJaJo(hBhhOJQJaJhBOJQJaJhBKHOJQJaJo(hBKHOJQJaJhBhhKHOJQJaJo(hBhhKHOJQJaJ.郆 C奀DlDnD侱`E綞鬍菷蜧rf $$Ifa$gdBxkdz$$If??$ ??644 laytB$勧$IfVD?WD?`勧a$gdB C&C@C€C圕奀怌腃艭菴銫DDD,DjDnD侱咲霥頓餌麯﨑EEE@E^E`EdE~E糆綞翬駿鬍鳨菷蘁嶨蘂蠫褿訥翩傧肯亵腺】骠骠湘翩萧骠骠骠嫦翩湘湘翩妐0h鄈h鄈OJPJQJaJfHo(q h? hh5hBhhKHOJQJaJhBKHOJQJaJ#hBOJQJaJfHq hBhh5丱JQJaJo(hBOJQJaJhBhhOJQJaJhBhhOJQJaJo(hBOJQJaJo(,蜧蠫褿鬐甀癐睮NJ凧|n`^WK $$Ifa$gd覵/ゐgd'k'劋dWD`劋gd鄈劋dWD`劋gd譠ddhxkd.$$If??$ ??644 laytB訥谿蹽釭鍳騁鬐礼H"H8H:H|H孒蘃蠬蹾頗餒I.I0I2I欼淚狪琁癐柘稜惰攭攭€攗攢攭攢uiXLXLXh譠h譠H*OJQJ jh譠h譠H*OJQJUh譠h譠OJQJo(h譠h譠OJQJh譠OJQJo(h? h譠OJQJh? h譠OJQJo(*h阓OJPJQJaJfHo(q 0h鄈hhOJPJQJaJfHo(q 0h鄈h譠OJPJQJaJfHo(q -h鄈h鄈OJPJQJaJfHq 癐睮窱篒菼蔍2J4J:J>JJJLJNJVJ`JdJpJ侸咼鲞聘珫儢kS>Sk0h!8 hhOJQJaJo()h阓5丱JQJaJfHo(q /h阓h譠5丱JQJaJfHo(q /h!8 hh5丱JQJaJfHo(q $h1{mhQB*H*KH^JaJphhQB*H*KH^JaJph hQ5jh? hh5乁h1{mhhOJPJQJo(0h1{mhhOJPJQJaJfHo(q -h1{mh1{mOJPJQJaJfHq h? hh5乷(凧咼怞燡狫篔翵菾 $$Ifa$gd!8 gkd獯$$If??€?644 layt!8 咼濲燡↗狫窲篔艼蔎躂轏郕$K&K4K6KKdKfKhK銴鍷鐺xLzL諰轑釲銵闘頛鳯﨤M疴疴疴疴允吭痹吭试渴允吭试吭媫o^ jh? hh5丱JQJUh1{mh?OJPJQJo(h1{mhhOJPJQJo( h1{m5?h1{mh1{mOJPJQJaJfHq h? hh5乷(h!8 h!8 OJQJaJo(h!8 OJQJaJo(h!8 OJQJaJh!8 hhOJQJaJo(h!8 hh5丱JQJaJh!8 hh5丱JQJaJo("菾蔎訨霬$K8,,, $$Ifa$gd!8 kd姷$$If謭? B>?hnF ?644 layt!8 $K.KBK↘,kd毝$$If攧謭? B>?hnF ?644 layt!8 $$Ifa$gd!8 ↘睰蜬蠯躃鬕lLpL~L郘xzkd阜$$If數???h??644 layt!8 $$Ifa$gd!8 郘釲銵凪碝86/& $Ifgd+"ゐgd'k'kdp$$If擣謭? B>?hnF ?644 layt!8 MhMjMpMrM~M€M凪嶮怣歁濵狹琈睲禡鲥泳渝稙噊Zo濨4h+"hhOJQJaJo(/h+"h?5丱JQJaJfHo(q )h阓5丱JQJaJfHo(q /h阓h阓5丱JQJaJfHo(q ,h+"h'k'5丱JQJaJfHq /h+"hh5丱JQJaJfHo(q h? hho((h1{mhQB*H*KHOJ^JaJph"hQB*H*KHOJ^JaJph jh? hh5丱JQJUhQ5丱JQJ碝禡繫萂 $$Ifa$gd+" $$Ifa$gd瘥ekd幑$$If?#q#?q#644 layt+"禡繫芃蔒諱餗N*N,NNJNLNTNVN^N`NfNhNnNpNxNzN圢奛扤擭琋甆糔O OBODONOPOfOxO濷窸蜲襉P PtPxPzP侾凱疣鹨乓呕乓乓乓乓乓乓乓乓乓虐遗遗⑴遗遗遗遗遗覙亅 h1{m5?h1{mh1{mOJPJQJaJfHq h? hh5乷(h+"h+"OJQJaJo(h+"OJQJaJo(h+"OJQJaJh+"hhOJQJaJh+"hhOJQJaJo(h+"h?5丱JQJaJo(h+"hh5丱JQJaJo(0萂蔒訫,N癗znn $$Ifa$gd+" $$Ifa$gd瘥xkd$$If??:#?q#644 layt+"癗睳糔jOzn $$Ifa$gd+" $$Ifa$gd瘥xkd暮$$If??:#?q#644 layt+"jOlOxOvPzq $$Ifa$ $$Ifa$gd瘥xkdx$$If??:#?q#644 layt+"vPxPzP擯蔖}q $$Ifa$gdjGOゐgdjGOxkd$$If??:#?q#644 layt+"凱扨擯淧濸燩狿甈篜萈蘌鑀鯬QQ,QLQTQ濹≦窺篞腝郠釷 RRR耒细蠣嫚蟷m}b}b}U}b}U}UJUb}h@OJQJaJo(hjGOhhOJQJaJhjGOOJQJaJo(hjGOhh5丱JQJaJo(hjGOhhOJQJaJo()h阓5丱JQJaJfHo(q /h阓h阓5丱JQJaJfHo(q ,hjGOh'k'5丱JQJaJfHq /hjGOhh5丱JQJaJfHo(q h? hh5乷(h1{mhhOJPJQJo(蔖蘌諴鍼 $$Ifa$gd袰kkd募$$IfT擔???644 layt iL奣鍼鑀騊Q.Q€www $$Ifa$~kd\$$IfT擔?? ??644 layt iL奣.Q0Q:Q猀€ww $$Ifa$~kd $$IfT攖?? ??644 layt@奣猀琎窺R€wk $$Ifa$gd@ $$Ifa$~kd凭$$IfT攖?? ??644 layt@奣RRR2RbR€~wn $Ifgdt\ゐgdt\~kdt$$IfT攖?? ??644 layt@奣RRR R0R2R:RRHRLRXR`RdRzR凴圧鬣秩孩嫝s^s@5*h盬7ht\OJQJh盬7hhOJQJht\hh5丱JQJaJo(ht\hhOJQJaJo()h阓5丱JQJaJfHo(q /h阓h阓5丱JQJaJfHo(q ,ht\h'k'5丱JQJaJfHq /ht\hh5丱JQJaJfHo(q h? hh5丱JQJo(h1{mhhOJPJQJo(h? hh5乷(-h1{mh1{mOJPJQJaJfHq h? hho(bRdRnRxR $$Ifa$gdt\kkd"$$IfT????644 layt鷙奣xRzR凴癛諶SjS糞€wwwwwwn $Ifgd盬7 $Ifgdt\~kd豪$$IfT???m??644 layt鷙奣圧扲琑甊癛芌萊蜶蠷訰諶赗躌鯮鳵SSS S"S(S*S0S2S6S8SXSZS^S`ShSjS凷哠琒甋睸碨篠糞維蘏釹TTT8T:T>THTPT^TbTdThT~T€T圱奣濼燭猅禩篢糡綯 UUUU蹶蹶蹶蹶蹶蹶蹶蹶蹶踽蹶蹶蹶蹶蹶蹶踽蹶瞩牾甚牾锦牾杲蹶蹶蹶蹶蹶蹶蹶蹶跎蹶蹶h盬7ht\6丱JQJh盬7hhOJQJaJh盬7h(OJQJh盬7OJQJo(h盬7ht\OJQJh盬7hhOJQJH糞維萐dT糡€www $Ifgdt\~kdh$$IfT攧??m??644 layt秥奣糡綯蔜U\U濽€wwwn $Ifgd盬7 $Ifgdt\~kd$$$IfT???m??644 layt鷙奣UUU U"U&U(U,UBUDUFUZU\U^UbUdUhUjUnU刄圲濽燯猆琔碪禪V V滹澍镤苡淙滹间淙浏厀f]fhQ5丱JQJ jh? hh5丱JQJUh1{mhhOJPJQJo( h1{m5?h1{mh1{mOJPJQJaJfHq h? hh5丱JQJo(h盬7hhOJQJaJh盬7h盬7OJQJo(h盬7ht\OJQJh{?OJQJo(h{?OJQJh盬7hhOJQJh盬7OJQJo(h盬7OJQJ濽燯>VlV€~wk $$Ifa$gdゐgd洱x~kd衣$$IfT攜??m??644 layt鷙奣 V&V6V:VVFVHVRVVVbVjVnV扸VW擶繵钯钊孩媠^s@P5Ph鏫€OJQJaJo(h洱xhh5丱JQJaJo(h洱xhhOJQJaJo()h阓5丱JQJaJfHo(q /h阓h阓5丱JQJaJfHo(q ,h洱xh'k'5丱JQJaJfHq /h洱xhh5丱JQJaJfHo(q h? hh5丱JQJo( jh? hh5丱JQJU(h1{mhQB*H*KHOJ^JaJph"hQB*H*KHOJ^JaJphlVnVxV俈怴 $$Ifa$gd鏫€ $Ifgd 5ekd€$$If???644 layt洱x怴扸淰朩瞁sj^^U $Ifgd鏫€ $$Ifa$gd鏫€ $Ifgd 5kd$$If諪??dn ?6    44 layt 5瞁碬禬竁網豔]THH? $Ifgd鏫€ $$Ifa$gd鏫€ $Ifgd 5kd棠$$If4斻謀?^?``dU?644 layt 5繵萕騑X"X\XlX|X€X瞂禭糥蘕鋁zY俌榊歒猋甕篩襓訷諽闥ZZZ Z"Z$Z(ZDZHZJZPZTZ€Z嶼榋歓淶箦阱阱箦绣箦筅迮迮遐弩弩弩弩遐逍宸②鍖v+h鏫€h鏫€OJQJaJmH nHo(sH tH+h洱xhhOJQJaJmH nHo(sH tHh鏫€H*OJQJaJh鏫€OJQJaJh洱xh(OJQJaJo(h阓OJQJaJo(h鏫€OJQJaJh鏫€OJQJaJo(h洱xhhOJQJaJo(h洱xhhOJQJaJ*豔赪躓轜頦X^X]THH?? $Ifgd鏫€ $$Ifa$gd鏫€ $Ifgd 5kd脚$$If4謀?^?  dU?644 layt 5^X`XbXdXlX]THH? $Ifgd鏫€ $$Ifa$gd鏫€ $Ifgd 5kd犉$$If4敳謀?^?  dU?644 layt 5╔瞂鎄鬤Y]THH? $Ifgd鏫€ $$Ifa$gd鏫€ $Ifgd 5kd兦$$If4斔謀?^?  dU?644 layt 5YYYYYY]THH? $Ifgd鏫€ $$Ifa$gd鏫€ $Ifgd 5kdt$$If4斚謀?^?``dU?644 layt 5YY Y"Y2Y@Y]THH? $Ifgd鏫€ $$Ifa$gd鏫€ $Ifgd 5kde$$If4?謀?^?  dU?644 layt 5@YBYDYFYNY\Y]THH? $Ifgd鏫€ $$Ifa$gd鏫€ $Ifgd 5kdV$$If4?謀?^?  dU?644 layt 5\Y^YjY瀁猋$Z]TH<3 $Ifgd鏫€ $$Ifa$gd鏫€ $$Ifa$gd阓 $Ifgd 5kdG$$If4斶謀?^?  dU?644 layt 5$Z俍刏哯圸嶼[THHH? $Ifgd鏫€ $$Ifa$gd鏫€kd8$$If4敔謀?^?``dU?644 layt 5 $Ifgd鏫€淶瀂篫糧綵耑鎆鑊 [[([0[6[J[~[糩綶耓腫萚躘胝朊罢冒闸暍晩eQJ<h1{mhhOJPJQJo(h1{m5乤J'h1{mOJPJQJaJfHq -h1{mh1{mOJPJQJaJfHq h? hh5丱JQJo(h鏫€OJQJaJo(h洱xhhOJQJaJh洱xhhOJQJaJo(%h鏫€OJQJaJmH nHo(sH tH"h鏫€OJQJaJmH nHsH tH+h洱xhhOJQJaJmH nHo(sH tH(h洱xhhOJQJaJmH nHsH tH[[[[$[€[]TTTT $Ifgd鏫€kd7$$If4敃謀?^?  dU?644 layt 5€[俒刐哰嶽篬]TTTT $Ifgd鏫€kdD$$If4敃謀?^?  dU?644 layt 5篬糩綶T\圽][TH $$Ifa$gd?ゐgd?kdC$$If4敃謀?^?  dU?644 layt 5躘轠F\H\P\R\T\^\`\哱奬耚蘚衆襖]]]燷轢郵鯹鴀^^&^(^>^@^V^X^n^p^哵坁瀆衈耜褛裎稛稇亼v憊憊憊慽慽慽慽慽慽慽慽h?hhOJQJaJh?OJQJaJo(h?hh5丱JQJaJo(h?hhOJQJaJo(,h?h'k'5丱JQJaJfHq /h?hh5丱JQJaJfHo(q h? hh5乤Jo(hQB*H*KH^JaJphhQ5乤Jjh? hh5乁aJ$圽奬擻瀄繺 $$Ifa$gd?ekd&$$If???644 layt?繺耚蘚]h]郵燸sjaaUa $$Ifa$gd? $$Ifa$ $$Ifa$kd缎$$If諪?^? ?6    44 layt?燸琟P_鴂qh__ $$Ifa$ $$Ifa$kdr$$If 諪?^? ?6    44 layt?衈謂_N_P_f_h_~_€_朹榑甠癬芲萠轤郷鯻鷂`4`6`n`p`aa0a2aHaJabadaza|a抋攁猘琣產腶芶躠疴租殊殊殊殊殊殊时庾首娛馐资馐馐馐鈣殊h?h?OJQJaJh?h?mOJQJaJo(h?mh?mOJQJaJo(hhOJQJaJo(0h?hh@OJQJaJfHo(q h?hhOJQJaJh?OJQJaJo(h?hhOJQJaJo(h?hhH*OJQJaJo()鴂鷂`6`p`躟a轪sjaaUUI $$Ifa$gd? $$Ifa$gd?m $$Ifa$ $$Ifa$kd@$$If諪?^? ?6    44 layt?轪郺鈇lb歜燽産糱sqg_VPD $$Ifa$gd橜b$If $$Ifa$$a$gd淴 $ゐa$gd?kd$$If諪?^? ?6    44 layt?躠郺鈇鋋鑑頰餫XbZbhbjblbpbxb檫侠皾帩u漣Q:,h{bh淴5丱JQJaJfHq /h{bh淴5丱JQJaJfHo(q hhOJPJQJaJ0h?hQB*H*KHOJPJQJ^JaJphh?hQOJPJQJaJ%jh?hhOJPJQJUaJh?hhOJPJQJaJo(h?h?OJPJQJaJh?h?OJPJQJaJo(h? hh0Jo(,h?hhOJQJaJfHo(q xb~b刡奲攂榖歜瀊赽,c.c0cbcdc坈芻詂鎐鑓.dldnd€d俤抎衐襠鋎鎑e\epe€e俥榚歟猠琫磂篹耬膃芿缧缧绺珱崨€v泹k泹v峩泙v€v泹v峩泹v峷峩峩峷h橜bOJQJaJo(h橜bOJQJaJh淴hhOJQJaJh淴hhOJQJaJo(h淴hh5丱JQJaJo(h橜b5丱JQJaJo(/h{bh淴5丱JQJaJfHo(q ,h{bh橜b5丱JQJaJfHq /h{bh橜b5丱JQJaJfHo(q *糱襜詁赽.cdc萩RI@::$If $Ifgd橜b $$Ifa$kd赣$$If攂謀?.?0?644 layt淴 $$Ifa$gd橜b萩蔯詂鑓nd俤襠鎑^e^ULLLLLL $Ifgd橜b $$Ifa$kd幵$$If謀?.?0?644 laytz% ^e`epe萫黣0f^f^ULLFL$If $Ifgd橜b $$Ifa$kdr$$If謀?.?0?644 laytz% 芿萫辝鄀鈋鋏阤靍鬳鷈黣fffff f(f.f0f@fBfDfFfLfNfVf\fpf刦唂榝歠甪癴謋豧鎓鑖gggg"gZg\g`g疴剽外外宛庳馔馔馔棱剽外外宛饫饫饫饫饫獍︹涒饌0h淴hhOJQJ^J aJfHo(q hCH*OJQJaJhCOJQJaJh?hhH*OJQJaJo(h淴hhOJQJaJh橜bOJQJaJo(h橜bOJQJaJh淴hhOJQJaJo(h淴hh5丱JQJaJo(.^f`fpf唂歠癴豧鑖^UEEEEE?$IfWD^?` $$Ifa$kdH$$If?謀?.?0?644 laytz% 鑖\g|g抔 h"h6h^h瀐 $IfWD`?$IfWD^?`gdC `g|g€g恎抔杇猤篻糶謌豨趃躦鄃鋑騡鷊h h h柘硅瞎柘锠鑷}od柘柘P@h淴hh5丱JQJaJo('h?OJQJ^J aJfHq hCH*OJQJaJh淴hCOJQJaJo(hCOJQJaJ0h淴hhH*OJQJ^J aJfHq 0h淴hhOJQJ^JaJfHo(q *h?OJQJ^J aJfHo(q 0h淴hhOJQJ^J aJfHo(q -h淴hhOJQJ^J aJfHq  hh h"h&h4h6h:h\h^hbh渉猦甴鑘阧頷iiii i.i2i>ifihipirivi╥鰅"j$j(jHjJjNj`jrj榡歫秊鬸鰆6kLk矜亳尜矜亳嫔窬亳举丧庱亳亳勆駓亳y亳y亳y删神y神yhTOJQJaJo(h橜bOJQJaJ-h淴hhOJQJ^J aJfHq 0h淴hhOJQJ^J aJfHo(q h橜bOJQJaJo(h淴hh5丱JQJaJo(h淴hhOJQJaJh?OJQJaJo(h淴hhOJQJaJo(/瀐爃猦阧ii iri^UKKU?? $IfWD` $If^ $$Ifa$kd$$If?謀?.?0?644 laytz% ri╥$jJjbjdjrj歫LC $$Ifa$kd糇$$If謀?.?0?644 laytz% $If $IfWD`歫鰆NkPkVk`k耴I@:$If $$Ifa$kd守$$If謀?.?0?644 laytz% $IfWD` $IfgdTLkVk^k`kvkxk€k唊妅宬択攌渒発瞜簁纊耴衚襨趉躪餶鰇鷎黭llll,l.l>lDlFlHlZlbldlllnl刲恖榣歭╨苐詌疴疴租租租租租租尊怜翜翜翜翜翜翜翜妧疴疴疴疴疴疴尊h淴hhaJo(#h淴hhaJmH nHo(sH tH%hTOJQJaJmH nHo(sH tH"hTOJQJaJmH nHsH tH+h淴hhOJQJaJmH nHo(sH tHhTOJQJaJo(h淴hhOJQJaJo(h淴hh5丱JQJaJo(2耴襨FlHlZldlnlULFL$If $$Ifa$kd犢$$If謀?.?0?644 laytz% $IfgdTnl唋坙恖歭萳RICI$If $$Ifa$kdv$$If謀?.?0?644 laytz% $IfWD`萳蔿詌 mxm糾靘Dn^UOOOOC $IfWD`$If $$Ifa$kdL$$If謀?.?0?644 laytz% 詌鄉鬺鴏mmmm8m:mvmxm|m簃糾續阭靘nBnDnHnzn|n€n緉纍膎頽餹鬾(ofoholo緊纎膐鰋鴒:pwhwjw倃剋皐瞱nxtx坸妜磝秞膞苮LyRy聐膟襷貁鋤鎧{ { {"{D{F{`{b{妠恵蜞锑锑距锑距锑锑距锑距锑距锑距锑距锑锑距锑锑距锑锑锑锑距锑锑距锑距锑锑距锑h﹍mCJKHOJQJaJ&h﹍mB*CJKHOJQJaJo(ph#h﹍mB*CJKHOJQJaJphh﹍mCJKHOJQJaJKq0r秗膕NtNunvjw秞膟鎧F{蘽抾}|}瞺tR€N鈨畡騾T 陥$劋刓?$8$H$^劋`刓$gd﹍m恵瀧爗蕒蘽趝躿鎨靮顊鴞恷抾聕葇}8}>}z}|}獇瑌紏緘膤蝳\~b~妦寏攡杶殈渵皛瞺28XZbdfhrtP€R€`€b€l€r€t€~€ "24DFLV碣硭碣碣碣硭碣硭碣硭碣碣泶碣碣碣碣硭碣碣碣碣硭碣碣碣硭碣碣碣硭碣碣碣泶,h﹍m6丅*CJKHOJQJ]乤Jo(phh﹍mCJKHOJQJaJ&h﹍mB*CJKHOJQJaJo(ph#h﹍mB*CJKHOJQJaJphGLNfh攤杺渹妰悆矁磧鄡鈨(*68jp€倓瑒畡蕜虅鈩鋭鼊渽绤聟饏騾*4 &(RTbdntv€ .0:@DN鑸陥46湁熠熠腾熠熠第熠熠腾熠熠熠熠腾熠熠熠第熠熠腾第熠熠腾熠熠熠腾熠熠熠腾熠熠,h﹍m6丅*CJKHOJQJ]乤Jo(phh﹍mCJKHOJQJaJ#h﹍mB*CJKHOJQJaJph&h﹍mB*CJKHOJQJaJo(phG缐聣蕢虊覊詨鋲鎵&袏謯@BZ\拫湅jp爩虒螌陮鞂 &0z€簬紟陰鞄6@HJdf異笎(.TVz|瀾爲*,矑磼貟趻鼟H碣碣碣硭泶碣碣硭碣泶碣碣硭碣碣泶碣碣硭碣碣泶碣碣硭泶碣碣硭碣碣硭碣碣碣,h﹍m6丅*CJKHOJQJ]乤Jo(phh﹍mCJKHOJQJaJ&h﹍mB*CJKHOJQJaJo(ph#h﹍mB*CJKHOJQJaJphG陥鎵B螌鞄f|磼J鴵€槙H>軜v&販礉pL姟Z娄z$$劋刓?$8$H$^劋`刓$gd﹍mHJf~稉紦軗迵钃魮鰮鴵"$@FRT~€湐灁枙槙皶矔臅茣跁鋾钖顤FH敆灄驐鴹 <>挊槝獦跇軜$*BDtv帣悪蜞锑锑锑锑蜞锑多锑锑蜞锑锑蜞锑锑熰锑锑蜞熰锑锑蜞锑锑蜞锑锑蜞锑,h﹍m6丅*CJKHOJQJ]乤Jo(ph*h﹍mB*CJKHOJQJ^JaJo(ph&h﹍mB*CJKHOJQJaJo(ph#h﹍mB*CJKHOJQJaJphh﹍mCJKHOJQJaJ>笝聶茪虤驓魵$&r|袥譀鏇铔*,6<>H譁販鏈铚驕鴾鷾矟礉聺臐螡詽譂酀np~€姙悶挒湠JL~€劅師:@df垺姟浮隆觯,.XZ尋帳敜灓熠泌熠熠第泌熠熠第熠熠熠第熠熠熠第熠熠熠第熠熠熠第熠泌熠熠第泌熠熠第熠h﹍mCJKHOJQJaJ,h﹍m6丅*CJKHOJQJ]乤Jo(ph#h﹍mB*CJKHOJQJaJph&h﹍mB*CJKHOJQJaJo(phG灓rx湨灕捆娄"FHxz抹唯缉漏颟舂*,LV歇知舄霆"$>@RTjlr|$*JLdprtLPxz湱灜拳虱蕲喹姝瓠禺蕻>@`bt碣碣硭碣泶碣碣硭泶碣碣硭碣泶碣碣硭碣碣碣泶碣碣碣硭碣碣硭碣碣泶碣碣硭碣,h﹍m6丅*CJKHOJQJ]乤Jo(phh﹍mCJKHOJQJaJ&h﹍mB*CJKHOJQJaJo(ph#h﹍mB*CJKHOJQJaJphG$t灜@~伪R^畲P娣蚋^毯x兰l捑 犊j饫h.$劋刓?$8$H$^劋`刓$gd﹍mtv尟幆挴湳BHZ\rz|~柊槹喊及掳贪偙埍槺毐瘫伪 $&PR 46\^xz尦幊⒊こ闯按却蚀齑畲&0"$NPhj埗姸湺灦ざ阜痉胤诜熠熠泌熠熠熠第熠熠泌熠熠第熠熠第熠熠第熠熠熠泌熠熠第泌熠熠第熠熠熠泌熠h﹍mCJKHOJQJaJ,h﹍m6丅*CJKHOJQJ]乤Jo(ph#h﹍mB*CJKHOJQJaJph&h﹍mB*CJKHOJQJaJo(phG诜浞娣灨じ栏赂鸶蚋<F24\^灪ずê屎毯28DFvx毣溁一鼗浠婊68pv尲幖炯兰&,8:jl冉谓芙藿 02^dpr惥捑妇壕婢炀磉硭硭磉泶硭硭磉硭硭磉硭硭磉硭硭硭硭磉硭硭硭磉硭硭磉硭硭磉硭硭硭磉硭硭,h﹍m6丅*CJKHOJQJ]乤Jo(ph&h﹍mB*CJKHOJQJaJo(phh﹍mCJKHOJQJaJ#h﹍mB*CJKHOJQJaJphG FH|偪尶幙纯犊芸蘅$*6:hj灷だ咐豪嗬饫(.:<fh屃幜玖牧诹芰.0lr|~喡捖樎衣月雎,.RT|偯樏毭烂旅廾嗝心夷鹉蚰tv膛闻嘏谂熠腾熠熠熠腾熠熠熠腾熠熠腾熠熠腾熠熠熠腾熠熠熠熠熠腾熠熠熠腾熠熠熠腾熠腾熠腾熠腾h﹍mCJKHOJQJaJ#h﹍mB*CJKHOJQJaJph&h﹍mB*CJKHOJQJaJo(phP.旅夷v谂,PR`j炂纹4f斍吻星厍@r⑷奕gd^M $7$8$H$a$ $7$8$H$a$gd﹍m$劋刓?$8$H$^劋`刓$gd﹍m *,.0JNPR^`hjてㄆ计缕吻星熠汤诞郸oaUI>I>I2h? h? CJaJo(h? h^MCJaJh? h^MCJaJo(htTsh^M5丆JaJhtTsh^M5丆JaJo(/htTshtTs5丅*CJKHOJQJ\乤Jph2htTshtTs5丅*CJKHOJQJ\乤Jo(ph h?o(h? hG4o( h? hhjh? hhUjh﹍mOJQJUh﹍mCJKHOJQJaJ#h﹍mB*CJKHOJQJaJph&h﹍mB*CJKHOJQJaJo(ph星厍淙枞 *4BLVZ\^bfhjlnp⑹甘XZ\`bfz€溚炌⑼ねν巴耐瓮谕尥敉蜴坻坻坻坻坻益母嬉嬉嬉姣Rf坻坻坻坻蹠噞孥孥孥孥h訸h^M5丆JaJh訸htTs5丆JaJo(h訸h^M5丆JaJo(h? h?CJaJo(h^MCJaJo(htTshtTsCJaJo(htTshtTs5丆JaJo(htTsCJaJo(h? h^MCJaJh? h^MCJaJo(htTsh^M5丆JaJo(0Bvι厣 TVp甘蚴&X屗妓钏 Z愄奶鎏0b溚炌ν酝.gd?gd^M (,.046:<@BFHvxz|偽勎單箬箬箬嘬嘬嘬嘬孕岳孕荑h岦Jh岦JmHnHsHtHuhjhUh岦Jjh岦JUh? h^MCJaJh? h^MCJaJo(.248:>@DF~€偽勎單gd^M$a$61?2P:p蒫皞. 捌A!?"?#悹$悹%癝班 愋$$If枖!vh555555g#v#v#v#v#v#vg:V 攂6,5o5555U56/ ayt?奣$$If枖!vh555555g#v#v#v#v#v#vg:V ?65o5555U56/ ayt?奣$$If枖!vh555555g#v#v#v#v#v#vg:V 65o5555U56ayt?奣$$If枖!vh555555g#v#v#v#v#v#vg:V 敿65o5555U56/ ayt?奣_$$If枖!vh5?#v?:V 65/ ayt?奣$$If枖!vh5g5 5~ #vg#v #v~ :V 6,55 5D/ aytyI奣$$If枖!vh5g5 5~ #vg#v #v~ :V 655 5D/ aytyI奣$$If枖!vh5g5 5~ #vg#v #v~ :V 斱655 5DaytyI奣$$If枖!vh5g5 5~ #vg#v #v~ :V 655 5D/ aytyI奣_$$If枖!vh5?#v?:V 65/ aytu2奣u$$If枖!vh55=!#v#v=!:V 655/ aytu2奣{$$If枖!vh55=!#v#v=!:V 6,55/ aytu2奣q$$If枖!vh55=!#v#v=!:V 斱6,55aytu2奣{$$If枖!vh55=!#v#v=!:V 6,55/ aytu2奣[$$If枖!vh5?#v?:V 65/ ayt$$If枖!vh5h55 #vh#v#v :V 655 5/ ayt碈s$$If枖!vh5h55 #vh#v#v :V ?655 5/ / ayt1tL$$If枖!vh5h55 #vh#v#v :V 4攇6+55 5/ / ayt1tL$$If枖!vh5h55 #vh#v#v :V 4斳6+55 5/ / ayt1tL$$If枖!vh5h55 #vh#v#v :V 數655 5/ / ayt碈s_$$If枖!vh5?#v?:V 65/ aytu2奣$$If枖!vh55 5t#v#v #vt:V 65d5`5 / / / ayt碈s奣$$If枖!vh55 55#v#v #v#v:V 4旝6++5d5`5f5]/ / / / / aytu2奣$$If枖!vh55 55#v#v #v#v:V 4擠6++5d5`5f5]/ / / / aytu2奣$$If枖!vh55 55#v#v #v#v:V 4攨6++5d5`5f5]/ / / / aytu2奣$$If枖!vh55 55#v#v #v#v:V 4攁6++5d5`5f5]/ / / / / aytu2奣$$If枖!vh55 55#v#v #v#v:V 4 6++5d5`5f5]/ / / / / aytu2奣$$If枖!vh55 55#v#v #v#v:V 4敹6++5d5`5f5]/ / / / aytu2奣$$If枖!vh55 55#v#v #v#v:V 4敩6++5d5`5f5]/ / / / aytu2奣$$If枖!vh55 55#v#v #v#v:V 4斄6++5d5`5f5]/ / / / / aytu2奣$$If枖!vh55 55#v#v #v#v:V 4攛6++5d5`5f5]/ / / / / aytu2奣$$If枖!vh55 55#v#v #v#v:V 46++5d5`5f5]/ / / / aytu2奣$$If枖!vh55 55#v#v #v#v:V 4?6++5d5`5f5]/ / / / aytu2奣$$If枖!vh55 55#v#v #v#v:V 4攎6++5d5`5f5]/  / / / / aytu2奣$$If枖!vh55€5#v#v€#v:V 6,5E55|/ ayt[z奣$$If枖!vh55€5#v#v€#v:V 65E55|/ ayt[z奣}$$If枖!vh55€5#v#v€#v:V 65E55|ayt[z奣}$$If枖!vh55€5#v#v€#v:V 65E55|ayt[z奣}$$If枖!vh55€5#v#v€#v:V 65E55|ayt[z奣}$$If枖!vh55€5#v#v€#v:V 65E55|ayt[z奣$$If枖!vh55€5#v#v€#v:V 65E55|/ ayt[z奣w$$If枖!vh55[#v#v[:V 6,55 / aytaww$$If枖!vh55[#v#v[:V 6,55 / aytawi$$If枖!vh55[#v#v[:V 6,55 aytawi$$If枖!vh55[#v#v[:V 6,55 aytaww$$If枖!vh55[#v#v[:V 6,55 / aytaw$$If枖!vh5 5#v #v:V 46+,5 5/ aytce奣$$If枖!vh5 55Y55#5V #v #v#vY#v#v##vV :V 46+5 55Y55#5/ aytce奣$$If枖!vh5 55Y55#5V #v #v#vY#v#v##vV :V 65 55Y55#5/ aytce奣$$If枖!vh5 55Y55#5V #v #v#vY#v#v##vV :V 65 55Y55#5aytce奣$$If枖!vh5 55Y55#5V #v #v#vY#v#v##vV :V 65 55Y55#5aytce奣$$If枖!vh5 55Y55#5V #v #v#vY#v#v##vV :V 65 55Y55#5aytce奣$$If枖!vh5 55Y55#5V #v #v#vY#v#v##vV :V 65 55Y55#5/ aytce奣[$$If枖!vh5?#v?:V 65/ ayt顰q$$If枖!vh5h5?#vh#v?:V 655/ aytq$$If枖!vh5h5?#vh#v?:V 655/ aytg$$If枖!vh5h5?#vh#v?:V 斱655aytq$$If枖!vh5h5?#vh#v?:V 655/ ayt_$$If枖!vh5?#v?:V 65/ aytM奣$$If枖!vh5M5M5V#vM#vM#vV:V 65(5*55/ / / ayt?奣$$If枖!vh5M5M55c#vM#vM#v#vc:V 4旝6++5(5*558 / / / / aytht4奣$$If枖!vh5M5M55c#vM#vM#v#vc:V 4擠6++,5(5*558 / / / ayt奣$$If枖!vh5M5M55c#vM#vM#v#vc:V 4攨6++,5(5*558 / / / ayt奣$$If枖!vh5M5M55c#vM#vM#v#vc:V 4?6++,5(5*558 / / / / ayt奣c$$If枖!vh5?#v?:V 攁65/ aytw奣$$If枖!vh55555,53 #v#v#v#v#v,#v3 :V 斖65d55555/ aytw奣$$If枖!vh55555,53 #v#v#v#v#v,#v3 :V 敔65d55555/ aytw奣$$If枖!vh55555,53 #v#v#v#v#v,#v3 :V 擽65d55555/ aytw奣[$$If枖!vh5?#v?:V 65/ aytwB'q$$If枖!vh55P#v#vP:V 655/ aytwB'q$$If枖!vh55P#v#vP:V 655/ aytwB'q$$If枖!vh55P#v#vP:V 655/ aytwB'[$$If枖!vh5?#v?:V 65/ aytGmq$$If枖!vh55C!#v#vC!:V 655/ aytGmq$$If枖!vh55C!#v#vC!:V 655/ aytGmq$$If枖!vh55C!#v#vC!:V 655/ aytGm_$$If枖!vh5?#v?:V 65/ aytoU奣u$$If枖!vh55 #v#v :V 655/ ayt*C奣$$If枖!vh55 #v#v :V 46+55/ / ayt|iR奣$$If枖!vh55 #v#v :V 4旪6+55/ / ayt奣$$If枖!vh55 #v#v :V 655/ / ayt*C奣_$$If枖!vh5?#v?:V 65/ ayt奣$$If枖!vh55 5#v#v #v:V 65n5H5 / / / ayt 1奣$$If枖!vh55 55#v#v #v#v:V 46++5n5H5U5}/ / / / ayt 1奣$$If枖!vh55 55#v#v #v#v:V 4斮6++5n5H5U5}/ / / ayt 1奣$$If枖!vh55 55#v#v #v#v:V 4攝6++5n5H5U5}/ / / ayt 1奣$$If枖!vh55 55#v#v #v#v:V 4攗6++5n5H5U5}/ / / / ayt 1奣$$If枖!vh55 55#v#v #v#v:V 4攎6++5n5H5U5}/ / / / ayt 1奣$$If枖!vh55 55#v#v #v#v:V 4攳6++5n5H5U5}/ / / ayt 1奣$$If枖!vh55 55#v#v #v#v:V 46++5n5H5U5}/ / / ayt 1奣$$If枖!vh55 55#v#v #v#v:V 4斪6++5n5H5U5}/ / / / ayt 1奣[$$If枖!vh5?#v?:V 65/ ayt?q$$If枖!vh55#v#v:V 65}5 / ayt?q$$If枖!vh55#v#v:V 65}5 / ayt?c$$If枖!vh55#v#v:V 65}5 ayt?q$$If枖!vh55#v#v:V 65}5 / ayt?[$$If枖!vh5?#v?:V 65/ aytLgu$$If枖!vh55 5 #v#v #v :V 65y55/ aytLgu$$If枖!vh55 5 #v#v #v :V 65y55/ aytLguy$$If枖!vh55 5 #v#v #v :V 65y55aytLguy$$If枖!vh55 5 #v#v #v :V 65y55aytLguy$$If枖!vh55 5 #v#v #v :V 65y55aytLgu$$If枖!vh55 5 #v#v #v :V 65y55/ aytLgu[$$If枖!vh5?#v?:V 65/ ayto4q$$If枖!vh55#v#v:V 655/ aytJO$$If枖!vh55#v#v:V 46++55/ / aytJO$$If枖!vh55#v#v:V 4敚6++55/ aytJO$$If枖!vh55#v#v:V 4攝6++55/ aytJO$$If枖!vh55#v#v:V 4斏6++55/ aytJO$$If枖!vh55#v#v:V 攎655/ / aytJO$$If枖!vh5M55M55n5 #vM#v#vM#v#vn#v :V 敁65(5V5*5595/ aytx奣$$If枖!vh5M55M55n5 #vM#v#vM#v#vn#v :V ?65(5V5*5595/ aytx奣$$If枖!vh5M55M55n5 #vM#v#vM#v#vn#v :V 攧65(5V5*5595aytx奣$$If枖!vh5M55M55n5 #vM#v#vM#v#vn#v :V ?65(5V5*5595aytx奣$$If枖!vh5M55M55n5 #vM#v#vM#v#vn#v :V 攎65(5V5*5595/ aytx奣$$If枖!vh5?#v?:V 擰?65/ ayt飈奣$$If枖!vh55)!#v#v)!:V 擰?655/ ayt飈奣$$If枖!vh55)!#v#v)!:V 擶?655/ ayt飈奣$$If枖!vh55)!#v#v)!:V 敳?655ayt飈奣$$If枖!vh55)!#v#v)!:V 攬?655ayt飈奣$$If枖!vh55)!#v#v)!:V 攬?655ayt飈奣$$If枖!vh5?#v?:V ?65/ aytE$$If枖!vh55#v#v:V ?655/ aytEm $$If枖!vh55#v#v:V ?655/ aytEm $$If枖!vh55#v#v:V 斱?655aytEm $$If枖!vh55#v#v:V ?655aytEm $$If枖!vh55#v#v:V ?655aytEm $$If枖!vh5?#v?:V 攙?65/ ayt?$$If枖!vh5L5K5Y#vL#vK#vY:V 攍?65(5 5/ ayt?$$If枖!vh5L5K5Y#vL#vK#vY:V 擲?65(5 5/ / ayt鞞$$If枖!vh5L5K5Y#vL#vK#vY:V 敭?65(5 5/ ayt鞞$$If枖!vh5L5K5Y#vL#vK#vY:V 擯?65(5 5/ ayt鞞$$If枖!vh5L5K5Y#vL#vK#vY:V 擯?65(5 5/ ayt鞞$$If枖!vh5?#v?:V ?65/ aytr$$If枖!vh555"#v#v#v":V ?65o5€5 / / / ayt抰^ $$If枖!vh5555 #v#v#v#v :V 4旍?6++5o5€55/ / / / ayt抰^$$If枖!vh5555 #v#v#v#v :V 4敩?6++5o5€55/ / / ayt抰^$$If枖!vh5555 #v#v#v#v :V 4攣?6++5o5€55/ / / ayt抰^ $$If枖!vh5555 #v#v#v#v :V 4敩?6++5o5€55/ / / / ayt抰^ $$If枖!vh5555 #v#v#v#v :V 4?6++5o5€55/ / / / ayt抰^ $$If枖!vh5555 #v#v#v#v :V 4攱?6++5o5€55/ / / / ayt抰^ $$If枖!vh5555 #v#v#v#v :V 4敭?6++5o5€55/ / / / ayt抰^ $$If枖!vh5555 #v#v#v#v :V 4斪?6++5o5€55/ / / / ayt抰^ $$If枖!vh5555 #v#v#v#v :V 4攦?6++5o5€55/ / / / ayt抰^$$If枖!vh5555 #v#v#v#v :V 4敚?6++5o5€55/ / / ayt抰^$$If枖!vh5555 #v#v#v#v :V 4擷?6++5o5€55/ / / ayt抰^ $$If枖!vh5555 #v#v#v#v :V 4擡?6++5o5€55/ / / / ayt抰^ $$If枖!vh5555 #v#v#v#v :V 4斲?6++5o5€55/ / / / aytS*$$If枖!vh5555 #v#v#v#v :V 4旪?6++5o5€55/ / / aytS*$$If枖!vh5555 #v#v#v#v :V 4旪?6++5o5€55/ / / aytS* $$If枖!vh5555 #v#v#v#v :V 4旪?6++5o5€55/ / / / ayt抰^$$If枖!vh559#v#v9:V 攪?655 / aytm_奣$$If枖!vh559#v#v9:V 攪?655 / / aytp`€奣$$If枖!vh559#v#v9:V 攪?655 / aytp`€奣$$If枖!vh559#v#v9:V 攪?655 / / aytp`€奣$$If枖!vh55=#v#v=:V ?65a 5' / aytk,W$$If枖!vh55=#v#v=:V ?65a 5' / aytk,W$$If枖!vh55=#v#v=:V ?65a 5' aytk,W$$If枖!vh55=#v#v=:V ?65a 5' aytk,W$$If枖!vh55=#v#v=:V ?65a 5' aytk,W$$If枖!vh55=#v#v=:V ?65a 5' aytk,W_$$If枖!vh5?#v?:V 攪65/ aytk,W$$If枖!vh5Q55#vQ#v#v:V 擠65,55[/ aytk,W$$If枖!vh5Q55#vQ#v#v:V 旜65,55[/ aytk,W[$$If枖!vh5?#v?:V 65/ aytq$$If枖!vh5%5#v%#v:V 655r/ ayt$$If枖!vh5%5#v%#v:V 655r/ / aytu$$If枖!vh5%5#v%#v:V 斱655r/ aytq$$If枖!vh5%5#v%#v:V 655r/ ayt$$If枖!vh5%5#v%#v:V 655r/ / ayt$$If栺!vh56&#v6&:V 敤?6,5/ 2 4 ayt?奣$$If栺!vh5|55o55#v|#v#vo#v#v:V 攂?6,5K5e5D55 / 2 4 ayt~奣$$If栺!vh5|55o55#v|#v#vo#v#v:V ?6,5K5e5D55 / 2 4 ayt~奣$$If栺!vh5|55o55#v|#v#vo#v#v:V 敘?6,5K5e5D55 2 4 ayt~奣$$If栺!vh5|55o55#v|#v#vo#v#v:V ?6,5K5e5D55 2 4 ayt~奣[$$If枖!vh5?#v?:V 65/ ayt頸q$$If枖!vh55P#v#vP:V 655/ aytb*q$$If枖!vh55P#v#vP:V 655/ aytb*q$$If枖!vh55P#v#vP:V 655/ aytb*$$If杛!vh5O5f#vO#vf:V 攣?,5O5f9/ 2 4 a?yt~奣$$If杛!vh5O5f#vO#vf:V 4擵?+5O5f9/ 2 4 a?yt~奣$$If杛!vh5O5f#vO#vf:V 4擻?+5O5f92 4 a?yt~奣$$If杛!vh5O5f#vO#vf:V 4敂?+5O5f92 4 a?yt~奣$$If杛!vh5O5f#vO#vf:V ??5O5f92 4 a?yt~奣$$If杛!vh5O5f#vO#vf:V 4斘?+5O5f92 4 a?yt~奣$$If杛!vh5O5f#vO#vf:V 4攤?+5O5f92 4 a?yt~奣$$If杛!vh5O5f#vO#vf:V 4敗?+5O5f92 4 a?yt~奣$$If枖!vh5?#v?:V 攺?65/ ayt-@$$If枖!vh5L5 5#vL#v #v:V 敼?65(55 / / / ayt-@ $$If枖!vh5L5 55x#vL#v #v#vx:V 4敺?6++5(555/ / / / ayt-@$$If枖!vh5L5 55x#vL#v #v#vx:V 4旍?6++5(555/ / / ayt-@$$If枖!vh5L5 55x#vL#v #v#vx:V 4攔?6++5(555/ / / ayt-@$$If枖!vh5L5 55x#vL#v #v#vx:V 4旚?6++5(555/ / / ayt-@$$If栺!vh56&#v6&:V 擕?659/ 2 4 ayt謓$$If栺!vh55n55D#v#vn#v#vD:V 擕?655n55D9/  / / / 2 4 ayt鑇?X$$If栺!vh55n55D#v#vn#v#vD:V 4?6+++55n55D99/ / / / / / / 2 4 ayt鑇?X$$If栺!vh55n55D#v#vn#v#vD:V 4斳?6+++55n55D99/ / / / / / / 2 4 ayt鑇?X$$If栺!vh55n55D#v#vn#v#vD:V 4擠?6+++55n55D99/ / / / / / / 2 4 ayt鑇?X$$If栺!vh55n55D#v#vn#v#vD:V 4??6+++55n55D99/ / / / / / / 2 4 ayt鑇?X$$If栺!vh55n55D#v#vn#v#vD:V 4擮?6+++55n55D99/ / / / / / / 2 4 ayt鑇?X$$If栺!vh55n55D#v#vn#v#vD:V 4??6+++55n55D99/ / / / / / / 2 4 ayt鑇?X$$If栺!vh55n55D#v#vn#v#vD:V 4??6+++55n55D99/ / / / / / / 2 4 ayt鑇?X$$If栺!vh55n55D#v#vn#v#vD:V 4??6+++55n55D99/ / / / / / / 2 4 ayt鑇?X$$If栺!vh55n55D#v#vn#v#vD:V 4??6+++55n55D99/ / / / / / / 2 4 ayt鑇?<$$If栺!vh55n55D#v#vn#v#vD:V 4??6+++55n55D99/  / / / / 2 4 ayt鑇?[$$If枖!vh5?#v?:V 65/ ayt隠q$$If枖!vh5%5#v%#v:V 655r/ ayt隠w$$If枖!vh5%5#v%#v:V 6,55r/ ayt廠.$$If枖!vh5?#v?:V ??6,59/ aytho'$$If枖!vh55n5 5n55 #v#vn#v #vn#v#v :V 斅?6,5o5955955/ aytho'$$If枖!vh55n5 5n55 #v#vn#v #vn#v#v :V 攙?65o5955955/ / aytJ"<$$If枖!vh55n5 5n55 #v#vn#v #vn#v#v :V 斅?65o5955955/ aytJ"<$$If枖!vh55n5 5n55 #v#vn#v #vn#v#v :V 斅?65o5955955/ aytJ"<$$If枖!vh55n5 5n55 #v#vn#v #vn#v#v :V 斅?65o5955955/ aytJ"<$$If枖!vh5?#v?:V ?65/ ayt5I$$If枖!vh5-5#v-#v:V ?65-5/ ayt5[$$If枖!vh5-5#v-#v:V ?65-5/ / ayt5[$$If枖!vh5-5#v-#v:V ?65-5/ / ayt5[$$If枖!vh5?#v?:V ?65/ ayt?T$$If枖!vh5-5#v-#v:V ?65-5/ ayt5[$$If枖!vh5-5#v-#v:V ?65-5/ / ayt5[$$If枖!vh5-5#v-#v:V ?65-5/ ayt5[$$If枖!vh5.525O5A#v.#v2#vO#vA:V ?555+5/  / / / ayt?\$$If枖!vh5.525O5A#v.#v2#vO#vA:V 4攂?++555+5/ / / / / ayt?\$$If枖!vh5.525O5A#v.#v2#vO#vA:V 4攁?+++555+5/ / / / ayt?\$$If枖!vh5.525O5A#v.#v2#vO#vA:V 4?+++555+5/ / / / ayt?\$$If枖!vh5.525O5A#v.#v2#vO#vA:V 4?+++555+5/ / / / ayt?\$$If枖!vh5.525O5A#v.#v2#vO#vA:V 4 ?++555+5/ / / / ayt?\$$If枖!vh5.525#v.#v2#v:V 4?++555 / / ayt?\$$If枖!vh5.525O5A#v.#v2#vO#vA:V 4?++555+5/ / / / ayt?\$$If枖!vh5.525O5A#v.#v2#vO#vA:V 4?++555+5/ / / / ayt?\$$If枖!vh5.525O5A#v.#v2#vO#vA:V 4?++555+5/ / / / ayt?\ $$If枖!vh5.525O5A#v.#v2#vO#vA:V 斢?555+5/  / / / / ayt?\$$If枖!vh5?#v?:V ?65/ aytw"*$$If枖!vh555q#v#v#vq:V ?6555q/  / / / ayt&G'$$If枖!vh5555#v#v#v:V 4攚?6++555/ / / / / / / aytd'$$If枖!vh5555#v#v#v:V 4??6++555/ / / / / / / aytd'$$If枖!vh5555#v#v#v:V 4??6++555/ / / / / / / aytd'$$If枖!vh5555#v#v#v:V 4攧?6++555/ / / / / / / aytd'$$If枖!vh5555#v#v#v:V 4斺?6++555/ / / / / / / aytd'$$If枖!vh5555#v#v#v:V 4斸?6++555/ / / / / / / aytd'$$If枖!vh5555#v#v#v:V 4旀?6++555/ / / / / / / aytd'$$If枖!vh5555#v#v#v:V 4斖?6++555/ /  / / / / / aytd$$If枖!vh5?#v?:V ?65/ aytB$$If枖!vh5 5`#v #v`:V ?655/ aytB$$If枖!vh5 5`#v #v`:V ?655/ / aytB$$If枖!vh5 5`#v #v`:V ?655/ / aytB$$If枖!vh5?#v?:V ?6,5/  / ayt!8 $$If枖!vh5h555n55F #vh#v#v#vn#v#vF :V ?65h555n55F / /  ayt!8 $$If枖!vh5h555n55F #vh#v#v#vn#v#vF :V 攧?65h555n55F / /  / ayt!8 $$If枖!vh5h5?#vh#v?:V 數?65h5?/ /  ayt!8 $$If枖!vh5h555n55F #vh#v#v#vn#v#vF :V 擣?65h555n55F / /  / ayt!8 $$If枖!vh5q##vq#:V ?q#65q#/ ayt+"$$If枖!vh55#v#v:V ?q#655/ ayt+"$$If枖!vh55#v#v:V ?q#655/ / ayt+"$$If枖!vh55#v#v:V ?q#655/ ayt+"$$If枖!vh55#v#v:V ?q#655/ ayt+"$$If枖!vh5?#v?:V 擔?65/ ayt iL奣$$If枖!vh5x5x#vx#vx:V 擔?655/ ayt iL奣$$If枖!vh5x5x#vx#vx:V 攖?655/ / ayt@奣$$If枖!vh5x5x#vx#vx:V 攖?655/ ayt@奣$$If枖!vh5x5x#vx#vx:V 攖?655/ ayt@奣$$If枖!vh5?#v?:V ??65/ ayt鷙奣$$If枖!vh55!#v#v!:V ??655/ ayt鷙奣$$If枖!vh55!#v#v!:V 攧?655/ / ayt秥奣$$If枖!vh55!#v#v!:V ??655/ ayt鷙奣$$If枖!vh55!#v#v!:V 攜?655/ ayt鷙奣$$If枖!vh5?#v?:V ?65/ ayt洱x$$If枖!vh5g5 5#vg#v #v:V ?655d5n / ayt 5$$If枖!vh5g5 55&#vg#v #v#v&:V 4斻?6++55d5U5/ / ayt 5$$If枖!vh5g5 55&#vg#v #v#v&:V 4?6++55d5U5/ ayt 5$$If枖!vh5g5 55&#vg#v #v#v&:V 4敳?6++55d5U5/ ayt 5$$If枖!vh5g5 55&#vg#v #v#v&:V 4斔?6++55d5U5/ / ayt 5$$If枖!vh5g5 55&#vg#v #v#v&:V 4斚?6++55d5U5/ / ayt 5$$If枖!vh5g5 55&#vg#v #v#v&:V 4??6++55d5U5/ / ayt 5$$If枖!vh5g5 55&#vg#v #v#v&:V 4??6++55d5U5/ / ayt 5$$If枖!vh5g5 55&#vg#v #v#v&:V 4斶?6++55d5U5/ / ayt 5$$If枖!vh5g5 55&#vg#v #v#v&:V 4敔?6++55d5U5/ / / ayt 5 $$If枖!vh5g5 55&#vg#v #v#v&:V 4敃?6++55d5U5/ / / / ayt 5$$If枖!vh5g5 55&#vg#v #v#v&:V 4敃?6++55d5U5/ / / ayt 5$$If枖!vh5g5 55&#vg#v #v#v&:V 4敃?6++55d5U5/ ayt 5$$If枖!vh5?#v?:V ?65/ ayt?$$If枖!vh555&#v#v#v&:V ?655 5/ ayt?$$If枖!vh555&#v#v#v&:V  ?655 5/ / ayt?$$If枖!vh555&#v#v#v&:V ?655 5/ ayt?$$If枖!vh555&#v#v#v&:V ?655 5/ ayt?$$If枖!vh525 5 5V #v2#v #v #vV :V 攂?655550/ ayt淴$$If枖!vh525 5 5V #v2#v #v #vV :V ?655550/ / aytz% $$If枖!vh525 5 5V #v2#v #v #vV :V ?655550/ aytz% $$If枖!vh525 5 5V #v2#v #v #vV :V ??655550/ aytz% $$If枖!vh525 5 5V #v2#v #v #vV :V ??655550/ aytz% $$If枖!vh525 5 5V #v2#v #v #vV :V ?655550/ aytz% $$If枖!vh525 5 5V #v2#v #v #vV :V ?655550/ aytz% $$If枖!vh525 5 5V #v2#v #v #vV :V ?655550/ aytz% $$If枖!vh525 5 5V #v2#v #v #vV :V ?655550/ aytz% $$If枖!vh525 5 5V #v2#v #v #vV :V ?655550/ aytz% $$If枖!vh525 5 5V #v2#v #v #vV :V ?655550/ aytz% j" 666666666vvvvvvvvv664646>6666666666666666666666666666666666666666666666646hH66666<6666666666>666666666666666666666666666666666666666666666666668 0@P`p€6(88 0@P`p€ 0@P`p€ 0@P`p€ 0@P`p€ 0@P`p€ 0@P`p€8XV~ OJPJQJ_HmH nHsH tHJ`?J ck噀 $1$a$ CJKH_HaJmH nHsH tHd`"d h槝 2a$$1$@&[$\$&5丆J$KHOJQJ\乤J$mHsHtH$A`?$ 貫祂=刉[SONi@?N 0nf恏圏h(:V 44l44l k ? 0鄀Rh 﨩 tgt"W`?" `亯筽5乗?U ?* 0厤 >*B* phc.??!. 0u w CharCJaJ.??1. 0u CharCJaJ6??A6 0 yb鑜噀W[ Char CJKHaJL??QL  h槝 2 Char"5CJ$KHOJPJQJ\^JaJ$L?aL font31'>*B*CJOJPJQJ^JaJo(ph6`r6 0yb鑜噀W[a$$ mHsHtH^ ^ 0u w'a$$G$&dP9r CJKHaJmHsHtHX^@X 0nf?Q賨)a$$1$[$\$CJOJQJ^JaJKHL `L 0ua$$G$9r CJKHaJmHsHtHd?d Default1$7$8$H$-B*CJOJ^J_HaJmH nHphsH tH0矦0  R鶴祂=WD劋`劋(' ?( 礚-0yb鑜_(uCJaJ*j qr* 礚-0yb鑜;N槝5乗???< 礚-0 yb鑜;N槝 Char5CJKH\aJ: : !礚-0yb鑜Fh噀,g CJaJmHsHtH8??8  礚-0 yb鑜Fh噀,g Char CJKHaJPK!倞[Content_Types].xml瑧薺?E鲄卸豶?ヘ微Iw},浔-j弰4 蛇w旄P-t#b螜{U畯銧擉T閁^h卍}悒)蛔*1P? 揯鬃W孱0)櫐T闉9<搇?ぼ$yi}佸;纞@囨?顚跄H滖男u? D谞z內/0娗盃瘥 $€ X3aZ⒁锣,癉0j~?叨蝏沩~i>赝3縗`??[G殁\??跼k.搒粣..椃碼婵?PK!ブх6 _rels/.rels剰蟡? 囷吔冄}Q颐%v/C/?h"脎O 劋秣?孂釘 毆免C?薶醰=偵叅?[xp啠{鄣_糚眩秣羌3緓镹男>掤搁U蟇L0斈屵呖z迃rx鳔脅稔h9T?奣/魁煜?鍃Y?雒'蟸?S琦棌~蜩鶅O_|w?馉镉圚t燒乤?d NG1-Rl苼?諶J鴚T锠疢1Kc柩"o he浪撣幝絇L-憒%绗臙甴Y7?qP.\L姼=岟薲穛炷?I爋fi墸?帽墘BRb?J款P_p蒅 茛▍i㎏鷗郿訉h汧梚櫷o?;7Q嫵2染媱珼?a/銐翾漱嶺厌W 藬霱卂膗H剄)薶 胺?:Vi豾?r態裶汐橌"r嫃?帓2l徠a麃C奲此U|嚮!8^顩?帼軤仯?A魶壭眲V韙鄨讕厏ls囔?4犁_=,涩返o聻TV 跥陲"苎鎎H唼灮???熯x薜躻-戏蹺鮸褾;氕衯踯`嘼3"G 'e\昮H柊O 话ㄩ恬愪'?劘i_wp伬 ??靺8魂i&丩Y%\铝?楎謝視=瞩伭壵阱綔 r6f 提3储淭厥厰)橗:陋ZK誏玸ゅ&C 鏜兣軟0€ [浪玴@注醏j扣? 媺耏咹唜Hi荤cT5A蕆跑@顢腍驇馴AZC硙i' RQ\m伕,zo?僩Q襲{Y\,Nψ?铸溷ら嵿L _?跆嘫7C6韽-fS宄h62密"5咍麥罭H凾[X?5太4X?Y龡豚殖2纅鷎h辈绅痠~tCKF#猥b +趙?m鑵4`眹!?U翞!昿5a:倊€{4韒笫m蝘o 萎c杽8m泛D矹秔S枪姗豓1铘?#S奿?3E?pS?疳W`る甸q]( ┻08樲w别 n撏A鲺[s枃)k8皓= Aa?R d趻删c楿咏瞬d)#換ueb恾满捷C!ず?i0福>4魫S?鋥z虮 F箎 4?sKvUKo瘸椒h垀1砵YU€奥V蠬塔5U8錠k;譁潘鮈9堚寂皹D 荀 ?*|FL迪鳡?A3兇伂>g类dm2iV值殍そ杕謌<殒r?[kv抶熞蠃p鎶sj?潩z伛礭[鑚堨叆Qv??縤u鈨?高?%M2羙J描?u舘%覎PK!褠煻'theme/theme/_rels/themeManager.xml.rels剰M ?匃倃oo雍?輬协勪56?$Q祉?.嘺緳i粭澤c2?h:闀q毩m胳嶡RN壻;d癭値o7g慘(M&$R(.1榬'J摐袏T鶂?V?&A然蠬鱱}狇|?絙{朠?除8塯/]As賲(⑵锑#洩L蔥汉倪PK-!倞[Content_Types].xmlPK-!ブх6 +_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!mQtheme/theme/theme1.xmlPK-!褠煻' theme/theme/_rels/themeManager.xml.relsPK] C ***-T z<.Hxj.|?4"??,%??€&8'?)?r-/?H2X45l6F7t8<:;秉^=怇*?淏~EF>GdI鍷孨2QTRhSNUDWJY耑衆H^_哶b`鴃琤╠猤pj╧lZm鷐Nn秐4o(?粿 C訥癐咼M禡凱R圧U V繵淶躘衈躠xb芿`g hLk詌榩恵H灓t诜星單PRSTUY[`cehiknpuy  "$%+.03689=ABEGJOQSVX[]`behjmoqtuwz  "+/367;>?CGJLMNPQRTUVXY[h$F(>\R^l `!?"@"|"?#??%<%??.&??8'?? ()|*?/?J2??45p5??X7?r8??8:;奎$=4?d?窣lA碅ZB奀ZD贒TE瓻0FbF朏蜦GjGK KL頟TQ^R銻`S嶴釹*VBW騒刏諾騔^[瞇芢俔J^j^鎊T_琠╜鯼aza哸繿Nb俠Bcpc鑓dTf╢鈌~g猤j鴍宬鄈渓8m謒Vnjn杗秐苙鰊.pvp`r餾RvHy{6{剓辿|恾鎪d`€杸蕗鼆0紒08鋬紖~妵~*L虊2悐缞R螊 |緦v€H剸畺钖N€b鷻顨@\`:H獮\湡簾顭08j8?r9?T:侜啁甥<唿楜猃f>绳?郆蜧凧菾$K↘郘碝萂癗jOvP蔖鍼.Q猀RbRxR糞糡濽lV怴瞁豔^XYY@Y\Y$Z[€[篬圽繺燸鴂轪糱萩^e^f鑖瀐ri歫耴nl萳Dnlpq陥$..單QVWXZ\]^_abdfgjlmoqrstvwxz{|}~€   !#&'()*,-/12457:;<>?@CDFHIKLMNPRTUWYZ\^_acdfgiklnprsvxy{|}~€   !#$%&'()*,-.0124589:<=@ABDEFHIKOSWZ\"&k(."<D%Ze I N b l,4@u}W)^c???$P$X$l&???''e'???( (<(q(w(???)8)@)?+#+#9X9]9}:柄耳沱<$<?埤帻X@岪扏lB〣鶨/F7FGF|F凢螱H H豀轍cL楲燣楾蚑誘銽U%UV碫縑赯[[頬#^(^鱜,a4a8hFh%&CQ?晫Q?晫Q?晫Q?晫X?晞X?晞Q?晫Q?晫Q?晫Q?晫Q?晫Q?晫Q?晫Q?晫Q?晫Q?晫Q?晫Q?晫Q?晫Q?晫Q?晫Q?晫Q?晫QT晫QT晫Q?晫Q?晫Q?晫Q?晫Q?晫Q?晫Q?晫Q?晫Q?晫Q?晫Q?晫Q?晫Q?晫Q?晫Q?晫Q?晫Q?晫Q?晫Q?晞Q?晫 $&-!?晙餈  @€€€餒 ??  饞??  養 S  ?X_GoBack(_nebECCEF6DC_575C_4742_AAF6_0E87F4EEEB26(_nebBE87273D_4595_4AFA_B37A_3D48728CDC58(_neb36503548_8A10_4EBC_9F3F_447913A18A52(_neb57F7D86A_19C9_4B48_ABC0_C2D2084006CA(_neb7174D053_6A9A_4E5B_BDCA_72F19068FCEA(_neb90D8BD0C_D39B_426E_AFF7_5DA272CE8C28(_neb30F6EBDF_CEEA_4A1C_938F_EBB69B11C5B5(_neb3FFD4586_5CC1_4B66_A844_FC2BA7619337(_nebEDAAD7B6_B141_4210_91B4_52F115481581(_nebC1A8E50C_BFAB_4A92_8204_3ADE3228EF5E(_neb4AF3BD50_4DE2_45F5_A53E_782805C3D67A(_neb134427DA_517C_4AA2_8185_A0061488DB0C(_nebA4E4C4D0_7A39_4642_90B8_03BED5C5A60D(_nebA916211C_D9CF_40FB_B7AF_0F4B11026950(_nebB7C37801_DF7B_4D03_97C0_250644E63650(_neb61D7A362_C7BC_435E_9C98_A83D9A1A4603(_neb1D9D119D_D6C8_48AA_BFD0_8269A348DFC0(_nebD268E227_89CA_427A_9D9D_F60C9CFA153D(_neb6BEF8191_DF57_422B_80BB_06A439D2657B(_neb2213FB0A_B81F_4F45_A2E4_AD1258549941(_nebBFB2AB3C_C659_4521_A7A8_4426BD8A502B(_neb810E7A41_8A33_45D9_B7DA_ACF3CBEB503C(_nebA562FADB_C79C_4590_9C31_75BCE2B9EA61(_neb44A8592D_486F_4292_8D23_B497010F7494(_neb23C69C58_C2BC_4F55_A824_9B84AE170DAB(_nebC314C0E1_04C7_4D3F_8FB2_1F2C66477115(_neb56341DF2_3244_4F9C_8A95_289388E4A0ED(_nebA66CDCBC_B116_4FFF_8F48_40FC5DB4CDD9(_nebD95AE208_9395_4534_B9FE_62EE0F1E2A59(_neb963E3BFE_6647_4C8F_B4AC_496A57A55D93(_neb523B0216_E67F_400B_B4C2_12DE4507252C(_neb5AEBF20E_6521_45F2_B665_5FF560EC5B7C(_neb8DAEAD49_A796_4158_8026_47FDB62D9BB0(_nebD94B11CF_23AC_47CC_A233_C6EDC995DE5C(_neb0E2E7728_8969_4056_A24B_FE286305D88C(_neb9F3BEFBC_F3E7_4F80_BC0C_0BB4EEFEB74A(_nebD2D7BB6F_1235_49D4_9145_DE96ADE208D0(_neb07036850_2E10_4C0C_B5DA_01FE9F24DF0B(_neb35C7A727_CE2E_4490_830B_4DD29C59BAB2(_neb7684EDBA_5357_47DA_9D23_8368DEB78200(_neb96FAF071_A32C_4A27_BF86_279F693E7144(_neb8F81CAAB_CD40_4908_90AF_494474FD6689(_nebC9C208A0_61FE_4084_AD29_A408DA9ECBA6(_neb160E9B88_ACA6_43B1_8ACB_A8550111F47A(_neb1D7A1F18_5C65_422F_A2E3_C3B3A4073CC2(_nebA5CCC842_0514_4045_9D99_ACCBF5649C0E(_neb2C9D4403_D894_4D68_A1DE_878CD032E1DC(_nebB53891A3_FD78_40CD_BFBF_396347F437F2(_nebCE019E57_65F3_49C6_A2B4_6AFA22365B38(_neb85385A31_72E9_462C_96BF_265E28970317(_neb9C1E7256_A781_4F98_A2F0_4F253B8BE155(_nebA613C6AC_1E8A_4497_9885_34BF360116EA(_neb287A7C2B_7ED8_4A72_B2D5_407EA623372E(_nebA60983F6_4E4C_4886_B1AC_51C7B0447347(_nebCDD534FC_E334_4A88_84A0_CBCF6A0C46A9(_neb0DFC024C_A596_47FA_AD7E_7D83279980DC(_nebF83CA43D_33BB_4876_98E6_1EC4350BD2D7(_neb17D7B95C_2998_4074_AFD8_9344F53E55F7(_neb241ACE94_90ED_458F_8B46_A8F42110896E(_neb77775DC0_BEC0_4338_AB7E_4442223F696E(_neb38685694_FA6F_48B6_A64A_4A3333C40505(_nebAE668E7E_859F_4B78_9719_3DC98A359FD0(_nebB59C41B5_36BE_4878_A282_3627AD147F1E(_nebB91D799A_D027_4BCD_8D57_0E4BE3F62BCC(_nebC7DA6C0A_CC6A_41CF_BE0B_0D2E7F6B9475(_nebF65D5D89_179B_4791_9FA6_B0C96D290524(_neb90E6DFCC_F0E8_4A98_A6D8_F2E090E5E9E9(_nebB9CABB8A_696A_49E9_9223_B5CB26DDCBF6(_nebAC181809_39C8_4835_914D_A66D9A44AA93(_neb186D7957_AB5C_4065_864B_6B17A0027B3A(_neb4F2E3063_FA7B_4D38_A8D7_1C8B9B6B6774(_neb768CE11E_5016_4752_BA2F_FF6B40750284(_nebC12144BD_2D3A_481D_9C1E_4C5BC415F654(_nebB1A9ECA5_63BA_405B_AD01_C77585689408(_neb4ACFE630_47D0_4C03_94A9_34D8BECAE5FA(_nebAD9179DE_1894_4842_8FB1_217D577FCD69(_neb95FFF611_0827_4D57_8186_33299A8DB378(_nebEBDDCFCE_D61A_4E45_9449_EF1E34BC7894(_nebE835CF37_8AC8_4C4A_9117_711BA6CA9465(_neb4B10C8A6_A140_4005_AC11_6288BBCC8D88(_neb609B2D26_D7AE_4050_8A76_C7E1980EAA8A(_neb46AD1A94_90D5_45EA_921D_167110864920(_neb3E242B7A_9059_44D7_B2F7_090EF0023DA4(_neb8213AEDA_8E15_4D0A_BEE1_584AE85F4F43(_nebECF38B7C_1105_4366_864B_60B7450B0EDA(_neb69AC1535_0492_4DB9_86FA_A5F915EBD837(_neb279B39C7_DCF8_4B50_9A92_571E3B406B58鵓Mh廻襤i[i鈏'j7k祂[l鈒sm鎚In€n緉Yo簅)p坧'q駋Wr鵵猻tut髏gvvw3x緓Zy鼀@z蘻|n|粅搣~l~趡8艀-a=拝:蠁爣?鐖)瘔w(髬y/f紞 `稁I悘蹚5q磹V棏釕i粧頀D  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVW鵓巋秇ii^ij*j猨磌Zl醠rm錷Hnn絥Xo筼(p噋&q餼Vr鴕﹕ttt騮爑fvuw2x絰襵鹹?zDz|m|簗拀~k~賬7膧,`<憛9螁焽>鎴(畨v'驄x.e粛_祹H弿趶4p硱U枒鄳鍛m鞉D #%@qu'*56:;ENdk/0ns#$'/0EFNUVW\lmqrvwz~ "#)359:?BCNRSZfkty{|*+elmns%hlrvx|  "*-3478CDFGMQRSUY_cfirsux        % + 6 < = > D R T X ^ d f j k u      S V W Z ` c d |  ! ' ( . 2 4 5 6 7 8 V Y ^ b + : K L R S [ j | € #$,-01:;=ABJKMNU[bqw (+,.6;<>?BHKLYZ_pqv€  ,.67=?CDRT[]eflnrs #*La ?CFPl<?F  aeo{}&*+7<IKLPSZ\`b}~ (+,/09\_`rv569>€ ",56IQV)-7?FGHMQ_cdkmqtz#'efko}  #$&/017;IJORYZbltxyz{.57CLMVWxy"LNP[beknou 02DITV[\`bcdefuvx{|}€  034QTUZkmr|}  "#+,45;<EFNOVWabhipst|   ^ b x y | }  ! !D!G!q!z!??????????""*"."2"5"<"o"??????"####### #!#"#%#0#1#8#?????$$ $[$\$a$e$w${$???????????????????%% % %%%%%)%0%1%7%9%I%K%S%V%d%f%g%q%r%y%z%{%~%??????????????????????????X&[&\&_&b&d&l&??'''G'e'????????()(z(}(?????)I)P)Q)R)W)[)l)p)q)x)z)~)?????????????????**!*)*.*9*N*Q*T*V*b*d*e*j*k*m*{*}*?????????????&+*+0+4+6+:+;+>+D+E+H+K+W+^+d+e+h+n+s+x++€+?????????????????????????????????????+,,,, , ,,,,,,,,,,!,$,-,.,4,5,8,;,<,=,@,A,[,a,b,c,h,l,|,€,??????????????,-(-+-.-5-A-E-r-x-??????????????.. ..4.S.V.j.l.u.x.?????????? ////&/2/D/G/S/V/c/j/l/m/p/v/z/|/?????????????0000=0?0H0K0`0o0???????????1111 111,1<1D1E1F1P1V1]1e1n1q1u1w1x1{1?????????????????????1222 2 2222222%2*2+2-202223282>2C2D2E2F2G2K2L2M2P2Q2S2T2U2X2^2_2b2e2j2p2v2w2y2|2~22??????????????????????????????????????????233333!3'3,3-303136373=3>3E3G3H3J3L3P3T3X3\3`3e3f3l3n3{33?????????????????????44"4#4$4)4-4;4?4@4D4F4J4M4q4???????????55/5155595>5V5[5b5e5???????????6666&6E6g6??????????6 77(7*7-707:7H7^7a7h7???????888888(8+8@8B8[8g8h8?????????9 999#9^9_9f9m9n9o9t9€9????????????????????????? :::j:}:氟跟窥弃曲鳃旺喧羸埴搡恸辁犏铤聱酊;; ;;;;-;0;E;H;[;^;u;z;擕狖胞耕钧葵利墅帖宣邀邴埯啕沱&<*<=<@<D<F<G<I<T<W<Z<[<_<a<b<d<m<n<{<}<圏堻孅岦慄掽擖朁???键奎傈咙泣牲它渣攸冱唿泓朦禳稂瘘酎觞鳇鼽=== ===== =#=&=1=:=I=S=T=U=_=`=a=c=l=r=v=~=€=?価嘄婟孆岧廄掿桚楜??泯瘕螨鳊?>>>>$>%>&>)>7>:>P>S>W>_>v>y>侢匎嶠慆扊旫烚〓?蔺泾纩?? ???!?1?4?5?A?H?I?V?Y?m?p?{????????????????????????8@A@B@L@X@朄楡濦瓳篅籃紷継菮藹虭蜙谸蹳酅釦顯餈駺驚鯜鰼兀AAAA AAAAA'A(A2A5A@ADAFAQARATAUA[A\A^AaAiAuAvAwAxA丄侫嘇圓旳朅楢橝淎滱盇礎糀紸続緼葾虯蜛螦貯軦釧鉇驛鬉鰽鳤嗀ABBBB BBBB B#B.B2B4B6B7BGBHBNBOBQBZB^BeBlB珺癇稡築紹蜝鉈馚C.C1CKCNCPCrC凜匔婥扖腃虲贑蹸軨釩鉉鏑闏鞢頒驝DD)D-D?D@DADBDCDDDEDFDMDNDODPDSDTDXDYDZD[D\D]D^D_DfDgDjDkD怐擠橠淒礑笵篋荄谼蹹鏒DENEsEE丒匛咵奅婨擡烢燛〦狤矱碋綞縀罞荅菶虴贓酔鶨8F9F;F匜咶嘑婩燜瓼碏籉繤翭蘁虵袴覨貴跢逨郌銯镕頕颋鳩鶩GG GGGGGG!G#G'G)G+G,G6G9G>GAGCGGGLGOGTGVGfGhGpGrGuGyG}G~G侴匞奊怗桮濭狦獹矴礕糋綠荊蘂HHH#H(H,H2H6H7H;HLOLULWL_LcL↙窵篖綥蘈蠰袻誏鯨鱈鳯鸏齃MMMM"M,M=MAMCMFMKMqMtMuMxM{M~M筂篗籑罬腗萂鏜闙鞰N NNNNCNDNENHNLN]NgNhNiNoNrN僋嘚嶯扤擭漀濶燦盢睳砃礜綨繬薔螻襈覰諲躈郚酦餘驨 O/O2O5O9O`OdOeOfOkO{O侽哋圤孫峅慜擮桹銸PP P PPPP)P?P^PdPgPiPmPrP嘝嶱桺≒琍甈萈薖訮軵轕銹錚黀QQ4Q7Q;QAQIQOQTQZQ]QcQoQsQ廞換燪繯腝萉蠶襋郠銺騋RR!R5R7R;RTZTfTnTwTxT僒峊桾軹銽'U(U+U-U0U2UCUGUPUTU]U`UeUiUoUpUvUU俇孶廢慤歎沀璘碪萓薝蚒裊襏訳豒鑅鞺骍鬠鶸 V'V+V2V5V?VLVRVXV^VdViVkVwV|V耉肰萔蔞蚔蟅踁遃錠閂黇齎WWWWWWYW]W禬籛糤蒞蚖蟇闣霿鞼XXX!X"X&X'X+X,X0X1X5X6XBXIXJXKXPXRXUXWXfXjXtXxX{X嘪奨朮漍蟈訶躕軽頧餢YYYYYYY!Y$Y&Y2Y6Y7Y;Y=YAYDYIYVYWYZY]Y^Y_YkYlYmYnYoYsYtYxY乊圷奩怸沋淵燳℡痀癥礩筜籝耏蔣薡蘗誝資赮遈鉟鎅餣馳鳼ZZ ZZ Z"Z)Z-Z4Z5Z9Z?Z@ZAZGZLZSZUZZZ_ZdZjZvZxZ哯嘮奪朲焃╖甖痁穁繸腪蒢諾赯[ [$[&[)[+[7[;[<[@[I[M[p[s[{[玔薣裑躘轠颷騕骩鯷鵞\\.\6\>\T\X\^\f\s\y\刓哱慭擻昞榎痋碶礬絓蟎衆裓診譢輁鑌閈隲鮘\]]]]]]]*]@]G]L]O][]a]g]i]q]v]哴嶿慮抅擼胅芣荾躚鋆頬*^+^3^C^E^I^O^R^S^_^h^i^媈╚砠禴籢羄衈鸮黕_____ _+_,_7_8_C_D_Q_U_V_h_k_坃砡確縚繽薩蘝譥豞鉥鋉颻餩齙````7`:`A`b`e`q`宍榒檂盽瞏絗綻蒨蔪誤謄鈆鉦鬬鱜6a7aHQRW]or倲啍嚁姅洈爺禂簲罃茢螖覕訑謹鐢霐鞌飻 !"+,./89;<QRVY\_tx|}帟挄槙瑫瘯罆艜藭謺迺釙驎鰰鷷麜 -.3=HINXbevz€嚃槚洊瑬皷稏紪蠔袞訓謻鐤闁飽鷸 "#>D#%$'/0FHUVlmqrvwz{}~ ()359:CDMNRS^_knz{Y^lmfhlmqrvx|}=>SUYZlm|+ 0 < = R T X Y ] ^ d f j k   O S Z [ | } ! ' ( . 2 4 5 N R Y Z K L R S c g i j | €   !&'45=?DEQ]abvwWYpq€ )23?AHOWXabnpx !IJ€=?CDijZ[ef{}EIKL}~$(/0X\_`rv69€56IL*+7:FG]_cdkmqr|}de{} 45_by|"#HLNO[_ef  ,023CDfg,034QTkm{|'(0278@AJLQR[\fhkl|}     € !!D!E!????""2"3"l"m"??????"#$$Z$[$v$w${$|$???????????????????? % %%%%%*%/%6%7%G%I%K%P%f%g%q%z%??????????????????''''????((x(z(}(~(A)D)P)Q)j)l)p)q)x)z)~))????????????????6*7*N*O*b*d*g*h*??????????$+&+*+++/+0+4+6+:+;+N+O+r+s+????????????,!,$,%,Q,V,a,b,z,|,€,????????????????????,$-(-+-,-?-A-E-F-q-r-x-y-??????????????....1.2.S.T.u.v.??????????)/-///0/D/E/S/T/f/j/p/q/???????????/-0.0H0I0???????????11111q1u1{1|1?????????????? 2 2227282M2O2T2U2i2j2?????????????233 3!3*3,3/303436393:3J3L3P3T3X3\3`3e3y3{33€3??????????44"4#494;4?4@4D4F4J4K4??????55/5155565R5S5????????66B6C6??????(7*7-7.7E7F7^7_7??????(8)8????_9a9m9n9€9??????????????????????? ::::跟胡弃曲?羸蔸搡恸潸纡琥聱蝥;; ; ;;;-;.;E;F;[;\;u;w;y;z;胞雏钧葵%<&<*<+</<6<J<M<d<g<}<凕桙Ⅻ茳唿==汖濤恺泯瘕螨鳊鼾??>>> >>>7>8>P>Q>v>w>侢傼烚燓荥蔺泾濑????8????V?W?m?n???????????????>@A@擛朄楡橜滰濦瓳疈矦碄這郂錊锧AA A!AFAKA^AaAiAjAnAoA匒咥婣廇狝癆盇礎禔郃酇鍭闍B BBB4B5B:B>BQBUB^B_B狟珺癇盉礏稡築籅郆酈CC.C/CKCLCoCpC廋怌蔆薈DD)D*D怐慏谼貲LCLWLZL窵篖綥縇肔腖蔐蘈誏諰鮈鯨鸏麹MMMM)M*M=MAMCMDMmMqMxMyM罬翸鉓鏜闙隡N NNNBNCNHNINoNpN嶯扤擭昇薔螻諲譔餘馧+O/O2O3OXO[OdOeO{O}O丱侽哋圤慜扥酧釵&P'P[P\P萈蒔鵓鶳QQ4Q5QoQpQ廞怮腝臦RR5R7R@RAR疪癛轗逺鵕鶵cSdS鍿镾鵖鶶楾賂&U'UAUCUGUHUOUPUTUUU\U]U`UaUcUeUiUjUuUvU慤扷朥桿燯襏訳豒賃鎁鑅鞺頤鵘鶸5V?VoVrV罺耉賄踁遃郪鉜錠閂闢WWWWYW]W^W碬禬籛糤:X=XIXJXdXfXjXkXrXtXxXyX嘪圶朮榅淴漍訶諼踃躕Y YYY0Y2Y6Y7Y;Y=YAYBYWYXYjYkY~YY塝奩碮礩軾遈鉟鋂1Z2Z]Z_ZdZeZ奪媄璟甖蝂裐[[5[7[;[<[@[A[G[I[M[N[蔥薣裑襕豙躘轠遊隱颷鯷鱗\\.\2\5\6\R\T\X\Y\r\s\y\z\€\刓哱嘰峔慭榎橽焅璡痋碶礬蝄蟎診誠]]@]D]F]G]哴奭慮抅縘胅芣荾躚遌)^*^C^E^I^J^N^O^_^a^e^f^坁塣砠碸颺館O_Q_U_V_╛鸰齙````7`8`m`n`宍峘頯馺5a6aLaMaOaPaVaWa]a^ahajalama朼梐盿瞐鉧錫閍阛骯鬭6b7b@bAbhbibrbsb産癰穊竍鉨鋌齜cc.c0c7c8cBcCcLcMcWcXckclcsctc璫甤絚綾萩蒫襝觕dddddd.d/dNdPdTdUdtdud嘾塪廳恉竏筪觗詃ee$e%e0e2e8e9eLeMeze{e╡猠玡痚癳鄀醗鑕閑"f$f,f-f1f2f6f7fBfDfGfHfLfMfQfRfcfefifjf廸恌籪糵輋辠鮢鰂!g"g=g>g_g`gwgxg砱磄遟鄃鹓黦hh5hHhLhMh巋廻裩襤iiZi[i醝鈏&j'j6k卥噆瀔0l8lDlIljl玪醠fmimsm錷阭HnInn€n絥$o/oEoJo弌歰琽眔耾萶衞謔-p噋鱬q qq秖苢賟辯駋Vr萺蟫鄏錼搒榮畇ttt"ttt萾蟭鄑錿坲島PvUvjvmv]wbw歸漺x x$x)xVxYx墄晉獂痻緓YyZy饄鹹鼀?z@z藌靭飠妠弡顊鷞| ||m|n|簗踻迀y}~}輢閩髛鴠~k~p~賬迆7<瞼穩鰜鼇饌鴤NS#(ad鶆z%*焼紗羻fm噰寚-2虉褕鐖(}厜殙焿di,X煁瘚鞁駤DP`e潓爩/ef粛紞 _`祹稁HI弿悘趶蹚45pq硱磹UV枒棏鄳釕hi簰粧鞉頀)/045NOfg€檽殦矒硴蓳蕮鎿钃霌鞊 89PQno啍嚁爺簲粩覕訑霐鞌)+78[\xy "#>D333333333333333333333333333333333333333333333333333333333333333333333333333333馭骃0U2U蚔蟅UXWX$Y&Y$[1[絓羂羂蘚蚛7`宍8h "#AD纜q纜qTYV TYV L L P'寋h?qO9$x磦e,,s濟窩,胈?胈??HA?HAvEr0旫齝gK,_?哣?哣?匼?匼?o]?o] Fl姚?w8條w8條1}1}刪剺刪`剺﨎*pho(^J.凥刓凥`刓)勳刓勳`刓.剱刓剱`刓.?刓?`刓)勜 刓勜 `刓.剕 刓剕 `刓. 刓 `刓)勀刓勀`刓.刪剺刪`剺(.凥刓凥`刓)勳刓勳`刓.剱刓剱`刓.?刓?`刓)勜 刓勜 `刓.剕 刓剕 `刓. 刓 `刓)勀刓勀`刓.劋刓劋`刓(.凥刓凥`刓)勳刓勳`刓.剱刓剱`刓.?刓?`刓)勜 刓勜 `刓.剕 刓剕 `刓. 刓 `刓)勀刓勀`刓.勼齘`勼齩(.勑?齘勑`?齩(. 勑?齘勑`?齩(. .?勅鸮?`勅鹢(. .. ?勅鸮?`勅鹢( . ... 劆刞鷁劆`刞鷒( . .... 劆刞鷁劆`刞鷒(. ..... 劆刞鷁劆`刞鷒(. ...... 匄鴁`匄鴒(. .......刪剺刪`剺(刪剺刪`剺(.勑?齘勑`?齩(..勑?齘勑`?齩(... ?勅鸮?`勅鹢( .... ?勅鸮?`勅鹢( ..... 劆刞鷁劆`刞鷒(...... 劆刞鷁劆`刞鷒(....... 匄鴁`匄鴒(........刪剺刪`剺﨩JQJo(^J.凥刓凥`刓)勳刓勳`刓.剱刓剱`刓.?刓?`刓)勜 刓勜 `刓.剕 刓剕 `刓. 刓 `刓)勀刓勀`刓.刪剺刪`剺(勼齘`勼齇JPJQJo(.勑?齘勑`?齇JPJQJo(..勑?齘勑`?齇JPJQJo(... ?勅鸮?`勅鸒JPJQJo( .... ?勅鸮?`勅鸒JPJQJo( ..... ?勅鸮?`勅鸒JPJQJo(...... 劆刞鷁劆`刞鶲JPJQJo(....... 劆刞鷁劆`刞鶲JPJQJo(........刪剺刪`剺(.凥刓凥`刓)勳刓勳`刓.剱刓剱`刓.?刓?`刓)勜 刓勜 `刓.剕 刓剕 `刓. 刓 `刓)勀刓勀`刓.劋刓劋`刓.凥刓凥`刓)勳刓勳`刓.剱刓剱`刓.?刓?`刓)勜 刓勜 `刓.剕 刓剕 `刓. 刓 `刓)勀刓勀`刓. 劼凗劼`凗(0€ 凥刓凥`刓h圚) 勳刓勳`刓h圚.€ 剱刓剱`刓h圚.€ ?刓?`刓h圚) 勜 刓勜 `刓h圚.€ 剕 刓剕 `刓h圚.€  刓 `刓h圚) 勀刓勀`刓h圚.刪剺刪`剺(刪剺刪`剺(.勑?齘勑`?齩(..?勅鸮?`勅鹢(... ?勅鸮?`勅鹢( .... 劆刞鷁劆`刞鷒( ..... 劆刞鷁劆`刞鷒(...... 匄鴁`匄鴒(....... 匄鴁`匄鴒(........刪剺刪`剺(.凥刓凥`刓)勳刓勳`刓.剱刓剱`刓.?刓?`刓)勜 刓勜 `刓.剕 刓剕 `刓. 刓 `刓)勀刓勀`刓.刪剺刪`剺(.凥刓凥`刓)勳刓勳`刓.剱刓剱`刓.?刓?`刓)勜 刓勜 `刓.剕 刓剕 `刓. 刓 `刓)勀刓勀`刓.劋刓劋`刓. 剺 `剺?o(.勳刓勳`刓.剱刓剱`刓.?刓?`刓)勜 刓勜 `刓.剕 刓剕 `刓. 刓 `刓)勀刓勀`刓.刪剺刪`剺(€ 凥刓凥`刓h圚) 勳刓勳`刓h圚.€ 剱刓剱`刓h圚.€ ?刓?`刓h圚) 勜 刓勜 `刓h圚.€ 剕 刓剕 `刓h圚.€  刓 `刓h圚) 勀刓勀`刓h圚.刪剺刪`剺(.凥刓凥`刓)勳刓勳`刓.剱刓剱`刓.?刓?`刓)勜 刓勜 `刓.剕 刓剕 `刓. 刓 `刓)勀刓勀`刓.刪剺刪`剺(.凥刓凥`刓)勳刓勳`刓.剱刓剱`刓.?刓?`刓)勜 刓勜 `刓.剕 刓剕 `刓. 刓 `刓)勀刓勀`刓.,纜q1}?HA胈??哣TYV w8條?匼L ?o]vEqO9$齝gKP's濟 FlVbv        h        Vp        0錦Z        9o\-@袰^MM?a Em ? z% !8 iT `薽 謓C{?蒫?lE(?杘h簉蝦?cf飈(.1茾+?GF5I眏+鉱 {H!筕"'#6@&頮&狳'wB'孻''k'ho'(w"*?*Da*/@+of+-礚-0.r:.廠.覵/ 1 1驞1躖2o4ht4 5NN6苐6IM7盬7P8?8 O8?:;J"<&u<烔=鏬=as=>-!>+J>qn>鑇?羑?@$7B C*CkCXD,E?E?F$dGH:$J?J岦J淴萕?gGm貰9W5[?禟Wx-L2+"aM唕`(i`?- 3瑿ym飖Bah臊bFw&En,?FI1?~\€?~)hSm &?*&G~8蠬.Z74S8'阓fU(n8﹛J?xl謕瀝 狣yI^mB?SX)_*up裫2?G6 D糱}縫4疪r =qU`7L4v=鏎鞞5U豦霮S*a??媡汖oX??w\?e緗:8;5*瘥%tu2zFRe秥?b*? xr89譠顰?'wW億9C嶸骮1,NE.Ref{088DADE7-335E-4110-AECD-9C5C7EC55D76}P,NE.Ref{0C84585A-B865-4709-8B44-00A06D03105F} ,NE.Ref{0D746542-8AC1-4494-9FE4-8439893E3B44}0 ,NE.Ref{0DF54945-39F8-458D-BF98-6C671ADCAD3B}€ ,NE.Ref{11C6ED64-D531-4BA5-A80D-FD00AA4A281C} ,NE.Ref{27EE47A2-70A3-44EE-8F3C-A59C7DCC491C}ㄇ ,NE.Ref{2869269B-E7A3-48CE-B2CA-A3DE4643011D} ,NE.Ref{2943A80D-16B4-4697-8D6B-479668C528B3} ,NE.Ref{2CF86265-4606-4760-AF38-70C32FDCBFFE} ,NE.Ref{30DED8CE-6C5E-4FB3-BA46-9DAC42F63CC7} ,NE.Ref{32068C8D-F5EC-4E81-B930-D88B9B305F5A}@,NE.Ref{3893B8DC-C8E2-4F7C-AE42-94B117C70F1A}€,NE.Ref{3D2031EB-4BB5-4D6C-91F3-E84370DF1E9E}苡 ,NE.Ref{476845A0-BFD9-4738-BC84-564264414C82} ,NE.Ref{482E4441-FA8F-4237-9058-789076F9D9BB} ,NE.Ref{5E374D1E-67AA-467F-A4F0-AE6E8C8FC827}d ,NE.Ref{5E76A7C8-D0B1-494D-8DD2-9EE27076F828}鄋 ,NE.Ref{61DE9375-A02B-46F7-A995-064DE9B9802B} ,NE.Ref{6DEFE052-4946-42C2-8D01-907F397881FA}萐,NE.Ref{70778B1C-BFEA-4868-A203-8E8602CB07D3}€,NE.Ref{71D74AE9-97C6-48FF-BF4A-36DA7CF4BE5C}溒 ,NE.Ref{7AB79A83-3B84-4717-9975-49ADCE0D6A25}0€,NE.Ref{8099D126-DDCF-4F5E-B607-683BF2E9BFD5}€,NE.Ref{8154265C-4022-4CBB-B613-DFAECCD4A3A3}$ ,NE.Ref{8674CBDE-6B1F-446F-B04C-3139FD58176B},NE.Ref{88BBB34F-1420-4158-A4F4-909318527091}x€,NE.Ref{8E24EFD7-97F6-4586-B2C0-A49D3087463A}█,NE.Ref{90F92D1F-8087-4E50-8B26-2CFAD2083DF4}0 ,NE.Ref{9139D63B-0240-43DD-B011-50885A3CA269}缐,NE.Ref{9324484C-4564-48F0-A3B3-15B0C539D11E}礋,NE.Ref{A9AE4835-B563-474C-9BFB-819F6E12CEFE} ,NE.Ref{A9C9B754-8563-48A6-A93E-E1C4C93B03C6}根 ,NE.Ref{B627ECB9-1C3D-4D91-A3D9-68B82CB3CB9B}` ,NE.Ref{B8C604D7-6603-4FF5-BFCF-4F24AC3A092A}$,NE.Ref{C4D2B188-DEAC-4B34-8770-EF0A0AFE9B75} ,NE.Ref{CA0D3997-3B62-4A05-BFB1-8CA5763DF85B}纗,NE.Ref{CD325934-BDAE-4F39-B424-6939C7345D6C}€ ,NE.Ref{D17FDD27-D071-475A-8D52-42B6AE893F7C}0,NE.Ref{D26BC0C4-7724-4180-BC2F-FE36B8941C13}o ,NE.Ref{D570E038-576C-4D73-B855-CC54DF2DD592}<,NE.Ref{D5AD1D5D-3A5A-46F9-8C53-F5B6D3AF0E8A}(o ,NE.Ref{DBC936E8-54B9-4490-ABBD-4261A68C6BDF}`,NE.Ref{E47D4E5D-318D-497B-9A38-BAC62DDFAE4E}<Group><References><Item><ID>548</ID><UID>{36503548-8A10-4EBC-9F3F-447913A18A52}</UID><Title>癳媁燪秗舥襨簚巔蕥梪筫Hh(諎L?{mQHr)</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>齎禰kSueP穅訷濺lQ匰</Author><Year>2020</Year><Details><_accessed>63208128</_accessed><_author_aff>齎禰kSueP穅訷濺lQ匰;齎禰-N;So儭{t@\濺lQ;</_author_aff><_collection_scope>PKU</_collection_scope><_created>63208128</_created><_date>2020-02-28</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_issue>02</_issue><_journal>-N齎a觛6RBg譥</_journal><_keywords>癳媁燪秗舥襨;癳媁燪秗舥襨簚巔;癳燪簚巔;a觛2枾c;h芉剺2曽2019-nCoV;SARS-COV-2</_keywords><_modified>63212671</_modified><_pages>192-195</_pages><_translated_author>Guo, Jiaweishengjiankangweibangongting</_translated_author><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=GRKZ202002020&amp;DbName=CJFQTEMP</_url><_volume>19</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>530</ID><UID>{BE87273D-4595-4AFA-B37A-3D48728CDC58}</UID><Title>sQ嶯pS裇癳媁燪秗舥襨簚巔蕥梪筫Hh諎L?{NHr 剉愬w</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>齎禰kSueP穅訷XTO</Author><Year>2020</Year><Details><_accessed>63206930</_accessed><_created>63206848</_created><_modified>63212667</_modified><_translated_author>Guo, Jiaweishengjiankangweiyuanhui</_translated_author></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation> 4 ADDIN NE.Ref.{0C84585A-B865-4709-8B44-00A06D03105F}<Citation><Group><References><Item><ID>545</ID><UID>{D95AE208-9395-4534-B9FE-62EE0F1E2A59}</UID><Title>Arbidol as a broad-spectrum antiviral: an update</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Blaising, J; Polyak, S J; Pecheur, E I</Author><Year>2014</Year><Details><_accession_num>24769245</_accession_num><_author_adr>CRCL, Inserm U1052, CNRS 5286, University of Lyon, Lyon, France.; Dept of Laboratory Medicine, University of Washington, Seattle, WA, USA; Dept of Global Health, University of Washington, Seattle, WA, USA.; CRCL, Inserm U1052, CNRS 5286, University of Lyon, Lyon, France. Electronic address: eve-isabelle.pecheur@inserm.fr.</_author_adr><_created>63208064</_created><_date>2014-07-01</_date><_date_display>2014 Jul</_date_display><_db_updated>PubMed</_db_updated><_doi>10.1016/j.antiviral.2014.04.006</_doi><_impact_factor> 4.130</_impact_factor><_isbn>1872-9096 (Electronic); 0166-3542 (Linking)</_isbn><_journal>Antiviral Res</_journal><_keywords>Animals; Antiviral Agents/*chemistry/pharmacokinetics/*pharmacology/toxicity; Chemical Phenomena; China; Humans; Indoles/*chemistry/pharmacokinetics/*pharmacology/toxicity; Licensure; RussiaAntiviral therapy; Arbidol; Entry; Fusion; Hepatitis C virus; Influenza</_keywords><_language>eng</_language><_modified>63212667</_modified><_ori_publication>Copyright (c) 2014 Elsevier B.V. All rights reserved.</_ori_publication><_pages>84-94</_pages><_tertiary_title>Antiviral research</_tertiary_title><_type_work>Journal Article; Research Support, Non-U.S. Gov&apos;t; Review</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24769245&amp;query_hl=1</_url><_volume>107</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>546</ID><UID>{963E3BFE-6647-4C8F-B4AC-496A57A55D93}</UID><Title>Pharmacokinetics, metabolism, and excretion of the antiviral drug arbidol in humans</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Deng, P; Zhong, D; Yu, K; Zhang, Y; Wang, T; Chen, X</Author><Year>2013</Year><Details><_accession_num>23357765</_accession_num><_author_adr>Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.</_author_adr><_created>63208070</_created><_date>2013-04-01</_date><_date_display>2013 Apr</_date_display><_db_updated>PubMed</_db_updated><_doi>10.1128/AAC.02282-12</_doi><_impact_factor> 4.715</_impact_factor><_isbn>1098-6596 (Electronic); 0066-4804 (Linking)</_isbn><_issue>4</_issue><_journal>Antimicrob Agents Chemother</_journal><_keywords>Adult; Antiviral Agents/blood/*pharmacokinetics/urine; Feces/chemistry; Humans; Indoles/blood/*pharmacokinetics/*urine; Male; Young Adult</_keywords><_language>eng</_language><_modified>63212667</_modified><_pages>1743-55</_pages><_tertiary_title>Antimicrobial agents and chemotherapy</_tertiary_title><_type_work>Clinical Trial; Journal Article; Research Support, Non-U.S. Gov&apos;t</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23357765&amp;query_hl=1</_url><_volume>57</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>547</ID><UID>{523B0216-E67F-400B-B4C2-12DE4507252C}</UID><Title>Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Musher, D M; Logan, N; Mehendiratta, V; Melgarejo, N A; Garud, S; Hamill, R J</Author><Year>2007</Year><Details><_accession_num>17337513</_accession_num><_author_adr>Medical Service (Infectious Disease Section), Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX 77030, USA. daniel.musher@med.va.gov</_author_adr><_created>63208072</_created><_date>2007-04-01</_date><_date_display>2007 Apr</_date_display><_db_updated>PubMed</_db_updated><_doi>10.1093/jac/dkl553</_doi><_impact_factor> 5.113</_impact_factor><_isbn>0305-7453 (Print); 0305-7453 (Linking)</_isbn><_issue>4</_issue><_journal>J Antimicrob Chemother</_journal><_keywords>Aged; Aged, 80 and over; Anti-Bacterial Agents/*therapeutic use; *Clostridium difficile; Enterocolitis, Pseudomembranous/*drug therapy/microbiology; Female; Humans; Male; Metronidazole/*therapeutic use; Middle Aged; Recurrence; Thiazoles/*therapeutic use; Treatment Failure</_keywords><_language>eng</_language><_modified>63212667</_modified><_pages>705-10</_pages><_tertiary_title>The Journal of antimicrobial chemotherapy</_tertiary_title><_type_work>Clinical Trial; Journal Article; Research Support, Non-U.S. Gov&apos;t; Research Support, U.S. Gov&apos;t, Non-P.H.S.</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17337513&amp;query_hl=1</_url><_volume>59</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>543</ID><UID>{56341DF2-3244-4F9C-8A95-289388E4A0ED}</UID><Title>Available from URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21498_Alinia_lbl.pdf</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>FDALabel</Author><Year>0</Year><Details><_accessed>63208142</_accessed><_created>63208142</_created><_modified>63212667</_modified></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>544</ID><UID>{A66CDCBC-B116-4FFF-8F48-40FC5DB4CDD9}</UID><Title>Available from URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/006002s045lbl.pdf</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>FDALabel</Author><Year>0</Year><Details><_accessed>63212730</_accessed><_created>63208146</_created><_modified>63212730</_modified></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation> A ADDIN NE.Ref.{0D746542-8AC1-4494-9FE4-8439893E3B44}<Citation><Group><References><Item><ID>537</ID><UID>{2213FB0A-B81F-4F45-A2E4-AD1258549941}</UID><Title> Available from URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020903s056,021546s012lbl.pdf</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>FDALabel</Author><Year>0</Year><Details><_accessed>63208014</_accessed><_created>63208008</_created><_modified>63212667</_modified></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>538</ID><UID>{BFB2AB3C-C659-4521-A7A8-4426BD8A502B}</UID><Title> Available from URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209347lbl.pdf</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>FDALabel</Author><Year>0</Year><Details><_accessed>63208020</_accessed><_created>63208020</_created><_modified>63212667</_modified></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation>  ADDIN NE.Ref.{0DF54945-39F8-458D-BF98-6C671ADCAD3B}<Citation><Group><References><Item><ID>530</ID><UID>{BE87273D-4595-4AFA-B37A-3D48728CDC58}</UID><Title>sQ嶯pS裇癳媁燪秗舥襨簚巔蕥梪筫Hh諎L?{NHr 剉愬w</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>齎禰kSueP穅訷XTO</Author><Year>2020</Year><Details><_accessed>63206930</_accessed><_created>63206848</_created><_modified>63212667</_modified><_translated_author>Guo, Jiaweishengjiankangweiyuanhui</_translated_author></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>548</ID><UID>{36503548-8A10-4EBC-9F3F-447913A18A52}</UID><Title>癳媁燪秗舥襨簚巔蕥梪筫Hh(諎L?{mQHr)</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>齎禰kSueP穅訷濺lQ匰</Author><Year>2020</Year><Details><_accessed>63208128</_accessed><_author_aff>齎禰kSueP穅訷濺lQ匰;齎禰-N;So儭{t@\濺lQ;</_author_aff><_collection_scope>PKU</_collection_scope><_created>63208128</_created><_date>2020-02-28</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_issue>02</_issue><_journal>-N齎a觛6RBg譥</_journal><_keywords>癳媁燪秗舥襨;癳媁燪秗舥襨簚巔;癳燪簚巔;a觛2枾c;h芉剺2曽2019-nCoV;SARS-COV-2</_keywords><_modified>63212671</_modified><_pages>192-195</_pages><_translated_author>Guo, Jiaweishengjiankangweibangongting</_translated_author><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=GRKZ202002020&amp;DbName=CJFQTEMP</_url><_volume>19</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation>  ADDIN NE.Ref.{11C6ED64-D531-4BA5-A80D-FD00AA4A281C}<Citation><Group><References><Item><ID>530</ID><UID>{BE87273D-4595-4AFA-B37A-3D48728CDC58}</UID><Title>sQ嶯pS裇癳媁燪秗舥襨簚巔蕥梪筫Hh諎L?{NHr 剉愬w</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>齎禰kSueP穅訷XTO</Author><Year>2020</Year><Details><_accessed>63206930</_accessed><_created>63206848</_created><_modified>63212667</_modified><_translated_author>Guo, Jiaweishengjiankangweiyuanhui</_translated_author></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>548</ID><UID>{36503548-8A10-4EBC-9F3F-447913A18A52}</UID><Title>癳媁燪秗舥襨簚巔蕥梪筫Hh(諎L?{mQHr)</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>齎禰kSueP穅訷濺lQ匰</Author><Year>2020</Year><Details><_accessed>63208128</_accessed><_author_aff>齎禰kSueP穅訷濺lQ匰;齎禰-N;So儭{t@\濺lQ;</_author_aff><_collection_scope>PKU</_collection_scope><_created>63208128</_created><_date>2020-02-28</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_issue>02</_issue><_journal>-N齎a觛6RBg譥</_journal><_keywords>癳媁燪秗舥襨;癳媁燪秗舥襨簚巔;癳燪簚巔;a觛2枾c;h芉剺2曽2019-nCoV;SARS-COV-2</_keywords><_modified>63212671</_modified><_pages>192-195</_pages><_translated_author>Guo, Jiaweishengjiankangweibangongting</_translated_author><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=GRKZ202002020&amp;DbName=CJFQTEMP</_url><_volume>19</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation> % ADDIN NE.Ref.{27EE47A2-70A3-44EE-8F3C-A59C7DCC491C}<Citation><Group><References><Item><ID>560</ID><UID>{85385A31-72E9-462C-96BF-265E28970317}</UID><Title>Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Lim, J; Jeon, S; Shin, H Y; Kim, M J; Seong, Y M; Lee, W J; Choe, K W; Kang, Y M; Lee, B; Park, S J</Author><Year>2020</Year><Details><_accession_num>32056407</_accession_num><_author_adr>Department of Laboratory Medicine, Myongji Hospital, Hanyang University College of Medicine, Goyang, Korea.; New Horizon Cancer Institute, Myongji Hospital, Goyang, Korea.; Department of Family Medicine, Myongji Hospital, Hanyang University College of Medicine, Goyang, Korea.; Department of Laboratory Medicine, Myongji Hospital, Hanyang University College of Medicine, Goyang, Korea.; Department of Internal Medicine, Myongji Hospital, Goyang, Korea.; Office of Chief Executive Officer and Chairman, Department of General Surgery, Myongji Hospital, Goyang, Korea.; Department of Infectious Diseases, Myongji Hospital, Goyang, Korea.; Department of Infectious Diseases, Myongji Hospital, Goyang, Korea.; CancerROP, Seoul, Korea. baeckseung@gmail.com.; Department of Pulmonary and Critical Care Medicine, Myongji Hospital, Goyang, Korea. drjoseph@mjh.or.kr.</_author_adr><_collection_scope>SCI;SCIE</_collection_scope><_created>63208294</_created><_date>2020-02-17</_date><_date_display>2020 Feb 17</_date_display><_db_updated>PubMed</_db_updated><_doi>10.3346/jkms.2020.35.e79</_doi><_impact_factor> 1.716</_impact_factor><_isbn>1598-6357 (Electronic); 1011-8934 (Linking)</_isbn><_issue>6</_issue><_journal>J Korean Med Sci</_journal><_keywords>COVID-19; Coronavirus; Pneumonia; Real-Time Reverse-Transcriptase Polymerase Chain Reaction; Tertiary Infection; Viral Load</_keywords><_language>eng</_language><_modified>63212667</_modified><_ori_publication>(c) 2020 The Korean Academy of Medical Sciences.</_ori_publication><_pages>e79</_pages><_tertiary_title>Journal of Korean medical science</_tertiary_title><_type_work>Journal Article</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=32056407&amp;query_hl=1</_url><_volume>35</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>561</ID><UID>{9C1E7256-A781-4F98-A2F0-4F253B8BE155}</UID><Title>Dual therapy with lopinavir/ritonavir plus lamivudine could be a viable alternative for antiretroviral-therapy-naive adults with HIV-1 infection regardless of HIV viral load or subgenotype in resource-limited settings: A randomised, open-label and non-inferiority study from China</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Li, L; He, H; Lan, Y; Chen, J; Zhong, H; Nie, J; Chen, X; Hu, F; Tang, X; Cai, W</Author><Year>2018</Year><Details><_accession_num>30880698</_accession_num><_author_adr>Center for Infectious Diseases, Guangzhou Eighth People&apos;s Hospital, Guangzhou Medical University, Guangzhou, China.; Center for Infectious Diseases, Guangzhou Eighth People&apos;s Hospital, Guangzhou Medical University, Guangzhou, China.; Institute of Infectious Diseases, Guangzhou Eighth People&apos;s Hospital, Guangzhou Medical University, Guangzhou, China.; Center for Infectious Diseases, Guangzhou Eighth People&apos;s Hospital, Guangzhou Medical University, Guangzhou, China.; Center for Infectious Diseases, Guangzhou Eighth People&apos;s Hospital, Guangzhou Medical University, Guangzhou, China.; Center for Infectious Diseases, Guangzhou Eighth People&apos;s Hospital, Guangzhou Medical University, Guangzhou, China.; Center for Infectious Diseases, Guangzhou Eighth People&apos;s Hospital, Guangzhou Medical University, Guangzhou, China.; Institute of Infectious Diseases, Guangzhou Eighth People&apos;s Hospital, Guangzhou Medical University, Guangzhou, China.; Institute of Infectious Diseases, Guangzhou Eighth People&apos;s Hospital, Guangzhou Medical University, Guangzhou, China.; Center for Infectious Diseases, Guangzhou Eighth People&apos;s Hospital, Guangzhou Medical University, Guangzhou, China.</_author_adr><_created>63208295</_created><_date>2018-10-01</_date><_date_display>2018 Oct-Dec</_date_display><_db_updated>PubMed</_db_updated><_doi>10.4103/ijmm.IJMM_18_172</_doi><_impact_factor> 0.950</_impact_factor><_isbn>1998-3646 (Electronic); 0255-0857 (Linking)</_isbn><_issue>4</_issue><_journal>Indian J Med Microbiol</_journal><_keywords>Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents/*administration &amp;amp; dosage/adverse effects; Antiretroviral Therapy, Highly Active/adverse effects/*methods; China; Drug-Related Side Effects and Adverse Reactions/epidemiology/pathology; Female; HIV Infections/*drug therapy; HIV-1/*isolation &amp;amp; purification; Humans; Lamivudine/*administration &amp;amp; dosage/adverse effects; Lopinavir/*administration &amp;amp; dosage/adverse effects; Male; Middle Aged; Ritonavir/*administration &amp;amp; dosage/adverse effects; Treatment Outcome; Viral Load; Young AdultAntiretroviral therapy; efavirenz; lopinavir/ritonavir; randomised controlled study; simplified regimen</_keywords><_language>eng</_language><_modified>63212667</_modified><_pages>513-516</_pages><_tertiary_title>Indian journal of medical microbiology</_tertiary_title><_type_work>Journal Article; Randomized Controlled Trial</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=30880698&amp;query_hl=1</_url><_volume>36</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>562</ID><UID>{A613C6AC-1E8A-4497-9885-34BF360116EA}</UID><Title>The Author&apos;s Response: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Lim, J; Jeon, S; Shin, H Y; Kim, M J; Seong, Y M; Lee, W J; Choe, K W; Kang, Y M; Lee, B; Park, S J</Author><Year>2020</Year><Details><_accession_num>32080993</_accession_num><_author_adr>Department of Laboratory Medicine, Myongji Hospital, Hanyang University College of Medicine, Goyang, Korea.; New Horizon Cancer Institute, Myongji Hospital, Goyang, Korea.; Department of Family Medicine, Myongji Hospital, Hanyang University College of Medicine, Goyang, Korea.; Department of Laboratory Medicine, Myongji Hospital, Hanyang University College of Medicine, Goyang, Korea.; Department of Internal Medicine, Myongji Hospital, Goyang, Korea.; Office of Chief Executive Officer and Chairman, Department of General Surgery, Myongji Hospital, Goyang, Korea.; Department of Infectious Diseases, Myongji Hospital, Goyang, Korea.; Department of Infectious Diseases, Myongji Hospital, Goyang, Korea.; CancerROP, Seoul, Korea. baeckseung@gmail.com.; Department of Pulmonary and Critical Care Medicine, Myongji Hospital, Goyang, Korea. drjoseph@mjh.or.kr.</_author_adr><_collection_scope>SCI;SCIE</_collection_scope><_created>63208294</_created><_date>2020-02-24</_date><_date_display>2020 Feb 24</_date_display><_db_updated>PubMed</_db_updated><_doi>10.3346/jkms.2020.35.e89</_doi><_impact_factor> 1.716</_impact_factor><_isbn>1598-6357 (Electronic); 1011-8934 (Linking)</_isbn><_issue>7</_issue><_journal>J Korean Med Sci</_journal><_language>eng</_language><_modified>63212667</_modified><_pages>e89</_pages><_tertiary_title>Journal of Korean medical science</_tertiary_title><_type_work>Letter</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=32080993&amp;query_hl=1</_url><_volume>35</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation> K ADDIN NE.Ref.{2869269B-E7A3-48CE-B2CA-A3DE4643011D}<Citation><Group><References><Item><ID>394</ID><UID>{D2D7BB6F-1235-49D4-9145-DE96ADE208D0}</UID><Title>sQ嶯pS裇癳媁燪秗舥襨簚巔蕥梪筫Hh諎L?{NHr 剉愬w</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>齎禰kSueP穅訷XTO</Author><Year>2020</Year><Details><_accessed>63236752</_accessed><_created>63206848</_created><_modified>63206930</_modified><_translated_author>Guo, Jiaweishengjiankangweiyuanhui</_translated_author></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation>  ADDIN NE.Ref.{2943A80D-16B4-4697-8D6B-479668C528B3}<Citation><Group><References><Item><ID>539</ID><UID>{810E7A41-8A33-45D9-B7DA-ACF3CBEB503C}</UID><Title>Development of a standard treatment protocol for severe acute respiratory syndrome</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>So, L K; Lau, A C; Yam, L Y; Cheung, T M; Poon, E; Yung, R W; Yuen, K Y</Author><Year>2003</Year><Details><_accession_num>12747883</_accession_num><_author_adr>Department of Medicine, Pamela Youde Nethersole Eastern Hospital, Hong Kong, Special Administrative Region, China. drcwlau@hkstar.com</_author_adr><_collection_scope>SCI;SCIE</_collection_scope><_created>63208045</_created><_date>2003-05-10</_date><_date_display>2003 May 10</_date_display><_db_updated>PubMed</_db_updated><_doi>10.1016/s0140-6736(03)13265-5</_doi><_impact_factor> 59.102</_impact_factor><_isbn>0140-6736 (Print); 0140-6736 (Linking)</_isbn><_issue>9369</_issue><_journal>Lancet</_journal><_keywords>Adult; Anti-Bacterial Agents/*therapeutic use; Drug Administration Schedule; Female; Humans; Male; Methylprednisolone/*therapeutic use; Ribavirin/*therapeutic use; Severe Acute Respiratory Syndrome/*drug therapy/physiopathology; Treatment Outcome</_keywords><_language>eng</_language><_modified>63212667</_modified><_pages>1615-7</_pages><_tertiary_title>Lancet (London, England)</_tertiary_title><_type_work>Journal Article</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12747883&amp;query_hl=1</_url><_volume>361</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation>  ADDIN NE.Ref.{2CF86265-4606-4760-AF38-70C32FDCBFFE}<Citation><Group><References><Item><ID>541</ID><UID>{23C69C58-C2BC-4F55-A824-9B84AE170DAB}</UID><Title>Arbidol: a broad-spectrum antiviral compound that blocks viral fusion</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Boriskin, Y S; Leneva, I A; Pecheur, E I; Polyak, S J</Author><Year>2008</Year><Details><_accession_num>18393857</_accession_num><_author_adr>Institute of Virology, Moscow, Russia.</_author_adr><_collection_scope>SCI;SCIE</_collection_scope><_created>63208054</_created><_date>2008-01-20</_date><_date_display>2008</_date_display><_db_updated>PubMed</_db_updated><_doi>10.2174/092986708784049658</_doi><_impact_factor> 3.894</_impact_factor><_isbn>0929-8673 (Print); 0929-8673 (Linking)</_isbn><_issue>10</_issue><_journal>Curr Med Chem</_journal><_keywords>Animals; Antiviral Agents/*pharmacology; *Cell Fusion; Humans; Indoles/*pharmacology; Virus Attachment/*drug effects</_keywords><_language>eng</_language><_modified>63212667</_modified><_pages>997-1005</_pages><_tertiary_title>Current medicinal chemistry</_tertiary_title><_type_work>Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov&apos;t; Review</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18393857&amp;query_hl=1</_url><_volume>15</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation>  ADDIN NE.Ref.{30DED8CE-6C5E-4FB3-BA46-9DAC42F63CC7}<Citation><Group><References><Item><ID>541</ID><UID>{23C69C58-C2BC-4F55-A824-9B84AE170DAB}</UID><Title>Arbidol: a broad-spectrum antiviral compound that blocks viral fusion</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Boriskin, Y S; Leneva, I A; Pecheur, E I; Polyak, S J</Author><Year>2008</Year><Details><_accession_num>18393857</_accession_num><_author_adr>Institute of Virology, Moscow, Russia.</_author_adr><_collection_scope>SCI;SCIE</_collection_scope><_created>63208054</_created><_date>2008-01-20</_date><_date_display>2008</_date_display><_db_updated>PubMed</_db_updated><_doi>10.2174/092986708784049658</_doi><_impact_factor> 3.894</_impact_factor><_isbn>0929-8673 (Print); 0929-8673 (Linking)</_isbn><_issue>10</_issue><_journal>Curr Med Chem</_journal><_keywords>Animals; Antiviral Agents/*pharmacology; *Cell Fusion; Humans; Indoles/*pharmacology; Virus Attachment/*drug effects</_keywords><_language>eng</_language><_modified>63212667</_modified><_pages>997-1005</_pages><_tertiary_title>Current medicinal chemistry</_tertiary_title><_type_work>Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov&apos;t; Review</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18393857&amp;query_hl=1</_url><_volume>15</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>542</ID><UID>{C314C0E1-04C7-4D3F-8FB2-1F2C66477115}</UID><Title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Wang, M; Cao, R; Zhang, L; Yang, X; Liu, J; Xu, M; Shi, Z; Hu, Z; Zhong, W; Xiao, G</Author><Year>2020</Year><Details><_accession_num>32020029</_accession_num><_author_adr>State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071, Wuhan, China.; National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, 100850, Beijing, China.; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071, Wuhan, China.; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071, Wuhan, China.; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071, Wuhan, China.; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071, Wuhan, China.; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071, Wuhan, China.; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071, Wuhan, China. huzh@wh.iov.cn.; National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, 100850, Beijing, China. zhongwu@bmi.ac.cn.; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071, Wuhan, China. xiaogf@wh.iov.cn.</_author_adr><_collection_scope>SCI;SCIE;CSCD</_collection_scope><_created>63208073</_created><_date>2020-03-01</_date><_date_display>2020 Mar</_date_display><_db_updated>PubMed</_db_updated><_doi>10.1038/s41422-020-0282-0</_doi><_impact_factor> 17.848</_impact_factor><_isbn>1748-7838 (Electronic); 1001-0602 (Linking)</_isbn><_issue>3</_issue><_journal>Cell Res</_journal><_language>eng</_language><_modified>63212667</_modified><_pages>269-271</_pages><_tertiary_title>Cell research</_tertiary_title><_type_work>Letter</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=32020029&amp;query_hl=1</_url><_volume>30</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>543</ID><UID>{56341DF2-3244-4F9C-8A95-289388E4A0ED}</UID><Title>Available from URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21498_Alinia_lbl.pdf</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>FDALabel</Author><Year>0</Year><Details><_accessed>63208142</_accessed><_created>63208142</_created><_modified>63212667</_modified></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>544</ID><UID>{A66CDCBC-B116-4FFF-8F48-40FC5DB4CDD9}</UID><Title>Available from URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/006002s045lbl.pdf</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>FDALabel</Author><Year>0</Year><Details><_accessed>63212730</_accessed><_created>63208146</_created><_modified>63212730</_modified></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation>  ADDIN NE.Ref.{32068C8D-F5EC-4E81-B930-D88B9B305F5A}<Citation><Group><References><Item><ID>452</ID><UID>{90D8BD0C-D39B-426E-AFF7-5DA272CE8C28}</UID><Title>癳媁燪秗舥襨2019-nCoV 剉vTo僫rxvzV{eu</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>RCS荝; 媠Sfo侟/Author><Year>0</Year><Details><_author_aff>'Y gNSYuir;So兤栤V gP杔Q鳶;-N齎;Sf[褃f[b杘僫rxvz@b;</_author_aff><_collection_scope>CSCD;PKU</_collection_scope><_created>63208409</_created><_date>2020-02-12</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_journal>o僨[f[</_journal><_keywords>癳媁燪秗舥襨;癳媁燪秗舥襨簚巔;vT籰梪;T€T(uo傷^t穇夋桘KQ汻潅</_keywords><_modified>63208409</_modified><_pages>1-17</_pages><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=YXXB20200211000&amp;DbName=CAPJ2020</_url><_translated_author>Liu, Qianyong;Wang, Xiaoliang</_translated_author></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>453</ID><UID>{30F6EBDF-CEEA-4A1C-938F-EBB69B11C5B5}</UID><Title>癳媁燪秗舥襨(2019-nCoV)籰梪o僫rSO匭Yxvz蔛o僫rx裇蹚U\</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>媅rg; b; O?崌e</Author><Year>0</Year><Details><_author_aff>nf1m^篘l;Sb曽</_author_aff><_collection_scope>CSCD;PKU</_collection_scope><_created>63208409</_created><_date>2020-02-11</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_journal>舥襨f[</_journal><_keywords>簚巔;癳媁燪秗舥襨(2019-nCoV);SO匭Yxvz;o僫r;蛻歔MO</_keywords><_modified>63208409</_modified><_pages>1-6</_pages><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=BDXB20200211000&amp;DbName=CAPJ2020</_url><_translated_author>Song, Gao;Cheng, Mengqun;Wei, Xianwen</_translated_author></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>462</ID><UID>{7174D053-6A9A-4E5B-BDCA-72F19068FCEA}</UID><Title>NS-N褃€b'Yf[ TNm;Sf[b朌朸\ TNm;Sb杝Q嶯癳媁燪秗舥襨簚巔-N;S蕥梪筫Hh蔛剺2柟eHh</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author/><Year>0</Year><Details><_author_aff>NS-N褃€b'Yf[ TNm;Sf[b朌朸\ TNm;Sb?N;S褃;</_author_aff><_created>63208411</_created><_date>2020-02-11</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_journal>;So凕[</_journal><_keywords>-N;So傷癳媁燪秗舥襨簚巔;-N;S蕥梪;-N;S剺2朁/_keywords><_modified>63208411</_modified><_pages>1-5</_pages><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=YYDB20200209002&amp;DbName=CAPJ2020</_url></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>463</ID><UID>{3FFD4586-5CC1-4B66-A844-FC2BA7619337}</UID><Title>S琋OS孴;Sb杝Q嶯 癳媁燪秗舥襨a觛剉簚巔 蕥梪鷁畫筫HhV2.0 </Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Ng*Yu; 鵩畇; )R; ?mO; 絜>N</Author><Year>0</Year><Details><_author_aff>S琋OS孴;Sb柊e媁燪秗舥襨a觛剉簚巔蕥籰N禰膥;S琋OS孴;Sba觛匭褃;S琋OS孴;Sb枀Q褃ICU;S琋OS孴;Sb東T8TNqS蛻莡;Sf[褃;</_author_aff><_created>63208411</_created><_date>2020-01-30</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_journal>OS孴;Sf[Bg譥</_journal><_keywords>癳媁燪秗舥襨;簚巔;蕥璭;籰梪</_keywords><_modified>63208411</_modified><_pages>1-5</_pages><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=XHYX20200129000&amp;DbName=CAPJ2020</_url><_translated_author>Li, Taisheng;Cao, Wei;Weng, Li;Fan, Hongwei;Shi, Juhong</_translated_author></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>446</ID><UID>{EDAAD7B6-B141-4210-91B4-52F115481581}</UID><Title>Therapeutic options for the 2019 novel coronavirus (2019-nCoV)</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Li, G; De Clercq, E</Author><Year>2020</Year><Details><_accession_num>32127666</_accession_num><_collection_scope>SCI;SCIE</_collection_scope><_created>63208384</_created><_date>2020-03-01</_date><_date_display>2020 Mar</_date_display><_db_updated>PubMed</_db_updated><_doi>10.1038/d41573-020-00016-0</_doi><_impact_factor> 57.618</_impact_factor><_isbn>1474-1784 (Electronic); 1474-1776 (Linking)</_isbn><_issue>3</_issue><_journal>Nat Rev Drug Discov</_journal><_language>eng</_language><_modified>63208387</_modified><_pages>149-150</_pages><_tertiary_title>Nature reviews. Drug discovery</_tertiary_title><_type_work>News</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=32127666&amp;query_hl=1</_url><_volume>19</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>447</ID><UID>{C1A8E50C-BFAB-4A92-8204-3ADE3228EF5E}</UID><Title>Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Nguyen, T M; Zhang, Y; Pandolfi, P P</Author><Year>2020</Year><Details><_accession_num>32071427</_accession_num><_author_adr>Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02115, USA.; Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02115, USA.; Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02115, USA. pierpaolo.pandolfiderinaldis@unito.it.; MBC, Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, TO, 10126, Italy. pierpaolo.pandolfiderinaldis@unito.it.</_author_adr><_collection_scope>SCI;SCIE;CSCD</_collection_scope><_created>63208385</_created><_date>2020-03-01</_date><_date_display>2020 Mar</_date_display><_db_updated>PubMed</_db_updated><_doi>10.1038/s41422-020-0290-0</_doi><_impact_factor> 17.848</_impact_factor><_isbn>1748-7838 (Electronic); 1001-0602 (Linking)</_isbn><_issue>3</_issue><_journal>Cell Res</_journal><_language>eng</_language><_modified>63208387</_modified><_pages>189-190</_pages><_tertiary_title>Cell research</_tertiary_title><_type_work>Editorial</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=32071427&amp;query_hl=1</_url><_volume>30</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation> ? ADDIN NE.Ref.{3893B8DC-C8E2-4F7C-AE42-94B117C70F1A}<Citation><Group><References><Item><ID>565</ID><UID>{CDD534FC-E334-4A88-84A0-CBCF6A0C46A9}</UID><Title>Favipiravir (T-705), a novel viral RNA polymerase inhibitor</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Furuta, Y; Gowen, B B; Takahashi, K; Shiraki, K; Smee, D F; Barnard, D L</Author><Year>2013</Year><Details><_accession_num>24084488</_accession_num><_author_adr>Toyama Chemical Co., Ltd., 4-1, Shimookui 2-chome, Toyama 930-8508, Japan. Electronic address: yousuke_furuta@toyama-chemical.co.jp.</_author_adr><_created>63208324</_created><_date>2013-11-01</_date><_date_display>2013 Nov</_date_display><_db_updated>PubMed</_db_updated><_doi>10.1016/j.antiviral.2013.09.015</_doi><_impact_factor> 4.130</_impact_factor><_isbn>1872-9096 (Electronic); 0166-3542 (Linking)</_isbn><_issue>2</_issue><_journal>Antiviral Res</_journal><_keywords>Amides/isolation &amp;amp; purification/*pharmacology/therapeutic use; Antiviral Agents/isolation &amp;amp; purification/*pharmacology/therapeutic use; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; DNA-Directed RNA Polymerases/*antagonists &amp;amp; inhibitors; Enzyme Inhibitors/isolation &amp;amp; purification/*pharmacology/therapeutic use; Humans; Influenza, Human/*drug therapy; Japan; Pyrazines/isolation &amp;amp; purification/*pharmacology/therapeutic use; RNA Viruses/*drug effects; United StatesFavipiravir; Influenza; RNA viruses; RNA-dependent RNA polymerase; T-705</_keywords><_language>eng</_language><_modified>63212667</_modified><_ori_publication>Copyright (c) 2013 Elsevier B.V. All rights reserved.</_ori_publication><_pages>446-54</_pages><_tertiary_title>Antiviral research</_tertiary_title><_type_work>Journal Article; Research Support, N.I.H., Extramural; Review</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24084488&amp;query_hl=1</_url><_volume>100</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>570</ID><UID>{77775DC0-BEC0-4338-AB7E-4442223F696E}</UID><Title>Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Warren, T K; Jordan, R; Lo, M K; Ray, A S; Mackman, R L; Soloveva, V; Siegel, D; Perron, M; Bannister, R; Hui, H C; Larson, N; Strickley, R; Wells, J; Stuthman, K S; Van Tongeren, S A; Garza, N L; Donnelly, G; Shurtleff, A C; Retterer, C J; Gharaibeh, D; Zamani, R; Kenny, T; Eaton, B P; Grimes, E; Welch, L S; Gomba, L; Wilhelmsen, C L; Nichols, D K; Nuss, J E; Nagle, E R; Kugelman, J R; Palacios, G; Doerffler, E; Neville, S; Carra, E; Clarke, M O; Zhang, L; Lew, W; Ross, B; Wang, Q; Chun, K; Wolfe, L; Babusis, D; Park, Y; Stray, K M; Trancheva, I; Feng, J Y; Barauskas, O; Xu, Y; Wong, P; Braun, M R; Flint, M; McMullan, L K; Chen, S S; Fearns, R; Swaminathan, S; Mayers, D L; Spiropoulou, C F; Lee, W A; Nichol, S T; Cihlar, T; Bavari, S</Author><Year>2016</Year><Details><_accession_num>26934220</_accession_num><_author_adr>United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702, USA.; United States Army Medical Research Institute of Infectious Diseases, Therapeutic Development Center, Frederick, Maryland 21702, USA.; Gilead Sciences, Foster City, California 94404, USA.; Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.; Gilead Sciences, Foster City, California 94404, USA.; Gilead Sciences, Foster City, California 94404, USA.; United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702, USA.; United States Army Medical Research Institute of Infectious Diseases, Therapeutic Development Center, Frederick, Maryland 21702, USA.; Gilead Sciences, Foster City, California 94404, USA.; Gilead Sciences, Foster City, California 94404, USA.; Gilead Sciences, Foster City, California 94404, USA.; Gilead Sciences, Foster City, California 94404, USA.; Gilead Sciences, Foster City, California 94404, USA.; Gilead Sciences, Foster City, California 94404, USA.; United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702, USA.; United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702, USA.; United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702, USA.; United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702, USA.; United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702, USA.; United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702, USA.; United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702, USA.; United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702, USA.; United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702, USA.; United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702, USA.; United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702, USA.; United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702, USA.; United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702, USA.; United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702, USA.; United States Army Medical Research Institute of Infectious Diseases, Therapeutic Development Center, Frederick, Maryland 21702, USA.; United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702, USA.; United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702, USA.; United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702, USA.; United States Army Medical Research Institute of Infectious Diseases, Therapeutic Development Center, Frederick, Maryland 21702, USA.; United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702, USA.; United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702, USA.; United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702, USA.; Gilead Sciences, Foster City, California 94404, USA.; Gilead Sciences, Foster City, California 94404, USA.; Gilead Sciences, Foster City, California 94404, USA.; Gilead Sciences, Foster City, California 94404, USA.; Gilead Sciences, Foster City, California 94404, USA.; Gilead Sciences, Foster City, California 94404, USA.; Gilead Sciences, Foster City, California 94404, USA.; Gilead Sciences, Foster City, California 94404, USA.; Gilead Sciences, Foster City, California 94404, USA.; Gilead Sciences, Foster City, California 94404, USA.; Gilead Sciences, Foster City, California 94404, USA.; Gilead Sciences, Foster City, California 94404, USA.; Gilead Sciences, Foster City, California 94404, USA.; Gilead Sciences, Foster City, California 94404, USA.; Gilead Sciences, Foster City, California 94404, USA.; Gilead Sciences, Foster City, California 94404, USA.; Gilead Sciences, Foster City, California 94404, USA.; Gilead Sciences, Foster City, California 94404, USA.; Boston University School of Medicine, Boston, Massachusetts 02118, USA.; Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.; Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.; Gilead Sciences, Foster City, California 94404, USA.; Boston University School of Medicine, Boston, Massachusetts 02118, USA.; Gilead Sciences, Foster City, California 94404, USA.; United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702, USA.; Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.; Gilead Sciences, Foster City, California 94404, USA.; Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.; Gilead Sciences, Foster City, California 94404, USA.; United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702, USA.; United States Army Medical Research Institute of Infectious Diseases, Therapeutic Development Center, Frederick, Maryland 21702, USA.</_author_adr><_collection_scope>SCI;SCIE</_collection_scope><_created>63208369</_created><_date>2016-03-17</_date><_date_display>2016 Mar 17</_date_display><_db_updated>PubMed</_db_updated><_doi>10.1038/nature17180</_doi><_impact_factor> 43.070</_impact_factor><_isbn>1476-4687 (Electronic); 0028-0836 (Linking)</_isbn><_issue>7594</_issue><_journal>Nature</_journal><_keywords>Alanine/*analogs &amp;amp; derivatives/pharmacokinetics/pharmacology/therapeutic use; Amino Acid Sequence; Animals; Antiviral Agents/pharmacokinetics/pharmacology/*therapeutic use; Cell Line, Tumor; Ebolavirus/drug effects; Female; HeLa Cells; Hemorrhagic Fever, Ebola/*drug therapy/prevention &amp;amp; control; Humans; Macaca mulatta/*virology; Male; Molecular Sequence Data; Organ Specificity; Prodrugs/pharmacokinetics/pharmacology/therapeutic use; Ribonucleotides/pharmacokinetics/pharmacology/*therapeutic use</_keywords><_language>eng</_language><_modified>63212667</_modified><_pages>381-5</_pages><_tertiary_title>Nature</_tertiary_title><_type_work>Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov&apos;t, Non-P.H.S.</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26934220&amp;query_hl=1</_url><_volume>531</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>449</ID><UID>{38685694-FA6F-48B6-A64A-4A3333C40505}</UID><Title>梑癳媁燪秗舥襨\o汻o僫r  ^t穇夋桙/Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>恄P[褢; 媠s^</Author><Year>2020</Year><Details><_author_aff>_l堺Sf[貧I{N褃f[!ho僨[鹼;Ym_l錧N'Yf[o僨[b曽</_author_aff><_collection_scope>CSCD</_collection_scope><_created>63208409</_created><_date>2020-02-15</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_issue>03</_issue><_journal>-N齎皊鉔擽(uo僨[</_journal><_keywords>癳媁燪秗舥襨;^t穇夋桘4N奮xvz</_keywords><_modified>63208409</_modified><_pages>264-268</_pages><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=XDYD202003002&amp;DbName=CJFQTEMP</_url><_volume>37</_volume><_translated_author>Xu, Zijin;Wang, Ping</_translated_author></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation>  ADDIN NE.Ref.{3D2031EB-4BB5-4D6C-91F3-E84370DF1E9E}<Citation><Group><References><Item><ID>617</ID><UID>{0E2E7728-8969-4056-A24B-FE286305D88C}</UID><Title>kxx憻/l筓籰梪nf悑W2019燪秗舥襨舥COVID-19 €Rekxvz</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>H枦Q; R9N凔 R墐; R凔 恄哵t^; Y2桘 蘍慛; 臑9N; 媅h=N; _9N9N; 睌譥s^; Ng沵; 坙鰯郷; bS*m2m</Author><Year>0</Year><Details><_author_aff> Nwm^lQqQkSu4N奮-N胈a觛NMQ玼褃;</_author_aff><_created>63235707</_created><_date>2020-03-09</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_journal>Ym_l'Yf[f[(;Sf[Hr)</_journal><_keywords>%N蛻%`'`|T8T鼅T乢燪秗舥襨2;2019燪秗舥襨舥;癳媁燪秗舥襨簚巔;kxx憻/l筓;籰梪He済;塠hQ'`</_keywords><_modified>63235707</_modified><_pages>1-8</_pages><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=ZJYB20200306002&amp;DbName=CAPJ2020</_url><_translated_author>Chen, Jun;Liu, Danping;Liu, Li;Liu, Ping;Xu, Qingnian;Xia, Lu;Ling, Yun;Huang, Dan;Song, Shuli;Zhang, Dandan;Qian, Zhiping;Li, Tao;Shen, Yinzhong;Lu, Hongzhou</_translated_author></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>618</ID><UID>{9F3BEFBC-F3E7-4F80-BC0C-0BB4EEFEB74A}</UID><Title>kxx憻/l筓剉4N奮otf[xvz蹚U\</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>]趮; HN陽wZ; 俶`*t; "mi`; Ngwm誵; RN3朁/Author><Year>2020</Year><Details><_author_aff>S琋'Yf[,{ N;Sb杘僫r4N奮諎寶:g刧;</_author_aff><_collection_scope>CSCD</_collection_scope><_created>63235708</_created><_date>2020-03-04</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_issue>02</_issue><_journal>-N齎4N奮otf[N籰梪f[</_journal><_keywords>癳燪舥襨簚巔;/l筓;4N奮ot</_keywords><_modified>63235708</_modified><_pages>221-226</_pages><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=YLZL202002020&amp;DbName=CJFQTEMP</_url><_volume>25</_volume><_translated_author>Cui, Cheng;Me, Xueting;Tu, Siqi;Xie, Jie&apos;en;Li, Haiyan;Liu, Dongyang</_translated_author></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation>  ADDIN NE.Ref.{476845A0-BFD9-4738-BC84-564264414C82}<Citation><Group><References><Item><ID>548</ID><UID>{36503548-8A10-4EBC-9F3F-447913A18A52}</UID><Title>癳媁燪秗舥襨簚巔蕥梪筫Hh(諎L?{mQHr)</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>齎禰kSueP穅訷濺lQ匰</Author><Year>2020</Year><Details><_accessed>63208128</_accessed><_author_aff>齎禰kSueP穅訷濺lQ匰;齎禰-N;So儭{t@\濺lQ;</_author_aff><_collection_scope>PKU</_collection_scope><_created>63208128</_created><_date>2020-02-28</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_issue>02</_issue><_journal>-N齎a觛6RBg譥</_journal><_keywords>癳媁燪秗舥襨;癳媁燪秗舥襨簚巔;癳燪簚巔;a觛2枾c;h芉剺2曽2019-nCoV;SARS-COV-2</_keywords><_modified>63212671</_modified><_pages>192-195</_pages><_translated_author>Guo, Jiaweishengjiankangweibangongting</_translated_author><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=GRKZ202002020&amp;DbName=CJFQTEMP</_url><_volume>19</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>530</ID><UID>{BE87273D-4595-4AFA-B37A-3D48728CDC58}</UID><Title>sQ嶯pS裇癳媁燪秗舥襨簚巔蕥梪筫Hh諎L?{NHr 剉愬w</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>齎禰kSueP穅訷XTO</Author><Year>2020</Year><Details><_accessed>63206930</_accessed><_created>63206848</_created><_modified>63212667</_modified><_translated_author>Guo, Jiaweishengjiankangweiyuanhui</_translated_author></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation> ' ADDIN NE.Ref.{482E4441-FA8F-4237-9058-789076F9D9BB}<Citation><Group><References><Item><ID>531</ID><UID>{57F7D86A-19C9-4B48-ABC0-C2D2084006CA}</UID><Title>癳媁燪秗舥襨a觛簚巔剉-N;S蕥梪筫Hh蔛剺2柟eHh</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>NS-N褃€b'Yf[ TNm;Sf[b?N堺S觺Txvz@b</Author><Year>2020</Year><Details><_created>63206850</_created><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_issue>01</_issue><_journal>匭褃%`qS蛻莡Bg譥</_journal><_modified>63212667</_modified><_pages>6-8</_pages><_translated_author>Hua, Zhongkejidaxuetongjiyixueyuanzhongxiyijieheyanjiusuo</_translated_author><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=NKJW202001002&amp;DbName=CJFQPREP</_url></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>462</ID><UID>{7174D053-6A9A-4E5B-BDCA-72F19068FCEA}</UID><Title>NS-N褃€b'Yf[ TNm;Sf[b朌朸\ TNm;Sb杝Q嶯癳媁燪秗舥襨簚巔-N;S蕥梪筫Hh蔛剺2柟eHh</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author/><Year>0</Year><Details><_author_aff>NS-N褃€b'Yf[ TNm;Sf[b朌朸\ TNm;Sb?N;S褃;</_author_aff><_created>63208411</_created><_date>2020-02-11</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_journal>;So凕[</_journal><_keywords>-N;So傷癳媁燪秗舥襨簚巔;-N;S蕥梪;-N;S剺2朁/_keywords><_modified>63208411</_modified><_pages>1-5</_pages><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=YYDB20200209002&amp;DbName=CAPJ2020</_url></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation> 4 ADDIN NE.Ref.{5E374D1E-67AA-467F-A4F0-AE6E8C8FC827}<Citation><Group><References><Item><ID>556</ID><UID>{A5CCC842-0514-4045-9D99-ACCBF5649C0E}</UID><Title> Available from URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21226lbl.pdf</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>FDALabel</Author><Year>0</Year><Details><_accessed>63208280</_accessed><_created>63208280</_created><_modified>63212667</_modified></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>557</ID><UID>{2C9D4403-D894-4D68-A1DE-878CD032E1DC}</UID><Title> Available from URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021976s056,202895s027lbl.pdf</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>FDALabel</Author><Year>0</Year><Details><_accessed>63208289</_accessed><_created>63208289</_created><_modified>63212667</_modified></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>558</ID><UID>{B53891A3-FD78-40CD-BFBF-396347F437F2}</UID><Title>Available from URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21251lbl.pdf</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>FDALabel</Author><Year>0</Year><Details><_accessed>63212369</_accessed><_created>63212369</_created><_modified>63212667</_modified></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>559</ID><UID>{CE019E57-65F3-49C6-A2B4-6AFA22365B38}</UID><Title>Available from URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021976s056,202895s027lbl.pdf</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>FDALabel</Author><Year>0</Year><Details><_accessed>63212382</_accessed><_created>63212382</_created><_modified>63212667</_modified></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation>  ADDIN NE.Ref.{5E76A7C8-D0B1-494D-8DD2-9EE27076F828}<Citation><Group><References><Item><ID>535</ID><UID>{D268E227-89CA-427A-9D9D-F60C9CFA153D}</UID><Title>Drug resistance in influenza A virus: the epidemiology and management</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Hussain, M; Galvin, H D; Haw, T Y; Nutsford, A N; Husain, M</Author><Year>2017</Year><Details><_accession_num>28458567</_accession_num><_author_adr>Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand.; Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand.; Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand.; Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand.; Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand.</_author_adr><_collection_scope>SCIE</_collection_scope><_created>63206960</_created><_date>2017-01-20</_date><_date_display>2017</_date_display><_db_updated>PubMed</_db_updated><_doi>10.2147/IDR.S105473</_doi><_impact_factor> 3.000</_impact_factor><_isbn>1178-6973 (Print); 1178-6973 (Linking)</_isbn><_journal>Infect Drug Resist</_journal><_keywords>M2 ion channel inhibitors; drug resistance; influenza A virus; neuraminidase inhibitors; oseltamivir; zanamivir</_keywords><_language>eng</_language><_modified>63212667</_modified><_pages>121-134</_pages><_tertiary_title>Infection and drug resistance</_tertiary_title><_type_work>Journal Article; Review</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28458567&amp;query_hl=1</_url><_volume>10</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>536</ID><UID>{6BEF8191-DF57-422B-80BB-06A439D2657B}</UID><Title>Influenza viruses - antiviral therapy and resistance</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Duwe, S</Author><Year>2017</Year><Details><_accession_num>30671326</_accession_num><_author_adr>Robert Koch Institute, Division of Influenza Viruses and Other Respiratory Viruses, National Reference Centre for Influenza, Berlin, Germany.</_author_adr><_created>63206961</_created><_date>2017-01-20</_date><_date_display>2017</_date_display><_db_updated>PubMed</_db_updated><_doi>10.3205/id000030</_doi><_isbn>2195-8831 (Electronic); 2195-8831 (Linking)</_isbn><_journal>GMS Infect Dis</_journal><_keywords>antiviral resistance; infection; monitoring; neuraminidase; surveillance</_keywords><_language>eng</_language><_modified>63212667</_modified><_pages>Doc04</_pages><_tertiary_title>GMS infectious diseases</_tertiary_title><_type_work>Journal Article; Review</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=30671326&amp;query_hl=1</_url><_volume>5</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation> 6 ADDIN NE.Ref.{61DE9375-A02B-46F7-A995-064DE9B9802B}<Citation><Group><References><Item><ID>547</ID><UID>{523B0216-E67F-400B-B4C2-12DE4507252C}</UID><Title>Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Musher, D M; Logan, N; Mehendiratta, V; Melgarejo, N A; Garud, S; Hamill, R J</Author><Year>2007</Year><Details><_accession_num>17337513</_accession_num><_author_adr>Medical Service (Infectious Disease Section), Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX 77030, USA. daniel.musher@med.va.gov</_author_adr><_created>63208072</_created><_date>2007-04-01</_date><_date_display>2007 Apr</_date_display><_db_updated>PubMed</_db_updated><_doi>10.1093/jac/dkl553</_doi><_impact_factor> 5.113</_impact_factor><_isbn>0305-7453 (Print); 0305-7453 (Linking)</_isbn><_issue>4</_issue><_journal>J Antimicrob Chemother</_journal><_keywords>Aged; Aged, 80 and over; Anti-Bacterial Agents/*therapeutic use; *Clostridium difficile; Enterocolitis, Pseudomembranous/*drug therapy/microbiology; Female; Humans; Male; Metronidazole/*therapeutic use; Middle Aged; Recurrence; Thiazoles/*therapeutic use; Treatment Failure</_keywords><_language>eng</_language><_modified>63212667</_modified><_pages>705-10</_pages><_tertiary_title>The Journal of antimicrobial chemotherapy</_tertiary_title><_type_work>Clinical Trial; Journal Article; Research Support, Non-U.S. Gov&apos;t; Research Support, U.S. Gov&apos;t, Non-P.H.S.</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17337513&amp;query_hl=1</_url><_volume>59</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation> M ADDIN NE.Ref.{6DEFE052-4946-42C2-8D01-907F397881FA}<Citation><Group><References><Item><ID>420</ID><UID>{160E9B88-ACA6-43B1-8ACB-A8550111F47A}</UID><Title>Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Omrani, A S; Saad, M M; Baig, K; Bahloul, A; Abdul-Matin, M; Alaidaroos, A Y; Almakhlafi, G A; Albarrak, M M; Memish, Z A; Albarrak, A M</Author><Year>2014</Year><Details><_accession_num>25278221</_accession_num><_author_adr>Division of Infectious Diseases, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.; Division of Infectious Diseases, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.; Department of Infection Prevention and Control, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.; Division of Infectious Diseases, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.; Department of Medicine, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.; Division of Infectious Diseases, Prince Sultan Military Medical City, Riyadh, Saudi Arabia; Department of Infection Prevention and Control, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.; Department of Critical Care, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.; Department of Critical Care, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.; Al-Faisal University and Ministry of Health, Riyadh, Saudi Arabia. Electronic address: zmemish@yahoo.com.; Division of Infectious Diseases, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.</_author_adr><_collection_scope>SCI;SCIE</_collection_scope><_created>63208263</_created><_date>2014-11-01</_date><_date_display>2014 Nov</_date_display><_db_updated>PubMed</_db_updated><_doi>10.1016/S1473-3099(14)70920-X</_doi><_impact_factor> 27.516</_impact_factor><_isbn>1474-4457 (Electronic); 1473-3099 (Linking)</_isbn><_issue>11</_issue><_journal>Lancet Infect Dis</_journal><_keywords>Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents/*therapeutic use; Cohort Studies; Coronavirus Infections/*drug therapy; Female; Humans; Interferon alpha-2; Interferon-alpha/*therapeutic use; Male; Middle Aged; Middle East Respiratory Syndrome Coronavirus/*drug effects; Recombinant Proteins/therapeutic use; Retrospective Studies; Ribavirin/*therapeutic use; Saudi Arabia; Survival Analysis; Treatment Outcome; Young Adult</_keywords><_language>eng</_language><_modified>63208263</_modified><_ori_publication>Copyright (c) 2014 Elsevier Ltd. All rights reserved.</_ori_publication><_pages>1090-1095</_pages><_tertiary_title>The Lancet. Infectious diseases</_tertiary_title><_type_work>Journal Article</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25278221&amp;query_hl=1</_url><_volume>14</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>421</ID><UID>{1D7A1F18-5C65-422F-A2E3-C3B3A4073CC2}</UID><Title>Treatment of SARS with human interferons</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Cinatl, J; Morgenstern, B; Bauer, G; Chandra, P; Rabenau, H; Doerr, H W</Author><Year>2003</Year><Details><_accession_num>12892961</_accession_num><_author_adr>Institute of Medical Virology, Frankfurt University Medical School, Paul-Ehrlich Strasse 40, D-60596, Frankfurt, Germany. cinatl@em.uni-frankfurt.de &amp;lt;cinatl@em.uni-frankfurt.de&amp;gt;</_author_adr><_collection_scope>SCI;SCIE</_collection_scope><_created>63208265</_created><_date>2003-07-26</_date><_date_display>2003 Jul 26</_date_display><_db_updated>PubMed</_db_updated><_doi>10.1016/s0140-6736(03)13973-6</_doi><_impact_factor> 59.102</_impact_factor><_isbn>1474-547X (Electronic); 0140-6736 (Linking)</_isbn><_issue>9380</_issue><_journal>Lancet</_journal><_keywords>Antiviral Agents/pharmacology/*therapeutic use; Coronavirus/classification/drug effects/isolation &amp;amp; purification; Humans; Interferon-alpha/therapeutic use; Interferon-beta/therapeutic use; Interferon-gamma/therapeutic use; Interferons/*therapeutic use; Recombinant Proteins/therapeutic use; Severe Acute Respiratory Syndrome/*drug therapy/virology; Treatment Outcome; Vesicular stomatitis Indiana virus/drug effects; Virus Replication/drug effects</_keywords><_language>eng</_language><_modified>63208265</_modified><_pages>293-4</_pages><_tertiary_title>Lancet (London, England)</_tertiary_title><_type_work>Journal Article; Research Support, Non-U.S. Gov&apos;t</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12892961&amp;query_hl=1</_url><_volume>362</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation>  ADDIN NE.Ref.{70778B1C-BFEA-4868-A203-8E8602CB07D3}<Citation><Group><References><Item><ID>554</ID><UID>{8F81CAAB-CD40-4908-90AF-494474FD6689}</UID><Title>S8TeQ梪誰(W|T8T緐舥-N剉擽(uN禰qQ茓</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>-NNS;Sf[O|T8T舥f[RO|T8T籰梪f[膥</Author><Year>2016</Year><Details><_accessed>63208275</_accessed><_collection_scope>CSCD;PKU</_collection_scope><_created>63208275</_created><_issue>96</_issue><_journal>-NNS;Sf[Bg譥</_journal><_modified>63212667</_modified><_pages>2696-2708</_pages><_translated_author>Zhong, Huayixuehuihuxibingxuefenhuihuxizhiliaoxuezu</_translated_author><_volume>34</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation> & ADDIN NE.Ref.{71D74AE9-97C6-48FF-BF4A-36DA7CF4BE5C}<Citation><Group><References><Item><ID>612</ID><UID>{44A8592D-486F-4292-8D23-B497010F7494}</UID><Title>?Q鍅鑍苸迉舥襨'`緐舥蕥璭孴2柣l剉鷁畫</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>-NNS;Sf[O?Q褃f[ROa觛f[膥; hQ齎?Q褃4N奮舥襨a觛OS\O膥; 憦訷XTO-NNS?Q褃Bg譥</Author><Year>2012</Year><Details><_collection_scope>CSCD;PKU</_collection_scope><_created>63212750</_created><_db_provider>S琋N筫penc齆 gP杔Q鳶</_db_provider><_db_updated>Wanfangdata</_db_updated><_doi>10.3760/cma.j.issn.0578-1310.2012.04.013</_doi><_isbn>0578-1310</_isbn><_issue>4</_issue><_journal>-NNS?Q褃Bg譥</_journal><_keywords>?Q鍅; 鑍苸迉舥襨a觛; 舥襨'`緐舥; HCMV; 蝷?Q孴癳u?Q; 篘鑍苸迉舥襨; -NNS;Sf[O; 莡秗'`a觛; 蕥璭N2柣l; tZ|^?Q鰁g; 鴙sQ'`緐舥; uirf[yr'`; 篘眜箄舥襨; 梑SO3?`噑; human; 魜舥郪P[; 蕥璭筫Hh; 蕥璭h芉; 烻裇a觛; tZ|^?Qg</_keywords><_language>chi</_language><_modified>63212750</_modified><_pages>290-292</_pages><_tertiary_title>Chinese Journal of Pediatrics</_tertiary_title><_url>http://www.wanfangdata.com.cn/details/detail.do?_type=perio&amp;id=zhek201204013</_url><_volume>50</_volume><_translated_author>Zhong, Huayixuehui&apos;erkexuefenhuiganranxuezu;Quan, Guo&apos;erkelinchuangbingduganranxiezuozu;Bian, Jiweiyuanhuizhonghua&apos;erkezazhi</_translated_author></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation>  ADDIN NE.Ref.{7AB79A83-3B84-4717-9975-49ADCE0D6A25}<Citation><Group><References><Item><ID>391</ID><UID>{ECCEF6DC-575C-4742-AAF6-0E87F4EEEB26}</UID><Title>廩鶺郪膥f[(W O觛舥2枾c-N剉擽(u蹚U\</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Ng沴; NgO濢 媅廩l_</Author><Year>2018</Year><Details><_accessed>63212656</_accessed><_author_aff>銐>e決緐舥剺2枾c6R@b;</_author_aff><_collection_scope>CSCD;PKU</_collection_scope><_created>63206835</_created><_date>62183520</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_issue>03</_issue><_journal>uir€b/g惀b</_journal><_keywords>廩鶺郪膥f[; O觛舥2枾c;貧愊慘m廭</_keywords><_modified>63212656</_modified><_pages>43-52</_pages><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=SWJT201803008&amp;DbName=CJFQ2018</_url><_volume>34</_volume><_translated_author>Li, Peihan;Li, Peng;Song, Hongbin</_translated_author></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation> 9 ADDIN NE.Ref.{8099D126-DDCF-4F5E-B607-683BF2E9BFD5}<Citation><Group><References><Item><ID>574</ID><UID>{C7DA6C0A-CC6A-41CF-BE0B-0D2E7F6B9475}</UID><Title>The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Gordon, C J; Tchesnokov, E P; Feng, J Y; Porter, D P; Gotte, M</Author><Year>2020</Year><Details><_accession_num>32094225</_accession_num><_author_adr>University of Alberta, Canada.; University of Alberta, Canada.; Biology, Gilead Sciences, United States.; Gilead, United States.; Medical Microbiology and Immunology, University of Alberta, Canada.</_author_adr><_collection_scope>SCI;SCIE;EI</_collection_scope><_created>63208371</_created><_date>2020-02-24</_date><_date_display>2020 Feb 24</_date_display><_db_updated>PubMed</_db_updated><_doi>10.1074/jbc.AC120.013056</_doi><_impact_factor> 4.106</_impact_factor><_isbn>1083-351X (Electronic); 0021-9258 (Linking)</_isbn><_journal>J Biol Chem</_journal><_keywords>Ebola virus (EBOV); Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV-2; RNA-dependent RNA polymerase (RdRp), viral replicase; coronavirus, positive-sense RNA virus; drug development; enzyme inhibitor; nucleoside/nucleotide analogue; plus-stranded RNA virus; remdesivir, antiviral drug, RNA chain-termination; viral polymerase</_keywords><_language>eng</_language><_modified>63212667</_modified><_ori_publication>Published under license by The American Society for Biochemistry and Molecular Biology, Inc.</_ori_publication><_tertiary_title>The Journal of biological chemistry</_tertiary_title><_type_work>Journal Article</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=32094225&amp;query_hl=1</_url></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>569</ID><UID>{241ACE94-90ED-458F-8B46-A8F42110896E}</UID><Title>Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Tchesnokov, E P; Feng, J Y; Porter, D P; Gotte, M</Author><Year>2019</Year><Details><_accession_num>30987343</_accession_num><_author_adr>Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB T6G 2E1, Canada. tchesnok@ualberta.ca.; Li Ka Shing Institute of Virology at University of Alberta, Edmonton, AB T6G 2E1, Canada. tchesnok@ualberta.ca.; Gilead Sciences, Inc., Foster City, CA 94404, USA. Joy.Feng@gilead.com.; Gilead Sciences, Inc., Foster City, CA 94404, USA. Danielle.Porter@gilead.com.; Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB T6G 2E1, Canada. gotte@ualberta.ca.; Li Ka Shing Institute of Virology at University of Alberta, Edmonton, AB T6G 2E1, Canada. gotte@ualberta.ca.</_author_adr><_created>63208371</_created><_date>2019-04-04</_date><_date_display>2019 Apr 4</_date_display><_db_updated>PubMed</_db_updated><_doi>10.3390/v11040326</_doi><_impact_factor> 3.811</_impact_factor><_isbn>1999-4915 (Electronic); 1999-4915 (Linking)</_isbn><_issue>4</_issue><_journal>Viruses</_journal><_keywords>*Ebola virus; *GS-5734; *RNA polymerase; *RdRp; *delayed chain termination; *remdesivir; *respiratory syncytial virus</_keywords><_language>eng</_language><_modified>63212667</_modified><_tertiary_title>Viruses</_tertiary_title><_type_work>Journal Article; Research Support, Non-U.S. Gov&apos;t</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=30987343&amp;query_hl=1</_url><_volume>11</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>567</ID><UID>{F83CA43D-33BB-4876-98E6-1EC4350BD2D7}</UID><Title>[Baloxavir marboxil: a potent cap-dependent endonuclease inhibitor of influenza viruses]</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Reina, J; Reina, N</Author><Year>2019</Year><Details><_accession_num>30676002</_accession_num><_author_adr>Jordi Reina, Unidad de Virologia, Servicio de Microbiologia, Hospital Universitario Son Espases, Palma de Mallorca. Spain. jorge.reina@ssib.es.</_author_adr><_created>63208327</_created><_date>2019-02-01</_date><_date_display>2019 Feb</_date_display><_db_updated>PubMed</_db_updated><_impact_factor> 0.760</_impact_factor><_isbn>1988-9518 (Electronic); 0214-3429 (Linking)</_isbn><_issue>1</_issue><_journal>Rev Esp Quimioter</_journal><_keywords>Adolescent; Adult; Antiviral Agents/pharmacology/*therapeutic use; Child; Endonucleases/*antagonists &amp;amp; inhibitors; Female; Humans; Influenza, Human/*drug therapy/virology; Male; Middle Aged; Orthomyxoviridae/*drug effects/*enzymology; Oxazines/pharmacology/*therapeutic use; Pyridines/pharmacology/*therapeutic use; Thiepins/pharmacology/*therapeutic use; Triazines/pharmacology/*therapeutic use; Young Adult</_keywords><_language>spa</_language><_modified>63212667</_modified><_ori_publication>(c)The Author 2019. Published by Sociedad Espanola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).</_ori_publication><_pages>1-5</_pages><_tertiary_title>Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia</_tertiary_title><_type_work>Journal Article; Review</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=30676002&amp;query_hl=1</_url><_volume>32</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>575</ID><UID>{F65D5D89-179B-4791-9FA6-B0C96D290524}</UID><Title>Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>FG, Hayden; N, Sugaya; N, Hirotsu</Author><Year>2018</Year><Details><_accessed>63208365</_accessed><_created>63208364</_created><_issue>10</_issue><_journal>N Engl J Med</_journal><_modified>63212667</_modified><_pages>913-923</_pages><_translated_title>Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents</_translated_title><_volume>379</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation>  ADDIN NE.Ref.{8154265C-4022-4CBB-B613-DFAECCD4A3A3}<Citation><Group><References><Item><ID>611</ID><UID>{1D9D119D-D6C8-48AA-BFD0-8269A348DFC0}</UID><Title>U[嘫Ama2柣lN禰qQ茓</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>-NNS;Sf[O鬡;Sf[RO; 憦訷XTO-NNS鬡;Sf[Bg譥</Author><Year>2019</Year><Details><_collection_scope>CSCD</_collection_scope><_created>63212742</_created><_db_provider>S琋N筫penc齆 gP杔Q鳶</_db_provider><_db_updated>Wanfangdata</_db_updated><_doi>10.3760/cma.j.issn.1007-9408.2019.02.001</_doi><_isbn>1007-9408</_isbn><_issue>2</_issue><_journal>-NNS鬡;Sf[Bg譥</_journal><_keywords>奩 Zv^裇莡; Ama; 篘; 蛓</_keywords><_language>chi</_language><_modified>63212742</_modified><_pages>73-78</_pages><_tertiary_title>Chinese Journal of Perinatal Medicine</_tertiary_title><_translated_title>Expert consensus on prevention and management of maternal influenza</_translated_title><_url>http://www.wanfangdata.com.cn/details/detail.do?_type=perio&amp;id=zhwcyxzz201902001</_url><_volume>22</_volume><_translated_author>Zhong, Huayixuehuiweichanyixuefenhui;Bian, Jiweiyuanhuizhonghuaweichanyixuezazhi</_translated_author></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation>  ADDIN NE.Ref.{8674CBDE-6B1F-446F-B04C-3139FD58176B}<Citation><Group><References><Item><ID>548</ID><UID>{36503548-8A10-4EBC-9F3F-447913A18A52}</UID><Title>癳媁燪秗舥襨簚巔蕥梪筫Hh(諎L?{mQHr)</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>齎禰kSueP穅訷濺lQ匰</Author><Year>2020</Year><Details><_accessed>63208128</_accessed><_author_aff>齎禰kSueP穅訷濺lQ匰;齎禰-N;So儭{t@\濺lQ;</_author_aff><_collection_scope>PKU</_collection_scope><_created>63208128</_created><_date>2020-02-28</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_issue>02</_issue><_journal>-N齎a觛6RBg譥</_journal><_keywords>癳媁燪秗舥襨;癳媁燪秗舥襨簚巔;癳燪簚巔;a觛2枾c;h芉剺2曽2019-nCoV;SARS-COV-2</_keywords><_modified>63212671</_modified><_pages>192-195</_pages><_translated_author>Guo, Jiaweishengjiankangweibangongting</_translated_author><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=GRKZ202002020&amp;DbName=CJFQTEMP</_url><_volume>19</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation>  ADDIN NE.Ref.{88BBB34F-1420-4158-A4F4-909318527091}<Citation><Group><References><Item><ID>555</ID><UID>{C9C208A0-61FE-4084-AD29-A408DA9ECBA6}</UID><Title>r^pb }(W?Q褃4N奮Tt擽(uN禰qQ茓</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>3uf瞫; \慛Sf; _齎b</Author><Year>2018</Year><Details><_accessed>63208260</_accessed><_collection_scope>CSCD;PKU</_collection_scope><_created>63208259</_created><_issue>17</_issue><_journal>-NNS瀃(u?Q褃4N奮Bg譥</_journal><_modified>63212667</_modified><_pages>1301-1308</_pages><_translated_author>Shen, Kunling;Shang, Yunxiao;Zhang, Guocheng</_translated_author><_volume>33</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation>  ADDIN NE.Ref.{8E24EFD7-97F6-4586-B2C0-A49D3087463A}<Citation><Group><References><Item><ID>550</ID><UID>{07036850-2E10-4C0C-B5DA-01FE9F24DF0B}</UID><Title>`!媁r^pb }剉梑舥襨:g6Rxvz蹚U\</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>騍R楖z; u峼f; 體癳ga; 闂9hb</Author><Year>2015</Year><Details><_author_aff>決婲;Sf[褃f[b桗W@x;Sf[xvz@bMQ玼f[xvz;褠轢悩孴;Sb曽銐>e決;`;Sb?{ND朸\;Sb曽</_author_aff><_collection_scope>PKU</_collection_scope><_created>63208151</_created><_date>2015-07-25</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_issue>07</_issue><_journal>決婲;Sf[</_journal><_keywords>IFN-`!;烺齹;酧鱏愶岥導c</_keywords><_modified>63212667</_modified><_pages>557-560</_pages><_translated_author>Shi, Qingzhu;Zhao, Zhi;Shi, Xinhui;Han, Gencheng</_translated_author><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=JSYX201507017&amp;DbName=CJFQ2015</_url><_volume>39</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation>  ADDIN NE.Ref.{90F92D1F-8087-4E50-8B26-2CFAD2083DF4}<Citation><Group><References><Item><ID>563</ID><UID>{287A7C2B-7ED8-4A72-B2D5-407EA623372E}</UID><Title>Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Yang, J; Nikanjam, M; Best, B M; Pinto, J; Chadwick, E G; Daar, E S; Havens, P L; Rakhmanina, N; Capparelli, E V</Author><Year>2018</Year><Details><_accession_num>30252146</_accession_num><_author_adr>Skaggs School of Pharmacy and Pharmaceutical Science, University of California, San Diego, CA, USA.; Division of Hematology-Oncology, University of California, San Diego, CA, USA.; Skaggs School of Pharmacy and Pharmaceutical Science, University of California, San Diego, CA, USA.; Division of Host-Microbe Systems and Therapeutics, University of California San Diego School of Medicine, San Diego, CA, USA.; Division of Immunology, School of Medicine, Federal University of Minas Gerais, Minas Gerais, Brazil.; Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.; Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Los Angeles, CA, USA.; Division of Pediatric Infectious Diseases, Medical College of Wisconsin and Children&apos;s Hospital of Wisconsin, Milwaukee, WI, USA.; Division of Pediatric Infectious Diseases, Children&apos;s National Medical Center, The George Washington University, Washington, DC, USA.; Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC, USA.; Skaggs School of Pharmacy and Pharmaceutical Science, University of California, San Diego, CA, USA.; Division of Host-Microbe Systems and Therapeutics, University of California San Diego School of Medicine, San Diego, CA, USA.</_author_adr><_collection_scope>SCI;SCIE</_collection_scope><_created>63208295</_created><_date>2018-12-01</_date><_date_display>2018 Dec</_date_display><_db_updated>PubMed</_db_updated><_doi>10.1002/jcph.1293</_doi><_impact_factor> 2.915</_impact_factor><_isbn>1552-4604 (Electronic); 0091-2700 (Linking)</_isbn><_issue>12</_issue><_journal>J Clin Pharmacol</_journal><_keywords>Adolescent; Adult; Anti-HIV Agents/administration &amp;amp; dosage/*pharmacokinetics; Biological Availability; Body Weight; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Infant; Lopinavir/administration &amp;amp; dosage/*pharmacokinetics; Models, Biological; Monte Carlo Method; Ritonavir/administration &amp;amp; dosage/*pharmacokinetics; World Health Organization; Young Adult*HIV; *lopinavir; *pediatrics; *population pharmacokinetics; *ritonavir; *semiphysiologic modeling</_keywords><_language>eng</_language><_modified>63212667</_modified><_ori_publication>(c) 2018, The American College of Clinical Pharmacology.</_ori_publication><_pages>1604-1617</_pages><_tertiary_title>Journal of clinical pharmacology</_tertiary_title><_type_work>Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov&apos;t</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=30252146&amp;query_hl=1</_url><_volume>58</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>564</ID><UID>{A60983F6-4E4C-4886-B1AC-51C7B0447347}</UID><Title>Pharmacokinetic profile and safety of adjusted doses of darunavir/ritonavir with rifampicin in people living with HIV</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Ebrahim, I; Maartens, G; Wiesner, L; Orrell, C; Smythe, W; McIlleron, H</Author><Year>2020</Year><Details><_accession_num>31942627</_accession_num><_author_adr>Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.; Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.; Desmond Tutu HIV Centre, Institute of Infectious Diseases and Molecular Medicine (IDM) and Department of Medicine, University of Cape Town, Cape Town, South Africa.; Clinical Research Centre, University of Cape Town, Cape Town, South Africa.; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.; Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.</_author_adr><_created>63208316</_created><_date>2020-01-13</_date><_date_display>2020 Jan 13</_date_display><_db_updated>PubMed</_db_updated><_doi>10.1093/jac/dkz522</_doi><_impact_factor> 5.113</_impact_factor><_isbn>1460-2091 (Electronic); 0305-7453 (Linking)</_isbn><_journal>J Antimicrob Chemother</_journal><_language>eng</_language><_modified>63212667</_modified><_ori_publication>(c) The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.</_ori_publication><_tertiary_title>The Journal of antimicrobial chemotherapy</_tertiary_title><_type_work>Journal Article</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=31942627&amp;query_hl=1</_url></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation> 9 ADDIN NE.Ref.{9139D63B-0240-43DD-B011-50885A3CA269}<Citation><Group><References><Item><ID>552</ID><UID>{7684EDBA-5357-47DA-9D23-8368DEB78200}</UID><Title>Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Omrani, A S; Saad, M M; Baig, K; Bahloul, A; Abdul-Matin, M; Alaidaroos, A Y; Almakhlafi, G A; Albarrak, M M; Memish, Z A; Albarrak, A M</Author><Year>2014</Year><Details><_accession_num>25278221</_accession_num><_author_adr>Division of Infectious Diseases, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.; Division of Infectious Diseases, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.; Department of Infection Prevention and Control, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.; Division of Infectious Diseases, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.; Department of Medicine, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.; Division of Infectious Diseases, Prince Sultan Military Medical City, Riyadh, Saudi Arabia; Department of Infection Prevention and Control, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.; Department of Critical Care, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.; Department of Critical Care, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.; Al-Faisal University and Ministry of Health, Riyadh, Saudi Arabia. Electronic address: zmemish@yahoo.com.; Division of Infectious Diseases, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.</_author_adr><_collection_scope>SCI;SCIE</_collection_scope><_created>63208263</_created><_date>2014-11-01</_date><_date_display>2014 Nov</_date_display><_db_updated>PubMed</_db_updated><_doi>10.1016/S1473-3099(14)70920-X</_doi><_impact_factor> 27.516</_impact_factor><_isbn>1474-4457 (Electronic); 1473-3099 (Linking)</_isbn><_issue>11</_issue><_journal>Lancet Infect Dis</_journal><_keywords>Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents/*therapeutic use; Cohort Studies; Coronavirus Infections/*drug therapy; Female; Humans; Interferon alpha-2; Interferon-alpha/*therapeutic use; Male; Middle Aged; Middle East Respiratory Syndrome Coronavirus/*drug effects; Recombinant Proteins/therapeutic use; Retrospective Studies; Ribavirin/*therapeutic use; Saudi Arabia; Survival Analysis; Treatment Outcome; Young Adult</_keywords><_language>eng</_language><_modified>63212667</_modified><_ori_publication>Copyright (c) 2014 Elsevier Ltd. All rights reserved.</_ori_publication><_pages>1090-1095</_pages><_tertiary_title>The Lancet. Infectious diseases</_tertiary_title><_type_work>Journal Article</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25278221&amp;query_hl=1</_url><_volume>14</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>553</ID><UID>{96FAF071-A32C-4A27-BF86-279F693E7144}</UID><Title>Treatment of SARS with human interferons</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Cinatl, J; Morgenstern, B; Bauer, G; Chandra, P; Rabenau, H; Doerr, H W</Author><Year>2003</Year><Details><_accession_num>12892961</_accession_num><_author_adr>Institute of Medical Virology, Frankfurt University Medical School, Paul-Ehrlich Strasse 40, D-60596, Frankfurt, Germany. cinatl@em.uni-frankfurt.de &amp;lt;cinatl@em.uni-frankfurt.de&amp;gt;</_author_adr><_collection_scope>SCI;SCIE</_collection_scope><_created>63208265</_created><_date>2003-07-26</_date><_date_display>2003 Jul 26</_date_display><_db_updated>PubMed</_db_updated><_doi>10.1016/s0140-6736(03)13973-6</_doi><_impact_factor> 59.102</_impact_factor><_isbn>1474-547X (Electronic); 0140-6736 (Linking)</_isbn><_issue>9380</_issue><_journal>Lancet</_journal><_keywords>Antiviral Agents/pharmacology/*therapeutic use; Coronavirus/classification/drug effects/isolation &amp;amp; purification; Humans; Interferon-alpha/therapeutic use; Interferon-beta/therapeutic use; Interferon-gamma/therapeutic use; Interferons/*therapeutic use; Recombinant Proteins/therapeutic use; Severe Acute Respiratory Syndrome/*drug therapy/virology; Treatment Outcome; Vesicular stomatitis Indiana virus/drug effects; Virus Replication/drug effects</_keywords><_language>eng</_language><_modified>63212667</_modified><_pages>293-4</_pages><_tertiary_title>Lancet (London, England)</_tertiary_title><_type_work>Journal Article; Research Support, Non-U.S. Gov&apos;t</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12892961&amp;query_hl=1</_url><_volume>362</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>547</ID><UID>{523B0216-E67F-400B-B4C2-12DE4507252C}</UID><Title>Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Musher, D M; Logan, N; Mehendiratta, V; Melgarejo, N A; Garud, S; Hamill, R J</Author><Year>2007</Year><Details><_accession_num>17337513</_accession_num><_author_adr>Medical Service (Infectious Disease Section), Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX 77030, USA. daniel.musher@med.va.gov</_author_adr><_created>63208072</_created><_date>2007-04-01</_date><_date_display>2007 Apr</_date_display><_db_updated>PubMed</_db_updated><_doi>10.1093/jac/dkl553</_doi><_impact_factor> 5.113</_impact_factor><_isbn>0305-7453 (Print); 0305-7453 (Linking)</_isbn><_issue>4</_issue><_journal>J Antimicrob Chemother</_journal><_keywords>Aged; Aged, 80 and over; Anti-Bacterial Agents/*therapeutic use; *Clostridium difficile; Enterocolitis, Pseudomembranous/*drug therapy/microbiology; Female; Humans; Male; Metronidazole/*therapeutic use; Middle Aged; Recurrence; Thiazoles/*therapeutic use; Treatment Failure</_keywords><_language>eng</_language><_modified>63212667</_modified><_pages>705-10</_pages><_tertiary_title>The Journal of antimicrobial chemotherapy</_tertiary_title><_type_work>Clinical Trial; Journal Article; Research Support, Non-U.S. Gov&apos;t; Research Support, U.S. Gov&apos;t, Non-P.H.S.</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17337513&amp;query_hl=1</_url><_volume>59</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation> 4 ADDIN NE.Ref.{9324484C-4564-48F0-A3B3-15B0C539D11E}<Citation><Group><References><Item><ID>556</ID><UID>{A5CCC842-0514-4045-9D99-ACCBF5649C0E}</UID><Title> Available from URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21226lbl.pdf</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>FDALabel</Author><Year>0</Year><Details><_accessed>63208280</_accessed><_created>63208280</_created><_modified>63212667</_modified></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>557</ID><UID>{2C9D4403-D894-4D68-A1DE-878CD032E1DC}</UID><Title> Available from URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021976s056,202895s027lbl.pdf</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>FDALabel</Author><Year>0</Year><Details><_accessed>63208289</_accessed><_created>63208289</_created><_modified>63212667</_modified></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>558</ID><UID>{B53891A3-FD78-40CD-BFBF-396347F437F2}</UID><Title>Available from URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21251lbl.pdf</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>FDALabel</Author><Year>0</Year><Details><_accessed>63212369</_accessed><_created>63212369</_created><_modified>63212667</_modified></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>559</ID><UID>{CE019E57-65F3-49C6-A2B4-6AFA22365B38}</UID><Title>Available from URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021976s056,202895s027lbl.pdf</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>FDALabel</Author><Year>0</Year><Details><_accessed>63212382</_accessed><_created>63212382</_created><_modified>63212667</_modified></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation> k, ADDIN NE.Ref.{A9AE4835-B563-474C-9BFB-819F6E12CEFE}<Citation><Group><References><Item><ID>571</ID><UID>{AE668E7E-859F-4B78-9719-3DC98A359FD0}</UID><Title>[Favipiravir, a new concept of antiviral drug against influenza viruses]</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Reina, J; Reina, N</Author><Year>2017</Year><Details><_accession_num>28176519</_accession_num><_author_adr>Jordi Reina, Unidad de Virologia, Servicio de Microbiologia, Hospital Universitario Son Espases, Palma de Mallorca, Spain. jorge.reina@ssib.es.</_author_adr><_created>63208326</_created><_date>2017-04-01</_date><_date_display>2017 Apr</_date_display><_db_updated>PubMed</_db_updated><_impact_factor> 0.760</_impact_factor><_isbn>1988-9518 (Electronic); 0214-3429 (Linking)</_isbn><_issue>2</_issue><_journal>Rev Esp Quimioter</_journal><_keywords>Amides/*pharmacology/therapeutic use; Animals; Antiviral Agents/*pharmacology/therapeutic use; Humans; Influenza, Human/*drug therapy/virology; Orthomyxoviridae/*drug effects; Pyrazines/*pharmacology/therapeutic use</_keywords><_language>spa</_language><_modified>63212667</_modified><_pages>79-83</_pages><_tertiary_title>Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia</_tertiary_title><_type_work>Journal Article; Review</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28176519&amp;query_hl=1</_url><_volume>30</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>566</ID><UID>{0DFC024C-A596-47FA-AD7E-7D83279980DC}</UID><Title>Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Sheahan, T P; Sims, A C; Graham, R L; Menachery, V D; Gralinski, L E; Case, J B; Leist, S R; Pyrc, K; Feng, J Y; Trantcheva, I; Bannister, R; Park, Y; Babusis, D; Clarke, M O; Mackman, R L; Spahn, J E; Palmiotti, C A; Siegel, D; Ray, A S; Cihlar, T; Jordan, R; Denison, M R; Baric, R S</Author><Year>2017</Year><Details><_accession_num>28659436</_accession_num><_author_adr>Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.; Department of Microbiology, Faculty of Biochemistry, Biophysics, and Biotechnology, Jagiellonian University, Krakow, Poland.; Gilead Sciences Inc., Foster City, CA 94404, USA.; Gilead Sciences Inc., Foster City, CA 94404, USA.; Gilead Sciences Inc., Foster City, CA 94404, USA.; Gilead Sciences Inc., Foster City, CA 94404, USA.; Gilead Sciences Inc., Foster City, CA 94404, USA.; Gilead Sciences Inc., Foster City, CA 94404, USA.; Gilead Sciences Inc., Foster City, CA 94404, USA.; Gilead Sciences Inc., Foster City, CA 94404, USA.; Gilead Sciences Inc., Foster City, CA 94404, USA.; Gilead Sciences Inc., Foster City, CA 94404, USA.; Gilead Sciences Inc., Foster City, CA 94404, USA.; Gilead Sciences Inc., Foster City, CA 94404, USA.; Gilead Sciences Inc., Foster City, CA 94404, USA.; Division of Infectious Diseases, Department of Pediatrics and Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA. mark.denison@vanderbilt.edu rbaric@email.unc.edu.; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. mark.denison@vanderbilt.edu rbaric@email.unc.edu.</_author_adr><_collection_scope>SCIE</_collection_scope><_created>63208367</_created><_date>2017-06-28</_date><_date_display>2017 Jun 28</_date_display><_db_updated>PubMed</_db_updated><_doi>10.1126/scitranslmed.aal3653</_doi><_impact_factor> 17.161</_impact_factor><_isbn>1946-6242 (Electronic); 1946-6234 (Linking)</_isbn><_issue>396</_issue><_journal>Sci Transl Med</_journal><_keywords>Alanine/*analogs &amp;amp; derivatives/metabolism/pharmacokinetics/pharmacology/toxicity; Animals; Antiviral Agents/metabolism/pharmacokinetics/*pharmacology/toxicity; Callithrix; Cell Line; Coronavirus/*drug effects; *Epidemics; Epithelial Cells/virology; Humans; Lung/pathology; Mice; Ribonucleotides/metabolism/pharmacokinetics/*pharmacology/toxicity; Virus Replication/drug effects; Zoonoses/*epidemiology/prevention &amp;amp; control/*virology</_keywords><_language>eng</_language><_modified>63212667</_modified><_ori_publication>Copyright (c) 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</_ori_publication><_tertiary_title>Science translational medicine</_tertiary_title><_type_work>Journal Article; Research Support, Non-U.S. Gov&apos;t; Research Support, N.I.H., Extramural</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28659436&amp;query_hl=1</_url><_volume>9</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>572</ID><UID>{B59C41B5-36BE-4878-A282-3627AD147F1E}</UID><Title>Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Sheahan, T P; Sims, A C; Leist, S R; Schafer, A; Won, J; Brown, A J; Montgomery, S A; Hogg, A; Babusis, D; Clarke, M O; Spahn, J E; Bauer, L; Sellers, S; Porter, D; Feng, J Y; Cihlar, T; Jordan, R; Denison, M R; Baric, R S</Author><Year>2020</Year><Details><_accession_num>31924756</_accession_num><_author_adr>Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. sheahan@email.unc.edu.; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.; Department of Pathology &amp;amp; Laboratory Medicine, University of North Carolina, Chapel Hill, NC, USA.; Gilead Sciences, Inc, Foster City, CA, USA.; Gilead Sciences, Inc, Foster City, CA, USA.; Gilead Sciences, Inc, Foster City, CA, USA.; Gilead Sciences, Inc, Foster City, CA, USA.; Gilead Sciences, Inc, Foster City, CA, USA.; Gilead Sciences, Inc, Foster City, CA, USA.; Gilead Sciences, Inc, Foster City, CA, USA.; Gilead Sciences, Inc, Foster City, CA, USA.; Gilead Sciences, Inc, Foster City, CA, USA.; Gilead Sciences, Inc, Foster City, CA, USA.; Department of Pediatrics-Infectious Diseases, Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. rbaric@email.unc.edu.</_author_adr><_collection_scope>SCI;SCIE</_collection_scope><_created>63208368</_created><_date>2020-01-10</_date><_date_display>2020 Jan 10</_date_display><_db_updated>PubMed</_db_updated><_doi>10.1038/s41467-019-13940-6</_doi><_impact_factor> 11.878</_impact_factor><_isbn>2041-1723 (Electronic); 2041-1723 (Linking)</_isbn><_issue>1</_issue><_journal>Nat Commun</_journal><_language>eng</_language><_modified>63212667</_modified><_pages>222</_pages><_tertiary_title>Nature communications</_tertiary_title><_type_work>Journal Article</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=31924756&amp;query_hl=1</_url><_volume>11</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>573</ID><UID>{B91D799A-D027-4BCD-8D57-0E4BE3F62BCC}</UID><Title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Wang, M; Cao, R; Zhang, L; Yang, X; Liu, J; Xu, M; Shi, Z; Hu, Z; Zhong, W; Xiao, G</Author><Year>2020</Year><Details><_accession_num>32020029</_accession_num><_author_adr>State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071, Wuhan, China.; National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, 100850, Beijing, China.; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071, Wuhan, China.; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071, Wuhan, China.; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071, Wuhan, China.; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071, Wuhan, China.; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071, Wuhan, China.; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071, Wuhan, China. huzh@wh.iov.cn.; National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, 100850, Beijing, China. zhongwu@bmi.ac.cn.; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, 430071, Wuhan, China. xiaogf@wh.iov.cn.</_author_adr><_collection_scope>SCI;SCIE;CSCD</_collection_scope><_created>63208337</_created><_date>2020-03-01</_date><_date_display>2020 Mar</_date_display><_db_updated>PubMed</_db_updated><_doi>10.1038/s41422-020-0282-0</_doi><_impact_factor> 17.848</_impact_factor><_isbn>1748-7838 (Electronic); 1001-0602 (Linking)</_isbn><_issue>3</_issue><_journal>Cell Res</_journal><_language>eng</_language><_modified>63212667</_modified><_pages>269-271</_pages><_tertiary_title>Cell research</_tertiary_title><_type_work>Letter</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=32020029&amp;query_hl=1</_url><_volume>30</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation> , ADDIN NE.Ref.{A9C9B754-8563-48A6-A93E-E1C4C93B03C6}<Citation><Group><References><Item><ID>597</ID><UID>{61D7A362-C7BC-435E-9C98-A83D9A1A4603}</UID><Title>AmL?`a扱蕥璭N籰梪cWS(2011t^Hr)</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author/><Year>2011</Year><Details><_created>63212677</_created><_date>2011-03-10</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_issue>05</_issue><_journal>>y:S;Sf[Bg譥</_journal><_keywords>AmL?`a扱;AmL埮uf[;v^裇莡;舥襨舥;v^裇舥;緐舥;Ama;eY鳶諲鏃;籰梪cWS;</_keywords><_modified>63212678</_modified><_pages>66-74</_pages><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=SQYX201105047&amp;DbName=CJFQ2011</_url><_volume>9</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation> 4 ADDIN NE.Ref.{B627ECB9-1C3D-4D91-A3D9-68B82CB3CB9B}A ADDIN NE.Ref.{B8C604D7-6603-4FF5-BFCF-4F24AC3A092A}<Citation><Group><References><Item><ID>537</ID><UID>{2213FB0A-B81F-4F45-A2E4-AD1258549941}</UID><Title> Available from URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020903s056,021546s012lbl.pdf</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>FDALabel</Author><Year>0</Year><Details><_accessed>63208014</_accessed><_created>63208008</_created><_modified>63212667</_modified></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>538</ID><UID>{BFB2AB3C-C659-4521-A7A8-4426BD8A502B}</UID><Title> Available from URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209347lbl.pdf</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>FDALabel</Author><Year>0</Year><Details><_accessed>63208020</_accessed><_created>63208020</_created><_modified>63212667</_modified></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation>  ADDIN NE.Ref.{C4D2B188-DEAC-4B34-8770-EF0A0AFE9B75}<Citation><Group><References><Item><ID>609</ID><UID>{A916211C-D9CF-40FB-B7AF-0F4B11026950}</UID><Title>AmL?`a扱蕥梪筫Hh(2018t^Hr頞Hr)</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author/><Year>2018</Year><Details><_author_aff>齎禰kSueP穅訷XTO;</_author_aff><_created>63212722</_created><_date>2019-01-03</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_issue>06</_issue><_journal> O觛舥酧o`</_journal><_keywords>AmL?`a扱;Ama舥襨;蕥梪筫Hh;</_keywords><_modified>63212723</_modified><_pages>500-504</_pages><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=CRBX201806002&amp;DbName=CJFQ2018</_url><_volume>31</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>533</ID><UID>{134427DA-517C-4AA2-8185-A0061488DB0C}</UID><Title>Product Information: RELENZA(R) oral inhalation powder, zanamivir oral inhalation powder.GlaxoSmithKline, Research Triangle Park,NC</Title><Template>Figure</Template><Star>0</Star><Tag>0</Tag><Author/><Year>2006</Year><Details><_accessed>63206935</_accessed><_created>63206896</_created><_custom1>Product Information:RELENZA(R) oral inhalation powder,zanamivir oral inhalation powder.GlaxoSmithKline,Research Triangle Park,NC,2006</_custom1><_modified>63212667</_modified></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>610</ID><UID>{B7C37801-DF7B-4D03-97C0-250644E63650}</UID><Title>Available from URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206426s005lbl.pdf</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>FDALabel</Author><Year>0</Year><Details><_accessed>63212731</_accessed><_created>63212731</_created><_modified>63212731</_modified></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation>  ADDIN NE.Ref.{CA0D3997-3B62-4A05-BFB1-8CA5763DF85B}<Citation><Group><References><Item><ID>576</ID><UID>{90E6DFCC-F0E8-4A98-A6D8-F2E090E5E9E9}</UID><Title>T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Furuta, Y; Takahashi, K; Shiraki, K; Sakamoto, K; Smee, D F; Barnard, D L; Gowen, B B; Julander, J G; Morrey, J D</Author><Year>2009</Year><Details><_accession_num>19428599</_accession_num><_author_adr>Toyama Chemical Co., Ltd., Nishishinjuku, Shinjuku-ku, Tokyo, Japan. yousuke_furuta@toyama-chemical.co.jp</_author_adr><_created>63208333</_created><_date>2009-06-01</_date><_date_display>2009 Jun</_date_display><_db_updated>PubMed</_db_updated><_doi>10.1016/j.antiviral.2009.02.198</_doi><_impact_factor> 4.130</_impact_factor><_isbn>1872-9096 (Electronic); 0166-3542 (Linking)</_isbn><_issue>3</_issue><_journal>Antiviral Res</_journal><_keywords>Amides/adverse effects/metabolism/pharmacology/*therapeutic use; Animals; Antiviral Agents/adverse effects/metabolism/pharmacology/*therapeutic use; Nucleosides/adverse effects/metabolism/pharmacology/*therapeutic use; Pyrazines/adverse effects/metabolism/pharmacology/*therapeutic use; RNA Replicase/antagonists &amp;amp; inhibitors; RNA Virus Infections/drug therapy; RNA Viruses/drug effects; Viral Proteins/antagonists &amp;amp; inhibitors</_keywords><_language>eng</_language><_modified>63212667</_modified><_pages>95-102</_pages><_tertiary_title>Antiviral research</_tertiary_title><_type_work>Journal Article; Research Support, N.I.H., Extramural; Review</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19428599&amp;query_hl=1</_url><_volume>82</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation> j. ADDIN NE.Ref.{CD325934-BDAE-4F39-B424-6939C7345D6C}<Citation><Group><References><Item><ID>565</ID><UID>{CDD534FC-E334-4A88-84A0-CBCF6A0C46A9}</UID><Title>Favipiravir (T-705), a novel viral RNA polymerase inhibitor</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Furuta, Y; Gowen, B B; Takahashi, K; Shiraki, K; Smee, D F; Barnard, D L</Author><Year>2013</Year><Details><_accession_num>24084488</_accession_num><_author_adr>Toyama Chemical Co., Ltd., 4-1, Shimookui 2-chome, Toyama 930-8508, Japan. Electronic address: yousuke_furuta@toyama-chemical.co.jp.</_author_adr><_created>63208324</_created><_date>2013-11-01</_date><_date_display>2013 Nov</_date_display><_db_updated>PubMed</_db_updated><_doi>10.1016/j.antiviral.2013.09.015</_doi><_impact_factor> 4.130</_impact_factor><_isbn>1872-9096 (Electronic); 0166-3542 (Linking)</_isbn><_issue>2</_issue><_journal>Antiviral Res</_journal><_keywords>Amides/isolation &amp;amp; purification/*pharmacology/therapeutic use; Antiviral Agents/isolation &amp;amp; purification/*pharmacology/therapeutic use; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; DNA-Directed RNA Polymerases/*antagonists &amp;amp; inhibitors; Enzyme Inhibitors/isolation &amp;amp; purification/*pharmacology/therapeutic use; Humans; Influenza, Human/*drug therapy; Japan; Pyrazines/isolation &amp;amp; purification/*pharmacology/therapeutic use; RNA Viruses/*drug effects; United StatesFavipiravir; Influenza; RNA viruses; RNA-dependent RNA polymerase; T-705</_keywords><_language>eng</_language><_modified>63212667</_modified><_ori_publication>Copyright (c) 2013 Elsevier B.V. All rights reserved.</_ori_publication><_pages>446-54</_pages><_tertiary_title>Antiviral research</_tertiary_title><_type_work>Journal Article; Research Support, N.I.H., Extramural; Review</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24084488&amp;query_hl=1</_url><_volume>100</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>566</ID><UID>{0DFC024C-A596-47FA-AD7E-7D83279980DC}</UID><Title>Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Sheahan, T P; Sims, A C; Graham, R L; Menachery, V D; Gralinski, L E; Case, J B; Leist, S R; Pyrc, K; Feng, J Y; Trantcheva, I; Bannister, R; Park, Y; Babusis, D; Clarke, M O; Mackman, R L; Spahn, J E; Palmiotti, C A; Siegel, D; Ray, A S; Cihlar, T; Jordan, R; Denison, M R; Baric, R S</Author><Year>2017</Year><Details><_accession_num>28659436</_accession_num><_author_adr>Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.; Department of Microbiology, Faculty of Biochemistry, Biophysics, and Biotechnology, Jagiellonian University, Krakow, Poland.; Gilead Sciences Inc., Foster City, CA 94404, USA.; Gilead Sciences Inc., Foster City, CA 94404, USA.; Gilead Sciences Inc., Foster City, CA 94404, USA.; Gilead Sciences Inc., Foster City, CA 94404, USA.; Gilead Sciences Inc., Foster City, CA 94404, USA.; Gilead Sciences Inc., Foster City, CA 94404, USA.; Gilead Sciences Inc., Foster City, CA 94404, USA.; Gilead Sciences Inc., Foster City, CA 94404, USA.; Gilead Sciences Inc., Foster City, CA 94404, USA.; Gilead Sciences Inc., Foster City, CA 94404, USA.; Gilead Sciences Inc., Foster City, CA 94404, USA.; Gilead Sciences Inc., Foster City, CA 94404, USA.; Gilead Sciences Inc., Foster City, CA 94404, USA.; Division of Infectious Diseases, Department of Pediatrics and Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA. mark.denison@vanderbilt.edu rbaric@email.unc.edu.; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. mark.denison@vanderbilt.edu rbaric@email.unc.edu.</_author_adr><_collection_scope>SCIE</_collection_scope><_created>63208367</_created><_date>2017-06-28</_date><_date_display>2017 Jun 28</_date_display><_db_updated>PubMed</_db_updated><_doi>10.1126/scitranslmed.aal3653</_doi><_impact_factor> 17.161</_impact_factor><_isbn>1946-6242 (Electronic); 1946-6234 (Linking)</_isbn><_issue>396</_issue><_journal>Sci Transl Med</_journal><_keywords>Alanine/*analogs &amp;amp; derivatives/metabolism/pharmacokinetics/pharmacology/toxicity; Animals; Antiviral Agents/metabolism/pharmacokinetics/*pharmacology/toxicity; Callithrix; Cell Line; Coronavirus/*drug effects; *Epidemics; Epithelial Cells/virology; Humans; Lung/pathology; Mice; Ribonucleotides/metabolism/pharmacokinetics/*pharmacology/toxicity; Virus Replication/drug effects; Zoonoses/*epidemiology/prevention &amp;amp; control/*virology</_keywords><_language>eng</_language><_modified>63212667</_modified><_ori_publication>Copyright (c) 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.</_ori_publication><_tertiary_title>Science translational medicine</_tertiary_title><_type_work>Journal Article; Research Support, Non-U.S. Gov&apos;t; Research Support, N.I.H., Extramural</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28659436&amp;query_hl=1</_url><_volume>9</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>567</ID><UID>{F83CA43D-33BB-4876-98E6-1EC4350BD2D7}</UID><Title>[Baloxavir marboxil: a potent cap-dependent endonuclease inhibitor of influenza viruses]</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Reina, J; Reina, N</Author><Year>2019</Year><Details><_accession_num>30676002</_accession_num><_author_adr>Jordi Reina, Unidad de Virologia, Servicio de Microbiologia, Hospital Universitario Son Espases, Palma de Mallorca. Spain. jorge.reina@ssib.es.</_author_adr><_created>63208327</_created><_date>2019-02-01</_date><_date_display>2019 Feb</_date_display><_db_updated>PubMed</_db_updated><_impact_factor> 0.760</_impact_factor><_isbn>1988-9518 (Electronic); 0214-3429 (Linking)</_isbn><_issue>1</_issue><_journal>Rev Esp Quimioter</_journal><_keywords>Adolescent; Adult; Antiviral Agents/pharmacology/*therapeutic use; Child; Endonucleases/*antagonists &amp;amp; inhibitors; Female; Humans; Influenza, Human/*drug therapy/virology; Male; Middle Aged; Orthomyxoviridae/*drug effects/*enzymology; Oxazines/pharmacology/*therapeutic use; Pyridines/pharmacology/*therapeutic use; Thiepins/pharmacology/*therapeutic use; Triazines/pharmacology/*therapeutic use; Young Adult</_keywords><_language>spa</_language><_modified>63212667</_modified><_ori_publication>(c)The Author 2019. Published by Sociedad Espanola de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).</_ori_publication><_pages>1-5</_pages><_tertiary_title>Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia</_tertiary_title><_type_work>Journal Article; Review</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=30676002&amp;query_hl=1</_url><_volume>32</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>568</ID><UID>{17D7B95C-2998-4074-AFD8-9344F53E55F7}</UID><Title>Competition between cellular and viral mRNAs in vitro is regulated by a messenger discriminatory initiation factor</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Golini, F; Thach, S S; Birge, C H; Safer, B; Merrick, W C; Thach, R E</Author><Year>1976</Year><Details><_accession_num>184455</_accession_num><_created>63208354</_created><_date>1976-09-01</_date><_date_display>1976 Sep</_date_display><_db_updated>PubMed</_db_updated><_doi>10.1073/pnas.73.9.3040</_doi><_impact_factor> 9.580</_impact_factor><_isbn>0027-8424 (Print); 0027-8424 (Linking)</_isbn><_issue>9</_issue><_journal>Proc Natl Acad Sci U S A</_journal><_keywords>Animals; Cell-Free System; Encephalomyocarditis virus/metabolism; Globins/biosynthesis; Mice; Multiple Myeloma; *Peptide Chain Initiation, Translational; *Peptide Initiation Factors; RNA, Messenger/*metabolism; RNA, Neoplasm/metabolism; RNA, Viral/*metabolism; Ribosomes/metabolism</_keywords><_language>eng</_language><_modified>63212667</_modified><_pages>3040-4</_pages><_tertiary_title>Proceedings of the National Academy of Sciences of the United States of America</_tertiary_title><_type_work>Journal Article; Research Support, U.S. Gov&apos;t, Non-P.H.S.; Research Support, U.S. Gov&apos;t, P.H.S.</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=184455&amp;query_hl=1</_url><_volume>73</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>569</ID><UID>{241ACE94-90ED-458F-8B46-A8F42110896E}</UID><Title>Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Tchesnokov, E P; Feng, J Y; Porter, D P; Gotte, M</Author><Year>2019</Year><Details><_accession_num>30987343</_accession_num><_author_adr>Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB T6G 2E1, Canada. tchesnok@ualberta.ca.; Li Ka Shing Institute of Virology at University of Alberta, Edmonton, AB T6G 2E1, Canada. tchesnok@ualberta.ca.; Gilead Sciences, Inc., Foster City, CA 94404, USA. Joy.Feng@gilead.com.; Gilead Sciences, Inc., Foster City, CA 94404, USA. Danielle.Porter@gilead.com.; Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, AB T6G 2E1, Canada. gotte@ualberta.ca.; Li Ka Shing Institute of Virology at University of Alberta, Edmonton, AB T6G 2E1, Canada. gotte@ualberta.ca.</_author_adr><_created>63208371</_created><_date>2019-04-04</_date><_date_display>2019 Apr 4</_date_display><_db_updated>PubMed</_db_updated><_doi>10.3390/v11040326</_doi><_impact_factor> 3.811</_impact_factor><_isbn>1999-4915 (Electronic); 1999-4915 (Linking)</_isbn><_issue>4</_issue><_journal>Viruses</_journal><_keywords>*Ebola virus; *GS-5734; *RNA polymerase; *RdRp; *delayed chain termination; *remdesivir; *respiratory syncytial virus</_keywords><_language>eng</_language><_modified>63212667</_modified><_tertiary_title>Viruses</_tertiary_title><_type_work>Journal Article; Research Support, Non-U.S. Gov&apos;t</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=30987343&amp;query_hl=1</_url><_volume>11</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation> ] ADDIN NE.Ref.{D17FDD27-D071-475A-8D52-42B6AE893F7C}<Citation><Group><References><Item><ID>551</ID><UID>{35C7A727-CE2E-4490-830B-4DD29C59BAB2}</UID><Title>畍 N鑜\-r^pb }籰梪2019t^癳媁燪秗舥襨剉猒翄隷惸?O</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>H柗\; 鍅cu; 箯烻; ?lhQ; hg荝; \g譟; Ng噀 n; R胈桘 霑鸤餦; 櫉i`fk; UO梘</Author><Year>0</Year><Details><_author_aff>踁輂w;Sf[褃f[b?踁輂w篘l;Sb?uP[褃€b'Yf[D朸\;Sb杘僨[钀*NSOSo僫r籰梪踁輂w蛻筽瀃寶;踁輂w;Sf[褃f[b?踁輂w篘l;Sb?uP[褃€b'Yf[D朸\;Sb杘僨[钀;</_author_aff><_created>63208253</_created><_date>2020-02-11</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_journal>;So凕[</_journal><_keywords>-r^pb };癳媁燪秗舥襨;畍 N鑜\;梑舥襨籰梪;蛻莡%`'`|T8T鼅T乢(SARS);-NN|T8T鼅T乢(MERS)</_keywords><_modified>63212667</_modified><_pages>1-19</_pages><_translated_author>Chen, Min;Tong, Rongsheng;Bian, Yuan;Shu, Yongquan;Yang, Yong;Du, Shan;Li, Wenyuan;Liu, Xinxia;Yan, Junfeng;Long, Enwu;He, Lin</_translated_author><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=YYDB20200208000&amp;DbName=CAPJ2020</_url></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation>  ADDIN NE.Ref.{D26BC0C4-7724-4180-BC2F-FE36B8941C13}<Citation><Group><References><Item><ID>532</ID><UID>{4AF3BD50-4DE2-45F5-A53E-782805C3D67A}</UID><Title>TAMIFLUoseltamivir phosphate Capsules, for Oral Suspension </Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>FDALabel</Author><Year>2018</Year><Details><_accessed>63206936</_accessed><_created>63206869</_created><_journal>https://www.fda.gov/drugs/information-drug-class</_journal><_modified>63212667</_modified></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>533</ID><UID>{134427DA-517C-4AA2-8185-A0061488DB0C}</UID><Title>Product Information: RELENZA(R) oral inhalation powder, zanamivir oral inhalation powder.GlaxoSmithKline, Research Triangle Park,NC</Title><Template>Figure</Template><Star>0</Star><Tag>0</Tag><Author/><Year>2006</Year><Details><_accessed>63206935</_accessed><_created>63206896</_created><_custom1>Product Information:RELENZA(R) oral inhalation powder,zanamivir oral inhalation powder.GlaxoSmithKline,Research Triangle Park,NC,2006</_custom1><_modified>63212667</_modified></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>534</ID><UID>{A4E4C4D0-7A39-4642-90B8-03BED5C5A60D}</UID><Title>^蒪s|鏃</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>媠j_; 醼%f</Author><Year>2015</Year><Details><_accessed>63206936</_accessed><_author_aff>坙3杘冄y'Yf[;</_author_aff><_collection_scope>CSCD</_collection_scope><_created>63206913</_created><_date>2015-08-20</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_issue>04</_issue><_journal>-N齎o僫rSf[Bg譥</_journal><_keywords>^蒪s|鏃;N鶺;謡藛}v;榺藛}v;YNp?l鶺;^y蟸(lx憊憫b6RBR;Ama舥襨;</_keywords><_modified>63212667</_modified><_pages>328</_pages><_translated_author>Wang, Biao;Hu, Chun</_translated_author><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=ZGYH201504018&amp;DbName=CJFQ2015</_url><_volume>25</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation>  ADDIN NE.Ref.{D570E038-576C-4D73-B855-CC54DF2DD592}<Citation><Group><References><Item><ID>548</ID><UID>{36503548-8A10-4EBC-9F3F-447913A18A52}</UID><Title>癳媁燪秗舥襨簚巔蕥梪筫Hh(諎L?{mQHr)</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>齎禰kSueP穅訷濺lQ匰</Author><Year>2020</Year><Details><_accessed>63208128</_accessed><_author_aff>齎禰kSueP穅訷濺lQ匰;齎禰-N;So儭{t@\濺lQ;</_author_aff><_collection_scope>PKU</_collection_scope><_created>63208128</_created><_date>2020-02-28</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_issue>02</_issue><_journal>-N齎a觛6RBg譥</_journal><_keywords>癳媁燪秗舥襨;癳媁燪秗舥襨簚巔;癳燪簚巔;a觛2枾c;h芉剺2曽2019-nCoV;SARS-COV-2</_keywords><_modified>63212671</_modified><_pages>192-195</_pages><_translated_author>Guo, Jiaweishengjiankangweibangongting</_translated_author><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=GRKZ202002020&amp;DbName=CJFQTEMP</_url><_volume>19</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation> 4 ADDIN NE.Ref.{D5AD1D5D-3A5A-46F9-8C53-F5B6D3AF0E8A}<Citation><Group><References><Item><ID>556</ID><UID>{A5CCC842-0514-4045-9D99-ACCBF5649C0E}</UID><Title> Available from URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21226lbl.pdf</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>FDALabel</Author><Year>0</Year><Details><_accessed>63208280</_accessed><_created>63208280</_created><_modified>63212667</_modified></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>557</ID><UID>{2C9D4403-D894-4D68-A1DE-878CD032E1DC}</UID><Title> Available from URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021976s056,202895s027lbl.pdf</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>FDALabel</Author><Year>0</Year><Details><_accessed>63208289</_accessed><_created>63208289</_created><_modified>63212667</_modified></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>558</ID><UID>{B53891A3-FD78-40CD-BFBF-396347F437F2}</UID><Title>Available from URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/21251lbl.pdf</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>FDALabel</Author><Year>0</Year><Details><_accessed>63212369</_accessed><_created>63212369</_created><_modified>63212667</_modified></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>559</ID><UID>{CE019E57-65F3-49C6-A2B4-6AFA22365B38}</UID><Title>Available from URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021976s056,202895s027lbl.pdf</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>FDALabel</Author><Year>0</Year><Details><_accessed>63212382</_accessed><_created>63212382</_created><_modified>63212667</_modified></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation>  ADDIN NE.Ref.{DBC936E8-54B9-4490-ABBD-4261A68C6BDF}<Citation><Group><References><Item><ID>615</ID><UID>{8DAEAD49-A796-4158-8026-47FDB62D9BB0}</UID><Title>New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Devaux, C A; Rolain, J M; Colson, P; Raoult, D</Author><Year>2020</Year><Details><_accession_num>32171740</_accession_num><_author_adr>Aix-Marseille Universite, IRD, APHM, MEPHI, IHU-Mediterranee Infection, Marseille, France; CNRS, Marseille, France; IHU-Mediterranee Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France. Electronic address: christian.devaux@mediterranee-infection.com.; Aix-Marseille Universite, IRD, APHM, MEPHI, IHU-Mediterranee Infection, Marseille, France; IHU-Mediterranee Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France.; Aix-Marseille Universite, IRD, APHM, MEPHI, IHU-Mediterranee Infection, Marseille, France; IHU-Mediterranee Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France.; Aix-Marseille Universite, IRD, APHM, MEPHI, IHU-Mediterranee Infection, Marseille, France; IHU-Mediterranee Infection, 19-21 boulevard Jean Moulin, 13005 Marseille, France.</_author_adr><_created>63235704</_created><_date>2020-03-11</_date><_date_display>2020 Mar 11</_date_display><_db_updated>PubMed</_db_updated><_doi>10.1016/j.ijantimicag.2020.105938</_doi><_impact_factor> 4.615</_impact_factor><_isbn>1872-7913 (Electronic); 0924-8579 (Linking)</_isbn><_journal>Int J Antimicrob Agents</_journal><_keywords>COVID-19; Chloroquine; Coronavirus; SARS-CoV-2</_keywords><_language>eng</_language><_modified>63235704</_modified><_ori_publication>Copyright (c) 2020. Published by Elsevier B.V.</_ori_publication><_pages>105938</_pages><_tertiary_title>International journal of antimicrobial agents</_tertiary_title><_type_work>Journal Article</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=32171740&amp;query_hl=1</_url></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>616</ID><UID>{D94B11CF-23AC-47CC-A233-C6EDC995DE5C}</UID><Title>New insights into the antiviral effects of chloroquine</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Savarino, A; Di Trani, L; Donatelli, I; Cauda, R; Cassone, A</Author><Year>2006</Year><Details><_accession_num>16439323</_accession_num><_collection_scope>SCI;SCIE</_collection_scope><_created>63235704</_created><_date>2006-02-01</_date><_date_display>2006 Feb</_date_display><_db_updated>PubMed</_db_updated><_doi>10.1016/S1473-3099(06)70361-9</_doi><_impact_factor> 27.516</_impact_factor><_isbn>1473-3099 (Print); 1473-3099 (Linking)</_isbn><_issue>2</_issue><_journal>Lancet Infect Dis</_journal><_keywords>Anti-HIV Agents/therapeutic use; Antimalarials/therapeutic use; Antiviral Agents/*therapeutic use; Chloroquine/*therapeutic use; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors/therapeutic use; HIV Infections/*drug therapy; *HIV-1; Humans; Hydroxychloroquine/therapeutic use; Severe Acute Respiratory Syndrome/*drug therapy; Treatment Outcome; Viral Load; Virus Replication/drug effects</_keywords><_language>eng</_language><_modified>63235704</_modified><_pages>67-9</_pages><_tertiary_title>The Lancet. Infectious diseases</_tertiary_title><_type_work>Letter</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16439323&amp;query_hl=1</_url><_volume>6</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation> ADDIN NE.Ref.{E47D4E5D-318D-497B-9A38-BAC62DDFAE4E}<Citation><Group><References><Item><ID>540</ID><UID>{A562FADB-C79C-4590-9C31-75BCE2B9EA61}</UID><Title>The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ Transplantation</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Kotton, C N; Kumar, D; Caliendo, A M; Huprikar, S; Chou, S; Danziger-Isakov, L; Humar, A</Author><Year>2018</Year><Details><_accession_num>29596116</_accession_num><_author_adr>Transplant and Immunocompromised Host Infectious Diseases Infectious Diseases Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA.; Transplant Infectious Diseases and Multi-Organ Transplant Program, University Health Network, Toronto, Ontario, Canada.; Rhode Island Hospital, Providence, RI.; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.; Division of Infectious Diseases, Oregon Health &amp;amp; Science University, Portland, OR.; Division of Infectious Diseases, Cincinnati Children&apos;s Hospital Medical Center, Cincinnati, OH.; Multi Organ Transplant Program, University Health Network, Toronto, Ontario, Canada.</_author_adr><_collection_scope>SCI;SCIE</_collection_scope><_created>63208048</_created><_date>2018-06-01</_date><_date_display>2018 Jun</_date_display><_db_updated>PubMed</_db_updated><_doi>10.1097/TP.0000000000002191</_doi><_impact_factor> 4.593</_impact_factor><_isbn>1534-6080 (Electronic); 0041-1337 (Linking)</_isbn><_issue>6</_issue><_journal>Transplantation</_journal><_keywords>Antiviral Agents/adverse effects/*therapeutic use; Consensus; Cytomegalovirus Infections/diagnosis/*drug therapy/immunology; Humans; Immunocompromised Host; Immunosuppressive Agents/adverse effects; Opportunistic Infections/diagnosis/*drug therapy/immunology; Organ Transplantation/*adverse effects/standards; Risk Factors; Treatment Outcome</_keywords><_language>eng</_language><_modified>63212667</_modified><_pages>900-931</_pages><_tertiary_title>Transplantation</_tertiary_title><_type_work>Consensus Development Conference; Journal Article; Practice Guideline; Research Support, Non-U.S. Gov&apos;t; Review</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=29596116&amp;query_hl=1</_url><_volume>102</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation>  ADDIN NE.Ref.{ECF6ADA0-F1EE-4419-B486-F93E14B13F38}<Citation><Group><References><Item><ID>575</ID><UID>{F65D5D89-179B-4791-9FA6-B0C96D290524}</UID><Title>Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>FG, Hayden; N, Sugaya; N, Hirotsu</Author><Year>2018</Year><Details><_translated_title>Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents</_translated_title><_journal>N Engl J Med</_journal><_issue>10</_issue><_volume>379</_volume><_pages>913-923</_pages><_accessed>63208365</_accessed><_created>63208364</_created><_modified>63212667</_modified></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation> H ADDIN NE.Ref.{F4E139F6-2826-4203-93FD-046194B7DAD2}<Citation><Group><References><Item><ID>577</ID><UID>{B9CABB8A-696A-49E9-9223-B5CB26DDCBF6}</UID><Title>瀃(u4N奮-No僨[-Nbo冭R </Title><Template>Book</Template><Star>0</Star><Tag>0</Tag><Author>Ngf[梘; ][t; 鵩蔕璡</Author><Year>2013</Year><Details><_accessed>63212621</_accessed><_created>63212621</_created><_modified>63212667</_modified><_publisher>篘lkSu鶴Hr>y</_publisher><_translated_author>Li, Xuelin;Cui, Ying;Cao, Junling</_translated_author></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>578</ID><UID>{AC181809-39C8-4835-914D-A66D9A44AA93}</UID><Title>N TBR蠎褢眰na棙抾鵞AmL?`a扱剉梪He蔛鵞€@n苸迉郪P[剉q_蚑</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Ay鷁s^; AySf沍; 媠SfZ</Author><Year>2016</Year><Details><_accessed>63212643</_accessed><_author_aff>砽S轢-N堺S觺T;Sb杘傿R褃;轢^-N胈;Sb枀Q褃;砽Sw?Q鍅;Sba觛緐舥褃;</_author_aff><_created>63212622</_created><_date>61526880</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_issue>12</_issue><_journal>皊鉔;Sf[</_journal><_keywords>AmL?`a扱;褢眰na棙抾;BR蠎;@n苸迉郪P[</_keywords><_modified>63212667</_modified><_pages>1664-1669</_pages><_translated_author>Qi, Jianping;Qi, Xiaoyuan;Wang, Xiaojuan</_translated_author><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=TDYX201612004&amp;DbName=CJFQ2016</_url><_volume>44</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>579</ID><UID>{186D7957-AB5C-4065-864B-6B17A0027B3A}</UID><Title>a扱愴pnN褢眰na棙抾籰梪Ama7h舥婳愴p梪He詋儚</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>_[sO; *PZS6q; 9\o倝s; 湝3曽 H 凔 Ng塠s^; Ngf眰; 鎦噀pg; 體琋眰; Ngzf</Author><Year>2015</Year><Details><_accessed>63212643</_accessed><_author_aff>S琋-N;So?Yf[鶺@x;Sf[b曽S琋/cNIQfo僫rxvzb曽-N齎-N;S褃f[bg琋;Sb曽</_author_aff><_collection_scope>CSCD;PKU</_collection_scope><_created>63212623</_created><_date>60570720</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_issue>05</_issue><_journal>-N;SBg譥</_journal><_keywords>Ama7h舥婳;a扱愴pn橕褢眰na棙抾;裇韕;愴p</_keywords><_modified>63212667</_modified><_pages>402-404</_pages><_translated_author>Meng, Jia;Ni, Boran;Yin, Liangyu;Xian, Fuyang;Chen, Meng;Li, Anping;Li, Minghua;Qin, Wenjie;Shi, Jinghua;Li, Zhi</_translated_author><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=ZZYZ201505014&amp;DbName=CJFQ2015</_url><_volume>56</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>580</ID><UID>{4F2E3063-FA7B-4D38-A8D7-1C8B9B6B6774}</UID><Title>褢眰na棙抾籰梪AmL?`a扱螛韕痳簚翄蘏騰彇:g鵞gqxvz</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Ng齎銻; u峐桘 `\譥沵; 塖\宔; Rn蒷; 騍)RS; 讉R桘 褌郹n; R癳eh; 櫉薙YO; R譥齎; u峸Z; Ng蕏; UhQ; UO螐%f; 箯8lT; 醼\n</Author><Year>2013</Year><Details><_accessed>63212643</_accessed><_author_aff>-N齎-N;S褃f[b^塠钑;Sb東T8T褃;S琋-N;So?Yf[N魐钑;Sb?`蕥褃;S琋-N;So?Yf[N筫;Sb東T8T褃;-N齎-N;S褃f[b壯侞Sb東T8T褃;枡龕;S褃'Yf[D朸\S琋-N;S;Sb東T8T褃;)Y%m-N;So?Yf[,{ND朸\;Sb東T8T褃;)Y%m-N;So?Yf[,{孨D朸\;Sb東T8T褃;S琋R藌褃R;So儉b/g_裇 gP杔Q鳶; Nwm-N;So?Yf[o僫r4N奮xvz-N胈;</_author_aff><_collection_scope>CSCD;PKU</_collection_scope><_created>63212623</_created><_date>59941440</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_issue>12</_issue><_journal>-N齎-N堺S觺TBg譥</_journal><_keywords>褢眰na棙抾;AmL?`a扱;螛韕痳簚翄;彇:g鵞gqxvz</_keywords><_modified>63212667</_modified><_pages>1631-1635</_pages><_translated_author>Li, Guoqin;Zhao, Jing;Tu, Zhitao;Li, Jiangbin;Liu, Qingquan;Shi, Liqing;Miao, Qing;Yuan, Huiqing;Liu, Xinqiao;Long, Youyu;Liu, Zhiguo;Zhao, Ting;Li, Lei;Tang, Quanhong;He, Yingchun;Bian, Yongjun;Hu, Jingqing</_translated_author><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=ZZXJ201312017&amp;DbName=CJFQ2013</_url><_volume>33</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>581</ID><UID>{768CE11E-5016-4752-BA2F-FF6B40750284}</UID><Title>N TBR蠎褢眰na棙抾鵞AmL?`a扱剉梪He蔛鵞€@n苸迉郪P[剉q_蚑</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Ay鷁s^; AySf沍; 媠SfZ</Author><Year>2016</Year><Details><_accessed>63212643</_accessed><_author_aff>砽S轢-N堺S觺T;Sb杘傿R褃;轢^-N胈;Sb枀Q褃;砽Sw?Q鍅;Sba觛緐舥褃;</_author_aff><_created>63212623</_created><_date>61526880</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_issue>12</_issue><_journal>皊鉔;Sf[</_journal><_keywords>AmL?`a扱;褢眰na棙抾;BR蠎;@n苸迉郪P[</_keywords><_modified>63212667</_modified><_pages>1664-1669</_pages><_translated_author>Qi, Jianping;Qi, Xiaoyuan;Wang, Xiaojuan</_translated_author><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=TDYX201612004&amp;DbName=CJFQ2016</_url><_volume>44</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>582</ID><UID>{C12144BD-2D3A-481D-9C1E-4C5BC415F654}</UID><Title>迯眰nv鰛蔞T€T)R鬩鏃梘S8TeQ籰梪\?Q|T8TST迉舥襨a觛剉梪He聣遊</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>體; 媠駛</Author><Year>2018</Year><Details><_accessed>63212643</_accessed><_author_aff>蛻哵^]N櫉aW:S篘l;Sb?Q褃;</_author_aff><_created>63212627</_created><_date>62386560</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_issue>07</_issue><_journal>NLu-N;So傸/_journal><_keywords>迯眰nv鰛蔞;)R鬩鏃梘;|T8TST迉舥襨a觛;S8TeQ;}v苸迉薔 };r^pb };MQ玼擽T{;梪He聣遊</_keywords><_modified>63212667</_modified><_pages>1666-1668+1672</_pages><_translated_author>Shi, Qun;Wang, Ying</_translated_author><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=SJZA201807026&amp;DbName=CJFQ2018</_url><_volume>13</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>583</ID><UID>{B1A9ECA5-63BA-405B-AD01-C77585689408}</UID><Title>迯眰nv鰛蔞鵞\ 熍u襨a觛T簚cpe剉q_蚑</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>韾wm; hg蹚; 殶UZ乕; _哵廩</Author><Year>2007</Year><Details><_accessed>63212643</_accessed><_author_aff>WS琋-N;So?Yf[;WS琋-N;So?Yf[;WS琋-N;So?Yf[;WS琋-N;So?Yf[ 2004Ux隭xvzu_l蟼WS琋210029;_l蟼WS琋210029;_l蟼WS琋210029;2004Ux隭xvzu_l蟼WS琋210029</_author_aff><_created>63212627</_created><_date>56374560</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_issue>03</_issue><_journal>砽WS-N;S</_journal><_keywords>迯眰nv鰛蔞;\ 烕Ama舥襨;oRAma舥襨;簚cpe</_keywords><_modified>63212667</_modified><_pages>35-36</_pages><_translated_author>Guo, Hai;Yang, Jin;Gong, Jiening;Zhang, Qinghong</_translated_author><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=HNZY200703016&amp;DbName=CJFQ2007</_url></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>584</ID><UID>{4ACFE630-47D0-4C03-94A9-34D8BECAE5FA}</UID><Title>迯眰nv鰛蔞SOY梑2u媁Ama舥襨剉瀃寶xvz</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>珒(; 飃 f噀; 褠睷s^; 煍WSq\</Author><Year>2007</Year><Details><_accessed>63212643</_accessed><_author_aff>^轢;Sf[b?{ND朸\;Sb^轢|T8T緐舥xvz@b;^Nw緐舥剺2枾c6R-N胈;^轢;Sf[b?{ND朸\;Sb^轢|T8T緐舥xvz@b;^轢;Sf[b?{ND朸\;Sb^轢|T8T緐舥xvz@b ^轢510120;^轢510001;^轢510120;^轢510120</_author_aff><_collection_scope>CSCD;PKU</_collection_scope><_created>63212627</_created><_date>56311200</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_issue>01</_issue><_journal>-No儼eoN4N奮ot</_journal><_keywords>迯眰nv鰛蔞;篘Ama舥襨;梑舥襨\O(u</_keywords><_modified>63212667</_modified><_pages>5-9</_pages><_translated_author>Mo, Hongying;Ke, Changwen;Zheng, Jingping;Zhong, Nanshan</_translated_author><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=ZYXY200701002&amp;DbName=CJFQ2007</_url></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>585</ID><UID>{AD9179DE-1894-4842-8FB1-217D577FCD69}</UID><Title>迯眰nv鰛蔞2柣lAma舥襨FM1a觛\ 焺v瀃寶xvz</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>珒(; hgP[餦; 褠睷s^; 珒陙€; 螢舓Oe; 杸ck&O</Author><Year>2008</Year><Details><_accessed>63212643</_accessed><_author_aff>^轢;Sf[b?{ND朸\;Sb東T8T緐舥齎禰蛻筽瀃寶;</_author_aff><_collection_scope>PKU</_collection_scope><_created>63212627</_created><_date>57143520</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_issue>08</_issue><_journal>-No働g</_journal><_keywords>迯眰nv鰛蔞;Ama舥襨FM1;簚cpe;>cpe;簚舥t;苸迉郪P[</_keywords><_modified>63212667</_modified><_pages>1230-1233</_pages><_translated_author>Mo, Hongying;Yang, Zifeng;Zheng, Jingping;Mo, Ziyao;Li, Yimin;Xiao, Zhenglun</_translated_author><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=ZYCA200808043&amp;DbName=CJFQ2008</_url></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>586</ID><UID>{95FFF611-0827-4D57-8186-33299A8DB378}</UID><Title>?栐kY\N迯眰nv鰛蔞鵞-NN|T8T鼅T乢燪秗舥襨剉SO匭Y慴6R\O(u詋儚</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>sQ噀緩; \g藋6O; _lwmf; u嵮慩[; hgP[餦</Author><Year>2018</Year><Details><_accessed>63212643</_accessed><_author_aff>^轢;S褃'Yf[D朸\,{N;Sb0^轢|T8TeP穅xvzb東T8T緐舥齎禰蛻筽瀃寶;</_author_aff><_collection_scope>PKU</_collection_scope><_created>63212627</_created><_date>62576640</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_issue>23</_issue><_journal>^N;Sf[</_journal><_keywords>?栐kY\;迯眰nv鰛蔞;-NN|T8T鼅T乢燪秗舥襨;慴6R\O(u</_keywords><_modified>63212667</_modified><_pages>3454-3458</_pages><_translated_author>Guan, Wenda;Du, Qiuling;Jiang, Haiming;Zhao, Jincun;Yang, Zifeng</_translated_author><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=GAYX201823003&amp;DbName=CJFQ2018</_url><_volume>39</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>587</ID><UID>{EBDDCFCE-D61A-4E45-9449-EF1E34BC7894}</UID><Title>迯眰nv鰛蔞梑Ama舥襨ot:g6Rxvz</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>媠圼決</Author><Year>2019</Year><Details><_accessed>63212643</_accessed><_author_aff>q\Nw4N憪縎-N;Sb曽</_author_aff><_created>63212627</_created><_date>62660160</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_issue>05</_issue><_journal>4N奮Tt(uo傿g譥</_journal><_keywords>迯眰nv鰛蔞;梑Ama舥襨;ot:g6R</_keywords><_modified>63212667</_modified><_pages>53-54</_pages><_translated_author>Wang, Shoujun</_translated_author><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=PLHY201905153&amp;DbName=CJFQ2019</_url><_volume>12</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>588</ID><UID>{E835CF37-8AC8-4C4A-9117-711BA6CA9465}</UID><Title>迯眰nv鰛蔞梑Ama舥襨4N奮梪He聣遊</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>H朂N慛; 媠鰯#Z; 臑Il</Author><Year>2017</Year><Details><_accessed>63212643</_accessed><_author_aff>-Nq\'Yf[D朸\,{擭;Sb曽</_author_aff><_created>63212627</_created><_date>61862400</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_issue>08</_issue><_journal>u儉;So傸/_journal><_keywords>迯眰nv;梑Ama舥襨;ot;4N奮</_keywords><_modified>63212667</_modified><_pages>666-667</_pages><_translated_author>Chen, Liyun;Wang, Yindi;Huang, Han</_translated_author><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=GSYY201708022&amp;DbName=CJFQ2017</_url><_volume>36</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>589</ID><UID>{4B10C8A6-A140-4005-AC11-6288BBCC8D88}</UID><Title>弖螛銐襨鰛蔞梑舥襨蔛梑虄剉SOYo僅ef[瀃寶xvz</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>TOO; 1g鍅Z; 睈"k; 醼沵; 臑GSwm</Author><Year>2013</Year><Details><_accessed>63212643</_accessed><_author_aff>塠絖;S褃'Yf[甠uirf[Yex;</_author_aff><_collection_scope>CSCD;PKU</_collection_scope><_created>63212631</_created><_date>59640480</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_issue>03</_issue><_journal>-No儼eoN4N奮ot</_journal><_keywords>弖螛銐襨鰛蔞;梑舥襨\O(u;梑虄\O(u;苸迉舥豐He擽</_keywords><_modified>63212667</_modified><_pages>234-238</_pages><_translated_author>Lu, Weiwei;Zhu, Tongna;Qiu, Huan;Hu, Tao;Huang, Shenghai</_translated_author><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=ZYXY201303007&amp;DbName=CJFQ2013</_url><_volume>24</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>590</ID><UID>{609B2D26-D7AE-4050-8A76-C7E1980EAA8A}</UID><Title>弖螛銐襨鰛蔞T€T?栐kY\籰梪癳媁燪秗舥襨簚巔剉轛~?`xvz</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>縲櫃dW; 輴h藌; l歰f:岥 O^薙; 媅KQIN; U厤; 貧 g筫; 乭蛜; \g噀pg</Author><Year>2020</Year><Details><_accessed>63212643</_accessed><_author_aff>砃轢^篘l;Sb曽</_author_aff><_collection_scope>CSCD;PKU</_collection_scope><_created>63212631</_created><_date>63194400</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_journal>-NI僶傸/_journal><_keywords>弖螛銐襨鰛蔞;癳媁燪秗舥襨簚巔;?栐kY\;癳媁燪秗舥襨;莡秗</_keywords><_modified>63212667</_modified><_pages>1-4</_pages><_translated_author>Ju, Xiangkun;Hao, Shuli;Ma, Jinghe;Wei, Guangyou;Song, Keyi;Tang, Chao;Gao, Youfang;Liang, Shaoqin;Du, Wenjie</_translated_author><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=ZCYO20200225000&amp;DbName=CAPJ2020</_url></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>591</ID><UID>{46AD1A94-90D5-45EA-921D-167110864920}</UID><Title>弖螛銐襨鰛蔞^1寳b舥襨烺Hexvz</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>崪‐‐; 貧駛pg; 鰁嘯Y桘 S~匊 赮c児Y; 踜k擕 ]SfpQ</Author><Year>2019</Year><Details><_accessed>63212643</_accessed><_author_aff>-N齎-N;S褃f[b?Noxvz@b;</_author_aff><_created>63212631</_created><_date>63074880</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_issue>12</_issue><_journal>癳-N;S</_journal><_keywords>簚巔;oRAma舥襨;弖螛銐襨鰛蔞;梑舥襨\O(u;≧ir瀃寶;苸迉瀃寶;\ 烖/_keywords><_modified>63212667</_modified><_pages>5-8</_pages><_translated_author>Bao, Yanyan;Gao, Yingjie;Shi, Yujing;Bao, Lei;Yao, Rongmei;Mao, Xin;Cui, Xiaolan</_translated_author><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=REND201912003&amp;DbName=CJFQ2019</_url><_volume>51</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>592</ID><UID>{3E242B7A-9059-44D7-B2F7-090EF0023DA4}</UID><Title>弖螛銐襨鰛蔞SO匭梑舥襨\O(u剉瀃寶xvz</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>睈"k; Ng/ctQ; 1g鍅Z; 4T噒; TOO; 臑GSwm</Author><Year>2014</Year><Details><_accessed>63212643</_accessed><_author_aff>塠絖;S褃'Yf[甠uirf[Yex;</_author_aff><_collection_scope>CSCD;PKU</_collection_scope><_created>63212631</_created><_date>59993280</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_issue>01</_issue><_journal>-No儼eoN4N奮ot</_journal><_keywords>弖螛銐襨鰛蔞;梑舥襨;T迉舥襨;US瘇眜箄舥襨I媁;飃(凣Y舥襨B3媁</_keywords><_modified>63212667</_modified><_pages>14-17</_pages><_translated_author>Qiu, Huan;Li, Zhenxing;Zhu, Tongna;Wu, Xuan;Lu, Weiwei;Huang, Shenghai</_translated_author><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=ZYXY201401006&amp;DbName=CJFQ2014</_url><_volume>25</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>477</ID><UID>{8213AEDA-8E15-4D0A-BEE1-584AE85F4F43}</UID><Title>癳媁燪秗舥襨簚巔蕥梪筫Hh-Nbo ?uR恎Notxvz蹚U\</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>Ng`j€; 疩ey; 誯蕏; R#k</Author><Year>0</Year><Details><_author_aff>S琋'Yf[o僨[b曽VnWS-N;So?Yf[垟xp╟bf[b曽S琋-N;So?Yf[-No僨[b曽</_author_aff><_collection_scope>PKU</_collection_scope><_created>63208411</_created><_date>2020-02-29</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_journal>-No働g</_journal><_keywords>-Nbo傷癳媁燪秗舥襨簚巔; O觛舥;◤翄簨籰</_keywords><_modified>63208413</_modified><_pages>1-10</_pages><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=ZYCA20200302000&amp;DbName=CAPJ2020</_url><_translated_author>Li, Sicong;Feng, Xiang;Bi, Lei;Liu, Xin</_translated_author></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>468</ID><UID>{ECF38B7C-1105-4366-864B-60B7450B0EDA}</UID><Title>hQ齎Tw:S-N;So兓l梪癳媁燪秗舥襨簚巔COVID-19 剉蕥梪筫HhR恎</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>鸑O皵; 蟼le; R8l&t; 疧飽)P; 褠淸茠; O?gT; s桽fpg; _)R駛; _譥f; RN瞫; 乕s倕h</Author><Year>0</Year><Details><_author_aff>u儉-N;So?Yf[u儉w貧!h蛻'Y緐舥RP[;Sf[N-N;So?柣lxvz蛻筽瀃寶;u儉-N;So?Yf[D朸\;Sbu儉w-N堺S觺T2柣l縺$v4N奮-N胈;Ye瞼钀feLq;Sf[NlS蛻筽瀃寶;</_author_aff><_collection_scope>CSCD;PKU</_collection_scope><_created>63208411</_created><_date>2020-02-25</_date><_db_provider>CNKI: g R</_db_provider><_db_updated>CNKI - Reference</_db_updated><_journal>-NI僶傸/_journal><_keywords>%N蛻%`'`|T8T鼅T乢燪秗舥襨2;癳媁燪秗舥襨緐舥;-N;So傷蕥梪筫Hh;(uo児eHh</_keywords><_modified>63208412</_modified><_pages>1-8</_pages><_url>http://kns.cnki.net/KCMS/detail/detail.aspx?FileName=ZCYO20200223000&amp;DbName=CAPJ2020</_url><_translated_author>Ren, Weiyu;Su, Jing;Liu, Yongqi;Hou, Wenqian;Zheng, Yiyun;Wei, Benjun;Jin, Xiaojie;Zhang, Liying;Zhang, Zhiming;Liu, Dongling;Ning, Yanmei</_translated_author></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>613</ID><UID>{69AC1535-0492-4DB9-86FA-A5F915EBD837}</UID><Title>-NNS篘lqQ孴齎4N奮(uo儃樺w[M]</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>齎禰o儀Q訷XTO</Author><Year>2017</Year><Details><_accessed>63222664</_accessed><_created>63222664</_created><_journal>S琋-N齎;So冄y€b鶴Hr>y</_journal><_modified>63222664</_modified><_translated_author>Guo, Jiayaodianweiyuanhui</_translated_author></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group><Group><References><Item><ID>614</ID><UID>{279B39C7-DCF8-4B50-9A92-571E3B406B58}</UID><Title>-N;S蕥璭f[[M]</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>1g噀 旣 亪噣颭</Author><Year>2013</Year><Details><_accessed>63222666</_accessed><_created>63222666</_created><_journal>S琋篘lkSu鶴Hr>y</_journal><_modified>63222666</_modified><_translated_author>Zhu, Wenfeng;Yuan, Zhaokai</_translated_author></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation>  ADDIN NE.Ref.{F59DD77C-9727-4FF2-A70E-1DCAE7D97164}<Citation><Group><References><Item><ID>549</ID><UID>{5AEBF20E-6521-45F2-B665-5FF560EC5B7C}</UID><Title>Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture</Title><Template>Journal Article</Template><Star>0</Star><Tag>0</Tag><Author>de Wilde, A H; Jochmans, D; Posthuma, C C; Zevenhoven-Dobbe, J C; van Nieuwkoop, S; Bestebroer, T M; van den Hoogen, B G; Neyts, J; Snijder, E J</Author><Year>2014</Year><Details><_accession_num>24841269</_accession_num><_author_adr>Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, Netherlands.; Rega Institute for Medical Research, KU, Leuven, Belgium.; Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, Netherlands.; Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, Netherlands.; Department of Viroscience, Erasmus Medical Center, Rotterdam, Netherlands.; Department of Viroscience, Erasmus Medical Center, Rotterdam, Netherlands.; Department of Viroscience, Erasmus Medical Center, Rotterdam, Netherlands.; Rega Institute for Medical Research, KU, Leuven, Belgium Johan.Neyts@rega.kuleuven.be E.J.Snijder@LUMC.nl.; Molecular Virology Laboratory, Department of Medical Microbiology, Leiden University Medical Center, Leiden, Netherlands Johan.Neyts@rega.kuleuven.be E.J.Snijder@LUMC.nl.</_author_adr><_created>63208135</_created><_date>2014-08-01</_date><_date_display>2014 Aug</_date_display><_db_updated>PubMed</_db_updated><_doi>10.1128/AAC.03011-14</_doi><_impact_factor> 4.715</_impact_factor><_isbn>1098-6596 (Electronic); 0066-4804 (Linking)</_isbn><_issue>8</_issue><_journal>Antimicrob Agents Chemother</_journal><_keywords>Animals; Antiviral Agents/*pharmacology; Cell Line; Chlorocebus aethiops; Chloroquine/pharmacology; Chlorpromazine/pharmacology; Coronavirus 229E, Human/*drug effects/physiology; Drug Approval; Hepatocytes/drug effects/pathology/virology; High-Throughput Screening Assays; Humans; Inhibitory Concentration 50; Loperamide/pharmacology; Lopinavir/pharmacology; Middle East Respiratory Syndrome Coronavirus/*drug effects/physiology; SARS Virus/*drug effects/physiology; Small Molecule Libraries/*pharmacology; Vero Cells; Virus Replication/drug effects</_keywords><_language>eng</_language><_modified>63212667</_modified><_ori_publication>Copyright (c) 2014, American Society for Microbiology. All Rights Reserved.</_ori_publication><_pages>4875-84</_pages><_tertiary_title>Antimicrobial agents and chemotherapy</_tertiary_title><_type_work>Journal Article; Research Support, Non-U.S. Gov&apos;t</_type_work><_url>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24841269&amp;query_hl=1</_url><_volume>58</_volume></Details><Extra><DBUID>{F96A950B-833F-4880-A151-76DA2D6A2879}</DBUID></Extra></Item></References></Group></Citation> MSWordNoteExpress 2.02019HrNSFC藌y槤Onc@€xT#'(+13;<=FHLChh h hhhhh$h&h(h2h4h6h<h>hFhNhVhXh^hjhnh~h€hhhh8Unknown G*郃x Times New Roman5€Symbol3. *郈x Arial;= €鷟?褳SOSimHei;?媅SOSimSun-= €鷟?N媅5. .醄`?Tahoma7.?@CalibriG=€  帑jMS Mincho-3 fg;. *郈x HelveticaA?$BCambria Math  萉h烈儑?媭M媭M5i€蕱蕱2僎P)?$PV2! xxNE.RepAdministratorLBDZP            ?鄥燆鵒h珣+'迟0,  < HT`hpx€AdministratorNE.Rep Normal.dotmLBDZ230Microsoft Office Word@vRm~@>2@te頷媭G Rt0 A€&" WMFC盹 ,,lah Rt EMF,€!@鑘   ahRp?媅SOl蔚醒P系銹醒任8械囱奜醒任 jEH1任醒  FH1€€€X;?媅SOSimunC1P@1%8系8系=R>1%`系 dv% % % Rp?@"Calibril蔚醒P系銹醒任8械囱奜醒任 jEH1任醒 lFH1€€/€od會1X%7.?@Calibrv=10犋1P@1%8系8系=R>1%`系ldv% % %  % % %  TT  m?嘆崊嘆 ZLahP1&% % % TT  m?嘆崊嘆 ZLahP D!ah"  % % % TTo?嘆崊嘆LahP rD!ah" Rp{1褳SOの业埾銹业系p械煅奜业系 jEH1系业  FH1€€?€X;= €鷟?褳SOSimei<1:0系C14系P@1%p系p系=R>1%樝 dv% % % Rp 媅SO€湜=10?v辔N]K1擥T "aK1 jEH1P蔚X训  FH1€€€2 d p€;€  ?媅SOSimun牢牢=R>1%栉 dv% % Rp{媅SO敉X训匚銹X训P蔚老<训奜X训P蔚 jEH1P蔚X训  FH1€€€X;?媅SOSimunㄎ0Q勎P@1%牢牢=R>1%栉 dv% % %  % % % T ?嘆崊嘆 Lahh梑|T8TS惻u襨o僫r4N奮o僨[c_TT U ?嘆崊嘆 LahP KRp?媅SOの业埾銹业系p械煅奜业系 jEH1系业  FH1€€€X;?媅SOSimun<1:0系C14系P@1%p系p系=R>1%樝 dv% % % % % %  TTq?嘆崊嘆LahPAXTpq;?嘆崊嘆LahX^Nwo僨[OXWXWWnTd<q?嘆崊嘆<LahT2020,,+BTTqm?嘆崊嘆LahPt^mTTnq?嘆崊嘆nLahP3ATTq?嘆崊嘆LahPgnTXq?嘆崊嘆LahP27,ATTq?嘆崊嘆LahP錯XTXq?嘆崊嘆LahP裇^WXTTq?嘆崊嘆LahP WTTq2?嘆崊嘆LahP K TTpJ?嘆崊嘆p?LahP K Tp ?嘆崊嘆pLah|T8TS惻u襨N/fN蛓US靣剉舥襨 /fT蛓舥襨剉;`饄 S靊XXWXWXWXWXWXXWWWXWXWXWXWWXVT ?嘆崊嘆 Lahp;熍u襨0燪秗舥襨0爛S惻u襨0z伵u襨0XWXVXWXXVXWXWWWXW* Tx%k?嘆崊嘆`Lah\|T8TST迉舥襨XXWXWXWTp&1k?嘆崊嘆&`LahXI{ 鶺嶯顅MRWWWWXXTx2k?嘆崊嘆2`Lah\癳媁燪秗舥襨WXWXWVXTdC k?嘆崊嘆`LahTSARS,,+,TTD n k?嘆崊嘆D `LahP-+T`o  k?嘆崊嘆o `LahTCoV,,,TT  k?嘆崊嘆 `LahP-,TT I k?嘆崊嘆 `LahP2+TlJ  k?嘆崊嘆J `LahX a觛 O璬WWXWXTT U k?嘆崊嘆 `LahP剉WTXV k?嘆崊嘆V `LahP艔怷WTT[k?嘆崊嘆`LahP'`WT\sk?嘆崊嘆\` Lahd  O觛'`0魜舥'`孴魜{k'`WWXWWWXWXWWXTTtk?嘆崊嘆t`LahP , TT?嘆崊嘆LahPvQXT?嘆崊嘆"Lah騗蟸b:NhQtsQ鑜剉&q筽0惽彏[寶剉hQ鶺郪膥廭R纇Km蔛舥烻8hx懤hKm XWXWXWXWXWXXWXWXWXWXWXXWXWXWXWXWXXTdh?嘆崊嘆LahTSARS,+,,TTi?嘆崊嘆iLahP-,T`?嘆崊嘆LahTCoV+,,TTC?嘆崊嘆LahP-,TTD?嘆崊嘆DLahP2QTp?嘆崊嘆LahX舥烻SOHT皊燪XWXWWVRp?媅SO厥<蔚妓銹<蔚4说ぬ 蔚奜<蔚4说 jEH14说<蔚  FH1€€€X;?媅SOSimun ?ph说P@1%にに=R>1%趟 dv% % % % % %  % % % T?3?嘆崊嘆Lahh秗舥襨b_` N孴KNMR裇皊剉XXWXWXWXWXWXXTT4?_?嘆崊嘆4LahP ,TX`??嘆崊嘆`LahP6 +,T?I ?嘆崊嘆Lahl蛓燪秗舥襨%N蛻%`'`|T8TS慄~T乢WXWXWXW&" WMFC ,t,WXXWXWXWsTdJ ? ?嘆崊嘆J LahTSARS,,+,T| ??嘆崊嘆 Lah\0-NN|T8T鼅T乢WXXWXWXsTd??嘆崊嘆LahTMERS+,,GT`??嘆崊嘆LahTI{ NWWW % % % TT,?嘆崊嘆!LahP TX% % %  T`]?嘆崊嘆LahT[1]% % %  T`^c,?嘆崊嘆^!LahT0鶺嶯WXWTxd,?嘆崊嘆d!Lah\|T8TS惻u襨錘蔛XWXWXWuTd,?嘆崊嘆!LahTSARS,+,,TT,?嘆崊嘆!LahP0WTd,?嘆崊嘆!LahTMERS,,,+TT,?嘆崊嘆!LahP0XTd,?嘆崊嘆!LahTSARS,+,,TT,?嘆崊嘆!LahP-,T`O ,?嘆崊嘆!LahTCoV+,+TTP { ,?嘆崊嘆P !LahP-,TT|  ,?嘆崊嘆| !LahP2IT  ,?嘆崊嘆 ! Lah` gP杽v4N奮籰梪蟸寶WXWXWXWXWTT .,?嘆崊嘆 !LahP孴WT`/5,?嘆崊嘆/!LahTg癳剉XXWT6,?嘆崊嘆6! Lah` 0癳媁燪秗舥襨a觛剉XWXWXWXWXV % % % Tpj?嘆崊嘆LahX簚巔蕥梪筫HhXXWXWXTTj?嘆崊嘆LahP +T|jz?嘆崊嘆Lah\諎L?{NHr  0XWXWWX,P% % %  TX{`?嘆崊嘆{LahP[2% % % TT`?嘆崊嘆LahP-% % % TX`?嘆崊嘆LahP3]% % %  Tj# ?嘆崊嘆 Lah`0 0fkIlOS孴;SbYn#XWXWXWWXXTT$ jO ?嘆崊嘆$ LahP ,TlP j) ?嘆崊嘆P LahX2019 +,,,+T* j?嘆崊嘆* Laht癳媁燪秗舥襨a觛V{eu蔛魦f 0Qe籰筫Hh-NXWXWXWXXWXWXWOXWWXW % % % TXpW?嘆崊嘆LLahP╟P僗XT`qvW?嘆崊嘆qLLahT諎(u剉WXWTw3W?嘆崊嘆wL Lahd梑舥襨o僫r 俌m9S鏃XWXWWRXXWXWTT4_W?嘆崊嘆4LLahP/,Tl` W?嘆崊嘆`LLahX)RXb鏃0WXWWSTT f W?嘆崊嘆 LLahP`!WTg ~W?嘆崊嘆g LLahp媁r^pb }0)R鬩鏃梘0?栐kY\0/l筓I{XXWWSWXWWSWXXWRXWX% % %  TX#?嘆崊嘆LahP[4% % % TT#?嘆崊嘆LahP-% % % TX#?嘆崊嘆LahP5]% % %  TTBW?嘆崊嘆LLahP RTXCW?嘆崊嘆CLLahP錘蔛XWTXW?嘆崊嘆LLahPg癳XV TT?嘆崊嘆LahP剉YT`"?嘆崊嘆LahT鴙sQ剉XXYT# ?嘆崊嘆#Lahxo僫rx裇俌^t穇夋0誰蒪鏃\I{\RP[o僫r珗XYXXYXXYXXYXYXXYXXYXXYTX k ?嘆崊嘆 LahPSOYXYT|l -?嘆崊嘆l Lah\瀃寶翄瀃颯齹 gHeXXYXXYXXTT.?嘆崊嘆.LahP0YTT?嘆崊嘆LahP(WXTp?嘆崊嘆LahX^Nwo僨[OYXXYXXTX?嘆崊嘆LahP€t^YV Tx+ % ?嘆崊嘆w Lah\o僨[NN訷XTOXXWXWXWTd&+  ?嘆崊嘆&w LahT剉膥莮 NXWXWTT+  ?嘆崊嘆w LahP,+Tl+ d ?嘆崊嘆w LahXR梩^訷XTOXXWXWTTe+  ?嘆崊嘆ew LahP剉XTX+ k ?嘆崊嘆w LahPN禰WXTXl+  ?嘆崊嘆lw LahP錱朩XT +  ?嘆崊嘆 w Lah€鴙sQcWS 耂€'Y蠎噀.s 垟鵞g癳剉o僫r蹚U\ 漁nc猒WXXWVWXWXWXUXXWXWXWXWVWXV Tx + ?嘆崊嘆 Lah\翄;Sf[剉漁nc YXXYXYXTX,  ?嘆崊嘆, LahP6R歔XYT  ?嘆崊嘆 Lahl哊梑|T8TS惻u襨o僫r剉o僨[c_ XXYXXYXYXXYXXYXTX  ?嘆崊嘆 LahP ^gXYT I ?嘆崊嘆 Laht鵞顅MR梑|T8TS惻u襨o僫r(W4N奮剉TtO(uXYXXYXXYXXYXYXXYXXYTTJ  ?嘆崊嘆J LahP0V % % % TXV p ?嘆崊嘆 LahP€XXTTqV  ?嘆崊嘆q LahP剉WTV ?嘆崊嘆 Lah|o僨[裿賬鶴哊wQSO剉t筫Hh :N4N奮剺2枌T籰梪DMXWXWXWXWXXWXWXWXWXWXXWXT` &" WMFC ,T,V ?嘆崊嘆 LahT|T8TSWXWT V  ?嘆崊嘆 Lah`舥襨@b魜緐舥衏汷耂€XWXWXXWXWX% % %  TXL Ey ?嘆崊嘆t LahP[5% % % TTFL \y ?嘆崊嘆Ft LahP-% % % T`]L y ?嘆崊嘆]t LahT10]% % %  TTV  ?嘆崊嘆 LahP0WTTV B ?嘆崊嘆 LahP KRp?@"Calibril蔚醒P系銹醒任8械囱奜醒任 jEH1任醒 ?FH1€€/€od會1X%7.?@CalibrP@1%8系8系=R>1%`系?dv% % %  % % % TT B ?嘆崊嘆+ LahP KRp ?1褳SO牢$业は銹$业系屝业奜$业系 jEH1系$业  FH1€€?€X;= €鷟?褳SOSimei%準楦业o1P系P@1%屜屜=R>1%聪 dv% % % Rp ?@"Arial牢 $业は銹$业系 屝业奜$业系 jEH1系$业 ,9FH1%€€?€X3. *郈x Arial纨X系钿'P系P@1%屜屜=R>1%聪,9dv% % % % % %  TTm  ?嘆崊嘆 LahP1,% % % TTj V ?嘆崊嘆 LahP j% % % TTWm  ?嘆崊嘆W LahP ,T|m > ?嘆崊嘆 Lah\^y蟸(lx憊憫b6RBRXWXWXWXWTT?m  ?嘆崊嘆? LahP K % % % TTrg  ?嘆崊嘆r ,Lah^y蟸(lx憊憫b6RBR;N亯惽N^y蟸(lx憊憚v)Y6q昢ir>U瞞x戅z塏  愰b'`慴6RS渷 N^y蟸(lx憊憚v;mYXXYXYXXYXXYXXYXYXXYXXYXXYXYXXYXXYXXYXYXXYXV TH @S?嘆崊嘆H*Lah'` 蹚 €;柇e舥襨棙抾蜰珗a觛縖;N苸迉1? ;朾k舥襨(W縖;N苸迉魰ibce 螿\舥襨Y6R vQYXXYXYXXYXXYXXYXYXXYXXYXXYXYXXYXXYXXYXYXXYT`A IS?嘆崊嘆AHLahT(W舥襨XXYTTJ S?嘆崊嘆JHLahPuV TT?嘆崊嘆LahP}T]T\?嘆崊嘆 Lah`hTg-NwQ g蛻亯\O(u\\]\\]\]\T] ?嘆崊嘆]Lahh 8^翂剉o僫r geY鳶諲鏃\]\\]\\]\]\\]TT 9 ?嘆崊嘆 LahPO,T: ?嘆崊嘆: Lah`seltamivir,+,,,+,,+1TT # ?嘆崊嘆 LahP 0Tl$ ?嘆崊嘆$ LahX0Nbs|鏃]\\\]TT?嘆崊嘆LahP(,TTI?嘆崊嘆LahPZ,T|J?嘆崊嘆JLah\anamivir+,,,+,,+TT?嘆崊嘆LahP)1Tl?嘆崊嘆LahX孴^蒪s|鏃\]\\W % % % TT'~?嘆崊嘆sLahP(,T`'p~?嘆崊嘆sLahTPer,,,Tpq'v~?嘆崊嘆qsLahXamivir,+,,,+TTw'~?嘆崊嘆wsLahP),% % %  T`J?嘆崊嘆ELahT[11% % % TTJ?嘆崊嘆ELahP-% % % T`BJ?嘆崊嘆ELahT13]% % %  TTC'~?嘆崊嘆CsLahP0WTT'~?嘆崊嘆sLahP KRp ?媅SOの业埾銹业系p械煅奜业系 jEH1系业  FH1€€€X;?媅SOSimun,Y4系P@1%p系p系=R>1%樝 dv% % %  TTs?嘆崊嘆s LahP KRp ?1N媅の业埾銹业系p械煅奜业系 jEH1系业 &鸢FH1€€?€t?X&-=€鷟?N媅对?€ M€ 0?v4系P@1%p系p系=R>1%樝鸢dv% % % Rp 0N媅€湜=1&0?vl恋N]K1擥T&"aK1 jEH1芾涿 FH1€€?€2&d p€&-=€鷟?N媅L砰NB1l$$恋尊1M恋P@1%L恋L恋=R>1%t恋dv% % % % % % % %  % % % T`RD?嘆崊嘆LahT1.1,,,TXER?嘆崊嘆ELahP ,,% % % TTR?嘆崊嘆LahP +TxR+?嘆崊嘆Lah\o冦N≧汻f[耂peXWXWXWWTT,Rv?嘆崊嘆,LahP K% % % % % %    '% Ld??r!€?€?% €(  &" WMFC ,4, TTL.?嘆崊嘆LahPhnTT/LZ?嘆崊嘆/LahP1,TT[L?嘆崊嘆[LahP-a,TTL?嘆崊嘆LahP1,TXL ?嘆崊嘆LahP ,,T L?嘆崊嘆 Lahl^y蟸(lx憫b6RBR;N亯o冦N≧汻f[耂peXXXXXXWXXXXXXXXWTTL?嘆崊嘆LahP K! Tdt?嘆崊嘆iLTo僫rT饄XXXWTT jt?嘆崊嘆 iLP K" ! % % %  Td$3?嘆崊嘆(LT@團m藛}vXXXWTT%o3?嘆崊嘆%(LP K T`^?嘆崊嘆LT觺T噑XXXTT^?嘆崊嘆LP K" !6  % % %  TXt?嘆崊嘆iL6 P鉔"孹XTTt?嘆崊嘆iL6 P K" !6 ]  % % %  Txc  t?嘆崊嘆c iL6 ] \鉙guir)R(uXXXXXXWTT  t?嘆崊嘆 iL6 ] P K" !] " % % %  T` t?嘆崊嘆 iL] "TJSpgXXXTTt?嘆崊嘆iL] "P K" !" % % %  TXOt?嘆崊嘆OiL"P抍膌XXTTIt?嘆崊嘆iL"P K" '% Ld!€?€?% €% Ld!€?€?% €% LdJ!€?€?% €% Ld!€?€?% €% Ld5 J!€?€?% €% Ld6 9 6 !€?€?% €% Ld: ] : $!€?€?% €% Ld^ a ^ !€?€?% €% Ldb !b !€?€?% €% Ld"%"!€?€?% €% Ld&&!€?€?% €! % % %  Td;?嘆崊嘆0LTeY鳶諲鏃XXWWTTi;?嘆崊嘆0LP K" ! % % %  Tl{;?嘆崊嘆0LX烻媁o僫r觺XXWXW T`f?嘆崊嘆LTT噑:NXWnT`fe?嘆崊嘆LT42%,,+TTff?嘆崊嘆fLP K" !6  % % %  T|;?嘆崊嘆0L6 \蟸潃乷憊憀廁NeYXXWXWXWW T|f?嘆崊嘆L6 \鳶諲鏃x懶v ^梄XWXWXWW Tp1??嘆崊嘆4L6 Xcyp450,,,,+BTl2??嘆崊嘆24L6 X剉昢ir孴慴WXWXW TXj?嘆崊嘆L6 P6RBRXWTTj?嘆崊嘆L6 P K" !6 ]  % % %  T`c  ;?嘆崊嘆c 0L6 ] T75%,,,Tp  ;?嘆崊嘆 0L6 ] X剉賬o兿懴~WXWXWW T|c f ?嘆崊嘆c L6 ] \x懶vb__蹚eQSO猒XXWXWXWW TTc  ??嘆崊嘆c 4L6 ] P痵XTT  ??嘆崊嘆 4L6 ] P K" !] " % % %  Tl U;?嘆崊嘆 0L] "X烻媁JSpgXXWWnTTV;?嘆崊嘆V0L] "P1,TT;?嘆崊嘆0L] "P^W TT f ?嘆崊嘆 L] "P3,TT f ?嘆崊嘆 L] "P TT f ?嘆崊嘆 L] "Ph,Tp f?嘆崊嘆 L] "Xx懶v剉JSHWXWXW TX O??嘆崊嘆 4L] "PpgXnTTPz??嘆崊嘆P4L] "P6+TT{??嘆崊嘆{4L] "P^XTX)??嘆崊嘆4L] "P10,+TT*U??嘆崊嘆*4L] "P ,TTV€??嘆崊嘆V4L] "Ph+TT??嘆崊嘆4L] "P K" !" % % %  T`O;?嘆崊嘆O0L"T99%,,,Tl;?嘆崊嘆0L"X蟸線ndWXWXWTT;?嘆崊嘆&" WMFC ,,0L"P K" % Ld!€?€?% €% Ld!€?€?% €% LdJ!€?€?% €% Ld!€?€?% €% Ld5 J!€?€?% €% Ld6 9 6 !€?€?% €% Ld: ] : $!€?€?% €% Ld^ a ^ !€?€?% €% Ldb !b !€?€?% €% Ld"%"!€?€?% €% Ld&&!€?€?% €! % % %  TdC?嘆崊嘆8LTNbs|鏃XXWWTTiC?嘆崊嘆8LP K" ! % % %  T`C?嘆崊嘆8LT觺T噑XXWTT$C?嘆崊嘆8LPXT`%C?嘆崊嘆%8LT10%,++TTC?嘆崊嘆8LP K" !6  % % %  T|C?嘆崊嘆8L6 \*g裿Km0R鉔"導NirXXWXWXWWTT C?嘆崊嘆8L6 P K" !6 ]  % % %  T|c  C?嘆崊嘆c 8L6 ] \S8TeQ鰁8TeQ蠎XXWXWXWW TTc n ?嘆崊嘆c L6 ] P4,TT n ?嘆崊嘆 L6 ] P%,TT n ?嘆崊嘆 L6 ] P^XT` n ?嘆崊嘆 L6 ] T17%,+,Td n ?嘆崊嘆 L6 ] T珗hQ珟8TWXWW TTc  G?嘆崊嘆c <L6 ] P6eXTT  G?嘆崊嘆 <L6 ] P K" !] " % % %  TX OC?嘆崊嘆 8L] "P@nXnT`PC?嘆崊嘆P8L] "T2.5+,,TT)C?嘆崊嘆8L] "P^WT`*C?嘆崊嘆*8L] "T5.1,,,TTC?嘆崊嘆8L] "P TTC?嘆崊嘆8L] "Ph+TT!C?嘆崊嘆8L] "P K" !" % % %  TpO[C?嘆崊嘆O8L"XhQ钀錘烻媁蟸XXWXWW TdOn?嘆崊嘆OL"T線nd朮XWWTTn?嘆崊嘆L"P K" ! % % %  Td?嘆崊嘆LT^蒪s|鏃XXWWTTi?嘆崊嘆LP K" ! % % %  Tl{?嘆崊嘆LXSOY觺T噑XXWXW TTp?嘆崊嘆eLPXTXup?嘆崊嘆eLP30,,TTvp?嘆崊嘆veLPWTTp?嘆崊嘆eLP K" !6  % % %  T|?嘆崊嘆L6 \(WSO匭 gf>f鉔XXWXWXWW TTlp?嘆崊嘆eL6 P"XTTmp?嘆崊嘆meL6 P K" !6 ]  % % %  Tdc  ?嘆崊嘆c L6 ] TY ?uo僗XWWTT  ?嘆崊嘆 L6 ] P K" !] " % % %  Tx ?嘆崊嘆 L] "\坢d朖Spg:NXXWXWXW TX  p?嘆崊嘆 eL] "P20,,TT p?嘆崊嘆 eL] "P ,TT8p?嘆崊嘆eL] "Ph+TT9p?嘆崊嘆9eL] "P K" !" % % %  TdO?嘆崊嘆OL"T^蒪s|鏃XXWnT`F?嘆崊嘆L"T90%+,,TTG?嘆崊嘆GL"P蟸W TdOp?嘆崊嘆OeL"T線亽c膌XXWWTTp?嘆崊嘆eL"P K" % Ld !€?€?% €% Ld!€?€?% €% LdP!€?€?% €% Ld!€?€?% €% , &NWMFC,,Ld5 P!€?€?% €% Ld0 3 0 !€?€?% €% Ld4 ] 4 *!€?€?% €% LdX [ X !€?€?% €% Ld\ !\ !€?€?% €% Ld!€?€?% €% Ld  !€?€?% €Rp?@"Calibril蔚醒P系銹醒任8械囱奜醒任 jEH1任醒 \<FH1€€/€od會1X%7.?@CalibrP@1%8系8系=R>1%`系\<dv% % %  % % %  TT *?嘆崊嘆LahP K% % % % % % % % % % % % %  % % % T`_D?嘆崊嘆LahT1.2,,,% % % TXE_?嘆崊嘆ELahP ,,TT_?嘆崊嘆LahP +Tl_}?嘆崊嘆LahX梑舥襨悢^XWXWXTT~_?嘆崊嘆~LahP翄W% % % TTW?嘆崊嘆LahP K!9   '% LdK\Kr!€?€?% €(   % % % TTX.?嘆崊嘆L9PhnTT/XZ?嘆崊嘆/L9P1,TT[X?嘆崊嘆[L9P-,TTX?嘆崊嘆L9P2,T`X6?嘆崊嘆L9T ,,,T7X\?嘆崊嘆7L9l^y蟸(lx憫b6RBR;N亯梑舥襨悢^翄XXXXXXWXXXXXXXWTT]X?嘆崊嘆]L9P K" % Ld?!€?€?% €% €% €( 6h6ah6a66g6`g6`66f6_f6_66e6^e6^66d6]d6]66c6\c6\66b6[b6[66a6Za6Z66`6Y`6Y6 6 _6X_6X 6  6 ^6W^6W 6  6 ]6V]6V 6  6 \6U\6U 6 6[6T[6T66Z6SZ6S66Y6RY6R66X6QX6Q66W6PW6P66V6OV6O6  JT.?宋体---?@"Calibri------ 2 'RJ1---2 +RJ ,JR'---2 6RJ ,JR'?1黑体---? 宋体--?宋体------52 ]6RJ抗呼吸道病毒药物临床药学指引2 ]RJ ?宋体------2 s6RJ( 2 s@ RJ威尼斯81818官网 2 sRJ20202 sRJ年2 sRJ32 sRJ月2 sRJ272 sRJ日 2 sRJ发布 2 sRJ) 2 sRJ 2 KRJ \2 K6RJ呼吸道病毒不是一种单独的病毒,是各种病毒的总称,包括: A2 e$RJ鼻病毒、冠状病毒、肠道病毒、腺病毒、  2 6RJ呼吸道合胞病毒 2  RJ等,基于目前 2 RJ新型冠状病毒( 2 RJSARS2 RJ-2 !RJCoV2 1RJ-2 6RJ22 ; RJ)感染传播 2 pRJ的 2 zRJ迅速 2 RJ性 /2 RJ,传染性、致病性和致死性 2 RJ,2 6RJ其 q2 @DRJ已经成为全球关注的焦点。通过实验室的全基因组序列检测及病原核酸检测, 2 RJSARS2 RJ-2 RJCoV2 RJ-2 RJ2 2  RJ病原体呈现冠 ?宋体---------22 6RJ状病毒形态,且和之前发现的 2 RJ 2 RJ6 ;2 RJ种冠状病毒(严重急性呼吸道综合征 2 yRJSARS#2 RJ、中东呼吸综合征 2 RJMERS2 RJ等)不 ---2 6RJ同 --- 2 @RJ[1]--- 2 IRJ。基于 2 hRJ呼吸道病毒以及 2 RJSARS2 RJ、 2 RJMERS2 RJ、 2 RJSARS2 RJ-2 RJCoV2 RJ-2 #RJ2 &2 ,RJ有限的临床治疗经验 2 RJ和 2 RJ最新的 )2 RJ《新型冠状病毒感染的 ---2 6 RJ肺炎诊疗方案 2 uRJ #2 yRJ(试行第七版)》  --- 2 RJ[2---2 RJ----2 RJ3]--- )2 RJ、《武汉协和医院处置 2 7RJ 2 <RJ2019 D2 V&RJ新型冠状病毒感染策略及说明》救治方案中 ---2 6RJ推荐 2 KRJ试用的 ,2 jRJ抗病毒药物,如洛匹那韦 2 RJ/2  RJ利托那韦、 2 RJⅠ A2  $RJ型干扰素、利巴韦林、阿比多尔、氯喹等 --- 2 RJ[4---2 RJ----2 RJ5]--- 2 RJ, 2 RJ以及 2 RJ最新 2 6RJ的 2 @RJ相关的 M2 `,RJ药物研发:如瑞德西韦、法拉韦尔等小分子药物被 2 IRJ体外 #2 ^RJ实验证实可能有效 2 RJ。 2 RJ在 2  RJ威尼斯81818官网 2 RJ老年  2 #6RJ药学专业委员会 2 #RJ的组织下 2 #RJ,2 # RJ青年委员会 2 #RJ的 2 #RJ专家 2 #RJ查阅 V2 #2RJ相关指南,参考大量文献,针对最新的药物进展,依据循  2 56RJ证医学的依据, 2 5€RJ制定 82 5RJ了抗呼吸道病毒药物的药学指引, 2 54RJ希望 D2 5I&RJ对目前抗呼吸道病毒药物在临床的合理使用 2 5RJ、 ---2 G6RJ患者 2 GKRJ的 P2 GU.RJ药学监护给出了具体的管理方案,为临床预防和治疗 2 GFRJ呼吸道 )2 GfRJ病毒所致疾病提供参考 --- 2 ARJ[5---2 ARJ----2 ARJ10]--- 2 GRJ。 2 GRJ ?@"Calibri------2 W6RJ ?1黑体---?@"Arial- - - ---2 h6RJ1- - - 2 h;RJ ---2 hHRJ #2 hMRJ神经氨酸酶抑制剂 2 hRJ ---2 KXRJ神经氨酸酶抑制剂主要通过与神经氨酸酶的天然底物唾液酸竞争,选择性抑制包膜上神经氨酸酶的活 2 6TRJ性,进而阻断病毒颗粒从被感染宿主细胞脱落,阻止病毒在宿主细胞间扩散,减少病毒复制,其 2 RJ在病毒 2 RJ生 2 6RJ命 &2 ARJ周期中具有重要作用 22 RJ,常见的药物有:奥司他韦( 2 4RJO2 : RJseltamivir2 nRJ)2 t RJ、扎那米韦 2 RJ(2 RJZ2 RJanamivir2 RJ)2  RJ和帕拉米韦 ---2 6RJ(2 ;RJPer2 KRJamivir2 jRJ)--- 2 pRJ[11---2 xRJ----2 {RJ13]--- 2 RJ。 2 RJ ?宋体- - - 2 KRJ ?1仿宋- - - ? 0仿宋- - - - - - - - ---2 6RJ1.12 FRJ - - - 2 PRJ  2 URJ药代动力学参数 2 RJ - - - - - -  - @ !6- 2 6RJ表2 CRJ12 HRJ-2 MRJ12 SRJ ;2 ] RJ神经氨酸抑制剂主要药代动力学参数 2 RJ ,#n02 60n#药物名称 2 `0n# ',#n- - -  2 tn#血浆蛋白 2 n# 2 tn#结合率 2 n# ',#- - -  2 #代谢 2 # ',#{- - -   2  {#口服生物利用度 2 i{# ',#{- - -  2 €{#半衰期 2 {# ',#"- - -  2 "#排泄 2 "# '- @ !>0-- @ !n-- @ !Fo-- @ !-- @ !d-- @ !-- @ !`-- @ !{-- @ !T|-- @ !-- @ !R-,bn#0--- 2 /60#nb奥司他韦 2 /`0#nb ',b#n--- 2 /t n#b原型药物结 2 ?tn#b合率为 2 ?n#b42%2 ?n#b ',b#--- #2 /#b经肝脏酯酶转为奥 #2 ?#b司他韦羧酸盐,非 2 N#bcyp4502 N #b的底物和抑 2 ^#b制剂 2 ^#b ',b{#--- 2 / #{b75%2 /0 #{b的给药量经羧 #2 ? #{b酸盐形式进入体循 2 N #{b环 2 N*#{b ',b#{--- 2 /€ {#b原型半衰期 2 /{#b12 /{#b~ 2 ?€{#b32 ?{#b 2 ?{#bh2 ? {#b;羧酸盐的半 2 N€{#b衰期 2 N{#b62 N{#b~ 2 N{#b102 N{#b 2 N{#bh2 N{#b ',b"#--- 2 /#"b99%2 / #"b经肾脏清除 2 /#"b '- @ !>#0-- @ !#n-- @ !F#o-- @ !#-- @ !d#-- @ !#-- @ !`#-- @ !#{-- @ !T#|-- @ !#-- @ !R#-,nb0--- 2 m60bn扎那米韦 2 m`0bn ',bn--- 2 mtnb结合率 2 mnb< 2 mnb10%2 mnb ',b--- #2 mb未监测到代谢产物 2 mb ',{b--- #2 m b{雾化吸入时吸入量 2 } b{42 }%b{%2 }*b{~ 2 }5b{17%2 }Eb{被全身吸 2  b{收 2 *b{ ',b{--- 2 m€{b血清 2 m{b2.52 m{b~ 2 m{b5.12 m{b 2 m{bh2 m{b ',"b--- 2 m b"全部以原型经 2 }b"肾脏清除 2 }b" ',n0--- 2 60n帕拉米韦 2 `0n ',n--- 2 t n体外结合率 2 tn< 2 ~n302 n% 2 n ',--- #2 在体内没有明显代 2 谢 2  ',{--- 2  {静脉用药 2 J{ ',{---  2 €{消除半衰期约为 2 €{202 { 2 {h2 { ',"--- 2 "帕拉米韦 2 "90%2 "经 2 "肾脏排泄 2 " '- @ !>0-- @ !n-- @ !Gn-- @ !-- @ !e-- @ !-- @ !a-- @ !z-- @ !U{-- @ !-- @ !R-?@"Calibri------ 2 6RJ - - - - - - - - - - ------2 6RJ1.2- - - 2 FRJ 2 PRJ 2 U RJ抗病毒适应 2 RJ证 ---2 RJ ,"0 - @ !6- - - - 2 60"表2 C0"12 H0"-2 M0"22 S0" 82 c0"神经氨酸抑制剂主要抗病毒适应证 2 0" '- @ !0-"System--JJRRJJRRJJRRJJRRJJRRJJRRJJQQIIQQIIQQIIQQIIQQIIQQIIQQIIQQIIPPHHPPHHPPHHPPHHPP?胀諟.摋+,D胀諟.摋+, X`t|  微软中国M蕱 ,([c _PID_HLINKSKSOProductBuildVerA WEjavascript:;WE javascript:;2052-11.1.0.9440  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~€     !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~€     !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]?_`abcdefghijklmnopqrstuvwxyz{|}~€?     !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~€     !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~€     !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~€?     !"#$%&'()*+,-./0123456789:;<=>??ABCDEFG??????????????VW??Z?Root Entry F鄁ziYData ^1TableㄡWordDocument 8SummaryInformation(\DocumentSummaryInformation8@MsoDataStore?ai鄤uiZEVECXFPPMZHA==2?ai鄤uiItem  PropertiesUCompObj e? ? ? ?  F#Microsoft Office Word 97-2003 文档 MSWordDoc?瞦